Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords | |
|---|---|---|---|---|---|---|
| 1 | Poster Presentation | Dissecting β-catenin associated inflammation in patients with desmoid fibromatosis to identify prognostic biomarkers | Laura Bergamaschi; Federica Perrone; Francesca Rini; Licia Rivoltini; Chiara Castelli, PhD; Alessandro Gronchi; Chiara Colombo; Viviana Vallacchi | Biomarkers, Immune Monitoring, and Novel Technologies | Immune monitoring;Inflammation | |
| 2 | Poster Presentation | Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) | Heather Cohen; Carly Campbell; Kristen Hurov; Johanna Lahdenranta; Tara Gelb; David Galbraith; Dan Rozelle; Mate L. Nagy; Qingyan Au; Erinn A. Parnell, PhD; Phil Brandish; Sebastien Hazard; Dominic Smethurst; Nicholas Keen; Stephen J. Blakemore | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Bispecifics;Costimulation;Gene expression;Immune contexture;Immune monitoring;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 3 | Poster Presentation | Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood | Louis E. Gonzalez, PhD; Bo Ma, PhD; Robert Hernandez, PhD; Hannah McKay; Fatima Rangwala, MD, PhD; Lini Pandite, MD; Taylor H. Schreiber, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune contexture | |
| 4 | Poster Presentation | 3D Coculture platform reveals insights into patient autologous immune cell-tumor interaction and immune modulation in vitro | Garima Kaushik, PhD; Amy K. Wesa, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade;Cytokine;Immune monitoring;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 5 | Poster Presentation | CD274 (PD-L1) gene expression and the 27-gene immuno-oncology (IO) assay are associated with efficacy to immune checkpoint inhibitor treated patients with non-small cell lung cancer (NSCLC). | Tyler J. Nielsen, MS; Matthew G. Varga, PhD; Kim McGregor, MD; Douglas T. Ross, MD, PhD; Brock L. Schweitzer, PhD; Rob S. Seitz; Gregory Vidal, MD PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Clinical study;Gene expression;RNA;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 6 | Poster Presentation | Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa | Yo-Ting Tsai, PhD; Renee N. Donahue, PhD; Nicole J. Toney, Ph.D; Julius Strauss, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Solid tumors;T cell;Targeted therapy | |
| 7 | Poster Presentation | Analytical comparison of a PD-L1 22C3 antibody laboratory-developed test protocol on the Benchmark XT and PD-L1 IHC 22C3 pharmDx: pan-tumor and triple-negative breast cancer samples | Gilad W. Vainer; Ghadeer Zatara; Lingkang Huang, Ph.D.; Shanthy Nuti, PhD; Kenneth Emancipator, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Solid tumors | |
| 8 | Poster Presentation | Multiparameter characterization of CAR T cells | Xueting Wang, M.Sc.; Christina Pitzka; Daniela Rheindorf; Nadine Mockel-Tenbrinck; Tatjana Holzer, PhD; Anne Richter, PhD; Toni Cathomen, PhD; Cesar Evaristo, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;CAR T cells;Costimulation;COVID and Immunotherapy;Immune monitoring;Immune tolerance;Leukemia/Lymphoma;Tumor evasion;Tumor microenvironment | |
| 9 | Poster Presentation | BRaf mutations are associated with T-helper cell infiltration and polarization in melanoma | Michael B. Ware, PhD; Bhavana Pavuluri; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Anna C. Cole, BA; Chrystal M. Paulos, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Chemokine;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 10 | Poster Presentation | Tertiary lymphoid structure in pancreatic ductal adenocarcinoma; a potential target in an immunologically inert malignancy | Kasimu U. Adoke, MBBS, FMCPath; Sanusi M. Haruna | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Antibody;B cell;Biomarkers;Dendritic cell;Immune toxicity;T cell | |
| 11 | Poster Presentation | Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents | Simon Deycmar, PhD; Brendan Johnson, DVM; Declan Ryan; William S. Sills, DVM; David L. Caudell, PhD; Greg Dugan, PhD; Kiran K. Solingapuram Sai, PhD; Michael Hettich, PhD; Bruno Gomes, DVM PhD; Maurizio Ceppi; Mark Cline, DVM PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Bispecifics;Carcinogenesis;Checkpoint blockade;Immune monitoring;Neoantigens;Solid tumors | |
| 12 | Poster Presentation | Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist | Heather Kinkead, PhD; Chelsie Macedo; Angelica Sanabria; Garrett Cyprus; Rajay Pandit; James Kalabus, PhD; Bryan R. Becklund, PhD; Florian J. Sulzmaier, PhD; John C. Timmer, PhD; Quinn Deveraux, PhD; Brendan P. Eckelman, PhD; Analeah B. Heidt, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Biomarkers;Bispecifics;Costimulation;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 13 | Poster Presentation | DexterTM microfluidic platform coupling single-cell resolution of dynamic tumor-immune interaction with AI for elucidating mechanistic modulation in cancer immunotherapy | Pradip K. Majumder, Ph.D.; Biswanath Majumder; Ranjeet Singh; Abhay Sane; Rushil Manglik; Ravi R. Keshari; Mohanasundaram S. M; Ashwin Dr. Lal, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;CAR T cells;Cytokine;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 14 | Poster Presentation | Claudin-6 affects the cell cycle and p53 signaling in Gastric cancer. | Sanyog Dwivedi, Mr., MSC | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Carcinogenesis;Gene expression;Metabolism;Solid tumors | |
| 15 | Poster Presentation | First-line platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors (ICI) prevents hyperprogression in non-small cell lung cancer (NSCLC) patients by reducing circulating immature neutrophils | Roberto Ferrara, MD; Giuseppe Lo Russo; Elena Jachetti; Giuseppina Calareso; Claudia Proto; Arsela Prelaj; Giulia Galli; Diego Signorelli; Marta Brambilla; Alessandro De Toma; Mario Occhipinti; Sara Manglaviti; Giulia Apollonio; Laura Mazzeo; Monica Ganzinelli; Antonia Martinetti; Filippo De Braud; Marina Garassino; Mario Paolo Colombo; Sabina Sangaletti, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Chemotherapy;Granulocyte;Immune monitoring;Myeloid cells;Solid tumors | |
| 16 | Poster Presentation | Tumor growth inhibition mediated by a single dose of intratumoral TransCon™ TLR7/8 agonist was associated with activated circulating T and B cells and sustained low levels of systemic cytokines | Amer M. Mirza, PhD; Luis A. Zuniga, PhD; Karan Uppal, PhD; Kathy Bang; Enping Hong, PhD; Simran Sabharwal, PhD; Yuchi Lee, PhD; Salomon Martinez; David Rosen, PhD; Juha Punnonen, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;Chemokine;Cytokine;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Myeloid cells;T cell lineages;TLR | |
| 17 | Poster Presentation | Predictive soluble biomarkers of immune response to checkpoint blockade in Non-Small Cell Lung Cancer (NSCLC) patients | Afsheen Raza, PhD; Reyad Mohsen; Aladdin Kanbour; Abdul Rehman Zar Gul; Anite Philip; Suma Vijayakumar; Shereena Hydrose; Maysaloun Merhi; Varghese Inchakalody; Shahab Uddin; Mohammed Ussama Al Homsi; Said Dermime | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune monitoring | |
| 18 | Poster Presentation | Systemic immune profiling of advanced biliary tract cancer patients defines altered cytokines and immune cell populations | Amanda N. Ruggieri, MS; Mark Yarchoan, MD; Yuan Liu, PhD; Subir Goyal, Ph.D; Elad Sharon, MD, MPH; Helen Chen, MD; Brian M. Olson, PhD; Shishir K. Maithel, MD; Bassel El-Rayes, MD; Nilofer Azad, MD; Gregory B. Lesinski, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Chemokine;Clinical study;Immune monitoring;Myeloid cells;Solid tumors;T cell | |
| 19 | Poster Presentation | Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST | Charles W. Abbott, PhD; Niamh Coleman; Jing Wang; Josette M. Northcott; Fabio Navarro; Lee D. McDaniel, Jr., MD, MSE; Eric Levy, PhD; Rachel M. Pyke, PhD; Filip Janku, MD, PhD; Richard Chen, MD; Sean M. Boyle, PhD, MS | Biomarkers, Immune Monitoring, and Novel Technologies | Gene expression;Neoantigens;T cell | |
| 20 | Poster Presentation | Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy | Charles W. Abbott, PhD; Nikita Bedi; Jing Wang; Josette M. Northcott; Rachel M. Pyke, PhD; Robin Li, MS; Lee D. McDaniel, Jr., MD, MSE; Eric Levy, PhD; Mena Mansour; Dimitrios Colevas, MD; John Lyle, PhD; John B. Sunwoo, MD; Sean M. Boyle, PhD, MS; Richard Chen, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells;Biomarkers;Neoantigens;T cell;Tumor evasion | |
| 21 | Poster Presentation | Neutrophil extracellular traps (NETs) can be measured non-invasively with CPa9-HNE - biomarker potential across different solid tumor types in the immuno-oncology setting | Christina Jensen, MSc, PhD; Jeppe Thorlacius-Ussing; Joachim H. Mortensen; Morten A. Karsdal; Nicholas Willumsen | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune monitoring;Immune suppression;Myeloid cells;Post-translational modifications;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 22 | Poster Presentation | The potential of serum autoantibodies against type III collagen in cancer | Christina Jensen, MSc, PhD; Jeppe Thorlacius-Ussing; Patryk Drobinski; Morten A. Karsdal; Anne-Christine Bay-Jensen; Nicholas Willumsen | Biomarkers, Immune Monitoring, and Novel Technologies | Autoimmunity;B cell;Biomarkers;Carcinogenesis;Immune monitoring;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 23 | Poster Presentation | Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients | Diego de Miguel Perez, PhD, MSc; Feliciano Barrón, MD, MSc; Alessandro Russo, MD, PhD; Luis Lara-Mejía, MD; Muthukumar Gunasekaran, PhD; Andrés F. Cardona, MD, PhD; Christine B. Peterson, PhD; Rivka R. Colen, MD; Aung Naing, MD; Philip C. Mack, PhD; Fred R. Hirsch, MD, PhD; Vincenzo Adamo, MD, PhD; Oscar Arrieta, MD, PhD; Christian Rolfo, MD, PhD, MBA, Dr.hc. | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Extracellular vesicles/exosomes;Solid tumors;Tumor microenvironment | |
| 24 | Poster Presentation | Nivolumab Serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome. | Domenico Mallardo, MD; Maria Grazia Vitale, MD; Diana Giannarelli, MD; Giusy Trillò; Assunta Esposito, PhD; Mariaelena Capone, MD; Maria Antonietta Isgrò; Gabriele Madonna, MS; grazia d'angelo; Lucia Festino; Vito Vanella; Claudia Trojaniello; Alessandro Manzoni; Andrew M. White, BSc; Michael Bailey; Ester Simeone, MD; Corrado Caracò; Piera Maiolino; Nicola Normanno; Sarah E. Warren, PhD; Ernesta Cavalcanti; Paolo A. Ascierto, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Gene expression;Immune suppression;T cell | |
| 25 | Poster Presentation | Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer | Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA; Dong-Uk Lee | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune toxicity | |
| 26 | Poster Presentation | Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials | Heinrich Roder, DPhil; Laura Maguire, PhD; Senait Asmellash, PhD; Steven Rightmyer; Patrick Norman; Mark McCleland, PhD; Wei Zou, PhD; Minu Srivastava, PhD; Lelia Net, PhD; Thomas Campbell, PhD; David Shames, PhD; Robert Georgantas III, PhD; Joanna Roder, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Proteomics;Solid tumors | |
| 27 | Poster Presentation | Cytokine signature of PD-1, CXCL10, and TNF-alpha predicts response to nivolumab and ipilimumab | Jesper G. Pedersen; Mateo Sokac; Nicolai J. Birkbak; Trine H. Øllegaard; Martin R. Jakobsen | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Cytokine | |
| 28 | Poster Presentation | Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology | Joanna Roder, PhD; Thomas Campbell, PhD; Senait Asmellash, PhD; Steven Rightmyer; Patrick Norman; Robert Georgantas III, PhD; Mark McCleland, PhD; Wei Zou, PhD; Minu Srivastava, PhD; Lelia Net, PhD; Laura Maguire, PhD; Heinrich Roder, DPhil; David Shames, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Proteomics;Solid tumors | |
| 29 | Poster Presentation | Elevated Flt3L predicts long-term survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms | Katharina Detjen; Raik Otto; Yvonne Giesecke; Lukas Geisler; Pamela Riemer; Henning Jann; Carsten Grötzinger; Christine Sers; Tom Luedde; Ulf Leser; Bertram Wiedenmann; Michael Sigal; Frank Tacke; Christoph Roderburg; Linda Hammerich, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Cytokine;Gene expression;Immune contexture;Solid tumors;Tumor microenvironment | |
| 30 | Oral Presentation | Blood-based Glycoprotein Signatures in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Receiving First-Line Immune Checkpoint Blockade | Klaus Lindpaintner, MD, MPH; Michael Cheng; Jillian M. Prendergast, PhD; Karl Normington, PhD, MBA; Maurice Y. Wong; Gege Xu; Xini Cong; Rachel Rice; Marissa N. Lawrence; Kesi Michael; Daniel Serie | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Systems biology;Targeted therapy | |
| 31 | Poster Presentation | Serum LAG-3 is associated with improved patient prognosis in high grade serous ovarian cancer. | Nicole E. James, PhD; Katrin Eurich; Erin Lips; Payton De La Cruz; Morgan Woodman; Jennifer Ribeiro | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Solid tumors | |
| 32 | Poster Presentation | Measuring soluble CD73 activity in high concentrations of human plasma to assess pharmacodynamics of CD73 inhibitors | Rick Sorensen, BS; Marianna Zavodovskaya, M.S.; Ping Cheng Yi, M.S.; Michael Lee, B.A.; Audrey D. Goddard, Ph.D.; Matthew L. Peach, MS | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune suppression;Tumor microenvironment | |
| 33 | Poster Presentation | Development of a clinical ex vivo assay for the assessment of therapeutic CD28 costimulatory pathway engagement | Chelsea J. Gudgeon, BS; Mark F. Maurer, BS; Gary D. Means, PhD, MS; Sherri Mudri, BS; Lori Blanchfield, PhD; Jing Yang, PhD; Stacey R. Dillon, PhD; Pamela M. Holland, PhD; Zelanna Goldberg, MD; Stanford Peng, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells;Biomarkers;Costimulation;Immune monitoring;T cell | |
| 34 | Poster Presentation | Selective infiltration of Antibody-Dependent Cellular Cytoxicity (ADCC) mediating immune cells in response to treatment in a human tumor histo-culture platform | Satish Sankaran, PhD; Nandini Basak, PhD; Sindhu Govindan, PhD; Prakash BV; Manjula BV; Ganesh MS; Amritha Prabha; Kowshik Jaganathan, PhD; Vasanth K, PhD; Gowri Shankar K, PhD; Manimaran A, PhD; Rajashekar M; Ritu Malhotra; Oliyarasi M; Rachita Rao | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Chemokine;Immune monitoring;Monocyte/Macrophage;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 35 | Poster Presentation | Chemokine-driven spatial organization of immune cell microaggregates marks oropharyngeal squamous cell carcinomas containing tumor-specific T cells | Ziena Abdulrahman, MD; Saskia J. Santegoets; Gregor Sturm; Pornpimol Charoentong; Marieke E. Ijsselsteijn; Antonios Somarakis; Thomas Höllt; Francesca Finotello; Zlatko Trajanoski; Sylvia L. van Egmond; Dana AM. Mustafa; Marij J. Welters, PhD; Noel F. de Miranda, PhD; Sjoerd H. van der Burg, Prof.Dr. | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells;Biomarkers;Chemokine;Dendritic cell;Gene expression;MDSC;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 36 | Poster Presentation | Digital Whole Slide Image (WSI) Scoring is Equivalent to Microscope Glass Slide Scoring for Evaluation of Programmed Death-Ligand 1 (PD-L1) Expression Across Multiple Tumor Indications | Micki Adams, BS; Deanna Moquin, BS; Joshua Littrell, BA; Jay Milo, M.A.S; Stephanie Hund, B.S.; Angeliki Apostolaki, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Biomarkers;Checkpoint blockade;COVID and Immunotherapy;Solid tumors;Targeted therapy;Tumor evasion | |
| 37 | Poster Presentation | Quantitative Lung Airway Morphology (QuaLM) features on chest CT scans are associated with response and overall survival in lung cancer patients treated with checkpoint inhibitors | Mehdi Alilou, PhD; Thomas Patton, BS; Pradnya Patil; Nathan Pennell; Kaustav Bera, MBBS; Amit Gupta; Pingfu Fu, PhD; Vamsidhar Velcheti; Anant Madabhushi, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Targeted therapy | |
| 38 | Poster Presentation | Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment. | Todd Bartkowiak, Ph.D.; Asa A. Brockman, B.S.; Sierra M. Barone, B.S.; Madeline J. Hayes, B.S.; Caroline E. Roe, MLI; Justine Sinnaeve, Ph.D.; Akshitkumar M. Mistry, M.D.; Nalin Leelatian, M.D.,Ph.D; Allison R. Greenplate, Ph.D.; Bret C. Mobley, M.D.; Lola B. Chambless, M.D.; Reid C. Thompson, M.D.; Kyle D. Weaver, M.D.; Rebecca A. Ihrie, Ph.D.; Jonathan M. Irish, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Immune contexture;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 39 | Poster Presentation | A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in NSCLC | Julie Berthe, PhD; Sriram Sridhar; Felix Segerer; Marco Testori; Megha Saraiya; Lorenz Rognoni; Harald Hessel; Alma Andoni; Anatoliy Shumilov, PhD; Andreas Spitzmüller; Mari Heininen-Brown; Jorge Blando; Felicia Ng; Emma Jones; Sophie Willis; Michael Surace; Rieneke van de Ven; Tanja D. de Gruijl, PhD; Helen K. Angell, PhD, BSc | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;Biomarkers;Dendritic cell;Gene expression;Immune contexture;Immunoscore;RNA;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 40 | Poster Presentation | Precise Spatial Multiplexing for Immune Profiling in Non-Small Cell Lung Cancer FFPE Samples with ChipCytometry | Thomas Campbell, Ph.D.; Arne Christians, Ph.D; Adam Northcutt, Ph.D.; Crystal Winkeler, Ph.D.; Kevin Gamber, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Immune monitoring;Tumor microenvironment;Tumor stroma | |
| 41 | Poster Presentation | Assessment of the spatial distribution of CD4+ T cells subpopulations in the tumor microenvironment by Brightplex®, a sequential chromogenic multiplex assay | aurelie Collignon; Alex Trinh; Marion Olive; Clémence Jaume; Maïté Chamourin; Nour Sfeir; Dylan Anselmo; Raana Ramouz-Charpentier; Georgia Culey; Christophe Haond; Jerome Galon, PhD; Jacques Fieschi-Meric, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune contexture;Immune monitoring;Regulatory T cell (Treg cell);T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 42 | Poster Presentation | The role of tissue stiffness in predicting the immunotherapy response in hepatocellular carcinoma | Betul Gok Yavuz, MD-PhD; Elshad Hasanov; Lianchun Xiao; Yehia I. Mohamed; Sunyoung S. Lee; Asif Rashid, MD, PhD; Ahmed O. Kaseb, MD; Aliya Qayyum, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade | |
| 43 | Oral Presentation | Intravital multiphoton imaging of infiltrating CD8 T cell and tumor cell metabolism during immunotherapy in a murine melanoma model | Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Angelica F. Lopez; Nathaniel J. Burkard; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Checkpoint blockade;Metabolism;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 44 | Poster Presentation | Detection of memory B cells cross-reactive against polymorphic malaria antigens using a multiplex FluoroSpot assay | David R. Spezzano; Peter Jahnmatz; Evan R. Johnson | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Antigen presenting cells;B cell;Biomarkers;Cytokine;Immune monitoring;Immune tolerance;Inflammation;T cell;Vaccine | |
| 45 | Poster Presentation | AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells | Jelena Levi, PhD; Timothy Perk, PhD; Lyna Huynh; Juliet Packiasamy, PhD; Serena Cheng, PhD; John B. Sunwoo, MD; A. Dimitrios Colevas, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 46 | Poster Presentation | Proximity between cytotoxic antigen-experienced T cells and tumor cells is associated with improved clinical outcomes in early-stage NSCLC | Qianyun Luo; Marcelo V. Negrao, MD; Edwin R. Parra, MD, PhD; Neal Akhave, MD; Erin M. Bayley, MD; Kyle Mitchell, MD; Jianjun Zhang, MD, PhD; John V. Heymach, MD, PhD; Boris Sepesi, MD; Ignacio Wistuba, MD; Don L. Gibbons, MD, PhD; Alexandre Reuben, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Solid tumors;Tumor microenvironment | |
| 47 | Poster Presentation | Tertiary lymphoid structures (TLS) in desmoplastic melanomas (DM) differ from non-DM-associated TLS by their intratumoral location and enhanced immune activity | Ileana S. Mauldin, PhD; Anne M. Stowman, MD; Alexandra W. Hickman, MD; Adela Mahmutovic; Alejandro A. Gru, MD; Kevin T. Lynch, MD; Samuel J. Young; Max O. Meneveau, MD; Nolan A. Wages, PhD; Victor H. Engelhard, PhD; Craig L. Slingluff Jr, MD | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;T cell;Tumor microenvironment | |
| 48 | Poster Presentation | Immune Environment Correlates with NSCLC and CRC Patient Survival | Dannah Miller, PhD; Dannah Miller; Huong Nguyen; Kate Hieber; Charles Caldwell, Jr., PhD; Roberto Gianani, MD, FCAP | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune monitoring;Immune suppression;Monocyte/Macrophage;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 49 | Poster Presentation | Highly multiplexed detection of critical immune checkpoints and immune cell subtypes in cancerous FFPE tissues using CODEX | Olive Shang; Judi Gordon; Nadya Nikulina; Sejal Mistry; Jasmine Singh; Hailing Zong; Jessica Yuan; Trillium Blackmer; Darren Locke; Oliver Braubach; Julia Kennedy-Darling; Peter Miller | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;Bioinformatics;Biomarkers;Dendritic cell;Immune contexture;Solid tumors;Systems biology;T cell | |
| 50 | Poster Presentation | In-situ visualization and measurement of tumor-infiltrating lymphocytes (TILs) on intact FFPE renal cell carcinoma (RCC) tissue using the spatial molecular imager (SMI) | Evan W. Newell, PhD; Youngmi Kim, PhD; Heeju Ryu; Shamin Li, PhD; Michael Leon; Sean Kim; Mark Gregory; Patrick Danaher, PhD; Joseph M. Beechem, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune contexture;Immune monitoring;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 51 | Poster Presentation | A novel cross-site analysis of Vectra® Polaris™ multiplex fluorescence PD-1/PD-L1 immunohistochemistry on colorectal cancer with high and low microsatellite instability | Sara Pollan, phD; Bethany Remeniuk, PhD; Arezoo Hanifi, PhD; Kristin Roman; Bei Hopkins; Natalie Monteiro; Harry Nunns, PhD; Erinn A. Parnell, PhD; Josette William, MD, PhD; Qingyan Au, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Regulatory T cell (Treg cell);Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 52 | Poster Presentation | Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI) | Jason Ptacek, PhD; Matthew D. Vesely, MD, PhD; David L. Rimm, MD, PhD; Monirath Hav, MD; Murat Aksoy, PhD; Ailey Crow; Jessica Finn, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Immune monitoring;Monocyte/Macrophage;Proteomics;Systems biology;T cell;Tumor microenvironment | |
| 53 | Poster Presentation | Unique insights into PDAC development revealed by both InSituPlex® and Imaging Mass Cytometry | Andrew Quong, PhD; Mark L. Rees; Kirsteen H. Maclean, Ph.D; Mael Manesse, PhD; Jordan Nieto; Amanda Esch; Devan Fleury; Keith Wharton, MD, PhD; Gourab Chatterjee | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune contexture;Immune monitoring;Proteomics;Solid tumors;T cell;Tumor microenvironment;Tumor stroma | |
| 54 | Poster Presentation | A strategy to quantitatively assess the accuracy and precision of multiplex immunofluorescence assays - application to Ultivue Insituplex® PD-L1, T-act and APC panels | Sripad Ram, PhD; Eric L. Powell, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 55 | Poster Presentation | Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors | Saulo B. Silva, Sr., MD; Carlos Wagner Wanderley, PhD; Jose Flavio G. Marin, PhD; Mariana P. De Macedo, PhD; Ellen CT. Nascimento, PhD; Fernanda F. Antonacio, MD; Fernando Q. Cunha, PhD; Gilberto de Castro Jr, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Metabolism;Solid tumors | |
| 56 | Poster Presentation | Quantitative evaluation of the tissue micro-environment by high-resolution 17-plex immunofluorescence reveals distinct cell populations | Kyla Teplitz; Daniel Campton, BS; Erin McCarty; Jeremy Cooper; Anne E. Hellebust, PhD; Donald Allen; Kimberly Collins; Kate Lillard, PhD; Eric P. Kaldjian, MD; Tad George, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune monitoring;Leukemia/Lymphoma;Monocyte/Macrophage;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment | |
| 57 | Poster Presentation | Assessment of the spatial distribution of B cells subpopulations in the tumor microenvironment and tertiary lymphoid structures by Brightplex®, a sequential chromogenic multiplex assay | Alex Trinh; Aurélie Collignon; Marion Olive; Clémence Jaume; Maïté Chamourin; Nour Sfeir; Dylan Anselmo; Raana Ramouz-Charpentier; Georgia Culey; Christophe Haond; Jerome Galon, PhD; Jacques Fieschi-Meric, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;Biomarkers;Immune contexture;Immune monitoring;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 58 | Poster Presentation | Analytical validation of a novel immunohistochemistry assay to determine nuclear AHR expression in human bladder cancer | Lei Wang, PhD; Marta Sanchez-Martin, PhD; Steve Tirrell, PhD; Nerymar Ortiz-Otero, PhD; Michelle Zhang, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Immune suppression;Tumor microenvironment | |
| 59 | Poster Presentation | Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial | Arika S. Feils, BS; Amy K. Erbe, PhD; Jen Birstler; KyungMann Kim, PhD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Danni Yu; Arlene O. Siefker-Radtke, MD; Nizar M. Tannir, MD, FACP; Matthew D. Hellmann, MD; Sara Tolaney; Adi Diab, MD; Paul M. Sondel, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Genetic polymorphism;NK/NKT cell;Solid tumors | |
| 60 | Poster Presentation | Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs | Francisco J. Ponce, BS; Stephanie Hund, B.S.; Lindsay Peltz, M.S.; Chris La Placa, M.S.; Monika Vilardo, B.S.; Brittany Watts, B.S.; Siena Tabuena-Frolli, B.A.; Grant Toland, B.S.; Alex Posch, B.S.; Jay Milo, M.A.S; Karina Kulangara, Ph.D.; Angeliki Apostolaki, Ph.D. | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody;Biomarkers;Immune monitoring;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor evasion | |
| 61 | Poster Presentation | Biomarkers of favorable prognosis guides the identification of tumor reactive CD4+ and CD8+ TILs in Endometrial Cancer | Jara Palomero, PhD; Carla Panisello; August Vidal, MD; Jordi Ponce, MD, PhD; Ana Vivancos, PhD; Josep Maria Piulats, MD, PhD; Xavier Matias-Guiu, MD, PhD; Alena Gros, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 62 | Poster Presentation | Applying machine vision to empower preclinical development of cell engager and adoptive cell therapeutics in patient-derived organoid models of solid tumors. | Sonal Khare, PhD; Chi-Sing Ho; Madhavi Kannan, MS; Brian M. Larsen, PhD; Brandon L. Mapes, MS; Jenna Shaxted; Jagadish Venkataraman, PhD; Ameen A. Salahudeen, MD PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Bispecifics;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 64 | Poster Presentation | A cloning and expression system of the neoantigen-specific TCRs from tumor-infiltrating lymphocytes by single-cell sequencing of paired TCRα and TCRβ chains | Yukari Kobayashi, BS; Koji Nagaoka, PhD; Kaori Kubo; Toshikazu Nishie; Sachiko Okamoto, PhD; Tatsuji Enoki; Junichi Mineno, PhD; Yasuyoshi Sato, MD, PhD; Shunji Takahashi, MD, PhD; Jun Nakajima, MD, PhD; Kazuhiro Kakimi, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 65 | Poster Presentation | Identification of frequently presented non-mutated tumor-specific immunogens for the development of both off-the-shelf and personalized vaccines without need for tumor biopsy | Orsolya Lorincz, PhD; Levente Molnar, Msc; Zsolt Csiszovszki, PhD; Eszter Somogyi, PhD; Jozsef Toth, MSc; Katalin Pantya, MSc; Peter Pales, MSc; Eniko R. Toke, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;T cell;Tumor antigens;Vaccine | |
| 66 | Oral Presentation | Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy. | Afaf Abed, MBBS, FRACP; Elin S. Gray; Michael Millward, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade | |
| 67 | Poster Presentation | Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer. | Joao Victor M. Alessi, MD; Biagio Ricciuti, MD; Yvonne Lin-Liu; Hersh Gupta; Xinan Wang; Giuseppe Lamberti, MD; Gonzalo Recondo, MD; Victor R. Vaz; Adriana Barrichello; Mizuki Nishino; Andrew D. Cherniack, PhD; James Lindsay; Bijaya Sharma; Kathleen L. Pfaff; Kristen D. Felt; Scott J. Rodig, MD, PhD; Mark Awad, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade | |
| 68 | Poster Presentation | Rapid detection of somatic variants in human leukocyte antigen class 1 genes from solid tumor samples. | Ramit Bharanikumar, MS; Aly A. Khan, PhD; Karl Beutner; Jason Perera, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Immune monitoring;Immune suppression;Immune tolerance;Immune toxicity | |
| 69 | Poster Presentation | Immunophenotyping of TCR and BCR clonotypes | Alex Chenchik, PhD; Michael Makhanov; Russell Darst; Tianbing Liu; Lester Kobzik | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;Bioinformatics;Biomarkers;Gene expression;Immune monitoring;NK/NKT cell;Regulatory T cell (Treg cell);RNA;T cell;T cell lineages | |
| 70 | Poster Presentation | Novel Immunotherapeutic Targets in Cancer of Unknown Primary (CUP) | Mary Nesline, M.S.; Paul DePietro, PhD; Yong Hee Lee, M.S.; Zachery Bliss; R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Sean T. Glenn, PhD; Shengle Zhang, MD; Sarabjot Pabla; Roger D. Klein, MD, JD, FACP; Jeffrey Conroy, BS | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Gene expression;Solid tumors | |
| 71 | Poster Presentation | Tumors with Higher Heterogeneity Were Associated with Superior Survival Outcome Amongst Stage I Lung Cancer Patients With Low Tumor Mutational Burden (TMB) | Stanislav Fridland, BS; Young Kwang Chae, MD, MPH, MBA | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;Bioinformatics;Biomarkers;Gene expression;MDSC;Regulatory T cell (Treg cell);RNA;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 72 | Poster Presentation | Spatial whole transcriptome profiling of the tumor microenvironment in prostate carcinomas. | Naishitha Anaparthy, PhD; Valeria Giangarra; Sarah E. Taylor; Mesruh Turkekul; Stephen R. Williams, PhD; Paulius Mielinis; Caroline Gallant | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Gene expression;RNA;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 73 | Poster Presentation | Characterization of tumor-infiltrating T-cell repertoire in human cancers | Taylor Harding, Ph.D.; Qidi Yang; Brittany Mineo; Jenna Malinauskas; Jason Perera, PhD; Karl Beutner; Denise Lau, PhD; Aly A. Khan, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Immune monitoring;RNA;T cell;Tumor microenvironment | |
| 74 | Poster Presentation | Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab | Tae Won Kim, MD; Keun-Wook Lee, MD; Joong Bae Ahn, MD; Young Suk Park, MD; Chan-Young Ock, MD, PhD; Hyejoo Park, PhD; Jiyeon Ryu, PhD; Bitna Oh, MD; Bo-Kyoung Kim, MD; Sunjin Hwang, MD; Ki Baik Hahm, MD; Seong-Jin Kim, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Gene expression;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 75 | Poster Presentation | Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome | Eric Levy, PhD; Pamela Milani, PhD; Fabio Navarro; Gabor Bartha, PhD; Charles W. Abbott, PhD; Jose Jacob, MS; Rena McClory, PhD; Robin Li, MS; John S. West, MBA; John Lyle, PhD; Sean M. Boyle, PhD, MS; Richard Chen, MD | Biomarkers, Immune Monitoring, and Novel Technologies | B cell;Bioinformatics;Biomarkers;Gene expression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 76 | Oral Presentation | Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy | Sophia Liu; Bryan Iorgulescu, MD; Shuqiang Li, PhD; Julia Morriss; Mehdi Borji; Evan Murray; David A. Braun; Kenneth J. Livak; Catherine J. Wu, MD; Fei Chen | Biomarkers, Immune Monitoring, and Novel Technologies | Gene expression;RNA;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 77 | Poster Presentation | Prevalence of Secondary Immunotherapeutic Targets in the Absence of Established Immune Biomarkers in Solid Tumors | Paul DePietro, PhD; Mary Nesline, M.S.; Yong Hee Lee, M.S.; R. J. Seager; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Sean T. Glenn, PhD; Shengle Zhang, MD; Roger D. Klein, MD, JD, FACP; Sarabjot Pabla; Jeffrey Conroy, BS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;T cell;Tumor antigens | |
| 78 | Poster Presentation | Novel RNA-seq Platform Improve Patient Outcome in Clinical Oncology and enable implementation of AI in the clinic | Vy Nguyen, B.S; Gitte Pedersen, MSc; Morten Pedersen | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Chemotherapy;Gene expression;RNA;Solid tumors | |
| 79 | Poster Presentation | Extensively validated HLA LOH algorithm demonstrates an association between HLA LOH and genomic instability | Rachel M. Pyke, PhD; Steven Dea, MS; Dattatreya Mellacheruvu, PhD; Charles W. Abbott, PhD; Simo V. Zhang, PhD; Lee D. McDaniel, Jr., MD, MSE; Eric Levy, PhD; Gabor Bartha, PhD; John S. West, MBA; Michael P. Snyder, PhD; Richard Chen, MD; Sean M. Boyle, PhD, MS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Checkpoint blockade;Genetic polymorphism;Neoantigens;Tumor antigens;Tumor evasion;Vaccine | |
| 80 | Poster Presentation | Cancer testis antigen burden: A novel predictive biomarker for immunotherapy in solid tumors | Sarabjot Pabla; R. J. Seager; Yong Hee Lee, M.S.; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Paul DePietro, PhD; Mary Nesline, M.S.; Sean T. Glenn, PhD; Shengle Zhang, MD; Jeffrey Conroy, BS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor antigens | |
| 82 | Poster Presentation | Single-cell RNA sequencing and CITE-Seq analysis of bladder cancer patient urine with matched tumor and peripheral blood suggests urine as a window into the tumor immune microenvironment | Michelle Tran, MD PhD Candidate; Adam M. Farkas, PhD; Kristin G. Beaumont; Timothy O'Donnell, PhD; Reza Mehrazin, MD; Amir Horowitz, PhD; Peter Wiklund, MD, PhD; Matthew D. Galsky, MD; John P. Sfakianos, MD; Nina Bhardwaj, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Gene expression;Immune monitoring;Immune suppression;Monocyte/Macrophage;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 83 | Poster Presentation | Spatially Resolved Transcriptomic and Proteomic Investigation of Breast Cancer and its Immune Microenvironment | Jennifer Chew, BS; Cedric R. Uytingco, PhD; Rapolas Spalinskas; Yifeng Yin, PhD; Joe Shuga; Benton Veire; Naishitha Anaparthy; Ryo Hatori; Anna-Maria Katsor; Layla Katiraee; Alexander Hermes; Jun Ding Chiang; Patrick Roelli; Stephen R. Williams, PhD; William Nitsch; Neil Weisenfeld, PhD; Dan Walkser; Jason Koth; Subham Basu, PhD; Will Howat; Karthik Ganapathy; Marlon Stoeckius | Biomarkers, Immune Monitoring, and Novel Technologies | Gene expression;Proteomics;Tumor microenvironment | |
| 84 | Poster Presentation | Comparative analysis of ImmunoID NeXT™ and ACE ImmunoID™ next generation sequencing platforms for investigating tumor-immune interactions to enable precision oncology driven biomarker discovery | Danyi Wang, PhD; Juergen Scheuenpflug, PhD; Zheng Feng | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor microenvironment | |
| 85 | Poster Presentation | Detection of human angiotensin-converting enzyme 2 receptor (hACE2R) on human cancer cell lines. | Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Hong-Ming Hu, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers | |
| 86 | Poster Presentation | Extensive FAP expression analysis in 23 tumor indications and potential application in defining the patient population in FAP-targeting cancer immunotherapies | Sebastian Dziadek, PhD; Anton Kraxner; Wei-Yi Cheng; Mike Flores, PhD; Tai-Hsien tai-hsien.ou_yang@roche.com, PhD; Noah Theiss, PhD; Tsu-Shuen Tsao, PhD; Emilia Andersson; Suzana Vega Harring; Gabriele Gabriele Hoelzlwimmer, Dr.; Ann-Marie Broeske; Maurizio Ceppi; Jehad Charo; Sebastian Dziadek | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Solid tumors;Tumor antigens;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 87 | Poster Presentation | Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known | Ahmad A. Tarhini, MD, PhD, MS; Aik Choon Tan, PhD; Issam El Naqa, PhD; Sandra Lee, ScD; F. Stephen Hodi, Jr., MD; Lisa H. Butterfield, PhD; William A. LaFramboise, PhD; Walter J. Storkus, PhD; Jose R. Conejo-Garcia, MD, PhD; Patrick Hwu; Howard Streicher, MD; Vernon K. Sondak, MD; John M. Kirkwood, MD, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Gene expression;Immune monitoring;Tumor microenvironment | |
| 88 | Poster Presentation | Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males | Mariam Saad, MD; Aik Choon Tan, PhD; Issam El Naqa, PhD; Sandra Lee, ScD; F. Stephen Hodi, Jr., MD; Lisa H. Butterfield, PhD; William A. LaFramboise, PhD; Walter J. Storkus, PhD; Jose R. Conejo-Garcia, MD, PhD; Patrick Hwu; Howard Streicher, MD; Vernon K. Sondak, MD; John M. Kirkwood, MD, MD; Ahmad A. Tarhini, MD, PhD, MS | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune monitoring;Tumor microenvironment | |
| 89 | Poster Presentation | The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma | Chun Chau Lawrence Cheung, MMedSc; Yong Hock Justin Seah; Juntao Fang; Nicole HC. Orpilla; Justina Nadia Li Wen Lee; Han Chong Toh, MD; Su Pin Choo; Kiat Hon T. Lim; Wai Meng David Tai; Joe P. Yeong, MD, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Checkpoint blockade;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 90 | Poster Presentation | Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers | Kristina Beeler, Dr.; Roland Bruderer, PhD; Marco Tognetti, PhD; Kamil Sklodowski, PhD; Sebastian Mueller, PhD; Dominique Kamber; Lukas Reiter, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Proteomics;Solid tumors | |
| 91 | Poster Presentation | Impact of ultra-fast 'FLASH' radiotherapy on single cell immunogenomics in diffuse intrinsic pontine glioma (DIPG) | Oscar Padilla, MD; Hanna Minns, BS; Hong-Jian Wei, PhD; Andrea Webster-Carrion, MD; Masih Tazhibi, BA; Nicholas McQuillan, BS; Xu Zhang, PhD; Zhiguo Zhang, PhD; Raul Rabadan, PhD; Peter Canoll, MD PhD; Luca Szalontay, MD; Jovana Pavisic, MD; Guy Garty, PhD; Stergios Zacharoulis, MD; Claire I. Vanpouille-Box, PhD; Vilas Menon, PhD; Marta Olah, PhD; Cheng-Chia Wu, MD PhD; Robyn D. Gartrell, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Gene expression;Pediatric tumors;Radiotherapy;Tumor microenvironment | |
| 92 | Poster Presentation | Single cell and spatial multiplex profiling of immune cell markers in FFPE tumor tissues using the novel RNAscope™ HiPlex v2 in situ hybridization assay | Sayantani Basak; Anushka Dikshit; Ming Yu; HaYeun Ji; Ching-Wei Chang; Bingqing Zhang | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Gene expression;Immune monitoring;Immune suppression;RNA;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 93 | Poster Presentation | Computational biology and tissue-based approaches to inform indication selection for a novel AHR inhibitor | Marta Sanchez-Martin, PHD; Lei Wang, PhD; Jeffrey Ecsedy; KAREN MCGOVERN, PhD; Michelle Zhang, PhD; Marta Sanchez-Martin, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Systems biology;Targeted therapy | |
| 94 | Poster Presentation | Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC) | Brie M. Chun, MD; Joanna Pucilowska, PhD; Shu Ching Chang, PhD; Isaac K. Kim, MD; Benjamin Nikitin; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Brady M. Bernard, PhD; Venkatesh Rajamanickam; Nathan W. Polaske; Paul Fields, PhD; Valerie K. Conrad, BS; Mark Schmidt; Walter J. Urba, MD, PhD; Alison K. Conlin, MD; Heather McArthur, MD; David B. Page, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 95 | Poster Presentation | MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy | Jennifer D. Oduro, PhD; Ronald Simon, Prof. PhD; Natalia Gorbokon; Christoph Fraune, PD MD; Julia Bluhm, PhD; Vivian Scheuplein, PhD; Elisa Kieback, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Eugen Leo, MD PhD MBA | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy;Biomarkers;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 96 | Poster Presentation | The Impact of Radiographic Tumor Thickness on the Complexity of the Tumor Immune Microenvironment in Malignant Pleural Mesothelioma | Katarzyna Tomczak, PhD; Jacqueline Liszeth Oliva, PhD; Nicolas Zhou, DO, MSc; Carlos Ramos; Nathaniel Deboeve, MD; Hope Feldman, MD; Percy Lee, MD; Chad D. Strange, MD; Annikka Weissferdt, MD; David C. Rice, MB, BCh; Reza J. Mehran, MD; Jianjun Zhang, MD, PhD; Anne Tsao, MD; Boris Sepesi, MD; Cara Haymaker, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Gene expression;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 97 | Poster Presentation | High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies | David Langan, PhD; Jourdain Lemaster; Lauren Suarez, PhD; Pratima Kunwar, PhD; Sojung Kim, PhD; Mathias Oelke, PhD | Cellular Therapies | Adoptive immunotherapy;T cell;Tumor antigens | |
| 98 | Poster Presentation | NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy | Sarah Whelan, PhD; Jennifa Gosling, MSc; Monisha Mani, MSc; Frederick Cohen, PhD; Austin Tenn-McClellan, BS; Janine Powers, PhD; Gwenn Hansen, PhD; Michael T. Lotze, MD; Arthur T. Sands, MD, PhD | Cellular Therapies | Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 99 | Poster Presentation | T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants | Daniel Hirschhorn, PhD; Sadna Budhu, PhD; David Schröder, MD, PhD; Lukas kraehenbuehl; Anne-Laurent Flammar; Andrew Chow, MD, PhD; Isabell Schulze; Sara Schad, BS; Jacob Ricca; Billel Gasmi; Olivier De Henau; Levi M. Mangarin, BS; David Redmond; Czrina Cortez, BS; Cailian Liu, MD; Aliya Holland; Mathieu Gigoux, PhD; Asrhi Arora; Katherine S. Panageas, PhD; Gabrielle Rizzuto; Jean Albrengues, PhD; Mikala Egeblad, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Costimulation;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 100 | Poster Presentation | Redirecting glucose flux during in vitro expansion improves the in vivo performance of adoptive T cell therapies for cancer | Andrew Frisch, BS; Yupeng Wang, BD; Yiyang Wang, N/A; Konstantinos Lontos, MD; Dayana Rivadeneira, PhD; Greg M. Delgoffe, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 101 | Poster Presentation | Expansion of tumor-infiltrating lymphocytes (TIL) using static bag for the clinical manufacturing rapid expansion protocol (REP) process | Kenneth Onimus; Adrian Wells; Nermin Gerges; Courtney Herman; Shwetha Lakshmipathi; Viktoria Gontcharova, PhD; Joe Wypych; Arvind Natarajan; Anand Veerapathran | Cellular Therapies | Adoptive immunotherapy;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 102 | Poster Presentation | The deep phenotype characterization of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) T Cells allows to identify their subset complexity and to optimize their manufacturing | Cristina Maccalli, PhD; Asma Al-Sulaiti; Mohammed El-Anbari, PhD; Moza Al Khulaifi, BSc; Mohammed Toufiq; Rebecca Mathew; Chiara Cugno, MD; Sara Deola, MD; Suruchi Mohan, MD; Damilola Olagunju; Chiara Bonini, MD; Monica Casucci, PhD; Sara Tomei, PhD; Damien Chaussabel, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell lineages | |
| 103 | Poster Presentation | Quality improvement of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and inhibition of tyrosine kinase | Yasunori Amaishi, MS; Izumi Maki; Maiko Sugizaki; Kenichiro Mihara, M.D., Ph.D.; Sachiko Okamoto, PhD; Junichi Mineno, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell;Targeted therapy;Tumor antigens | |
| 104 | Poster Presentation | Development and characterization of human chimeric antigen receptor Monocytes (CAR-Mono), a novel cell therapy platform | Daniel Blumenthal, PhD; Linara Gabitova, PhD; Brett Menchel; Patricia Reyes-Uribe; Andrew Best, BS, MS; Michael Lynch; Sotheavy Chhum; Maggie Schmierer; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD | Cellular Therapies | Adoptive immunotherapy;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 105 | Poster Presentation | 4-1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells | Emiliano Roselli, Ph.D.; Justin C. Boucher; Gongbo Li; Hiroshi Kotani; Kristen Spitler; Kayla M. Reid, M.S.; Yannick Bulliard; Nhan Tu; Sae Bom Lee; Bin Yu; Frederick L. Locke, M.D.; Marco L. Davila, M.D., Ph.D. | Cellular Therapies | Adoptive immunotherapy;Bispecifics;CAR T cells | |
| 106 | Poster Presentation | Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel) | Archana Brahmandam, MS; Jim J. Qin, BS; Susan Kim; Yue Jiang; Brook Barajas; Soraya Carrancio; Leanne Peiser | Cellular Therapies | CAR T cells;Cytokine;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy | |
| 107 | Poster Presentation | Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity | Eytan Breman, MSc; Ann-Sophie Walravens; Isabelle Gennart; Amelie Velghe; Thuy Nguyen; Benjamin Violle; Fanny Huberty; Nancy Ramelot; Laure Twyffels; Emilie Gauthy; Hannes Iserentant; David E. Gilham, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 108 | Poster Presentation | Fast and accurate prediction of optimal CAR T-cell function using z-Movi® Cell Avidity Analyzer | Will Singleterry, Phd; Andrea Candelli, PhD; Rogier M. Reijmers, PhD; Jens Eberlein, PhD | Cellular Therapies | CAR T cells;T cell;Tumor antigens;Tumor evasion | |
| 110 | Poster Presentation | IL-2 variant improves CAR-T functionality and efficacy against solid tumors | Qi Dong, Msc; Wenjie Yin, Ph.D.; Pengfei Jiang, Ph.D.; Manli Yin; Tao Wang; Ping Wang; Xinxin Wang, Ph.D.; William Wei Cao, Ph.D.; Lianjun Shen, Ph.D. | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 111 | Poster Presentation | Armored CAR T Cells Secreting 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor for Enhanced Solid Tumor Efficacy | Zachary S. Dunn, MS; Yun Qu, Doctorate; Melanie MacMullan; Xianhui Chen, Doctorate; Gunce Cinay; Pin Wang, Doctorate | Cellular Therapies | Adoptive immunotherapy;Antibody;Bispecifics;CAR T cells;Checkpoint blockade;Costimulation;Solid tumors;T cell;Tumor microenvironment | |
| 112 | Poster Presentation | Tumor-specific Reactivity and Effector Function of Chimeric Antigen Receptor Engineered Macrophages Targeting MUC1 | Seth H. Eisenberg; Amy A. Powers, MS; Jason C. Lohmueller, PhD; James D. Luketich, MD; Rajeev Dhupar, MD; Adam C. Soloff, PhD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Tumor antigens | |
| 113 | Poster Presentation | CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition | Chao Guo, PhD; Yanying Fan; Alexander Aronov; Luxuan Buren, Ph.D.; Ming-Hong Xie, MD; Ivan H. Chan, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | NK/NKT cell;Tumor microenvironment | |
| 115 | Poster Presentation | An NFAT Promoter Based Fluorescent Jurkat Cell Platform for High-Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs | Brikena Gjeci, MS; Sadik H. Kassim, PhD; Julian Scherer | Cellular Therapies | CAR T cells | |
| 116 | Poster Presentation | Development of Logic Gated CAR-NK cells for the treatment of solid tumors | Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Marcus Gainer; Alyssa Mullenix; Miguel Palermo; Derrick Lee; Frances D. Liu, PhD; Russell M. Gordley, PhD; Chen-Ting Lee, PhD; Assen Roguev, PhD; Niran Almudhfar; Mengxi Tian; Gary Lee, PhD | Cellular Therapies | Immune toxicity;NK/NKT cell;Solid tumors;Tumor antigens | |
| 117 | Oral Presentation | FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy. | John Goulding, PhD; Bryan Hancock, PhD; Robert Blum, MS; Moyar Ge, PhD; Svetlana Gaidarova, MS; Paul Rogers, PhD; Sajid Mahmood, PhD; Rina Mbofung, PhD; Wen-I Yeh, PhD; Bi-Huei Yang, PhD; Chia-Wei Chang, PhD; Brian Groff, BS; Soheila Shirinbak, PhD; Joy Grant; Martin Hosking, PhD; Mochtar Pribadi; Yijia Pan; Hui-Yi Chu; Shohreh Sikaroodi, PhD; Lauren Fong, PhD; Nicholas Brookhouser, PhD; Fernanda Rodrigues Cugola, PhD; Ramzey Abujarour, PhD; Janel Huffman, MS; Pei-Fang Tsai, PhD; Antonio Fernandez-Perez, PhD; Karina Palomares, PhD; Natalie Marquez-Solorzano, MS; Riya Kanherkar, PhD; Andrew Burns, PhD; Aidan Keefe, MS; Samvel Nazaretyan, BS; Christine Chen, PhD; Raedun Clarke, PhD; Thomas Dailey, BS; Miguel Meza, BS; Jason O'Rouke, PhD; Jerome Bressi, PhD; Tom Lee; Ryan Bjordahl, PhD; Lucas Ferrari de Andrade, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;Chemotherapy;Clinical study;Leukemia/Lymphoma;NK/NKT cell;Radiotherapy;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion | |
| 118 | Poster Presentation | Development of Claudin 18.2 TAC T cells for the treatment of gastric cancer | christopher CW. Helsen, PhD; Tania Benatar, PhD; Philbert IP, PhD; Stacey Xu, PhD; Laura Shaver; Thanyashanthi Nitya-Nootan, MSc; Andreas G. Bader; Prabha Lal, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell | |
| 119 | Poster Presentation | ADI-002: an IL-15 armored allogeneic “off-the-shelf” Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3) | Amani Makkouk, PhD; Xue (Cher) Yang; Taylor Barca; Anthony Lucas; Mustafa Turkoz; Jonathan Wong; Kevin P. Nishimoto; Mary M. Brody; Maryam Tabrizizad; Smitha Gundurao; Lu Bai; Arun Bhat; Zili An; Stewart Abbot; Daulet Satpayev; Marissa Herrman | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens | |
| 120 | Poster Presentation | Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors | Martin Hosking, PhD; Soheila Shirinbak, PhD; Joy Grant; Yijia Pan; Angela Gentile; Amit Mehta; Bjoern Gaertner, PhD; Bishwas Shrestha, PhD; Mochtar Pribadi; Jason ORourke, PhD; Alec Witty; Tom Lee; Bob Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Chemokine;Chemotherapy;Radiotherapy;Solid tumors;T cell;Tumor microenvironment | |
| 121 | Poster Presentation | ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging | Jingmei Hsu, MD, PhD; Eric von Hofe, PhD; Michael Hsu, MD, PhD; Koen Van Besien, MD; Thomas Fahey, MD; Jana Ivanidze, MD, PhD; Janusz Puc, PhD; Karrie Du, PharmD; Moonsoo M. Jin, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 122 | Poster Presentation | A powerful, precise targeting system controlled by tumor deletions transforms CEA and MSLN CAR-T cells into tumor-selective agents | Agnes Hamburger; Han Xu, PhD; Yuta Ando; Grace Asuelime; Kristian Bolanos-Ibarra; Mark Daris, PhD; Kiran Deshmukh; Breanna DiAndreth; Fernando Fisher; Grant Gabrelow; Maria Imun; David Ju; Wen-Hua Lee; Chuck Li; Edwin Liu; Aaron D. Martin, M.A.; Michele Mcelvain; Jee-Young Mock; Daniel Nampe; Martin Naradikian; Mark Sandberg, PhD; Sanam Shafaattalab; Shruti Sharma; Talar Tokatlian; Dora Toledo-Warshaviak; Xueyin Wang, PhD; Lu-Min Wong; Alexander Kamb, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor antigens | |
| 123 | Poster Presentation | P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor | Yan Zhang, Ph.D.; Anna K. Kozlowska, Ph.D.; Jacqueline Fritz; Yingying Zhao; Claudia Palomino La Torre; Stacey Cranert, Ph.D.; Steven Wang; Rebecca Codde; Elvira Argus, Ph.D.; Samad Ibitokou, Ph.D.; Vanitra Richardson; Sumiti Jain, Ph.D.; Maximilian Richter, Ph.D.; Deepak Patil, Ph.D.; Yening Tan; Min Tong; Lu Yao, Ph.D.; Majid Ghoddusi, Ph.D.; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, Ph.D. | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 124 | Poster Presentation | Functionalizing CAR T cells for selective proliferation and dual-targeting using the meditope technology | Cheng-Fu Kuo, MS; Yi-Chiu Kuo; Miso Park; Zhen Tong; Brenda Aguilar; Agata Xella; Vanessa Salvary; Stephen J. Forman; John C. Williams, PhD; Christine Brown, PhD | Cellular Therapies | Antibody;CAR T cells;T cell | |
| 125 | Poster Presentation | Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma | Jessica Lake, MD MPH; Kevin Winkler, BA; Alexander Harrant, BS; Ashley Yingst, MS; Kristin Schaller, PhD; Eric Hoffmeyer, BS; Madeline Larson, BS; Dejene Tufa, PhD DVM; Laura Cobb, MD; Dallas Jones, PhD; Michael Verneris, MD | Cellular Therapies | CAR T cells;Chemokine;Pediatric tumors;Radiotherapy;Solid tumors;T cell | |
| 126 | Poster Presentation | Regional administration of IL-12 endowed CAR T cells effectively targets systemic disease | Hee Jun Lee, BA; Cody Cullen; John P. Murad; Jason Yang; Wen-Chung Chang; Stephen J. Forman; Saul Priceman, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell | |
| 127 | Poster Presentation | CAR T cells targeting the integrin alpha v beta 3 exhibit robust anti-tumor responses against diffuse intrinsic pontine glioma and glioblastoma | Dustin A. Cobb, PhD; Jacopo de Rossi; Lixia Liu; Erin An; Daniel W. Lee, III, MD | Cellular Therapies | CAR T cells;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 128 | Poster Presentation | KIR haplotype can inform donor selection production of allogeneic memory-like CAR NK cells for clinical application | Hadia Lemar, BS; Anmol Vohra, MS; Ming-Hong Xie, MD; Ivan H. Chan, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | Cytokine;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
| 129 | Poster Presentation | Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors | Hoyong Lim, PhD; Amanda Medcalf; Lisa Guerrettaz, PhD; Eun Ji Choi; Hansol Kim; Bitna Yang; Eun Ji Kim; Eun-Sol Lee; Jeong Min Kim; Yusun Kim; Bokyung Min; Sang-Min Paik; Hyeong Jin Nam; Seungryel Han; Srinivas Somanchi, PhD; Eugene Helsel; Jason Litten, MD; Peter Flynn, PhD; Heather Raymon, PhD; Yu-Kyeong Hwang, PhD | Cellular Therapies | NK/NKT cell;Solid tumors | |
| 130 | Oral Presentation | Engineered natural killer cells reactively block TIGIT and CD73 in the GBM microenvironment | Kyle B. Lupo, BS; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 131 | Poster Presentation | Genetic disruption of negative immune regulators to enhance CAR-T efficacy against solid tumors | David Mai, BS; Omar S. Johnson; Carl H. June, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell | |
| 132 | Oral Presentation | HLA-independent T cell receptors effectively target low abundance antigens | Jorge Mansilla-Soto, PhD; Justin Eyquem; Sascha Haubner; Mohamad Hamieh; Judith Feucht; Noémie Paillon; Andres E. Zucchetti; Zhuoning Li; Maria Sjöstrand; Pieter L. Lindenbergh; Michelle Saetersmoen; Mathieu Maurin; Archana Iyer; Anton Dobrin; Andreina Garcia Angus; Matthew M. Miele; Zeguo Zhao; Theodoros Giavridis; Sjoukje JC. van der Stegen; Fella Tamzalit; Morgan Huse; Ronald C. Hendrickson; Claire Hivroz; Michel Sadelain | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell | |
| 133 | Poster Presentation | CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity | Jonathan Terrett, PhD; Brigid Mcewan, MA; Daniel Hostetter; Luis Gamboa; Meghna Kuppuraju; Mohammed Ghonime; Robert Chain; Zinkal Padalia; Demetrios Kalaitzidis | Cellular Therapies | CAR T cells | |
| 135 | Poster Presentation | Identification and Characterization of an allogeneic iNKT-CAR targeting BCMA | Xavier Michelet, PhD; Eleni Chantzoura, PhD; Efrat Altman-Sharoni; Martyna Popis; Reed Masakyan; Paul Ibbett; Deborah Wright; Moira Pinzan Rossi; Marc A. Van Dijk, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
| 136 | Poster Presentation | ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors | Xianhui Chen, PhD; Jiangyue Liu; Shuai Yang; Amogh Oke; Sarah Davies; Bryan Ruiz-Juarez; Yannick Bulliard; Cokey Nguyen | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 137 | Poster Presentation | Development of anti-Mucin1 CAR-T against solid tumors | Jihyun Lee, Ph.D.; Areum Park, Ph. D.; Jungwon Choi; Dae Gwan Yi, Ph. D.; Hee Jung Yang, Ph. D.; Hae-youn Lee, Ph.D.; Eurim Song; Sung Woong Jang, Ph.D.; Hyoju Yi, Ph.D.; Heedong Park; Eun-ji Jeun, Ph.D.; Minjeong Park; Peter S. Hong, Ph.D. | Cellular Therapies | CAR T cells;T cell | |
| 138 | Poster Presentation | Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors | Eigen Peralta; Emily Carron, PhD; Hui-Yi Chu; Lorraine Loter; Natalie Navarrete; Arvin Tam; Amit Mehta; Dan Lu; Philip Chu; Kenyon Lyon; Yijia Pan; Mochtar Pribadi; Alec Witty; Tom Lee; Bob Valamehr, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment | |
| 139 | Poster Presentation | Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD1 blockade in immunocompetent mouse models of HER2+ solid tumors | Stefano Pierini, PhD; Michael Klichinsky, PharmD, PhD; Rashid Gabbasov, PhD; Alison Worth; Ilyssa Ramos; Daniel Blumenthal, PhD; Linara Gabitova, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Michael Ball; Yumi Ohtani, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 140 | Poster Presentation | Allogeneic CAR T cells with deoxycytidine kinase knockdown demonstrate resistance to fludarabine | Michelle B. Pires, MS; Aaron J. Martin, PhD | Cellular Therapies | CAR T cells;T cell | |
| 142 | Poster Presentation | Enhanced antitumoral activity of HER2-CAR-Ts in comparison to Trastuzumab in a live cell imaging supported 3D assay | Katharina Schaich, MSc; Gemma Moiset; Sophie C. Vermond, MSc; Monique Hazenoot; Kanstantsin Lashuk; Eva Oswald, PhD; Sanne Holt; Julia Schuler, DVM PhD | Cellular Therapies | Antibody;CAR T cells;Solid tumors;T cell;Tumor antigens | |
| 143 | Poster Presentation | Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment | Cecile Schiffer-Mannioui; Sophie Leduc; Isabelle Chion-Sotinel; Diane le Clerre; Valérie Guyot; Marco Rotondi; Roman Galetto, PhD; Agnès Gouble | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 144 | Poster Presentation | SIRP⍺ deficient CAR-Macrophages exhibit enhanced anti-tumor function and bypass the CD47 immune checkpoint | Chris Sloas, PhD; Rashid Gabbasov, PhD; Nicholas R. Anderson, PhD; Sascha Abramson, PhD; Michael Klichinsky, PharmD, PhD; Yumi Ohtani, PhD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 145 | Poster Presentation | Comparison of CAR-T cell manufacturing platforms reveals distinct phenotypic and transcriptional profiles | Hannah W. Song, PhD; Lipei Shao, PhD; Michaela Prochazkova; Adam Cheuk, PhD; Ping Jin, PhD; David F. Stroncek, MD; Javed Khan, MD; Steven L. Highfill, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Clinical study;Gene expression;Solid tumors;T cell | |
| 146 | Poster Presentation | Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy | Mikhail Steklov; Benjamin Lecalve; Jerome Marijse; Fanny Huberty; Nancy Ramelot; Celine Jacques-Hespel; Hannes Iserentant; Eytan Breman, MSc; David E. Gilham, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell | |
| 147 | Poster Presentation | Memory phenotype in allogeneic anti-BCMA CAR-T cell therapy (P-BCMA-ALLO1) correlates with in vivo tumor control | Hubert Tseng, PhD; Yan Zhang, Ph.D.; Stacey Cranert, Ph.D.; Maximilian Richter, Ph.D.; Karl Marquez; Jing Qiu; Benjamin Cho; Yening Tan; Min Tong, MS; Christine Domingo, BS; Leslie A. Weiss, M.S.; Elvira Argus, Ph.D.; Jessica Sparks; Eric M. Ostertag, Ph.D. M.D.; Julia Coronella, Ph.D.; Devon J. Shedlock, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;T cell | |
| 148 | Poster Presentation | Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro | Sophie C. Vermond, MSc; Monique Hazenoot; Rene McLaughlin; Sabrina de Munnik; Marco Guadagnoli; Gemma Moiset; Sanne Holt; Marijn Vlaming | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 149 | Poster Presentation | In vitro efficacy studies to support engineered T cell therapies | Sabrina de Munnik; Monique Hazenoot; Sophie C. Vermond, MSc; Rene McLaughlin; Marco Guadagnoli; Gemma Moiset; Sann Holt; Marijn Vlaming | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;T cell;Targeted therapy;Tumor antigens | |
| 150 | Poster Presentation | Targeted delivery of a PD-L1-blocking scFv by CAR-NK cells shows potential as a new approach to immunotherapy for glioblastoma | Jiao Wang, PhD; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 151 | Poster Presentation | Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application | Michael I. Whang, PhD; Ming-Hong Xie, MD; Kate Jamboretz, MS; Hadia Lemar, BS; Chao Guo, PhD; Nafees Rahman, PhD; Ivan Chan, PhD; Erik M. Whiteley, PhD; Ralph Brandenberger, PhD; Sasha Lazetic; James B. Trager, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy | |
| 152 | Oral Presentation | Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages | Taylor L. Wilson, BS; Hyunjin Kim, PhD; Jeremy C. Crawford, PhD; Ching-Heng Chou, PhD; Deanna Langfitt, PhD; E. Kaitlynn Allen, PhD; Timothy Lockey, PhD; Michael Meagher, PhD; Aimee C. Talleur, MD; Stephen Gottschalk, MD; Paul G. Thomas, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Gene expression;T cell;T cell lineages | |
| 153 | Poster Presentation | Nanoscale, antigen-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment | Zhifen Yang, Dr.; Francesco M. Marincola, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 154 | Poster Presentation | Context-dependent reversible modulation of cJUN expression by CAR T cells for cancer treatment | Zhifen Yang, Dr.; Francesco M. Marincola, MD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 155 | Poster Presentation | CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies | Yinmeng (Amy) Yang, PhD; Ryan Murray; Adam J. Camblin, PhD; Faith Musenge; Lindsey Coholan; MarkVic Naniong; David Sweezy; Scott Haskett; Lauren Young; Yingying Zhang, PhD; Amanda Costa; Hui Wu; Alden Ladd; Luis Barrera, PhD; Lisa Schlehuber, PhD; Sarah Smith; Yeh-Chuin Poh, PhD; Giuseppe Ciaramella, PhD; Jason Gehrke, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell | |
| 156 | Poster Presentation | RBC-Derived, Activating Antigen Carriers (SQZ AACs) Prime Potent T Cell Responses and Drive Tumor Regression In Vivo | Katarina Blagovic, PhD; Carolyne Smith, PhD; Lindsay Moore; Emrah Ilker Ozay, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD | Cellular Therapies | Adoptive immunotherapy;Chemotherapy;Immune adjuvant;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine | |
| 157 | Poster Presentation | Lymph node targeted boosting with cognate Amphiphile-peptide vaccines enhances TCR-T Cell therapy to eradicate solid tumors | Dylan J. Drakes, PhD; Abdulraouf M. Abbas, M.Sc.; Jacqueline Shields; Peter C. DeMuth, PhD | Cellular Therapies | Adoptive immunotherapy;Immune adjuvant;Solid tumors;T cell;Targeted therapy;Vaccine | |
| 158 | Poster Presentation | Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killing | Kate M. Rochlin, PhD; Amber Jones; Lawrence S. Lamb, Jr., PhD; Anita Hjelmeland, PhD | Cellular Therapies | Checkpoint blockade;Chemotherapy;Gene expression;Solid tumors;T cell;Tumor antigens | |
| 159 | Poster Presentation | Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers | Irene Raitman, PhD; John Fitzgerald, BS; Valentina Rousseva, MS; Salvatore Rotondo, MS; Xuan Guo, PhD; Hemlata Rana, MS; Andrea DiFiglia, BS; Tanel Mahlakoiv, PhD; Shuyang He, PhD; Lin Kang, PhD; Robert Hariri, MD PhD; Xiaokui Zhang, PhD | Cellular Therapies | Antibody;NK/NKT cell;Solid tumors;Targeted therapy | |
| 160 | Poster Presentation | Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors | Paul D. Rennert, PhD; Lan Wu, PhD; Lihe Su, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD | Cellular Therapies | Adoptive immunotherapy;Bispecifics;CAR T cells;Tumor antigens | |
| 161 | Poster Presentation | Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors | Peter M. Sullivan, PhD; Rajesh Kumar, PhD; Wei Li, PhD; Lingyang Wang, PhD; Yue Zhang, MS; Adam Cheuk, PhD; Javed Khan, MD; Dimiter S. Dimitrov, PhD; Rimas J. Orentas, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Myeloid cells;Pediatric tumors;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma | |
| 162 | Poster Presentation | Nicotinamide rejuvenates ex-vivo expanded natural killer cells and enhances their tumor killing capacity | Aviad AP. Pato, Dr, PhD; Astar Hailu; Nurit Brickman; Dima Yackoubov; Frank S. Cichocki, PhD; Amnon Peled, PhD; Yona Geffen, PhD; Avishay Edri, PhD; Ronit Simantov, MD; Tracey Lodie, PhD; Julia Rifman, PhD; Orit Berhani-Zipori, PhD; Aviad Pato | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors | |
| 163 | Poster Presentation | Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression | Gagan Bajwa; Justin T. Gunesch; Inbar Azoulay-Alfaguter; Melinda Mata; Ali Mohamed; Mamta Kalra; Steffen Walter | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;Costimulation;Cytokine;T cell;Targeted therapy;Tumor microenvironment | |
| 164 | Poster Presentation | Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells | Frank Borriello, MD, PhD; Joshua Keegan; James A. Lederer, PhD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;T cell | |
| 165 | Poster Presentation | Generating Enhanced Tumor Infiltrating Lymphocytes Through Microfluidic Cell Squeezing | Devin Bridgen, PhD; Arindam Bhattacharjee; Colin J. Thalhofer, PhD; Ryan D. Montler, MBA; Andrew D. Weinberg, PhD; Armon Sharei, PhD; Jonathan Gilbert, PhD | Cellular Therapies | Cytokine;RNA;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 166 | Poster Presentation | Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo | Rachel A. Burga, PhD; Mithun Khattar, PhD; Scott Lajoie; Kyle Pedro, PhD; Colleen Foley; Alonso Villasmil Ocando; Jack Tremblay; Benjamin Primack; Meghan Langley, BS; Dan Thornton; Stanley Tam; Emily Brideau; Theresa Ross; Gwen Wilmes, PhD; Sunandan Saha, PhD; Gabriel Helmlinger, PhD; Jeremy Tchaicha, PhD; Dhruv Sethi, PhD; Michelle L. Ols, PhD; Gary Vanasse, MD; Shyam Subramanian, PhD; Jan ter Meulen, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 167 | Poster Presentation | High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest | Praveen D. Chatani, MD; Frank J. Lowery, PhD; Neilesh B. Parikh, M.D.; Rami Yossef, PhD; Victoria Hill, PhD; Zhiya Yu, PhD; Todd D. Prickett, PhD; Jared Gartner; Biman C. Paria, M.S.; Satyajit Ray; Maria Florentin; Paul F. Robbins, PhD; Sri Krishna, PhD; Steven A. Rosenberg, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Biomarkers;Clinical study;Neoantigens;T cell;T cell lineages;Tumor antigens | |
| 168 | Poster Presentation | Expanding and characterizing tumor infiltrating lymphocytes from myxofibrosarcoma and undifferentiated pleomorphic sarcoma | Jacky HK. Chen, HBSc; Jay S. Wunder, MD., MSc; Kim Tsoi, MD., PhD; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Costimulation;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 169 | Poster Presentation | Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo | Frank S. Cichocki, PhD; Jianfang S. Ning; Zachary B. Davis, PhD; Hongbo S. Wang; Katie S. Tuininga; Ryan Bjordahl, PhD; Paul Rogers, PhD; Moyar Ge, PhD; Tom Lee; Bob Valamehr, PhD; Clark C. Chen, MD; Jeffrey S. Miller, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell | |
| 170 | Poster Presentation | Novel gene editing approach to enhance CD38-directed antitumor activity of primary human natural killer cells | Joseph A. Clara, MD; Emily Levy; Robert Reger; Mala Chakraborty; David Allan; Richard W. Childs, M.D. | Cellular Therapies | Adoptive immunotherapy;Antibody;NK/NKT cell;Targeted therapy | |
| 171 | Poster Presentation | Targeting the Immunomodulatory Roles of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 on Natural Killer Cells in Glioblastoma | Tram N. Dao; Sandro Matosevic, PHD | Cellular Therapies | Adoptive immunotherapy;Metabolism;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 172 | Poster Presentation | Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering | Samantha M. Fix, PhD; Marie-Andrée Forget; Donastas Sakellariou-Thompson, BS; Yunfei Wang; Ana Lucía Dominguez; Rafet Basar; Christopher Reyes; Sanjay Kumar; Larissa A. Meyer; Patrick Hwu; Chantale Bernatchez, PhD; Amir Jazaeri, MD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 173 | Poster Presentation | Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells | Michelle Fleury, PhD; Derrick P. McCarthy, PhD; Holly Horton, PhD; Courtney Anderson, PhD; Amy Watt; Adam Zieba, MS; Lindsay Webb, PhD; Jian Ding, PhD; Robert Tighe; Robert Hofmeister, PhD; Dario Gutierrez, PhD | Cellular Therapies | Cytokine;Solid tumors;T cell | |
| 174 | Poster Presentation | Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes | Meredith Frank, MSc; Parin Shah; Marie Andree Forget, PhD; Lorenzo Federico, PhD; Peixin Jiang; Roohussaba Khairullah; Ignacio Wistuba, MD; Chi-Wan Chow; Yan Long; Junya Fujimoto; Shiaw-Yih Lin, Ph.D.; Anirban Maitra, MBBS; Marcelo V. Negrao, MD; Kyle Mitchell, MD; Annika Weissferdt, MD; Ara A. Vaporciyan, MD; Tina Cascone, MD, PhD; Jack Roth; Jianjun Zhang, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Cara Haymaker, PhD; Daniel J. McGrail, PhD; Chantale Bernatchez, PhD; Alexandre Reuben, PhD | Cellular Therapies | Adoptive immunotherapy;Clinical study;Neoantigens;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 175 | Poster Presentation | High-dose TIL product with improved phenotype and functionality | Christina Friese, PhD; Christina Heeke, PhD; Nikolaj Kirketerp-Møller, MS; Sandra Færch; Maria Juul Nielsen; Amalie Hey, PhD; Ulrik Cordes | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 176 | Poster Presentation | Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy | Brian Halbert, MD MPH; David Einstein, MD; David F. McDermott, MD; Emanuelle I. Andrianopoulos; Mamta Gupta, MD; Virginia Seery, MSN, RN, ANP-BC; Kenneth Onimus; Courtney Herman; Adrian Wells; Shwetha Lakshmipathi; Arvind Natarajan; Anand Veerapathran; Rupal Bhatt, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 177 | Poster Presentation | Treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibition–refractory advanced cutaneous melanoma | Robert E. Hawkins, MD, PhD; Yizhou Jiang; Paul C. Lorigan; Fiona C. Thistlethwaite; Manon Pillai; Martine Thomas; Natalia Kirillova; John S. Bridgeman; Gray Kueberuwa; Ryan D. Guest; Zachary J. Roberts | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 178 | Poster Presentation | Expansion of Tumor-Infiltrating Lymphocytes and Marrow-Infiltrating Lymphocytes from Pediatric Malignant Solid Tumors | Jonathan Metts, MD; Jonathan A. Hensel, PhD; Alejandro Alfaro; Brook Olmo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD; Ivanna Leon | Cellular Therapies | Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell | |
| 179 | Poster Presentation | CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity | Jonathan A. Hensel, PhD; Alejandro Alfaro; Mary Rau; Patricio Perez-Villarroel; Zachary Sannasardo; Shari A. Pilon-Thomas, PhD; John E. Mullinax, MD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 180 | Poster Presentation | T Cell Phenotype Drives Restructuring of Tumor Microenvironment to Balance T Cell Longevity and Tumor Control: Insights from Multiplexed Imaging and Multi-scale Agent Based Modeling | John W. Hickey, PhD; Garry P. Nolan, PhD; Markus Covert; Eran Agmon; Nina B. Horowitz, MS; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;Bioinformatics;CAR T cells;Immune contexture;Immune monitoring;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 181 | Poster Presentation | Intraepithelial group 1 innate lymphoid cells generated in vitro exhibit enhanced cytotoxicity and infiltration into solid tumoroids | Nina B. Horowitz, MS; John W. Hickey, PhD; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 183 | Poster Presentation | Therapeutic T cells exhibit distinct vulnerability to glucose deprivation in tumors which can be overcome with an engineered glucose transporter | Jessica A. Jana, BSE; Yiyang Wang, N/A; Ashley Menk, MS; Andrew Frisch, BS; Greg M. Delgoffe, PhD | Cellular Therapies | Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 184 | Poster Presentation | Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers | Peter Kim, PhD; Steven A. Rosenberg, MD, PhD; Nolan Vale | Cellular Therapies | Adoptive immunotherapy;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 185 | Poster Presentation | Ex vivo efficacy of adoptive T cell therapy using autologous CD8+ T cells isolated by PD-1 positivity from peripheral blood mononuclear cells in solid tumors | Sungkyu Lee, Ph.D; yong wha Moon | Cellular Therapies | Adoptive immunotherapy;Coinhibition;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 186 | Poster Presentation | Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 | Karrie K. Wong, PhD; Sharon Lin, PhD; Christopher Wrocklage; Katri Sofjan; Leila Williams; Mallory Brady; Nicholas Colletti, PhD; Noah Tubo; Hugh Gannon; Robert A. LaMothe; Tianlei Xu, PhD; Tracy VandenBerg; Sol Shenker, PhD; Caroline Dugopolski; Frank Stegmeier, PhD; Louise Cadzow; Michael Schlabach, PhD; Micah J. Benson, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 187 | Poster Presentation | Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival | Melisa Angela M. Paniagua, PhD; Melisa A. Martinez Paniagua, PhD; Cara Haymaker, PhD; Jay R Adolacion; Xingyue An, BS; Caitlin Creasy, MS; Mohsen Fathi; Ali Rezvan; Tamar Geiger; Michal Harel; Jonathan Robinson; Amit Amritkar; Scott Woodman; Patrick Hwu; Chantale Bernatchez, PhD; Navin Varadarajan, PhD | Cellular Therapies | Adoptive immunotherapy;Gene expression;Metabolism;Proteomics;RNA;Tumor infiltrating lymphocytes (TILs) | |
| 188 | Poster Presentation | Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity. | Ryan Sullivan, PhD; Mary Mathyer; Jennifer Govero; John Dean; Andrew Martens; You Zhou; Malik Darwech; Brunda Tumala; Alex Vessoni; Alexander Hamil; Tom Leedom; Corey Johnson; Melissa Berrien-Elliot; Mark Foster; Michelle Becker-Hapak; Ethan McClain; Carly Neal; Todd A. Fehniger, MD, PhD; Niraj Shrestha, PhD; Mike Dee; Hing C. Wong, PhD; Ayman Kabakibi; Matthew L. Cooper; Ken Chrobak | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;NK/NKT cell;T cell | |
| 189 | Poster Presentation | Targeting a novel shared tumor-specific antigen with T cell receptor transduced T cells for the treatment of ovarian cancer | Justyna Ogonek, PhD; Justyna Ogonek; Tiziana Franceschetti; Andreas Acs; Alexander Schmidt; Alexandra Kuhlenkamp; Krystel Vincent; Claude Perreault; Barbara Loesch; Adriana Turqueti Neves; Slavoljub Milosevic; Dolores J. Schendel; Daniel Sommermeyer | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor antigens | |
| 190 | Poster Presentation | Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers | Anup Y. Parikh, MD; Maria Parkhurst, PhD; Paul F. Robbins, PhD; Steven A. Rosenberg, MD, PhD; James C. Yang, MD, PhD | Cellular Therapies | Adoptive immunotherapy;Gene expression;Neoantigens;RNA;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 191 | Poster Presentation | GAPDH knock-in of high affinity CD16 in iPSC derived NK cells drives high-level expression and increased anti-tumor function | Rithu Pattali; Kaitlyn M. Izzo; Edward J. Goncz; Steven Sexton; Kevin M. Wasko; John A. Zuris, Ph.D.; Michael Nehil, Ph.D.; Kate Zhang, Ph.D.; Mark Shearman, Ph.D.; Kai-Hsin Chang, Ph.D.; Alexander G. Allen, Ph.D. | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors | |
| 192 | Poster Presentation | POoled T Cell Receptor Screening (POTS) Provides Unbiased, High-Throughput Method for TCR Discovery | Jack L. Reid, BSc; Shihong Zhang, Ph.D; Ariunaa Munkhbat; Matyas Ecsedi, MD, PhD; Megan S. McAfee, PhD; Aude Chapuis, MD | Cellular Therapies | Adoptive immunotherapy;T cell;Tumor antigens | |
| 193 | Poster Presentation | The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies | Eleni Kotsiou, PhD; Joe Robinson; Amber Rogers; Daisy Melandri; Amy Baker; Anabel Ramirez Aragon; Sidra Nawaz; Michael Epstein; Shreenal Patel; Jennine Mootien; Andrew W. Craig, PhD; Satwinder Kaur-Lally; Hinal Patel; Andreas Schmitt; Farah Islam; Mariam Jamal-Hanjani; David Lawrence; Martin Foster; Samra Turajlic, MD PhD; Sergio A. Quezada, PhD; Katy Newton, BSc PhD | Cellular Therapies | Adoptive immunotherapy;Dendritic cell;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 195 | Poster Presentation | Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy | Renata AM. Rossetti, PhD; Leticia Tordesillas; Matthew Beatty, PhD; Yian Ann Chen; Dongliang Du; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD; Daniel Abate-Daga, PhD | Cellular Therapies | Adoptive immunotherapy;B cell;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 196 | Poster Presentation | TLR9-activated B cells directly license adoptively transferred CD8+ T cells with potent tumor immunity | Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Brandon Ware, PhD; Amalia M. Rivera Reyes, BS; Connor J. Dwyer, PhD; David M. Neskey, MD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Chrystal M. Paulos, PhD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;B cell;Costimulation;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
| 197 | Poster Presentation | Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells | Kristin M. Snyder, DVM/PhD Student; Kate Dixon, PhD; Melissa Khaw; Zachary B. Davis, PhD; Paul Rogers, PhD; Martin Hosking, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Jianming Wu, DVM/PhD; Bruce Walcheck, PhD | Cellular Therapies | Antibody;NK/NKT cell;Solid tumors | |
| 198 | Poster Presentation | Costimulatory antigen receptor (CoStAR): a novel platform that enhances the activity of tumor infiltrating lymphocytes (TILs) | Sujita Sukumaran, PhD; Milena Kalaitsidou; Michelle Mojadidi; Clare Yarka; Yong (Stella) Ouyang; Eric Gschweng; Gray Kueberuwa; John S. Bridgeman, PhD; Bob Hawkins; Rubén Alvarez-Rodríguez | Cellular Therapies | Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 199 | Poster Presentation | Potent T cell costimulation mediated by a novel costimulatory antigen receptor (CoStAR) with dual CD28/CD40 signaling domains to improve adoptive cell therapies | Martina Sykorova; Leyuan Bao; Cynthia Chauvin-Fleurence; Milena Kalaitsidou; Michelle Le Brocq; Robert E. Hawkins, MD, PhD; Gray Kueberuwa; John S. Bridgeman, PhD; Rubén Alvarez-Rodríguez | Cellular Therapies | Adoptive immunotherapy;Antibody;Costimulation;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 200 | Poster Presentation | TGFβ-Armoring Boosts Potency and Persistence of Engineered TCR T Cells, Unlocking Superior Efficacy Against HPV-positive Solid Tumors | Gail D. Turner, PhD; Gabriela Diaz, BS; Andreia Costa, PhD; Yeonjoo Oh, MS; Jianguo Huang, PhD; Jenna Bailey, BS; Cyr C. De Imus, BS; Stephanie E. Busch, PhD; Teresa Foy, PhD; Pallavur Sivakumar, PhD; Ruth A. Salmon, PhD; Cédric Cleyrat, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor microenvironment | |
| 201 | Poster Presentation | BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer | Christina Arieta, PhD; Diana Velez, MS; Susan B. Hannes, BS; Shirisha Meda, MS; Brian McCarthy; Divya R. Lenkala, MS; Dewi Harjanto; Prerna Suri; Jessica Kohler, PhD; Jonathan McGee; Daniel Kallin; Paul Turcott; Cynthia Nijenhuis; Maarje W. Rohaan; Gabe Sonke; John B. Haanen, MD; Mark DeMario, MD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD | Cellular Therapies | Adoptive immunotherapy;Neoantigens;RNA;T cell | |
| 202 | Poster Presentation | In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells | Ruipeng Wang, PhD; Lauren Suarez, PhD; Emily Lu, PhD; Pratima Kunwar, PhD; Daniel Dembrow; Sojung Kim, PhD; Mathias Oelke, PhD | Cellular Therapies | Antigen presenting cells;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 203 | Poster Presentation | A Membrane-Tethered IL-15/IL-15 Receptor Fusion Protein Enhances the Persistence and Efficacy of CD70-Targeted TRuC-T Cells | Jian Ding, PhD; Lindsay Webb; Troy Patterson; Michelle Fleury, PhD; Adam Zieba, MS; Holly Horton, PhD; Robert Hofmeister, PhD; Dario Gutierrez; Robert Tighe, NN | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 204 | Poster Presentation | KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors | Karrie K. Wong, PhD; Christopher Wrocklage; Sharon Lin, PhD; Isabelle Le Mercier, PhD; Caroline Bullock; Louise Cadzow; Anja Hohmann, PhD; Sol Shenker, PhD; Katri Sofjan; Leila Williams; Gregory Kryukov, PhD; Conor Calnan; Frank Stegmeier, PhD; Micah J. Benson, PhD; Michael Schlabach, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 205 | Poster Presentation | agenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models | Burcu Yigit, PhD; Darrian Moskowitz; Xavier Michelet, PhD; Antoine Tanne, PhD; Marc A. Van Dijk, PhD | Cellular Therapies | Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;T cell | |
| 206 | Poster Presentation | The development of 'chimeric CD3e fusion protein' and 'anti-CD3-based bispecific T cell activating element' engineered T (CAB-T) cells for the treatment of solid malignancies | Andy Tsun, PhD; Zhiyuan Li; Zhenqing Zhang; Weifeng Huang; Shaogang Peng; Jitian Chai | Cellular Therapies | Antibody;Bispecifics;CAR T cells;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 207 | Poster Presentation | Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells | Daniel Corey, MD; Sunil Thomas, PhD; Brandon Cieniewicz, PhD; Linh Nguyen, PhD; Jared Clever, PhD; Josephine Brysting, BS; Remus Vezan, MD PhD; John M. Rossi, MS; Kurt Diem, PhD; Lei Jin, PhD; Lawrence Corey, MD | Cellular Therapies | Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Costimulation;Dendritic cell;Leukemia/Lymphoma;Monocyte/Macrophage;T cell;TLR;Tumor evasion | |
| 208 | Poster Presentation | RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice | Anne-Sophie Dugast, PhD; Shannon L. McArdel; Zafira Castano; Maegan E. Hoover; Arjun Reddy Bollampalli; Enping Hong; Shannon Leonard; Ryan Pepi; Alex Nanna; Laurence A. Turka; Sivan Elloul | Cellular Therapies | Costimulation;Cytokine;Monocyte/Macrophage;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 209 | Oral Presentation | Genetically Engineered Myeloid Cells (GEMys) as a Platform to Enhance Antitumor Immunity | Sabina Kaczanowska, PhD; Daniel Beury, PhD; Haiying Qin, MS; Rosandra N. Kaplan, MD | Cellular Therapies | Adoptive immunotherapy;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;Tumor microenvironment | |
| 210 | Poster Presentation | A novel medium for increased cytotoxicity and serum-minimal ex vivo expansion of natural killer (NK) cellular immunotherapies | Marc A. Gillig, PhD; Graeme Lambert; Donna Sonntag; Rachit Ohri, Ph.D.; Jason G. Cahoon, BS; Avishai Shemesh, PhD; Nadhim A. Mukhaiter, MS | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell | |
| 211 | Poster Presentation | SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines | Michael F. Maloney, PhD; Emrah Ilker Ozay, PhD; Amy Merino; Andrea A. Silva; Amber M. Martin, MS; Sanjana Manja, MS; Madhav Upadhyay, MS; Christine Trumpfheller, PhD; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Scott M. Loughhead, PhD | Cellular Therapies | Antigen presenting cells;Costimulation;Cytokine;RNA;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 212 | Poster Presentation | Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates | Amanda Nash; Maria Jarvis, PhD; Samira Aghlara-Fotovat; Sudip Mukherjee, PhD; Andrea Hernandez; Andrew Hecht; Peter Rios, PhD; Sofia Ghani; Ira Joshi; Douglas Isa; Yufei Cui; Shirin Nouraein; Jared Lee; Chunyu Xu; David Zhang, PhD; Rahul Sheth, MD; Weiyi Peng, PhD; Jose Oberholzer, MD; Oleg Igoshin, PhD; Amir Jazaeri, MD; Omid Veiseh, PhD | Cellular Therapies | Cytokine;Immune toxicity;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 213 | Poster Presentation | AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to MSLN CAR T cells | Stephen Santoro, PhD; Aaron Cooper, PhD; Natalie Bezman, PhD; Jun Feng, PhD; Kanika Chawla, PhD; Jaspar Williams, PhD; John Gagnon, PhD; Jason Hall, PhD; Dina Polyak, PhD; Angela Boroughs, PhD; Michelle Nguyen; Suchismita Mohanty, PhD; Adam Litterman, PhD; Jeff Granja; David DeTomaso, PhD; Grace Zheng, PhD; Jenessa Smith, PhD; Drake LeFace, PhD; Tarjei Mikkelsen, PhD; Susie Jun, MD, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor microenvironment | |
| 214 | Poster Presentation | SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma | Zhen Bian, PhD; Lei Shi, PhD; Koby Kidder, PhD; Yuan Liu, MD PhD | Cellular Therapies | Antigen presenting cells;Immune suppression;Monocyte/Macrophage;Myeloid cells;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 215 | Poster Presentation | Tissue-resident natural killer cells resembling intraepithelial ILC1 have potent anti-tumor activity in human head and neck cancer and represent a novel class of effector cells for immunotherapy | JuneHo JS. Shin, Ph; Nina B. Horowitz, MS; Quan L. Tran; Chen Chen; Uriel Y. Moreno-Nieves, PhD; Joshua K. Tay, MD PhD; Saumyaa Saumyaa; John B. Sunwoo, MD | Cellular Therapies | Adoptive immunotherapy;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 216 | Oral Presentation | Multiplex base editing of NK cell to enhance cancer immunotherapy | Minjing Wang, BSc; Mitchell G. Kluesner, BSc; Patricia N. Claudio Vázquez, BSc; Beau R. Webber, PhD; Branden S. Moriarity, PhD | Cellular Therapies | Gene expression;NK/NKT cell | |
| 217 | Poster Presentation | Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabolome | Dima DY. Yackoubov, MSc; Aviad Pato; Julia Rifman, PhD; Sherri Cohen; Astar Hailu; Nurit Brycman; Orit Berhani-Zipori, PhD; Avishay Edri, PhD; Boaz Buhandler; Moshe Shahor; Nathan Dinowitz; Amram Ben David; Avi Izraeli; Vered Chalifa-Caspi, PhD; Liron Levin, PhD; Joshua D. Rabinowitz, Prof.; Wenyun Lu, PhD; Tracey Lodie, PhD; Julian Adams, PhD; Yona Geffen, PhD | Cellular Therapies | Adoptive immunotherapy;Bioinformatics;Biomarkers;Gene expression;Leukemia/Lymphoma;Metabolism;NK/NKT cell;Proteomics | |
| 218 | Poster Presentation | Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses | Jenny Zilberberg, Ph.D.; Amelia Zellander, Ph.D.; Kenneth Kirby, M.S.; Christopher Uhl, Ph.D.; Christopher Cultrara, Ph.D.; Charles Scott, Ph.D.; David Andrews, M.D.; Mark Exley, Ph.D.; Mark Exley, MS, Ph.D. | Cellular Therapies | Cytokine;Immune adjuvant;T cell;Tumor antigens;Vaccine | |
| 219 | Poster Presentation | CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001 | Haoxiao Zuo; Satwinder Kaur Singh, PhD; Marie-José Van Lierop; Jorn Kaspers; Remco Bos; Alwin Kamermans; Helga E. de Vries; Tanja D. de Gruijl, PhD; Ada M. Kruisbeek, PhD; Erik Manting | Cellular Therapies | Antigen presenting cells;Chemokine;Cytokine;Dendritic cell;Immune adjuvant;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Tumor antigens;Vaccine | |
| 220 | Poster Presentation | Transfection of human adipose-derived mast cells: A characteristic study using different chemical reagents | Mona Motaghed, PhD Candidate; Christopher Kepley, Ph.D.; Kristen Dellinger, Ph.D.; Elnaz Ahani, Ph.D. Candidate; Mohammad Fereydouni, Ph.D. Candidate | Cellular Therapies | Adoptive immunotherapy;Gene expression;Monocyte/Macrophage | |
| 221 | Oral Presentation | CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors | Rebecca C. Larson, BS; Michael Kann; Stefanie R. Bailey, PhD; Nicholas J. Haradhvala; Kai Stewart; Amanda Bouffard; Irene Scarfo; Mark Leick; Trisha R. Berger; Max Jan; Julia Joung; Tamara Ouspenskaia; Travis Law; Aviv Regev, PhD; Gad Getz, PhD; Marcela V. Maus, MD, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Solid tumors | |
| 222 | Poster Presentation | Genetic reprogramming of Merkel cell carcinoma and melanoma leads to increased MHC-I expression and antitumor immune activation in vitro and in vivo | Kathryn M. Luly, BS; Jordan J. Green, PhD; Stephany Y. Tzeng, PhD; Joel C. Sunshine, MD, PhD | Cellular Therapies | Costimulation;Cytokine;Immune adjuvant;NK/NKT cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 223 | Poster Presentation | Potent inhibition of PI3Kδ promotes enhanced T cell stemness and mitochondrial fitness | Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Anna C. Cole, BA; Megan M. Wyatt, MS; Brandon Ware, PhD; Chrystal M. Paulos, PhD | Cellular Therapies | Adoptive immunotherapy;Immune adjuvant;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
| 224 | Poster Presentation | M2 macrophage-mediated immune suppression of chimeric antigen receptor T cells via PD-L1 signaling in prostate cancer | Yukiko Yamaguchi; Jackson Gibson; Kevin Ou; Saul Priceman, PhD | Cellular Therapies | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 225 | Poster Presentation | Optimal-affinity MAGE-A1-specific T cell receptors (TCRs) generated using the humanized TCR-transgenic mouse platform HuTCR are superior to human donor-derived TCRs | Ioannis IG. Gavvovidis, PhD; Matthias Leisegang, Prof. Dr.; Vivian Scheuplein, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Elisa Kieback, PhD | Cellular Therapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 226 | Poster Presentation | Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers | Ana B. Korngold, PhD; Jean Lin-Kin Yong, PhD; Ugochi C. Ibekwe; Julissa Simmons; Phillip Eckels, MPH; Elizabeth Figueroa, PhD; Michelle Hotard; Frances Adeyemi; Thomas Hunt; Tegan Markus; Lenka V. Hurton, PhD; Yaoyao Shi, PhD; Matthew R. Collinson-Pautz, PhD; Priya Balasubramanian, PhD; Cathy Wang, PhD; Jourdan Andersson, PhD; Lauren Heese; Mariam Khalil; David Torres; Emarco Olivares; Geraldine Bardelli; Kelly O'Brien, PhD; Haroon Hashmi; Alena Chekmasova; Raffaele Baffa, MD; Tom Spencer, PhD; Eleanor De Groot, PhD; Drew C. Deniger, PhD | Cellular Therapies | Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens | |
| 227 | Poster Presentation | A computational semi-mechanistic pharmacology model of ATG101, a PD-L1/4-1BB bispecific antibody for treatment of solid tumors and NHL | David C. Flowers, PhD; Marc Presler; Kas Subramanian; Theresa Yuraszeck; Hui Yuwen; Bing Hou, Ph.D; Dirk Hoenemann, MD | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Costimulation;Leukemia/Lymphoma;Solid tumors;Systems biology;Tumor infiltrating lymphocytes (TILs) | |
| 228 | Poster Presentation | Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity | Thomas Thisted, PhD; Arnab Mukherjee, PhD; Kanam Malhotra; Zuzana Biesova, PhD; Yuliya Kleschenko, PhD; Zhi-Gang Jiang, PhD; Anokhi Cifuentes; Nadthakarn Boland; Nels Nielson; Edward H. van der Horst, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;MDSC;Myeloid cells;T cell;Tumor microenvironment | |
| 229 | Poster Presentation | CX3CR1 in exhausted CD8 T cell states | Apoorvi Chaudhri, MS; Yunfei Wang; Shao-Hsi Hung; Gregory A. Lizee, PhD; Ulrich Von Andrian, MD, PhD; Patrick Hwu; Gordon J. Freeman, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Tumor infiltrating lymphocytes (TILs) | |
| 230 | Poster Presentation | Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology | Vanessa Gauttier, PhD; Marion Drouin; Sabrina Pengam; Javier Saenz; Bérangère Evrard; Stéphanie Neyton; caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Emmanuelle Wilhelm; Nicolas Poirier; Elise Chiffoleau | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 231 | Poster Presentation | Molecular Insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 | Yang Liu, PhD; Yan Zhang; Xuexiang Du, PhD; Mingyue Liu, PhD; Xianfeng Fang, PhD; Libing Mu, PhD; Vadim Z. Tevetnitsky; Martin Devenport; Pan Zheng, MD, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune tolerance;Regulatory T cell (Treg cell);Tumor microenvironment | |
| 232 | Poster Presentation | INCB090244, a potent small molecule that inhibits the PD-L1/PD-1 axis and functions similarly to PD-L1 antibodies | Jonathan Rios-Doria, PhD; Alla Volgina; Prafulla C. Gokhale, PhD; Hao Liu; Christina N. Stevens; Nina Zolotarjova; Darlise DiMatteo; Kanishk Kapilashrami; Elham Behshad; Pramod Thekkat, MS; Gengjie Yang; Leslie Hall; Chrysi Kanellopoulou; Mark Rupar; Christopher Maddage; April Horsey; Krista Burke; Yan-ou Yang; Maryanne Covington; Steve Wang; Phillip Liu; Richard Wynn; David A. Reardon, MD; Holly K. Koblish, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;T cell;Targeted therapy | |
| 233 | Poster Presentation | Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1 | Anupallavi Srinivasamani, MS; Michael A. Curran, PhD; Qinying Liu; Shwetha M. Hegde; Chao-Hsien Chen, MD, PhD; Kimal Rajapakshe, PhD; Cristian Coarfa | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Coinhibition;Cytokine;Gene expression;T cell;Tumor microenvironment | |
| 234 | Oral Presentation | Distinct efficacy and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in aged versus young hosts | Yilun Deng, PhD; Harshita Gupta; Myrna G. Garcia, BS; Aravind Kancharla, MS; Ryan M. Reyes; Alvaro S. Padron; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Cytokine;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 235 | Poster Presentation | Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity | Yuji Mishima, PhD; Kanto Nakajima; Mamoru Shiraishi; Haruka Matsumura; Takahiko Aramaki; Noriko Matsumoto; Norihiro Nakamura | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Targeted therapy | |
| 236 | Poster Presentation | Predictors of ICI Renal Toxicity: A Pathological Approach | Ala Abudayyeh, MD; Liye Suo; Heather Lin, PhD; Omar Mamlouk; Cassian Yee, MD; Amanda Tchakarov; Jamie S. Lin, MD | Checkpoint Blockade Therapy | Autoimmunity;Immune toxicity;Inflammation | |
| 237 | Poster Presentation | Infectious complications in patients with non-small cell lung cancer treated with anti-PD(L)1 immune checkpoint inhibitors | Matthew Z. Guo, BA; Aanika Balaji, MD, MPH; Joseph C. Murray, MD, PhD; Joshua E. Reuss, MD; Seema A. Mehta Steinke, MD, MS; Jarushka Naidoo, MD, MHS | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Immune toxicity;Solid tumors | |
| 238 | Poster Presentation | Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy | Seung Pyo D. Hong, MD; Min Jeong Kim, MD; Allison Belette, MD; Youjin Oh, MD; Sukjoo Cho, MD; Young Kwang Chae, MD, MPH, MBA | Checkpoint Blockade Therapy | Checkpoint blockade;Immune toxicity;Solid tumors | |
| 239 | Poster Presentation | Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study | Caroline A. Nebhan, MD, PhD; Alessio AC. Cortellini, MD; Weijie Ma, MD; Teja Ganta, MD; Haocan Song, MS; Fei Ye, PhD; Rebecca Irlmeier, MS; Neha Debnath, MD; Anwaar Saeed, MD; Maluki Radford; Asrar Alahmadi, MBBS; Akiva Diamond, MD; Christopher J. Hoimes, MD; Nikhil Ramaiya, MD; Carolyn J. Presley; Dwight H. Owen; Sarah Abou Alaiwi, MD; Amin Nassar, MD; Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Melissa Bersanelli, MD; Chiara Casartelli, MD; Sebastiano Buti, MD; Paolo Marchetti, MD; Raffaele Giusti; Marco Filetti; Vito Vanella; Domenico Mallardo, MD; Shravanti Macherla, MD; Tamara A. Sussman, MD; Andrea Botticelli, MD, PhD; Domenico Galetta, MD; Annamaria Catino, MD; Pamela Pizzutilo, MD; Carlo Genova, MD, MD; Maria Giovanna Dal Bello, MD; Foteini Kalofonou, MD, PhD; Ella Daniels; Paolo A. Ascierto, MD; David J. Pinato, MD, MRes, PhD; Toni K. Choueiri, MD; Douglas B. Johnson, M.D.; Thomas U. Marron, MD, PhD; Yinghong Wang, MD, PhD; Abdul Rafeh Naqash, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune toxicity;Solid tumors | |
| 240 | Poster Presentation | Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling. | Myrto Moutafi, MD; Sandra Martinez-Morilla, PhD; Prajan Divakar; Ioannis A. Vathiotis, MD; Niki Gavrielatou, MD; Thazin N. Aung, PhD; Vesal Yaghoobi, MD; Aileen I. Fernandez, PhD; Jon Zugazagoitia Fraile, MD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD | Checkpoint Blockade Therapy | Antibody;Biomarkers;Checkpoint blockade;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 241 | Poster Presentation | Immune Checkpoint Blockade (ICB) in Brain Metastases (BM) from Advanced Small Cell Urothelial Cancer (aSCUC) | Nathaniel R. Wilson, MD; Omar Alhalabi, MD; Elshad Hasanov; Lianchun Xiao; John Papadopoulos, MD; Matthew T. Campbell, MD; Amishi Shah; Jianjun Gao, MD PhD; Paul G. Corn, MD, PhD; Ana Aparicio; Jennifer Wang, MD; Bogdan A. Czerniak; Charles C. Guo; Christopher J. Logothetis, MD; Jing Li; Seungtaek Choi; Chad Tang, MD, MS; Nizar M. Tannir, MD, FACP; Arlene O. Siefker-Radtke, MD | Checkpoint Blockade Therapy | Chemotherapy;Clinical study;Radiotherapy;Solid tumors | |
| 242 | Poster Presentation | Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive | Haiyan HB. Bai, PhD; Álvaro Padrón; Yilun Deng, PhD; Anand Kornepati; Srikanth R. Polusani; Suresh C. Kari, PhD; Clare E. Murray; Myrna Garcia; Ryan M. Reyes; Niannian Ji; Harshita Gupta; Matthew J. Hart; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;NK/NKT cell;Post-translational modifications;T cell | |
| 243 | Poster Presentation | Understanding and overcoming the mechanism of resistance to anti-PD-1 monotherapy in brain metastasis | Laura Falceto Font, BS; Catherine Flores; Jack Figg; Bayli DiVita Dean; Connor Francis; Carmelle Kuizon; Ginger Moore | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;Tumor evasion | |
| 244 | Poster Presentation | Genomic determinants of response to chemoradiation and durvalumab consolidation for stage III non-small cell lung cancer | Matthew Z. Guo, BA; Joseph C. Murray, MD, PhD; Paola Ghanem, MD; Khinh Ranh Voong, MD, MPH; Russell K. Hales, MD; Josephine L. Feliciano, MD; Kristen A. Marrone, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;Radiotherapy;Solid tumors | |
| 245 | Poster Presentation | Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1 | Ann Hanna, PhD; Xiaopeng Sun, BS; Paula I. Gonzalez-Ericsson, MD; Violeta I. Sanchez, BS; Melinda I. Sanders, MD; Justin M. Balko, PharmD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Chemotherapy;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 246 | Poster Presentation | Effectiveness and utilization of first-line immune checkpoint inhibitors for patients with extracranial & intracranial metastatic melanoma | Nayan Lamba, MD; Bryan Iorgulescu, MD | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 247 | Poster Presentation | The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo | Stephan J. Matissek, PhD; Marisella Panduro Sicheva; Secil Koseoglu, PhD; Ricard Masia, MD PhD; Michael C. Warren; Matthew P. Rausch, PhD; Benjamin H. Lee, MD PhD; Sandra Pommey; Isabelle Cousineau, PhD; John Stagg; Vito J. Palombella, PhD; Andrew C. Lake, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Tumor microenvironment | |
| 248 | Poster Presentation | Empiric profiling of peripheral T cell recall responses to tumor mutanomes versus in silico predictions in NSCLC patients undergoing pembrolizumab treatment ± chemotherapy | Madison Milaszewski, BS; James Loizeaux; Emily Tjon, M.S.; Crystal Cabral, BS, MSc; Tulin Dadali, PhD; Justin Strickland; Jamie Foti, PhD; Kevin J. Mancini, MS; Kesi Michael; Louisa Dowal, PhD; Vijetha Vemulapalli; Alberto Visintin, PhD; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; Mark Awad, MD, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Neoantigens;T cell | |
| 249 | Poster Presentation | Characterization of unresectable and/or metastatic solid tumors patients treated with systemic anticancer therapy in first-line settings: A Pan-tumor community-oncology based study | Elise Wu, PhD; Sneha Sura, MS, PhD; Alexander I. Spira, MD, PhD, FACP | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;Epidemiology;Solid tumors | |
| 250 | Poster Presentation | Spatial-transcriptomic analysis of tumor-immune microenvironment in AML patients receiving pembrolizumab and decitabine | Chen Zhao, MD; Abigail Wong-Rolle, BSc; Prajan Divakar; Katherine R. Calvo, MD, PhD; Christopher S. Hourigan, MD, PhD | Checkpoint Blockade Therapy | Chemotherapy;Immune monitoring;Leukemia/Lymphoma;RNA;T cell;Tumor microenvironment | |
| 251 | Poster Presentation | The Use of Small Molecule Inhibitors to Target Novel Pathways in Exhausted T Cells for Immuno-Oncology Therapeutic Intervention | Francis Acklam; Joanne Hay; Darryl Turner; Mark Barbour; Preeti Singh; Courtney Grant; Hayley Gooding; Justyna Rzepecka; Rhoanne McPherson | Checkpoint Blockade Therapy | Bispecifics;Checkpoint blockade;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 252 | Poster Presentation | Novel DNAM-1 axis member, PVRIG, is potentially a dominant checkpoint involved in stem-like memory T cells – dendritic cell interaction | Zoya Alteber, PhD; Gady Cojocaru; Masha Frenkel; Emmanuel Weyl; Niv Sabath; Assaf Wool; Amit Novik; Yossef Kliger; Zurit Levine; Eran Ophir, PhD | Checkpoint Blockade Therapy | Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Gene expression;Immune monitoring;Immune suppression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 253 | Poster Presentation | PD1 and LAG3 converge to limit polyfunctionality and systemic immunity | Lawrence P. Andrews, PhD; Sasikanth Manne, PhD; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD | Checkpoint Blockade Therapy | Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 254 | Poster Presentation | NTX-1088, A POTENT ANTI-PVR MAB INDUCES DNAM1-MEDIATED ANTITUMOR IMMUNITY | Anas Atieh; Akram Obiedat, PhD; Guy Cinamon, PhD; Tihana Lenac Rovis; Paola Kucan Brlic; Lea Hirsl; Ofer Mandelboim, PhD; Stipan Jonjic, MD; Keren Paz, PhD; Pini Tsukerman, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 255 | Poster Presentation | Investigating VISTA's role intrinsic to T cells in the tumor microenvironment | Cassandra K. Gilmour, BS; Li Wang, PhD; Juan Dong, MD; Sarah Stone; Keman Zhang; Hieu M. Ta, Ph D | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 256 | Poster Presentation | The TIGIT/CD226/CD155 axis and the effects of combining PD-1/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models | Prafulla C. Gokhale, PhD; Bryan Iorgulescu, MD; Max Klapholz; Michael Poitras; Benjamin Eschle; Gordon J. Freeman, PhD; Ana C. Anderson, PhD; David A. Reardon, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs) | |
| 257 | Poster Presentation | Combination of Adenosine antagonists A2AR (TT-10) and A2BR (TT-4) with checkpoint inhibitors demonstrate anti-tumor activity in CT-26 Murine Colon Tumor Allograft Model | Desa Rae E. Pastore, MS, BS; Sushant Kumar, PhD; Brian Schwartz; Kasim Mookhtiar; Vijay Reddy | Checkpoint Blockade Therapy | Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs) | |
| 258 | Poster Presentation | AB308 is an Anti-TIGIT Antibody That Enhances Immune Activation and Anti-tumor Immunity Alone and in Combination with Other I-O Therapeutic Agents | Dana Piovesan, MSc; Alejandra Lopez, BSc; Patrick G. Schweickert, PhD; Ferdie Soriano, BS; Soonweng Cho, PhD; Ada Chen, BS; Hema Singh; Xiaoning Zhao; Stephen W. Young; Nigel P. Walker, PhD; Matthew J. Walters, PhD; Kelsey E. Sivick Gauthier, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;T cell;Tumor microenvironment | |
| 259 | Poster Presentation | Injectable chitosan hydrogel for localized delivery of immune checkpoint inhibitors | Siena M. Mantooth, BS; David A. Zaharoff, PhD | Checkpoint Blockade Therapy | Solid tumors;Targeted therapy;Tumor microenvironment | |
| 260 | Poster Presentation | CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics | Gabriela Andrejeva, PhD; Benjamin J. Capoccia, Ph.D; Rachel B. Delston, PhD; Michael J. Donio, MS; Ronald R. Hiebsch, BS; Robyn J. Puro, PhD; Casey Wilson, PhD; Arun K. Kashyap, PhD; Daniel S. Pereira, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Targeted therapy | |
| 261 | Oral Presentation | A functional genetic screen uncovers regulators of intratumoral macrophage function and reveals CD24 as a novel target for cancer immunotherapy by macrophages | Amira Barkal, MD, PhD; Rachel Brewer, MS; Irving L. Weissman, MD | Checkpoint Blockade Therapy | Monocyte/Macrophage;Myeloid cells | |
| 262 | Poster Presentation | Preclinical characterization of humanized anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression | Huyen Dinh; Sam Lam; Valerie Wall, PhD; Francisco Zapata; Darbie Whitman; Ramya Chandrasekaran; Lauren Loh; Texia Loh; Tom Graddis, PhD; Peter Probst; Myriam N. Bouchlaka, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 263 | Poster Presentation | ASD141, an innate checkpoint inhibitor, modulates tumor associated myeloid cells through CD11b and enhances current immune checkpoint blockade in preclinical model | Chia-Ming Chang, PHD; ??? Mr. Jason, MD; I-Fang Tsai, MS; Yen-Ta Lu, MD, PHD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 264 | Poster Presentation | SIRPa blockade synergizes with radiation therapy in murine breast cancer models | Maud Charpentier, PhD; Claire Lhuillier; Ines Mota; Sergio Trombetta; Sandra Demaria, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Dendritic cell;Tumor evasion;Tumor microenvironment | |
| 265 | Poster Presentation | CD47xPD-L1 bispecific antibodies for cancer therapy | Xavier CHAUCHET, PhD; Elise PENARRIETA; Nicolas BOSSON; Sébastien CALLOUD; Louis HELLEQUIN; Margaux LEGRAND; Alizée VIANDIER; Françoise RICHARD; Laura CONS; Pauline MALINGE; Tereza BAUTZOVA; Jérémie BOURGUIGNON; Guillemette PONTINI; Mengzhu SUN; Ulla RAVN; Valéry MOINE; Yves POITEVIN; Stéphanie HUGUES; Nicolas FISCHER; Limin SHANG; Walter G. FERLIN; Krzysztof MASTERNAK | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Monocyte/Macrophage;Solid tumors;T cell | |
| 266 | Poster Presentation | AK117, A CD47 Blocking Antibody with Robust Macrophage Activation without Red Blood Cell Hemagglutination | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; Tailong Qu; Chunshan Jin; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Monocyte/Macrophage;T cell | |
| 267 | Poster Presentation | Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window | Shih-Hsun Chen, PhD; Pawel Dominik; Jessica Stanfield; Sheng Ding; Wenjing Yang; Ryan Llewellyn; Jonathan Heyen; Carole Wang; Zea Melton; Kevin Lindquist; Thomas Van Blarcom; Javier Chaparro-riggers; Shahram Salek-Ardakani | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 268 | Poster Presentation | KVA 12.1 a novel fully human anti-VISTA antibody: Clinical trial design in monotherapy and in combination with an anti-PD1 antibody | Thierry Guillaudeux, PhD; Shawn Iadonato, PhD; Eric Tarcha, PhD; Craig Philips | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 269 | Poster Presentation | Utilizing serum proteome to understand response and resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer | Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA; Dong-Uk Lee | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Clinical study | |
| 270 | Oral Presentation | Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis | Jessica D. Mackert, PhD; Elizabeth R. Stirling, MS; Mitra Kooshki, MS; Dawen Zhao, MD; PhD; Alexandra Thomas, MD; Glenn Lesser, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Gene expression;Monocyte/Macrophage;Solid tumors | |
| 271 | Poster Presentation | Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages | Peter Probst; Randi Simmons; Huyen Dinh; Meghan E. Zuck, PhD; Valerie Wall, PhD; Myriam N. Bouchlaka, PhD; Sam Lam; Ray Fox; Darbie Whitman; Tom Graddis, PhD; Kamal D. Puri, PhD | Checkpoint Blockade Therapy | Antibody;B cell;Checkpoint blockade;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor evasion;Tumor microenvironment | |
| 272 | Poster Presentation | A Novel Bispecific Macrophage Engager Antibody (BiME) Designed for Cancer Immunotherapy | Hongtao Lu, PhD; Dawei Sun, Ph.D.; Xiaofeng Niu, Ph.D.; Yanan Geng; Jing Wang; Haixia Jiang; Rui Gao, Ph.D.; Zhihao Wu, Ph.D; Yangsheng Qiu, PhD | Checkpoint Blockade Therapy | Antibody;Antigen presenting cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy | |
| 273 | Poster Presentation | Application of pharmacokinetic-pharmacodynamic modeling to select the optimal dose of ALX148, a CD47 blocker. | Oleg Demin Jr, MSc; Elena Vasileva | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Leukemia/Lymphoma;Monocyte/Macrophage | |
| 274 | Poster Presentation | CD47 x EpCAM Bispecific Antibody Represents a Novel Approach for Treating EpCAM Overexpressing Solid Tumors | Xinhua Wang, Ph.D; Oi Kwan Wong, Ph.D; Lei Shi; Qi Fei; Leonard Post; Xiaocheng Chen, PhD | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Solid tumors | |
| 275 | Poster Presentation | Flow cytometry and NanoString provide a comprehensive cell- and gene-based tumor profile following checkpoint inhibition in a murine bladder cancer model | David W. Draper, PhD; Philip E. Lapinski, PhD; Scott Wise, BS | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Chemokine;Cytokine;Immune monitoring;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 276 | Poster Presentation | Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression | Meghan E. Zuck, PhD; Huyen Dinh; Valerie Wall, PhD; Sam Lam; Ramya Chandrasekaran; Francisco Zapata; Texia Loh; Lauren Loh; Myriam N. Bouchlaka, PhD; Tom Graddis, PhD; Kamal D. Puri, PhD; Peter Probst | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Myeloid cells;T cell;Tumor microenvironment | |
| 277 | Poster Presentation | Safety and Efficacy of Intratumoral Ipilimumab with IV Nivolumab in Metastatic Melanoma. The NIVIPIT Trial. | Lambros Tselikas, MD; Caroline Robert, MD, PhD; Stephane Dalle; Nicolas Meyer; Celeste Lebbe, MD, PhD; Samy Ammari; François-Xavier Danlos; Severine Roy; Camille Jannin; Siham Farhane; Severine Mourad; Guillaume Escriou; Thibault Raoult; Jean-Yves Scoazec, MD; Matthieuu Texier; Nathalie Chaput-Gras; Laurence Zitvogel, MD, PhD; Thierry De Baere, MD, PhD; Aurélien Marabelle | Checkpoint Blockade Therapy | Antibody;Biomarkers;Checkpoint blockade;Chemokine;Immune monitoring;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment | |
| 278 | Poster Presentation | Systematic review and meta-analysis evaluating the impact of antibiotic use on clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors | Athéna Crespin; Athéna Crespin, Engineer; Pierre-Alain Bandinelli; Clément Le Bescop; Renaud Buffet; Jean De Gunzburg; Fabien Vitry; Gérard Zalcman; Julie Cervesi, PharmD | Checkpoint Blockade Therapy | Checkpoint blockade;Microbiome;Solid tumors | |
| 279 | Poster Presentation | ILT3 blockade reduces tumor blast cells in Acute Myeloid Leukemia PBMC and inhibits tumor cell growth in a humanized AML tumor model | Alan J. Byford, MS; Yujie Qu; Haiyan Xu, MD PhD; Gain Robinson; Latika Singh; Eric Muise, MS; Elaine Pinheiro, PhD; Mei Chen, MD; Lily Moy; Stephen Alves, PhD; Jie Zhang-Hoover, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells | |
| 280 | Poster Presentation | Clinical Outcomes of Immunotherapy Continued Beyond Radiographic Progression In Older Adults with Advanced Non-Small Cell Lung Cancer | Eric K. Singhi, MD; Frank Mott; Michelle A. Worst, PharmD, BCOP, MBA; Cheuk Hong Leung; Jack J. Lee, PhD/DDS; Brett Carter; Carolyn J. Presley; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; Ara A. Vaporciyan, MD; John V. Heymach, MD, PhD; Mehmet Altan | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 281 | Poster Presentation | Measuring immune checkpoint inhibitor efficacy using primary patient-derived 3D spheroids | Kathryn M. Appleton, PhD; Katy A. Lassahn, MS; Ashley K. Elrod; Tessa M. DesRochers, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 282 | Poster Presentation | Bispecific antibodies (BsAbs) targeting ABCB1/PgP and CD47 provide a multi-modal, tumor specific approach to combat drug resistant cancers. | Robert Arathoon, PhD; Raffaella Briante, PhD; Alissa O'Connor; Cindy Tan; Pamela Klein, MD; Jessica Morgan, PhD; Paul Ponath, PhD; Leonard Presta; Qianting Zhai; Suchismita Mohanty; Pinping Zhang | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Chemotherapy;Solid tumors;Targeted therapy;Tumor antigens | |
| 283 | Poster Presentation | TIM-3 blockade modulates the tumor microenvironment improving the outcome of preclinical pediatric Diffuse Midline Glioma models | Iker Ausejo-Mauleon, MSc; Sara Labiano, MSc; Virginia Laspidea; Marc Garcia-Moure; Daniel de la Nava; Oren J. Becher; Mariella G. Filbin; Fernando Pastor; Marta M. Alonso | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune suppression;NK/NKT cell;Pediatric tumors;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 284 | Poster Presentation | Integrated Molecular Characterization of primary resistance mechanisms to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Carcinoma (a-NSCLC) | Benjamin Besse, MD, PhD; Colette DIB, PhD; Eladio J. Marquez, Ph.D.; Joon Sang Lee, PhD; Shu Yan; Marielle Chiron, PhD; Cecile N. Combeau, Ph D; Angelique Biancotto; Félix Blanc-Durand; Mihaela Aldea; David Planchard, MD, PhD; Jean-Yves Scoazec, MD; Ludovic Lacroix, PharmD; Etienne Rouleau, MD; Nathalie Chaput-Gras; Saloomeh Rafie; Aurélien Marabelle; Eric Angevin, MD, PhD; Jack Pollard, PhD | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Gene expression;Immune contexture;RNA;Tumor microenvironment | |
| 285 | Poster Presentation | Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease | Norma Bloy, PhD; Aitziber Buqué Martinez, PhD; Bhavneet Binder; Giulia Petroni; Takahiro Yamazaki, PhD; Ai Sato; Olivier Elemento, PhD; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune contexture;Immune monitoring;Solid tumors | |
| 286 | Poster Presentation | Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC). | Poromendro Burman, MS; Boyang Zhang; Zhicheng Ji; Justina Caushi; Frank Housseau; Andrew M. Pardoll, MD, PhD; Zhang Jiajia; Hongkai Ji; Kellie Smith | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Clinical study;Gene expression;RNA;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 287 | Poster Presentation | Combined COX-2 inhibition with fish oil and aspirin as adjuncts to anti-PD-1 immunotherapy in metastatic melanoma | Alexander C. Chacon, MD; Alexa D. Melucci, MD; Shuyang S. Qin, M.S; Paul R. Burchard, MD; Katherine M. Jackson, M.D.; Rachel Jewell; Peter A. Prieto, MD, MPH | Checkpoint Blockade Therapy | Checkpoint blockade;Inflammation;Metabolism;Monocyte/Macrophage;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 288 | Poster Presentation | The COX-2 pathway as a mediator of resistance to anti-PD-1 therapy | Shuming Chen, PhD, MB; Tracee L. McMiller, MS; Preethi Sankaran; Kyle Kampta; Suzanne L. Topalian, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor evasion;Tumor microenvironment | |
| 289 | Poster Presentation | Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;T cell | |
| 291 | Poster Presentation | Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity | Coline A. Couillault, PhD; Anupallavi Srinivasamani, MS; Shweta M. Hedge; Qinying Liu; Ashwin Jaiswal; Dongxing Zha; Michael A. Curran, PhD | Checkpoint Blockade Therapy | Bispecifics;Checkpoint blockade;Coinhibition;Immune suppression;MDSC;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 292 | Poster Presentation | Ex vivo profiling of PD-1 blockade using an organotypic tissue slice model in Solid Tumors | Lina Ding, PHD; Kristin Sullivan; Chensheng Zhou; Jimena Trillo-Tinoco; anne lewin; Catherine King; David Nelson; Benjamin J. Chen, MD, PhD; Michaela Bowden | Checkpoint Blockade Therapy | Biomarkers;Cytokine;Solid tumors;T cell;Tumor microenvironment | |
| 293 | Poster Presentation | Distinct tumor infiltrating Treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer. | Arbor G. Dykema, BS; Boyang Zhang, BS; Jiajia Zhang, MD, MPH; Zhicheng Ji; Taibo Li, MS; BS; Poromendro Burman, MS; Justina Caushi; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie N. Smith, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Immune toxicity;Regulatory T cell (Treg cell);T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 294 | Poster Presentation | Evaluation of radiographic response in the intact renal mass (intact-Rmass) to immune checkpoint inhibitor (ICI) combination regimens in patients with metastatic renal cell carcinoma (mRCC) | Hamid Emamekhoo, MD; Danubia Hester; Saqib Abbasi; Jens Eickhoff, PhD; Tristan Bice; Luna Archaya; Ellen B. Jeager; Moshe C. Ornstein; Ali Pirasteh; Pedro Barata, MD, MSc; Yousef Zakharia; Deepak Kilari; Elizabeth Wulff-Burchfield; Christos E. Kyriakopoulos, MD | Checkpoint Blockade Therapy | Angiogenesis;Checkpoint blockade;Clinical study;Targeted therapy | |
| 295 | Poster Presentation | Tumor cell- intrinsic expression of FGFR3 drives anti-PDL-1 immunotherapy resistance in a murine bladder cancer model | Erica Fleming-Trujillo, PhD; Jeffrey C. Bloodworth; Anthony Fernald; Aubrianna Ramsland; Thomas F. Gajewski, MD, PhD; Randy F. Sweis, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Solid tumors;Tumor evasion;Tumor microenvironment | |
| 296 | Poster Presentation | A comprehensive clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small cell lung cancer | Paola Ghanem, MD; Joseph C. Murray, MD, PhD; Melinda Hsu; David S. Ettinger, MD; Josephine L. Feliciano, MD; Patrick Forde; Christine L. Hann, MD, PhD; Vincent K. Lam, MD; Benjamin P. Levy; Julie R. Brahmer, MD, MS; Kristen A. Marrone, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Clinical study;Solid tumors | |
| 298 | Poster Presentation | Tumor cell-intrinsic mTORC1 signaling through Raptor makes melanoma and ovarian cancer immunotherapy resistant by regulating interferon-gamma responsiveness and promoting tumor-initiating cells | Harshita Gupta; Suresh C. Kari, PhD; Emily L. Salinas, BS; Haiyan HB. Bai, PhD; Erica Osta, BS; Anand Kornepati; Juan Wang; Xinyue Zhang; Yidong Chen; Ratna Vadlamudi; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Cytokine;Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 299 | Poster Presentation | Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive Merkel Cell Carcinoma | Ulla K. Hansen, PhD; Candice D. Church, PhD; Amalie K. Bentzen; Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Suzanne L. Topalian, MD; Paul T. Nghiem, MD, PhD; Sine R. Hadrup, Prof | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Immune monitoring;T cell;Targeted therapy;Tumor antigens | |
| 300 | Oral Presentation | Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade-based therapy | Michal Harel, PhD; Coren Lahav; Eyal Jacob, PhD; Itamar Sela, PhD; Yehonatan Elon, PhD; Galit Yahalom, PhD; Iris Kamer, PhD; Ofer Sharon, MD; Yuval Shaked, PhD; Adam P. Dicker, MD, PhD; David P. Carbone, MD, PhD; Jair Bar, MD, PhD | Checkpoint Blockade Therapy | Bioinformatics;Biomarkers;Checkpoint blockade;Proteomics;Systems biology | |
| 301 | Poster Presentation | OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to apoptosis and eradicates tumors in combination with PD-1 inhibition | Christina Hartl; Tillmann Michels; Ronny Milde; Vanessa Klein; Philipp Beckhove; Hannes Loferer; Stefan Bissinger, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 302 | Poster Presentation | Characterization of TIGIT and PVR expression in colorectal liver metastases | Antoine BERNARD, PhD; David Henault; Sandy Pelletier; Pamela Thebault; Benoit Barrette; Simon Turcotte, MD, MSc | Checkpoint Blockade Therapy | Checkpoint blockade;Gene expression;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 303 | Poster Presentation | Non-functional T cell responses in non-small cell lung cancer are induced during tumor antigen-specific T cell priming in the mediastinal lymph node | Brendan L. Horton, PhD; Duncan Morgan; Elen Torres-Mejia, PhD; Maria Zagorulya, B.S.; Vidit Bhandarkar; Noor Momin; K. D. Wittrup; J C. Love; Stefani Spranger, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Gene expression;Immune contexture;Solid tumors;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 304 | Poster Presentation | Antagonistic antibodies targeting LAIR1 enhance T lymphocyte activation and promote inflammatory phenotypes in myeloid cells | Tao Huang, PhD; Caroline Bonnans, PhD; Maria Jose Costa, PhD; Azita Tabrizi; Jing-Tyan Ma; Jingjing Xie; Heyu Chen, PhD; Kyu Hong; Krista McCutcheon; Ryan Stafford; Hongyu Tian; Cheng Cheng Zhang, PhD; Xun Gui; Ningyan Zhang; Zhiqiang An, PhD; X. Charlene Liao; An Song, PhD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 305 | Poster Presentation | Unravelling the role of CD4+ and CD8+ T cells in Pembrolizumab Induced Mycobacterium Tuberculosis Granuloma Formation in Nasopharyngeal Carcinoma | Tae Yang Desmond Hung, Mphil; Ngar Woon Kam; Victor Ho Fun Lee | Checkpoint Blockade Therapy | Checkpoint blockade;NK/NKT cell;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 306 | Poster Presentation | Decr2 regulates tumor cell ferroptosis and is required for immunotherapy efficacy | Shuyin Li, PhD; Thomas F. Gajewski, MD, PhD; Emily Higgs | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 307 | Poster Presentation | Interaction of anti-PD-1/PD-1 immunocomplexes with human FcRs: binding properties and functional implication | Elena Daveri, PhD; Elena Luison; Viviana Vallacchi; Barbara Vergani; Veronica Huber; Agata Cova; Biagio Eugenio Leone; Marina Garassino; Mariangela Figini; Licia Rivoltini | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Myeloid cells;Tumor evasion | |
| 308 | Poster Presentation | Transcriptomic analysis of melanoma patients in adjuvant setting treated with Anti PD1 therapy: real life study | Domenico Mallardo, MD; Claudia Trojaniello; Maria Grazia Vitale, MD; grazia d'angelo; Andrew M. White, BSc; Mariaelena Capone, MD; Antonio Sorrentino, MD; Gabriele Madonna, MS; Marilena Tuffanelli; Vito Vanella; Lucia Festino; Ester Simeone, MD; Corrado Caracò; Nicola Normanno; Sarah E. Warren, PhD; Paolo A. Ascierto, MD | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Carcinogenesis;Gene expression;Immune adjuvant;Immune suppression;T cell lineages | |
| 309 | Poster Presentation | Visualizing the immunotherapy-induced spatial reorganization of the tumor-immune microenvironment by CODEX multiplex imaging | Ruan FV. MEDRANO, PhD; Fei Han; Bassem Ben Cheikh; Patrick Leinert Jr; Wm. Pat Leinert Sr; Oliver Braubach; Robert D. Schreiber, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 310 | Oral Presentation | T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade. | Yuki Muroyama, MD, PhD; Sasikanth Manne, PhD; Allison R. Greenplate, PhD; Divij Mathew, PhD; Derek A. Oldridge, MD, PhD; Lakshmi Chilukuri; Caiyue Xu; Ramin S. Herati, MD; Alexander C. Huang, MD; Dimitriy Zamarin, MD, PhD; Claire F. Friedman, MD; E. John Wherry, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Immune monitoring;T cell | |
| 312 | Poster Presentation | Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90% | Biagio Ricciuti, MD; Joao Victor M. Alessi, MD; Stephanie L. Alden; Giuseppe Lamberti, MD; Victor R. Vaz; Adriana Barrichello; Lynette M. Sholl, MD; Mark Awad, MD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade | |
| 313 | Poster Presentation | Stealthier mutanomes are induced after nivolumab immunotherapy | Guilhem Richard, PhD; Michael F. Princiotta, PhD; Gary D. Steinberg, MD; William Martin, BA MD; Anne S. de Groot, MD | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Immune tolerance;Neoantigens;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor evasion | |
| 314 | Poster Presentation | NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer | Berengere Salome, PharmD, PhD; John P. Sfakianos, MD; Andrew Charap; Adam M. Farkas, PhD; Daniel Geanon; Geoffrey Kelly; Ronaldo de Real; Brian Lee; Kristin G. Beaumont; Sanjana Shroff, PhD; Ying-Chih Wang; Yuan-Shuo A. Wang; Robert Sebra; Li Wang, PhD; Alice O. Kamphorst, PhD; Karl-Johan Malmberg, MD, PhD; Emanuela Marcenaro, PhD; Pedro J. Romero, MD; Rachel Brody, MD, PhD; Yuko Yuki; Maureen Martin, MD; Mary Carrington, PhD; Reza Mehrazin, MD; Peter Wiklund, MD; Jun Zhu, PhD; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD; Amir Horowitz, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 315 | Poster Presentation | Application of the SITC Immunotherapy Resistance Taskforce definitions of anti-PD-1 resistance to studies evaluating patients with advanced melanoma | Irene Shui, ScD; Emilie Scherrer, MSc; Andrew M. Frederickson, MS; Eric Druyts, MSc; Hussein A. Tawbi, MD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Epidemiology;Solid tumors;Targeted therapy | |
| 316 | Poster Presentation | Leucine-rich repeats and immunoglobulin-like domains protein 1 is highly expressed on tumor-infiltrating T cells and may play a role in modulating T cell activation | Li Wang, PhD; Timothy A. Chan, MD, PhD; Cassandra K. Gilmour, BS; Keman Zhang; Tyler J. Alban; Hieu M. Ta, Ph D | Checkpoint Blockade Therapy | Checkpoint blockade;T cell | |
| 317 | Poster Presentation | An immunosuppressive tumor population drives global and regional patterns of immune infiltration in heterogeneous tumors | Miho Tanaka, Ph.D.; Lotus Lum, B.Sc.; Zoe Adams, B.Sc.; Kenneth Ng, B.Sc.; Daphne Superville, B.Sc.; Melissa Reeves, Ph.D. | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 318 | Poster Presentation | Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance | Brandie C. Taylor, MS; Justin M. Balko, PharmD, PhD; Melinda Sanders, MD; Paula I. Gonzalez-Ericsson, MD; Violeta I. Sanchez, BS | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 319 | Poster Presentation | The Tumor-intrinsic NLRP3 Inflammasome Establishes a Pulmonary Metastatic Niche via Type II Epithelial HSP70/TLR4 Signaling and Facilitates Disease Hyperprogression in Response to Immunotherapy | Balamayooran BT. Theivanthiran, PhD; Fang Liu, M.D.; Nicholas C. DeVito, MD; Michael P. Plebanek, PhD; Brent A. Hanks, MD, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Granulocyte;Immune suppression;Inflammation;MDSC;Myeloid cells;TLR;Tumor microenvironment;Tumor stroma | |
| 320 | Poster Presentation | Tumor cell-intrinsic signaling mediates T cell exclusion and promotes resistance to checkpoint blockade therapy in non-small cell lung cancer | Elen Torres-Mejia, PhD; Kim B. Nguyen, B.A.; Ellen Duong, Sc.B.; Stefani Spranger, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 321 | Poster Presentation | PD-L1 checkpoint blockade eradicates residual leukemia in a mouse model of acute lymphoblastic leukemia by countering exhaustion of cytotoxic and effector CD4+ T-cells | Sean I. Tracy, MD,PhD; Sean I. Tracy, MD, PhD; Hrishi Venkatesh; Lynn Heltemes-Harris, PhD; Gregory Hubbard; Can Hekim, PhD; Michael A. Farrar | Checkpoint Blockade Therapy | B cell;Checkpoint blockade;Immune tolerance;Leukemia/Lymphoma;Regulatory T cell (Treg cell);T cell;Tumor evasion | |
| 322 | Poster Presentation | Melanoma-intrinsic hypoxia-inducible factor-1α results in diminished T cell accumulation within the tumor microenvironment | Emily Higgs; Thomas F. Gajewski, MD, PhD; Jonathan Trujillo, MD PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor evasion;Tumor microenvironment | |
| 323 | Poster Presentation | Immunogenic Syngeneic Model MC38-OVA for the Preclinical Evaluation of Immune Evasion and Checkpoint Blockade | Jessie J. Wang, PhD; Kaixia Lian; Jia Zheng; Chenpan Nie; Annie An; Henry Q. Li | Checkpoint Blockade Therapy | Adoptive immunotherapy;Checkpoint blockade;Solid tumors;T cell | |
| 324 | Poster Presentation | Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model | Fiona E. Scott, BSc (Hons) GDip IP Law; Christian W. Wichmann, PhD; Ingrid JG. Burvenich, PhD; Alexander F. McDonald, PhD; Nancy Guo, MSc; Angela Rigopoulos, MSc; Raul Soikes, MSc; Steven Angelides, MD; Reinhard von Roemeling, MD; Andrew M. Scott, MB BS, MD, FAHMS, FAICD, FAANMS | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Targeted therapy | |
| 325 | Poster Presentation | Eliminating Tumor Immune Privilege through Immune Checkpoint Cytoreduction | Michelle Winkler, BS; Michael A. Curran, PhD | Checkpoint Blockade Therapy | Antibody;Bioinformatics;Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 326 | Poster Presentation | The anti-TIGIT antibody M6223 induces significant anti-tumor efficacy and immune response via multiple mechanisms of action | Chunxiao Xu, PhD; Feng Jiang, PHD; Hui Huang, Ph.D.; Lindsay M. Webb; Sireesha Yalavarthi; Clotilde Bourin; Hong Wang; Natalya Belousova; Zhouxiang Chen; Christie Kelton; Dong Zhang, PhD; Joern-Peter Halle; Andree Blaukat; Jacques Moisan | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 327 | Poster Presentation | Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma | Jiajia Zhang, MD, MPH; Justina Caushi; Giacomo Oliveira, PhD; Boyang Zhang; Zhicheng Ji; Jarushka Naidoo, MD, MHS; Kristen A. Marrone, MD; Janis M. Taube, MD; Matthew D. Hellmann, MD; Julie R. Brahmer, MD, MS; Taha Merghoub, PhD; Patrick Forde; Srinivasan Yegnasubramanian; Catherine J. Wu, MD; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie Smith | Checkpoint Blockade Therapy | Checkpoint blockade;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 328 | Oral Presentation | Batf3 dendritic cells and 4-1BB/4-1BB ligand axis are required at the effector phase within the tumor microenvironment for anti-PD-L1 efficacy | Andrea Ziblat, PhD; Brendan L. Horton, PhD; Emily Higgs; Ken Hatogai, MD PhD; Thomas F. Gajewski, MD, PhD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Costimulation;Dendritic cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 329 | Poster Presentation | Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials | Jian-Guo Zhou, MD; Ada Hang-Heng Wong; Haitao Wang; Su-Han Jin; Fangya Tan; Yu-Zhong Chen; Si-si He; Gang Shen; Benjamin Frey; Markus Hecht; Rainer Fietkau; Bo Shen; Hu Ma; Udo S. Gaipl | Clinical Trials Completed | Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Epidemiology;Monocyte/Macrophage;Solid tumors | |
| 330 | Poster Presentation | Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors | Daruka Mahadevan; Li Ma, PhD; Kai Treuner, PhD; Jenna Wong, MS; Catherine A. Schnabel, PhD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Gene expression;Solid tumors;Targeted therapy | |
| 331 | Poster Presentation | Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma | Daniela A. Bota, MD., PhD; David E. Piccioni, MD,PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Frank Hsu, MD PhD; Xiao-Tang Kong, MD PhD; Mehrdad Abedi, MD; Robert D. Aiken, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD | Clinical Trials Completed | Biomarkers;Clinical trial;Dendritic cell;Neoantigens;Stem cell/cancer-initiating cell | |
| 332 | Poster Presentation | Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma | Christopher M. Duma, MD; Daniela A. Bota, MD., PhD; Frank Hsu, MD PhD; David E. Piccioni, MD,PhD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Mehrdad Abedi, MD; Jose A. Carrillo, MD; Robert D. Aiken, MD; Xiao-Tang Kong, MD PhD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD | Clinical Trials Completed | Clinical trial;Dendritic cell;Neoantigens;Stem cell/cancer-initiating cell;Vaccine | |
| 333 | Poster Presentation | Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma | Santosh Kesari, MD, PhD; Daniela A. Bota, MD., PhD; David E. Piccioni, MD PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Xiao-Tang Kong, MD PhD; Frank Hsu, MD PhD; Jose A. Carrillo, MD; Mehrdad Abedi, MD; Robert D. Aiken, MD; Thomas H. Taylor, PhD; Aleksandra J. Poole, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD | Clinical Trials Completed | Clinical trial;Dendritic cell;Immune monitoring;Neoantigens;Proteomics;Vaccine | |
| 334 | Poster Presentation | Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with Tumor Treating Fields for newly diagnosed glioblastoma patients | Adilia Hormigo, MD, PhD; Julia Kodysh, MSc; Cansu Cimen Bozkus, PhD; Mansi Saxena, PhD; Marcia Meseck, MS, JD; Alexander Rubinsteyn, PhD; Timothy J. O, PhD; Tin Htwe Thin, PhD; Rachel Brody, MD, PhD; John Mandeli, PhD; Nina Bhardwaj, MD, PhD | Clinical Trials Completed | Bioinformatics;Clinical study;Clinical trial;Immune monitoring;Immune suppression;Neoantigens;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 335 | Poster Presentation | Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma | Renato V. LaRocca, MD; Daniela A. Bota, MD., PhD; David E. Piccione, MD, PhD; Christopher M. Duma, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Xiang-Tang Kong, MD PhD; Frank Hsu, MD PhD; Robert D. Aiken, MD; Mehrdad Abedi, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD | Clinical Trials Completed | Clinical trial;Dendritic cell;Monocyte/Macrophage;Neoantigens;Stem cell/cancer-initiating cell;Vaccine | |
| 336 | Poster Presentation | Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma | David E. Piccioni, MD,PhD; Daniela A. Bota, MD., PhD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carillo, MD; Xiao-Tang Kong, MD, PhD; Christopher M. Duma, MD; Mehrdad Abedi, MD; Robert D. Aiken, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD | Clinical Trials Completed | Clinical trial;Dendritic cell;Immune toxicity;Stem cell/cancer-initiating cell;Vaccine | |
| 337 | Oral Presentation | Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab | Craig L. Slingluff, Jr., MD; Ileana S. Mauldin, PhD; Elizabeth M. Gaughan, MD; Patrick Dillon, MD; Mateusz Opyrchal, MD PhD; Igor Puzanov, MD, MSCI; Megan Kruse, MD; Brian Gastman, MD; Philip Friedlander, MD PhD; Thomas U. Marron, MD, PhD; Kristen Aufiero; Mary Macri, BSc; Paul Schwarzenberger, MD; Toni Ricciardi, BSMT; Aileen Ryan, MS; Ralph R. Venhaus, MD; Mansi Saxena, PhD; Nicole Edmonds; Nina Bhardwaj, MD, PhD | Clinical Trials Completed | Antibody;Checkpoint blockade;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 338 | Poster Presentation | Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study | Peter Schmid, MD, PhD; Yeon Hee Park; Eva Muñoz-Couselo; Sung-Bae Kim; Joohyuk Sohn; Seock-Ah Im; Esther Holgado; Theodoros Foukakis; Sherko Kümmel, MD, PhD; Rebecca Dent; Yuan Sun; Lingkang Huang, Ph.D.; Jennifer Yearley, PhD; Petar Jelinic, MD; Vassiliki Karantza; Javier Cortés | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Gene expression;Tumor microenvironment;Tumor stroma | |
| 339 | Poster Presentation | Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy | Aaron D. Stevens; Joyce O'Shaughnessy; Subing Cao; Jessica Sorrentino; Janet Horton; John S. Yi; Antoinette R. Tan | Clinical Trials Completed | Chemotherapy;Clinical study;Gene expression;Immune monitoring;RNA;Solid tumors;T cell;T cell lineages;Tumor microenvironment | |
| 340 | Poster Presentation | A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC) | Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Keith Dredge, PhD; Darryn Bampton; Edward Hammond; Amanda Stanley; Lucie Leveque-ElMouttie; Grace Chojnowski; Andrew M. Haydon, PhD; Nick Pavlakis; Matthew Burge; Michael P. Brown; David Goldstein | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;T cell;TLR | |
| 341 | Poster Presentation | A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC). | Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Keith Dredge, PhD; Darryn Bampton; Edward Hammond; Andrew Clouson; Nigel Waterhouse; Amanda Stanley; Lucie Leveque-ElMouttie; Grace Chojnowski; Andrew M. Haydon, PhD; Nick Pavlakis; Matthew E. Burge; Michael P. Brown; david goldstein, MD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
| 342 | Poster Presentation | Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study | David Krige, PhD; Marwan Fakih; Lee Rosen; Ding Wang, MD; Wael A. Harb, MD, CPI; Hani Babiker; Jordan Berlin, MD; Gianfranco Di Genova; David Miles; Mark Powell; Minesh Patel; Jo Carter; Richard A. Brown, PhD; Tom Lillie, MD PhD | Clinical Trials Completed | Checkpoint blockade;Clinical study;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 343 | Poster Presentation | Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer. | Deena M. Maurer, PhD; Jia Xin Yu, PhD; Kamil Sklodowski, PhD; Marco Tognetti, PhD; Lukas Reiter, PhD; Roland Bruderer, PhD; Jakob Vowinckel, PhD; Shannon M. Pfeiffer, MS; Mark H. O'Hara, MD; Eileen M. O’Reilly, MD; Robert A. Wolff, MD; Zev A. Wainberg, MD; Andrew H. Ko, MD; Osama Rahm, MD; George A. Fisher, MD; Jaclyn P. Lyman, MS; Christopher R. Cabanski, PhD; Pier Federico Gherardini, PhD; Jill O’Donnell-Tormey, PhD; Theresa M. LaVallee, PhD; Robert H. Vonderheide, MD, PhD; Lacey J. Kitch, PhD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Clinical trial;Costimulation;Immune suppression;Solid tumors | |
| 344 | Poster Presentation | Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial | Jordi Rodon; Daniel S. Weng Tan; Ignacio Garrido Laguna; Wael Harb; J. Thaddeus Beck; Nathan Bahary, MD PhD; Sylvie Rottey, MD; Zhou Zhu; Shibing Deng; Karen Kowalski; Grainne O'Neill; Caimiao Wei; Nuzhat Pathan; Wells A. Messersmith, MD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy | |
| 345 | Poster Presentation | Phase I/II trial of cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies (CAMILLA): Phase Ib safety and efficacy results | Anwaar Saeed, MD; Robin Park; Junqiang Dai; Raed Al-Rajabi; Anup Kasi; Joaquina Baranda; Stephen Williamson; Zachary Collins; Jacob Ripp; Azhar Saeed; Kelly Mulvaney; Vanna Manirad; Rashna Madan; Dharmalingam Subramaniam; Shrikant Anant; Milind Phadnis; Weijing Sun | Clinical Trials Completed | Angiogenesis;Checkpoint blockade;Clinical trial;Tumor microenvironment | |
| 346 | Poster Presentation | Translational program of the phase II MEDITREME trial: Identification of prognostic factors for response to durvalumab and tremelimumab in combination with FOLFOX in metastatic colorectal cancer. | Marion Thibaudin, PhD; Elise Ballot; Emeric Limagne, PhD; Caroline Laheurte, PhD; Jean-David Fumet, MD; Caroline Truntzer, PhD; Olivier Adotevi, MD, PhD; François Ghiringhelli, MD, PhD | Clinical Trials Completed | Clinical trial;Immune monitoring;Neoantigens;T cell | |
| 347 | Poster Presentation | KEYNOTE-365 cohort C: Pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—Data after minimum of 22 months of follow-up | Leonard J. Appleman, MD, PhD; Tilman Todenhoefer; William Berry; Howard Gurney; Margitta Retz; Henry Conter; Brigitte Laguerre; Peter Fong; Cristiano Ferrario; Gwenaelle Gravis; Josep M. Piulats, MD, PhD; Urban Emmenegger; Neal Shore, MD, FACS; Emanuela Romano, MD, PhD; Loic Mourey; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Johann S. De Bono, PhD; Evan Y. Yu, MD | Clinical Trials Completed | Checkpoint blockade;Clinical trial | |
| 348 | Poster Presentation | Interleukin 2(IL-2) Systems Immunology Modeling: Machine Learning for Cancer Immunotherapy | Jennifer Bone, PhD; Newell R. Washburn, PhD; Jian Han, PhD; Miranda Steele; Pranav Murthy, BS; Michael T. Lotze, MD | Clinical Trials Completed | B cell;Bioinformatics;Immune monitoring;Systems biology;T cell | |
| 349 | Poster Presentation | Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 | Vijay Kasturi, MD; Bernard J. Escudier, MD; Brian I. Rini, MD; Sumanta K. Pal, MD; David F. McDermott, MD; Camillo Porta, MD; Elena Verzoni | Clinical Trials Completed | Checkpoint blockade;Clinical trial;Targeted therapy | |
| 350 | Oral Presentation | Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) | Douglas G. McNeel, MD, PhD; Jens Eickhoff, PhD; Ellen Wargowski, BS; Laura E. Johnson, PhD; Christos E. Kyriakopoulos, MD; Hamid Emamekhoo, MD; Joshua M. Lang, MD MS; Mary Jane Brennan, RN; Glenn Liu, MD | Clinical Trials Completed | Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immune toxicity;Solid tumors;Tumor antigens;Vaccine | |
| 351 | Poster Presentation | KEYNOTE-365 cohort D: Pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) | Josep M. Piulats, MD, PhD; Cristiano Ferrario; Mark Linch, MD; Michael Stoeckle; Brigitte Laguerre; Jose A. Arranz; Tilman Todenhoefer; Peter Fong; William Berry; Urban Emmenegger; Loic Mourey; Nataliya Mar, MD; Leonard J. Appleman, MD, PhD; Anthony M. Joshua, MBBS, PhD; Henry Conter; Xin Tong Li; Charles Schloss; Christian H. Poehlein, MD; Johann S. De Bono, PhD; Evan Y. Yu, MD | Clinical Trials Completed | Checkpoint blockade;Clinical trial | |
| 352 | Poster Presentation | Target Modulation within the Tumor Microenvironment (TME) by Daratumumab (anti-CD38) but not Edicotinib (CSF-1R inhibitor) in Men with High-Risk Localized Prostate Cancer | Bilal A. Siddiqui, MD; Brian F. Chapin, MD; Sonali Jindal, MD; Fei Duan, PhD; Shalini Singh, PhD; Curtis A. Pettaway, MD; John F. Ward, III, MD; Rebecca S. Tidwell; Paul G. Corn, MD, PhD; Christopher J. Logothetis, MD; James P. Allison, PhD; Padmanee Sharma, MD, PhD; Sumit K. Subudhi, MD, PhD | Clinical Trials Completed | Clinical trial;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Surgery;T cell;Tumor microenvironment | |
| 353 | Poster Presentation | Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer | Oliver Dorigo, MD, PhD; Walead Ebrahimizadeh, PhD; Barry Kennedy, PhD; Lisa MacDonald, MSc; Stephan Fiset, MSc, MBA; Jeannine Villella, DO, FACOG, FACS; Amit OZA, MD; Tanja Pejovic, MD, PhD; Prafull Ghatage, MD, FRCSC; Sharad A. Ghamande, MD; Diane Provencher, MD FRCS FACOG; Yogesh Bramhecha, PhD | Clinical Trials Completed | Biomarkers;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 354 | Poster Presentation | Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study | Vicky Makker, MD; Carol Aghajanian; Allen L. Cohn; Margarita Romeo; Raquel Bratos; Marcia S. Brose, MD PhD; Mark Messing; Lea Dutta; Corina E. Dutcus; Jie Huang; Emmett V. Schmidt, MD PhD; Robert J. Orlowski, MD; Matthew H. Taylor | Clinical Trials Completed | Angiogenesis;Antibody;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 355 | Poster Presentation | Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients. | Judith Michels, MD PhD; Jean-Sebastien Frenel; Catherine Genestie; François Ghiringhelli; Caroline Brard; Benoit You; Anne Floquet, MD; Lauriane Eberst; Rastilav BAHLEDA; Corinne Balleyguier; Angelo Paci; Joseph Ciccolini; Emeline Colomba; Fanny Pommeret; Christophe Massard, MD, PhD; Patricia Pautier, MD; Aurelien Marabelle; Alexandra Leary | Clinical Trials Completed | Angiogenesis;Checkpoint blockade;Clinical trial | |
| 356 | Poster Presentation | Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer | Els M. Verdegaal, PhD; Marten Visser, MSc; Lien E. van der Minne, MSc; Linda de Bruin; Inge F. Roozen; Pauline Meij, PhD; Sjoerd H. van der Burg, Prof.Dr.; Judith R. Kroep, MD, PhD | Clinical Trials Completed | Adoptive immunotherapy;Chemotherapy;Clinical study;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 357 | Poster Presentation | Toripalimab plus chemoradiotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II trial | Xiaoting Xu; Jian Huan; Hui Miao; Hao Wang; Yue Wang; Hongyu Zhu; Jun Jiang; Juying Zhou, MD | Clinical Trials Completed | Antibody;Carcinogenesis;Chemotherapy;Clinical study;Clinical trial;Coinhibition;Genetic polymorphism;Immune contexture;Immune suppression;Solid tumors | |
| 358 | Poster Presentation | Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: A phase 1-2 trial | Douglas R. Adkins, MD; Jessica Ley; Kevin Palka; Miriam T. Jacobs; Jingxia Liu, MS, PhD; Peter Oppelt, MD | Clinical Trials Completed | Angiogenesis;Checkpoint blockade;Clinical trial;Solid tumors | |
| 359 | Poster Presentation | Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC) | Antonio López Pousa; Enriqueta Felip, MD, PhD; Martin Forster; Bernard Doger; Patricia Roxburgh; Pawan Bajaj; Julio A. Peguero, MD; Enric Carcereny, MD; Matthew G. Krebs, MD, PhD; Christian Mueller, MSc; Frederic Triebel, MD, PhD | Clinical Trials Completed | Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;T cell | |
| 360 | Poster Presentation | Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC) | Chiun Hsu; Julien Edeline; Gianluca Masi; Yuk Ting Ma; Weilin Wang; Henning Wege; Cong Fei; Chen Ling; Xiaopeng Ma; Pei Zhang; Ruiqi Huang; Xikun Wu; Zhirong Shen; Bai Li; Sandra Chica Duque; Zhiqiang Meng | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Tumor microenvironment | |
| 361 | Poster Presentation | Heterogeneity of PD-1hi T cells associates with response to PD-1 blockade in hepatocellular carcinoma | Assaf Magen, PhD; Pauline Hamon, PhD; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Alice O. Kamphorst, PhD; Miriam Merad, MD, PhD | Clinical Trials Completed | Antigen presenting cells;Bioinformatics;Biomarkers;Checkpoint blockade;Costimulation;Immune monitoring;Immune suppression;Immunoscore;Tumor infiltrating lymphocytes (TILs);Tumor stroma | |
| 362 | Poster Presentation | Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma | Philippe Merle; Helena Verdaguer Mata; Congying Xie; Richard Hubner; Yong Liu; Jane Margetts; Ying Cheng, MD; Yee Chao; Cong Fei; Chen Ling; Ruiqi Huang; Xikun Wu; Zhirong Shen; Bai Li; Sandra Chica Duque; Zhenggang Ren | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Immune monitoring;Solid tumors | |
| 363 | Poster Presentation | KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer | Gilberto De Castro, Jr., DR; Gilberto de Castro Jr, MD, PhD; Iveta Kudaba; Yi-Long Wu; Gilberto Lopes; Dariusz M. Kowalski; Hande Z. Turna; Christian Caglevic; Li Zhang; Boguslawa Karaszewska; Konstantin K. Laktionov; Vichien Srimuninnimit; Igor Bondarenko; Kaoru Kubota; Rinee Mukherjee; Jianxin Lin; Fabricio Souza; Tony S. K. Mok; Byoung Chul Cho, MD, PhD | Clinical Trials Completed | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial;Solid tumors | |
| 364 | Poster Presentation | KRAS Mutations in Patients With Nonsquamous Non–Small-Cell Lung Cancer: Prevalence and Relationship With PD-L1 Expression, Tumor Mutation Burden and Smoking Status | Marina Chiara Garassino, MD; Marina C. Garassino; Delvys Rodriguez-Abreu; Shirish M. Gadgeel; Dariusz M. Kowalski; Kazuo Kasahara; Enriqueta Felip, MD, PhD; Yi-Long Wu; Gilberto de Castro Jr, MD, PhD; Byoung Chul Cho, MD, PhD; Hande Z. Turna; Hidehito Horinouchi; Martin Reck; Rina Hui; Edward B. Garon; Michael Boyer, MB BS PhD; Tony S.K. Mok; Gilberto Lopes; Julie Kobie; Yongjin Li; Mark A. Ayers; Razvan Cristescu; Bin Zhao; M. Catherine Pietanza; Roy S. Herbst | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Gene expression;Targeted therapy | |
| 365 | Poster Presentation | Computational pathology delivers objective and quantitative PD-L1 expression analysis for enrichment of responders to durvalumab in non-small cell lung cancer (NSCLC) | Guenter Schmidt, PhD; Ansh Kapil; Lina Meinecke, PhD; Farzad Sekhavati, PhD; Jan Lesniak, PhD; Anatoliy Shumilov, PhD; Thomas Padel, PhD | Clinical Trials Completed | Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors | |
| 366 | Poster Presentation | Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial | Santiago Viteri, MD; Werner Hilgers; Fabrice Denis; Elisabeth Quoix, MD; Gilles Robinet, MD; Enriqueta Felip, MD, PhD; Rafal Dziadziuszko, MD; Nicolas Poirier; Claudia Fromond, PhD; Isabelle Girault; Thomas Vandewalle; Dominique Costantini, MD; Bérangère Vasseur, MD; Federico Cappuzzo, MD; Giuseppe Giaccone, MD; Benjamin Besse, MD, PhD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immunoscore;Solid tumors;Tumor antigens;Tumor microenvironment;Vaccine | |
| 367 | Poster Presentation | Pharmacokinetic and immunologic data from a Phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform | Vivek A. Bhadri, MD, PhD; Vivek Subbiah, MD; James F. Strauss, MD; Sant P. Chawla, MD; Nam Bui, MD; Vineet Kwatra, MD; Mia Weiss, MD; Kathleen Batty, MD; Michael Zakharian, MS; Jose M. Mejia Oneto, MD, PhD; Sangeetha Srinivasan, PhD; Nathan A. Yee, PhD; Rosalind Wilson, MD; M. Wayne Saville, MD; Alexander Guminski, MD, PhD | Clinical Trials Completed | Antigen presenting cells;Clinical study;Clinical trial;Immune adjuvant;Immune suppression;Inflammation;Tumor antigens;Tumor stroma | |
| 368 | Poster Presentation | Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors | Lukasz Kuryk, PhD; Anne-Sophie Moller; Sandeep Kumar; Alexander N. Shoushtari, MD; Luis Paz Ares, MD, PhD; Magnus Jaderberg; Erik Digman Wiklund, PhD; Victor Levitsky, MD, PhD | Clinical Trials Completed | Checkpoint blockade;Chemotherapy;Gene expression;Immune monitoring;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 369 | Poster Presentation | Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers | Devalingam Mahalingam, MBBCh BAO; Mary Mulcahy, MD; Dejan Juric; Manish R. Patel, MD; Shubham Pant, MD; Susanna Ulahannan, MD, MMED; Afshin Dowlati; Andrea J. Bullock, MD; Lou Vaickus, MD; Susanne Fyfe; Melanie Vincent, PhD; Suming Wang, Ph.D; Jian J. Chen, PhD; Marsha Crochiere, PhD; Randolph Watnick, Ph.D; Michael Cieslewicz, Ph.D; Jing Watnick, Ph.D | Clinical Trials Completed | Biomarkers;Clinical study;Clinical trial;MDSC;Solid tumors;Tumor microenvironment | |
| 370 | Poster Presentation | Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial | Bhavana Pothuri, MD; Dominique Berton, MD; Victor Moreno; Ana Oaknin, MD; Jose Manuel Trigo Perez, MD, PhD; Giuseppe Curigliano, MD, PhD; Susan Ellard; Joanna Pikiel, Dr n. med.; Susana Banerjee; Maria-Pilar Barretina-Ginesta; Rowan Miller; Anna Tinker; Andrea Jewell; Ruth Plummer; Florence Joly; Jennifer Veneris; Tao Duan; Thierry Andre, MD PhD | Clinical Trials Completed | Clinical trial;Solid tumors | |
| 371 | Poster Presentation | Analysis of changes in plasma cytokine levels in response to IL-12 therapy in three clinical trials | Emily Schwarz, BS; Brooke Benner, PhD; Lianbo Yu, PhD; William E. Carson, III, MD, FACS | Clinical Trials Completed | Chemokine;Clinical study;Clinical trial;Cytokine;Immune monitoring;Myeloid cells;NK/NKT cell;T cell | |
| 372 | Poster Presentation | Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab | Lin Shen; Qingyuan Zhang; Tianshu Liu; Hongming Pan; Yuxian Bai; Ying Yuan; Xuerui Luo; Yang Shi; Yun Zhang; Ruiqi Huang; Juan Zhang; Zhirong Shen | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Solid tumors | |
| 373 | Poster Presentation | Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion | Emily Schmidt, PhD; Katerina Mardilovich, PhD; Natalie Bath, MSc; Gareth Betts, PhD; William Spinner; Kathryn Sun; Ian Donaldson; Cheryl McAlpine; Raymond Luke; Jean-Marc Navenot; Joseph P. Sanderson, PhD; Phil Bassett; Chris Evans; Karen Miller, PhD; Quan Lin; Mark Dudley; Alex J. Tipping, PhD | Clinical Trials Completed | T cell | |
| 374 | Oral Presentation | A Phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors | Kevin Tyan, BA; Osama E. Rahma, MD; Anita Giobbie-Hurder, MS; Andrew S. Brohl, MD; Philippe Bedard, MD; Daniel Renouf, MD; Elad Sharon, MD, MPH; Howard Streicher, MD; Emma Hathaway; Rachel Cunningham; Michael P. Manos; Mariano Severgnini, MSc; Scott J. Rodig, MD, PhD; F. Stephen Hodi, Jr., MD | Clinical Trials Completed | Angiogenesis;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Solid tumors;T cell;T cell lineages;Tumor microenvironment | |
| 375 | Poster Presentation | Development of Thrombospondin-1 as a clinical pharmacodynamic biomarker for VT1021, a first-in-class therapeutic agent that reprograms the tumor microenvironment. | Jian J. Chen, PhD; Marsha Crochiere, PhD; Melanie Vincent, PhD; Suming Wang, Ph.D; Susanne Fyfe; Wendy Li; Simai Deng; Randolph Watnick, Ph.D; Jing Watnick, Ph.D; Michael Cieslewicz, Ph.D | Clinical Trials Completed | Biomarkers;Clinical study;Clinical trial;MDSC;Solid tumors;Tumor microenvironment | |
| 376 | Poster Presentation | Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922) | James Welsh; Danxia Ke; Nahum Puebla Osorio; Hampartsoum Barsoumian; Bryan Jackson; Jane Bai; Marisa B. Rosenberg, MS; Cheryl McAlpine; Robyn Broad; Ashley Liddle; Jean-Marc Navenot; Stavros Rafail; Ruoxi Wang; Amy Sauer; Quan Lin; Hassan Danesi; David S. Hong, Professor | Clinical Trials Completed | T cell | |
| 377 | Poster Presentation | Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a Phase 1 dose escalation study in patients with advanced solid tumors | Marianna Zavodovskaya, M.S.; Anthony Tolcher, M.D., FRCPC, FACP; Michael Gordon, MD; James F. Strauss, MD; Kathleen Mahoney, MD, PhD; Ping Cheng Yi, M.S.; Rick Sorensen, BS; Xiaoyun Yang, PhD; Kai-Wen Lin; Biao Li, PhD; Anna Seto, PharmD; Matthew L. Peach, MS; Audrey D. Goddard, Ph.D.; Tianling Chen, MD, MSc; Juliane M. Jürgensmeier, PhD | Clinical Trials Completed | Antibody;Biomarkers;Bispecifics;Clinical trial;Solid tumors;Tumor microenvironment | |
| 378 | Poster Presentation | Efficacy, Safety and Ancillary analyses of Pembrolizumab in combination with Nintedanib for the treatment of Patients with relapsed Advanced Mesothelioma. | Francois-Xavier Danlos, MD, PhD student; Capucine Baldini, MD; Matthieu Texier; Andreea Varga, MD; Séverine Mouraud, MS; Bastien Job; Diane Letourneur; Lydie Cassard, PhD; Delphine Bredel; Salim Laghouati; Julien Adam, MD; Nathalie Droin, PhD; Aurelien Parpaleix; Nathalie Chaput-Gras; Audrey Rabeau, MD; Gerard Zalcman; David Planchard, MD, PhD; Christophe Massard, MD, PhD; Jean-Charles Soria, MD, PhD; Aurelien Marabelle | Clinical Trials Completed | Angiogenesis;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Immune monitoring;Inflammation;Solid tumors;Tumor microenvironment | |
| 379 | Oral Presentation | Immune infiltrates are associated with clinical outcomes in patients with resectable soft tissue sarcoma (STS) treated with neoadjuvant immune checkpoint blockade (ICB) | Emily Z. Keung, MD, MA; Elise F. Nassif; Heather Lin, PhD; Alexander J. Lazar, MD / PhD; Wei-Lien Wang; Edwin R. Parra, MD, PhD; Cibelle F. Lima; Ignacio Wistuba, MD; Ashleigh Guadagnolo; Andrew J. Bishop; Valerae O. Lewis; Keila Torres; Kelly K. Hunt, MD; Barry W. Feig; Christopher P. Scally; Ahmed N. Al Rawi; Shadarra D. Crosby; Grace Mathew; Davis Ingram; Khalida Wani, PhD; Jennifer A. Wargo, MD, MMSc; Neeta Somaiah, MD, MBBS; Christina L. Roland, MD, MS, FACS | Clinical Trials Completed | B cell;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Surgery;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 380 | Poster Presentation | GS-3583, a novel FLT3 agonist Fc fusion protein, expands conventional dendritic cells in healthy volunteers | Nishanthan Rajakumaraswamy, MD; Anees Dauki; Michelle R. Kuhne, PhD; Torsten Trowe; Winnie Weng; Kai-Wen Lin; Emon Elboudjwarej; Brian Carr; Angela Worth; Anshu Vashishtha; Christian Schwabe; Ahmed A. Othman | Clinical Trials Completed | Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune monitoring;Solid tumors;Tumor antigens;Tumor microenvironment | |
| 381 | Poster Presentation | Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: The phase 1b MITCI study | Carlo D. Bifulco, MD; Jon Richards; John Hyngstrom, MD; Gregory Daniels; Mark B. Faries, MD; Lynn Feun; Kim Margolin; Sigrun Hallmeyer; Mark Grose; Yiwei Zhang; Anlong Li; Robert H. I. Andtbacka | Clinical Trials Completed | Checkpoint blockade;Clinical trial;Immune toxicity;Vaccine | |
| 382 | Poster Presentation | The synthetic long peptide cancer vaccine UV1 in combination with ipilimumab induces a CD4+ Th1 anti-hTERT immune response and an inflammatory tumor microenvironment in patients with melanoma | Espen B. Ellingsen, MD; Iliana Kerzeli; Irantzu Anzar; Nadia Mensali, PhD; Trevor Clancy; Sara M. Mangsbo, PhD MSc; Steinar Aamdal; Elin Aamdal; Tormod K. Guren, MD, PhD; Else-Marit Inderberg-Suso; Eivind Hovig; Gustav Gaudernack | Clinical Trials Completed | Checkpoint blockade;Clinical trial;Gene expression;Immune monitoring;RNA;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 383 | Poster Presentation | Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from Keynote 695 | Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, M.D., Ph.D.; Katy K. Tsai, MD; Victoria G. Atkinson, MD; Monaster Shaheen; Sajeve S. Thomas; Catalin Mihalcioiu, MD, FRCP; Tom Van Hagen, MD; Rachel Roberts-Thomson, MD; Andrew M. Haydon, PhD; Andrew Mant, MD; Marcus O. Butler; Gregory Daniels; Elizabeth Bunchbinder; John Hyngstrom, MD; Mecker Moller; Igor Puzanov, MD, MSCI; C Lance Cowey; Eric D. Whitman, MD, FACS; Carmen Ballesteros-Merino, PhD; Shawn Jensen, PhD; Bernard Fox, PhD; Emmett V. Schmidt, MD PhD; Scott J. Diede, MD, PhD; Rebecca Setta; Jendy Sell; David Canton; Sandra Aung; Christopher Twitty; Sunny Xie; Ying Lu; Bridget O'Keefe; Alain P. Algazi, MD; Adil I. Daud, MD | Clinical Trials Completed | Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;Tumor microenvironment | |
| 384 | Poster Presentation | An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy | MacLean Hall, BS; Holly Branthoover; Patrick Innamarato, B.S.; Amy M. Hall; Alex Alfaro; Allison Richards; Jeani Rich; Jonathan A. Hensel, PhD; Jim Bender; Jake Ceccarelli; TJ Langer; Matthew Beatty, PhD; John E. Mullinax, MD; Jamie Teer, PhD; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD | Clinical Trials Completed | Adoptive immunotherapy;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 385 | Poster Presentation | Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL) | MacLean Hall, BS; Holly Branthoover; Matthew Beatty, PhD; Kwame Twumasi-Boateng; Jim Bender; Jake Ceccarelli; TJ Langer; Jamie Teer, PhD; Amod A. Sarnaik; Shari A. Pilon-Thomas, PhD | Clinical Trials Completed | Adoptive immunotherapy;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 387 | Poster Presentation | The utility of AI-powered spatial classification of intratumoral CD8+ immune-cell distribution in predicting overall survival in patients with melanoma as part of the CheckMate 067 clinical trial | George Lee, PhD; Keyur Desai, PhD; Hao Tang, PhD; Daniel N. Cohen, MD, PhD; Scott Ely; John B. Wojcik, MD, PhD; Jimena Trillo-Tinoco; Benjamin J. Chen, MD, PhD; Akshita Gupta; Daniel Tenney; Vipul Baxi, MS; Robin Edwards, MD; Megan Wind-Rotolo, PhD | Clinical Trials Completed | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 388 | Poster Presentation | A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vaccine and correlative studies) | Craig L. Slingluff, Jr., MD; Kimberly A. Chianese-Bullock, PhD; Ileana S. Mauldin, PhD; Walter C. Olson, Jr., PhD; Kelly Smith; Lynn T. Dengel, MD; Kathleen Haden, NP, MS; Elizabeth M. Gaughan, MD; Varinder Kaur, MD; William W. Grosh, MD | Clinical Trials Completed | Antibody;Checkpoint blockade;Clinical trial;Immune adjuvant;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 389 | Poster Presentation | Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy | Sarah A. Weiss, MD; Mario Sznol, MD; Montaser Shaheen, MD; Miguel-Ángel Berciano-Guerrero, MD, PhD; Enriqueta Felip, MD, PhD; Delvys Rodríguez-Abreu, MD; Ana Maria Arance, MD, PhD; Valentina Boni, MD, PhD; Gerald P. Linette, MD, PhD; Lynn M. Schuchter, MD; Maria Gonzalez-Cao, MD, PhD; Nicholas O. Iannotti, MD; Apar Kishor Ganti, MD, MS; Ralph J. Hauke, MD; Alfonso Berrocal, MD; Erin L. Filbert, PhD; Harriet M. Kluger, MD | Clinical Trials Completed | Antibody;Antigen presenting cells;Clinical trial;Costimulation;Solid tumors | |
| 390 | Poster Presentation | A Global, Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials | Melissa L. Johnson, MD; Adrian Sacher; Marcus O. Butler; Hassane Zarour; Jeffrey Weber; Edward B. Garon; David P. Carbone, MD, PhD; Arindam Dhar; Cristina H. Messina; Roma Patel; Kristin Blouch; Axel Hoos; Anne-Marie Martin | Clinical Trials In Progress | Biomarkers;Clinical study;Gene expression;Immune contexture;Tumor microenvironment | |
| 391 | Poster Presentation | Biomarker correlates of response in patients with advanced Myxoid/Round Cell Liposarcoma (MRCLS) treated with NY-ESO-1 TCR T cells (Letetresgene autoleucel) | Gurpreet S. Kapoor, PhD; Stefan Zajic; Sunil Suchindran; Jaegil Kim; Ioanna S. Eleftheriadou; Anne Huff; Michael Nathenson; Mihaela Druta; Brian A. Van Tine, MD, PhD; Neeta Somaiah, MD, MBBS; David A. Liebner, MD; Scott Schuetze; Sandra D’Angelo | Clinical Trials In Progress | Adoptive immunotherapy;Biomarkers;Chemokine;Cytokine;Gene expression;Immune monitoring;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 392 | Poster Presentation | A Phase 1a/b Study of IK-175, an Oral AHR Inhibitor, Alone and in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | Meredith McKean, MD; Jason J. Luke; Nehal J. Lakhani, MD; Babar Bashir, MD, MS; David H. Aggen, MD, PhD; Alan Tan, MD; Katherine Kacena, PhD; Lei Wang, PhD; Marissa Timothy, MS; Sergio L. Santillana, MD, MSc, MBA | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 393 | Poster Presentation | A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers | Samuel J. Klempner, MD; John H. Strickler, MD; Lindsey Gourley; Celine Jacquemont; Vinona Bhatia; Naomi Hunder; Valerie Odegard, PhD; Sarina A. Piha-Paul, MD | Clinical Trials In Progress | Antibody;Biomarkers;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Neoantigens;NK/NKT cell;T cell;TLR | |
| 395 | Poster Presentation | Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma | Francesca Barone, MD, PhD; Sean e. Lawler, PhD; Laura K. Aguilar, MD, PhD; Jessica E. Dwyer; Brian Guzik, PhD; Isaac H. Soloman; Hiroshi Nakashima, PhD; Daniel Triggs, NP; Abigail Tianai Zhang; Yu Zeng, PhD; Jared Woods, MD, PhD; James Grant; David A. Reardon, MD; Patrick Y. Wen, MD; Eudocia Quant Lee, MD, MPH; Keith L. Ligon, MD, PhD; William Pisano; Scott J. Rodig, MD, PhD; Mario Suva, MD, PhD; Kai W. Wucherpfennig, MD, PhD; Sascha Marx, MD; Simon Gritsch, MD, PhD; Nathan D. Mathewson, PhD; Mariano Severgnini, MSc; Anita Giobbie-Hurder, MS; David Krisky, MD, PhD; Estuardo Aguilar-Cordova, MD, inf., PhD; Paul P. Tak, MD, PhD, FMedSci; E. Antonio Chiocca, MD, PhD | Clinical Trials In Progress | Chemokine;Clinical study;Clinical trial;Cytokine;Immune monitoring;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 396 | Poster Presentation | NT-I7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation | Alice Y. Zhou, MD, PhD; Michael P. Rettig, PhD; Jennifer A. Foltz, PhD; Jingqin Luo, PhD; Omar H. Butt, MD, PhD; Chai Avvaru; Ruth GN. Katumba; Albert H. Kim, MD, PhD; Gavin P. Dunn, MD, PhD; Christopher D. Abraham, MD; Se Hwan Yang, PhD; Jean Fan, MD, MSc; Byung Ha Lee, PhD; NgocDiep Le, MD, PhD; George Ansstas, MD; Tanner M. Johanns, MD, PhD; Jiayi Huang, MD; Milan G. Chheda, MD; Todd A. Fehniger, MD, PhD; Jian L. Campian, MD, PhD | Clinical Trials In Progress | Clinical study;Clinical trial;Immune adjuvant;Immune monitoring | |
| 397 | Poster Presentation | A phase I/II trial of intracerebroventricular 177Lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors | Elena Pentsova; Maria Düring; Charlotte Lybek Lind; John Rømer Nielsen | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Radiotherapy;Targeted therapy | |
| 398 | Poster Presentation | neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC) | Katherine Sanchez, MD; Alison K. Conlin, MD; Parvin Peddi, MD; Sasha E. Stanton, MD; Janet Ruzich, MD; Kelly Perlewitz, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Zhaoyu Sun, Ph.D.; William L. Redmond, Ph.D.; David B. Page, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial | |
| 399 | Poster Presentation | A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer | David B. Page, MD; Krystle L. Collins, MD; Brie M. Chun, MD; Zhaoyu Sun, Ph.D.; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Maritza Martel, MD; Yaping Wu, MD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Walter J. Urba, MD, PhD; Ayca Gucalp, MD; Tiffany A. Traina, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Immune adjuvant;Solid tumors;T cell;Tumor microenvironment | |
| 400 | Poster Presentation | Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product | Marco Purbhoo, PhD; Burcu Yigit, PhD; Darrian Moskowitz; Min Lim; Irina Shapiro; Ayat Alsaraby; Xavier Michelet, PhD; Marc A. Van Dijk, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Clinical trial;COVID and Immunotherapy;Leukemia/Lymphoma;NK/NKT cell;T cell lineages | |
| 402 | Poster Presentation | Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer | William HARRIS, MD; Adyb BAAKILI, MD; Yoon-Koo KANG, MD; Brigitte DEMERS, MD; Fatima-Zohra Menas, MD; Alice GOSSELIN; Giovanni Abbadessa, MD; Eric Van Cutsem, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 403 | Poster Presentation | Correlative analysis of blood and biopsy samples from a clinical trial of Hsp90 inhibition in combination with pembrolizumab reveals increased intratumoral myeloid cell accumulation after treatment | Cameron J. Herting, PhD; Yuchen Zhang; Deon B. Doxie, PhD; Michael B. Ware, PhD; Olatunji B. Alese, MD; Christina Wu, MD; Mehmet Akce; Mohammad Y. Zaidi, MD, MS; Amanda N. Ruggieri, MS; Madhav Dhodapkar, MD; Kavita M. Dhodapkar, MD; Juan M. Sarmiento, MD; Rafi Ahmed, PhD; Shishir K. Maithel, MD; Bassel El-Rayes, MD; Gregory B. Lesinski, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemokine;Clinical trial;Immune monitoring;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 404 | Poster Presentation | Initial Biomarker and Clinical Data of a Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-naïve Advanced MSS-Colorectal Cancer | Richard D. Kim, MD; Minal A. Barve, MD; Hirva M. Mamdani, MD; Melissa L. Johnson, MD; Byung Ha Lee, PhD; Sara Ferrando-Martinez, PhD; Marya F. Chaney, PhD; Jean Fan, MD, MSc; NgocDiep Le, MD, PhD; Aung Naing, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 405 | Poster Presentation | Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): a phase Ⅱ, single-arm, exploratory research | Jianqun Ma, MD; Jinfeng Zhang; Yingnan Yang; Dayong Zheng; Xiaoyuan Wang; Hao Liang; Luquan Zhang; Yanzhong Xin; Xiaodong Ling; Chengyuan Fang; Hao Jiang; Hongxue Meng; Wei Zheng | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Surgery | |
| 406 | Poster Presentation | Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: a phase Ⅱ, single-arm, exploratory research | Jianqun Ma, MD; Jinfeng Zhang; Yingnan Yang; Dayong Zheng; Xiaoyuan Wang; Hao Liang; Luquan Zhang; Yanzhong Xin; Xiaodong Ling; Chengyuan Fang; Hao Jiang; Wei Zheng | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy | |
| 407 | Poster Presentation | A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients | Anne Flament, MD; Frédéric F. Lehmann, MD; Erik M. Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Caroline Lonez, PhD; David E. Gilham, PhD; Charles Morris, MD | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Clinical trial;Solid tumors | |
| 408 | Poster Presentation | Preliminary Biomarker and Clinical Data of a Phase 2a Study of NT-I7, a Long-Acting Interleukin-7, plus Pembrolizumab: Cohort of Subjects with Checkpoint Inhibitor-naïve Advanced Pancreatic Cancer | Aung Naing, MD; Richard D. Kim, MD; Minal A. Barve, MD; Melissa L. Johnson, MD; Byung Ha Lee, PhD; Sara Ferrando-Martinez, PhD; Shubham Pant, MD; Robert A. Wolff, MD; Cara Haymaker, PhD; Marya F. Chaney, PhD; Dae Won Kim, MD; Jean Fan, MD, MSc; NgocDiep Le, MD, PhD; Hirva M. Mamdani, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 409 | Poster Presentation | Trial in progress: A phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer | Do-Youn Oh, MD, PhD; Min Hee Ryu, MD, PhD; Jun-Eul Hwang, MD, PhD; Jaeyong Cho, MD, PhD; Dae Young Zang, MD, PhD; Sang Cheul Oh, MD, PhD; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Hyun Cheol Chung, MD, PhD; Byoung Yong Shim, MD, PhD; Michael Chisamore, PhD; William Y. Ho, MD, PhD; Paul D. Rhee, Ph.D.; Ji Yeong Won, PhD; Taewan Kim; Eunhye Baek; SeungJae Baek, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment | |
| 410 | Poster Presentation | Phase I Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite Instability (dMMR/MSI) | Michael J. Overman, MD; Marwan Fakih; Dung T. Le, MD; Anthony F. Shields, MD PhD; Katrina S. Pedersen; Manish A. Shah, MD; Sarbajit Mukherjee, MD, MS; Thea Faivre; Guido Leoni, PhD; Anna Morena D'Alise; Gabriella Cotugno, PhD; Francesca Langone, PhD; Stefania Capone; Maria Rosaria Del Sorbo; Elisa Scarselli; Patricia Delaite, MD | Clinical Trials In Progress | Bioinformatics;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Vaccine | |
| 411 | Poster Presentation | INNATE: Immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses. | Nina N. Sanford, MD; Eslam Elghonaimy, PhD; Adel Kardosh, MD; Syed A. Kazmi, MD; Javier Salgado Pogacnik, MD; Xiaodong Yang, MD PhD; Robert Timmerman, MD; Todd A. Aguilera, MD, PhD | Clinical Trials In Progress | Antigen presenting cells;Bioinformatics;Chemotherapy;Radiotherapy;Solid tumors;Tumor microenvironment | |
| 412 | Poster Presentation | CAMrelizumab and apatiniB combIned with chemoTherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced rIght-sided colON cancer (AMBITION) | Zhou Tong, master; Sen Lu; Xiaomeng Dai; Xiaobin Cheng; Xuanwen Bao; Xudong Zhu; Xiaofei Cheng; Qihan Fu; Danyang Wang; Hangyu Zhang; Qinsong Sheng; Lulu Liu; Guoliang Zhang; Yi Zheng; Fanlong Liu; Peng Zhao; Wenbin Chen; Weijia Fang, PHD; Xiangmin Xu | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial | |
| 413 | Poster Presentation | Toripalimab in combination with concurrent chemoradiation in patients with advanced/metastatic esophageal carcinoma: protocol for a single-arm, prospective, open-label, phase II clinical trial | Lei Wu, M.M.; Yi Wang, M.M.; Gang Wan, M.M.; Jiahua Lv, M.M.; Qifeng Wang, M.D.; Jinyi Lang, M.D.; Tao Li, M.D. | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial;Radiotherapy | |
| 414 | Poster Presentation | A randomized phase II study of systemic therapy plus WeiLeShu (WLS) versus systemic therapy alone in patients with metastatic colorectal cancer (mCRC). | Ruyi Zhang; Xiaoxuan Tu, MS; Zhou Tong, master; Hangyu Zhang; Xudong Zhu; Weijia Fang, PHD; Lanfang Yu; Haibo Mou | Clinical Trials In Progress | Chemokine;Chemotherapy;Clinical trial;Inflammation;Microbiome;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 416 | Poster Presentation | An open-label phase 2 study of 2 doses of the hypoxia-inducible factor (HIF)–2α inhibitor belzutifan for the treatment of advanced clear cell renal cell carcinoma after progression on systemic therapy | Michael B. Atkins, MD; Yanfang Liu; Rodolfo Perini, MD; Ananya Roy; John B. Haanen, MD | Clinical Trials In Progress | Clinical study;Clinical trial;Targeted therapy | |
| 417 | Poster Presentation | Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma | Toni K. Choueiri, MD; Elizabeth R. Plimack, MD MS; Thomas Powles, MBBS, MD, MRCP; Martin Voss, MD; Howard Gurney; Rachel Silverman; Rodolfo Perini, MD; Karla Rodriguez-Lopez; Brian I. Rini, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial | |
| 418 | Poster Presentation | Phase 1b/2 KEYNOTE-365 cohort I: Platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma | Johann S. De Bono, PhD; Neal Shore, MD, FACS; Gero Kramer, MD; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Evan Y. Yu, MD | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial | |
| 419 | Poster Presentation | Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F | Gero Kramer, MD; Neal Shore, MD, FACS; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Johann S. De Bono, PhD; Evan Y. Yu, MD | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Clinical trial | |
| 420 | Poster Presentation | PROSTVAC in combination with Nivolumab enhanced immune cell infiltration in prostate cancer. | Shania A. Bailey, BS; Wiem Lassoued, PhD; Antonios Papanicolau-Sengos, MD; Jennifer L. Marte, MD, MPH; Nikki Williams; amy hankin; michell manu; William Dahut, MD; peter pinto; Fatima Karzai, MD; Ravi A. Madan, MD; Houssein Abdul Sater, MD; James L. Gulley, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 421 | Poster Presentation | A first-in-human (FIH) Phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT | Mark Linch; Zsuzsanna Papai; Istvan Takacs; Esteban Rodrigo Imedio; Marie-Cristine Kühnle; Evelyna Derhovanessian; Isabel Vogler; Stephanie Renken; Philippa Graham; Ugur Sahin; Özlem Türeci | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;RNA;T cell;Tumor antigens;Vaccine | |
| 422 | Poster Presentation | Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma | Tanner S. Miest; Bradley Leibovich; Stephen Bardot; Paul R. Young; Stephen A. Boorjian; Mark Gonzalgo; Loren Herrera-Hernandez; Matthew K. Tollefson; Jeffrey Karnes; Paige Nichols; Tessa Kroeninger; Rachel Graham; Carole Lahana; Monica Reckner; Alysha Newsom; Nandakumar Packiriswamy; Janice Anoka; Kah Whye Peng; Erol Wiegert; Alice Bexon; Shruthi Naik | Clinical Trials In Progress | Clinical trial;Targeted therapy;Vaccine | |
| 423 | Poster Presentation | A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients with Localized Prostate Cancer | Russell Pachynski, MD; Melissa A. Reimers; Cody Weimholt, MD; Katie Slane, NP; Peter Oppelt, MD; Jason Frankel, MD; Robert Figenshau, MD; Eric Kim, MD; Gerald Andriole, MD; Lawrence Fong, MD | Clinical Trials In Progress | B cell;Clinical study;Clinical trial;Inflammation;Myeloid cells;Surgery;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 424 | Poster Presentation | A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment | Kathryn E. Beckermann, MD, PhD; Nicholas J. Vogelzang, MD; Mao Shifeng; Moshe C. Ornstein; Neil Shah, MD; Hans Hammers, MD, PhD; Matthew T. Campbell, MD; Xin Gao; David F. McDermott, MD; Randy Anderson; Vanessa Esquibel, Director; Eduardo J. Pennella, MD; Reshma Rangwala, MD, PhD; Eric Jonasch, MD | Clinical Trials In Progress | Angiogenesis;Antibody;Chemotherapy;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 425 | Poster Presentation | Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts G/H | Neal Shore, MD, FACS; Johann S. De Bono, PhD; Gero Kramer, MD; Anthony M. Joshua, MBBS, PhD; Xin Tong Li; Christian H. Poehlein, MD; Charles Schloss; Evan Y. Yu, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial | |
| 426 | Poster Presentation | A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) | Ed M. Uchio, MD; Donald Lamm, MD, FACS; Neal Shore, MD; Paul Anderson, MD; Tran Ben, MD; Ashish M. Kamat, MD; John McAdory, MHA; Melody Keel; Paola Grandi, PhD, MBA; James Burke, MD | Clinical Trials In Progress | Clinical trial | |
| 427 | Poster Presentation | Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study | Jermaine Coward; Sophia Frentzas; Anna Mislang; Bo Gao; Charlotte Lemech, MBBS BSc(med) FRACP MD(res); Xiaoping Jin, PhD; Baiyong Li, Ph.D; Max Wang; Kon Yew Kwek; Yiting Zhou; Yu Xia | Clinical Trials In Progress | Angiogenesis;Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Immune suppression;Solid tumors | |
| 428 | Poster Presentation | Preliminary Clinical Results of Toripalimab Monotherapy or Combination Therapy for Recurrent or Refractory Gynecologic Cancer | Peng Diao; Qian Peng; Xingbo Luo; Qing Huang; Gaoshu Yan; Yan Tan | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Radiotherapy | |
| 429 | Poster Presentation | Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer | Nehal J. Lakhani, MD; Debra Richardson, MD; Timothy Kristedja, MD; Fatima Rangwala, MD, PhD; Hannah McKay; Louis E. Gonzalez, PhD; Bo Ma, PhD; Erika P. Hamilton, MD; Lini Pandite, MD | Clinical Trials In Progress | Antigen presenting cells;Biomarkers;Bispecifics;Checkpoint blockade;Clinical trial;Costimulation | |
| 430 | Poster Presentation | A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer | Lingying Wu; Guiling Li; Bairong Xia; Rong Li; Jing Wang; Ruifang An; Li Wang; Yunxia Li; Kun Song; Hongying Yang; Yaqing Chen; Yuzhi Li; Huiling Huang; Xiaoping Jin; Baiyong Li, Ph.D; Yu Xia | Clinical Trials In Progress | Angiogenesis;Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Targeted therapy | |
| 431 | Poster Presentation | First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer | Payal D. Shah, MD; Richard Shlanksy-Goldberg, MD; Lainie Martin, MD; Gregory Nadolski, MD; Elizabeth Hexner, MD; Susan Shamimi-Noori, MD; Wei-Ting Hwang, Ph.D.; Tina Matlawski, RN; Amanda L. Cervini; Joanne B. Shea, RN; Lauren M. Nelson; Simon F. Lacey, Ph.D.; Gabriela Plesa, MD, Ph.D.; Lester R. Lledo, DNP, RN, CRNP; Karen L. Dengel, BSN, RN; Amy E. Marshall, MPH; Rachel M. Leskowitz, Ph.D.; Lana Kandalaft, Pharm.D.; Mariangela Figini; Silvana Canevari, Ph.D.; George Coukos, MD, Ph.D.; Daniel J. Powell Jr., Ph.D. | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors | |
| 432 | Poster Presentation | Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study) | Brian Gastman, MD; Mac A. Cheever, MD; Steven P. Fling, PhD; Cesar A. Perez, MD; Manish R. Patel, MD; Jessica L. Geiger, MD; Zujun Li, MD; Marshall R. Posner, MD; Conor E. Steuer, MD; Leonard A. D'Amico, PhD; Angela Shaulov Kask, PhD; Yangchun Du, PhD; Derek Matthies, PharmD; Sung Jin Huh, PhD; Yan Wang, PhD; Julie R. Graham, PhD; Laura QM. Chow, MD | Clinical Trials In Progress | Biomarkers;Clinical study;Clinical trial;Cytokine;Immune monitoring;Immune suppression;Immune tolerance;Immune toxicity;Tumor microenvironment | |
| 433 | Poster Presentation | A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 | Beatriz B. Cirauqui, MD; Ezra EW. Cohen, MD; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting, MD, PhD; Tim Welliver, MD, PhD; Shanhong Guan, PhD; Feng Jin, PhD; Alison J. Forgie, PhD; Philip S. Fanning, PhD; Katherine Ruffner, MD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment | |
| 434 | Poster Presentation | Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) | Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Crystal Mallow, BS; Amber Foster; Ernest S. Smith, PhD; John E. Leonard, MD PhD; Marya F. Chaney, PhD; Maurice Zauderer, PhD | Clinical Trials In Progress | Antibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;MDSC;Myeloid cells;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 435 | Poster Presentation | Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma | Robin Meng, MD, PhD; Caroline Even; Lisa Licitra, MD; Chia-Jui Yen, MD, PhD; Myung Ju Ahn, MD; Giovanni Abbadessa, MD; Fatima-Zohra Menas, MD; Miao Zang; George R. Blumenschein, Jr., MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 436 | Poster Presentation | A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy | Haiqiang Mai; haiqiang Mai; Shaojun Lin; Dongping Chen; Xiaozhong Chen; Song Qu; Qin Lin; Ying Luo; Chunhong Hu; Dehua Wu; Tianxin Qin; Feng Jin; Nianyong Chen; Yunxiu Luo; Zhifang Yao; Xiaoping Jin; Baiyong Li, Ph.D; Yu Xia; Rui-Hua Xu | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors | |
| 437 | Poster Presentation | A multicentre phase 1b study of NG-641, a novel transgene-armed and tumour-selective adenoviral vector, and pembrolizumab as neoadjuvant treatment for squamous cell carcinoma of the head and neck | Christian Ottensmeier; Mererid Evans; Emma King; Ioannis Karydis; Tom Lillie, MD PhD; David Krige, PhD; Jenny Lee; Matthew R. Thomas, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Solid tumors;Tumor microenvironment | |
| 438 | Poster Presentation | A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer | Christine H. Chung, MD; A. Dimitrios Colevas, MD; Michael K. Gibson, MD PhD; Douglas R. Adkins, MD; Ammar Sukari, MD; Lori J. Wirth, MD; Barbara A. Burtness, MD; Julie E. Bauman, MD, MPH; Cristina P. Rodriguez, MD; Francis P. Worden, MD; Nabil F. Saba, MD; Bonnie S. Glisson, MD; Lara A. Dunn, MD; Tanguy Y. Seiwert, MD; Laura Agensky; Matteo Levisetti; Reena Lynam; Steven P. Margossian, MD, PhD; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Kenneth J. Pienta, MD; Sara I. Pai, MD PhD | Clinical Trials In Progress | Adoptive immunotherapy;Checkpoint blockade;Clinical trial;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 439 | Poster Presentation | A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 | Jong Chul Park, MD; Kevin Harrington, PhD, FRCP, FRCR; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting, MD, PhD; Tim Welliver, MD, PhD; Shanhong Guan, PhD; Feng Jin, PhD; Alison J. Forgie, PhD; Philip S. Fanning, PhD; Katherine Ruffner, MD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Ezra EW. Cohen, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment | |
| 440 | Poster Presentation | A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC) | Julio A. Peguero, MD; Frederic Triebel, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell | |
| 441 | Poster Presentation | Population pharmacokinetics of an anti-PD-1 antibody, Penpulimab in patients with advanced malignancies | Benchao Chen, master; Xiaoping Jin; Yongcheng Dong, Ph.D; Max Wang; Dennis Xia, Ph.D; Michelle Xia, Ph.D; Baiyong Li, Ph.D | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Leukemia/Lymphoma;Metabolism;Solid tumors | |
| 443 | Poster Presentation | Open-label, phase 2 study to assess the safety of mogamulizumab at 2 mg/kg Q4W maintenance dosing in patients with relapsed/refractory MF/SS subtypes of CTCL | Karen Dwyer, BA; Roland Meier, PhD; Matthew Hruska, PharmD, PhD; Floyd E. Fox, PhD; Takahiro Ito, MSc | Clinical Trials In Progress | Antibody;Clinical trial;COVID and Immunotherapy;Leukemia/Lymphoma;T cell;Targeted therapy | |
| 444 | Poster Presentation | GTB-3550 Tri-specific Killer Engager TriKE™ drives NK cells Expansion and Cytotoxicity in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients | Martin Felices, PhD; Erica Warlick, MD; Mark S. Juckett, MD; Daniel Weisdorf, MD; Daniel A. Vallera; Sarah Miller; Rose Wangen; Dixie Lewis, RN; JoAnne Knox; Martin Schroeder; Jeffrey S. Miller, MD; Jeffrey S. Miller MD | Clinical Trials In Progress | Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy | |
| 445 | Poster Presentation | Trial in progress: A phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine, in patients with relapsed/refractory acute myeloid leukemia (R/R AML) | Yifan Zhai; Tapan M. Kadia | Clinical Trials In Progress | Clinical trial;Leukemia/Lymphoma | |
| 447 | Poster Presentation | Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma | Shaji Kumar, MD; Admasu Mamuye, MD, MSc; Kristina Dabovic, PharmD; Jingyuan Wang, PhD; Banmeet Anand, PhD; Amy Yuet, PhD; Bhagirathbhai Dholaria, MBBS; Vivek Roy, MD | Clinical Trials In Progress | Clinical study;Clinical trial;Leukemia/Lymphoma;Targeted therapy | |
| 448 | Poster Presentation | Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study | Edward A. Stadtmauer, MD, FACP; Lionel Karlin; Katja Weisel; Moshe Etzion Gatt; Ankit Kansagra; Gregory P. Monohan, MD; Andrew Yee; Shayna Rockow-Magnone; Jose Cordero; David Hoffman; Orlando Bueno; Kevin Y. Wu; Cristina Gasparetto, MD | Clinical Trials In Progress | Antibody;Chemotherapy;Clinical trial;Monocyte/Macrophage;Myeloid cells;Targeted therapy | |
| 449 | Oral Presentation | Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy | Jerill Thorpe, M.S.; Julie A. Rytlewski; Heidi H. Gillenwater; Ken Ogasawara; Yeonhee Kim; Diana Shpektor; Eniko Papp; Leanne Peiser | Clinical Trials In Progress | CAR T cells;Gene expression;Leukemia/Lymphoma;T cell;Targeted therapy | |
| 450 | Poster Presentation | Trial in progress: A phase 1b study of alrizomadlin, alone or plus 5-azacitidine or cytarabine, in pts with relapsed/refractory acute myeloid leukemia and relapsed higher-risk myelodysplastic syndrome | Yifan Zhai; Jianxiang Wang | Clinical Trials In Progress | Clinical trial;Leukemia/Lymphoma;Myeloid cells | |
| 452 | Poster Presentation | Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC) | Zhendong Chen; Nianfei Wang; Dayong Luo; Bo Jiang; Mu Yuan; Xinzhong Li; Chunmei Yao; Hong Qian; Qingsheng Kan; Erxuan Wang | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical trial;Coinhibition;Immune suppression;Targeted therapy | |
| 453 | Poster Presentation | Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma | Mark Yarchoan, MD; Edward Gane; Thomas U. Marron, MD, PhD; Sarah Rochestie; Neil Cooch; Joann Peters; Ildiko Csiki; ALFREDO PERALES-PUCHALT, MD, PhD; Niranjan Y. Sardesai | Clinical Trials In Progress | Clinical study;Clinical trial;Costimulation;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens;Vaccine | |
| 454 | Poster Presentation | Analysis of NY-ESO-1 expression in specimens from a Phase I/II NY-ESO-1 T-cell therapy clinical trial in non-small cell lung cancer and from exploratory studies in multiple tumor types | Bryan Barnes; Ming Shan; Kristin Blouch; Mehmet Altan; Jaegil Kim; Natalia Ramos-Hernandez; Ellie Corigliano | Clinical Trials In Progress | Antibody;Biomarkers;CAR T cells;Clinical study;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 455 | Poster Presentation | Pegasus Lung, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with non-small cell lung cancer (NSCLC) and mesothelioma | Robin Meng, MD, PhD; Benjamin Besse, MD, PhD; Melissa L. Johnson, MD; Jaafar Bennouna, MD, PhD; Luca Toschi; Giovanni Abbadessa; Amele Amrate; Miao Zang; Luis Paz Ares, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 456 | Poster Presentation | A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress | Michael Boyer, MB BS PhD; Sandip Patel; Thomas U. Marron, MD, PhD; Nick Pavlakis; Sagun Parakh; Shirish Gadgeel; Michael Shafique, MD; Robert Hoyer; D Ross Camidge; Charles M. Farber, MD, PhD; Ranee Mehra, MD; Tarek Mekhail; Prunella Blinman; Karey Kowalski; Craig B. Davis, PhD; Dmitri Pavlov; Nayra Gad; Erminia Massarelli, MD, PhD, MS | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Solid tumors | |
| 457 | Oral Presentation | KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC) | Martin Gutierrez, MD; Wei-Sen Lam; Matthew D. Hellmann, MD; Matthew Gubens, MD, MS; Charu Aggarwal, MD MPH; Daniel Shao Weng Tan; Enriqueta Felip, MD, PhD; Joanne W. Y. Chiu; Jong-Seok Lee; James Chih-Hsin Yang; Edward B. Garon; Giovanna Finocchiaro; Myung-Ju Ahn; Alexander Luft; Gregory A. Landers; Andrea Basso; Hua Ma; Julie Kobie; John Palcza, MS; Razvan Cristescu; Lawrence Fong, MD; Alexandra Snyder; Jianda Yuan, MD, PhD; Roy S. Herbst, MD, PhD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Solid tumors;Targeted therapy | |
| 458 | Poster Presentation | First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC) | Adam J. Schoenfeld, MD; Sylvia Lee, MD; Luis Paz-Ares; Bernard Doger; Scott N. Gettinger, MD; Simon Haefliger; Angela Orcurto, MD; Ammar Sukari, MD; Sophie Papa, PhD, MBBS, MRCP; Juan Francisco Rodriguez Moreno; Friedrich Graf Finckenstein, MD; Madan Jagasia; Rana Fiaz; Giri Sulur; Guang Chen; Viktoria Gontcharova, PhD; Kai He, MD, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 459 | Poster Presentation | Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC | Matthew D. Hellmann, MD; Byoung C. Cho, MD, PhD; Rosalyn A. Juergens, MD, PhD; Ying Cheng, MD; Gilberto de Castro, Jr; Mustafa Erman, MD; Jessica Bauman; Toshiaki Takahashi, MD, PhD; Paul Schwarzenberger, MD; Pingye Zhang, PhD; M. Catherine Pietanza; James Chih-Hsin Yang | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial | |
| 460 | Poster Presentation | Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T Cells Exhaustion test helps stratification of NSCLC patients treated with PD1 / PDL1 inhibitors in the PIONeeR project | Vanina Leca, PhD; Alboukadel Kassambara, PhD; Lamia Ghezali, PhD; Pernelle Outters; Christelle Cotteaux-Lautard; Fanny Arnoux, PhD; Thomas Sbarrato, PhD; Florence Monville, PhD; Maryannick Le Ray, PharmD; Marie Roumieux, PhD; Stephane Garcia; Richard Malkoun; Noémie Resseguier; Arnaud Boyer; Louisiane Lebas; Hervé Pegliasco; Patricia Barré; Clarisse Audigier-valette; Sarah Zahi; Luc Odier; Stéphane Hominal; Maurice Perol; Julien Mazieres; Laurent Greillier; Fabrice Barlesi, Prof, MD, PhD; Jacques Fieschi-Meric, PhD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Immune contexture;Immunoscore;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 461 | Poster Presentation | Updated PFS analysis of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) | Hao Luo, MD; Dan Jian; Yan Feng; Li Zhong; Qian Chen; Wei Guan; Shiheng Zhang; Jiamin Luo; Xueqin Yang; Kan Gong; Yanli Xiong; Mengxia Li; Mingfang Xu; Yu Pu; Liang Zhao; Chengyuan Qian; Nan Dai; Dong Wang | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 462 | Poster Presentation | A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data | Magnus Jaderberg; Luis Paz-Ares; Susana Cedres, MD; Charles Ricordel, MD; Nicolas Isambert; Santiago Ponce Aix; Victor Levitsky, MD, PhD; Lukasz Kuryk, PhD; Anne-Sophie Moller; Sylvia Vetrhus | Clinical Trials In Progress | Clinical trial;Gene expression;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 463 | Poster Presentation | Vibostolimab plus pembrolizumab with/without docetaxel vs docetaxel in NSCLC after platinum chemotherapy and immunotherapy | Solange Peters, MD, PhD; Dae Ho Lee, MD, PhD; Rodryg Ramlau, MD, PhD; Balazs Halmos, MD; Christian Schumann, MD, PhD; David Planchard, MD, PhD; Niyati Bhagwati, MD; Diana (Qiusheng) Chen, PhD; Debra Kush, BSN, MBA; Silvia Novello, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemotherapy;Clinical trial | |
| 464 | Poster Presentation | 2SMALL (NCT04253145) phase I part: Lurbinectidine (LUR) in combination with Atezolizumab (ATZ) for second line Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients (pts) | Santiago Ponce Aix, MD; Alejandro Navarro; Reyes Bernabe; Maria Eugenia Olmedo; Trigo Jose Manuel; Jon Zugazagoitia Fraile, MD; Luis Paz-Ares; Santiago Ponce Aix | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical trial;Solid tumors | |
| 465 | Poster Presentation | Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study | Christian Rolfo, MD, PhD, MBA, Dr.hc.; Laurent Greillier; Remi Veillon; Firas Badin, MD; Francois Ghiringhelli; Nicolas Isambert, MD, PhD; Astrid Paulus; Marc Lambrechts; Surendra Chaudhary; Xiaoli You; Yulia Vugmeyster; Christoph Helwig, MSc; Sandrine Hiret | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Coinhibition;Solid tumors | |
| 466 | Poster Presentation | Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort. | David L. Saltman, MD PhD; Nicole S. Croteau, MSc; Heather M. Lockyer; Rob S. Seitz; Frank B. McMahon; Jeremy Spille; Andrea Dickey; Matthew G. Varga, PhD; Kim McGregor, MD; Tyler J. Nielsen, MS; David R. Hout, PhD; Brock L. Schweitzer, PhD; Douglas T. Ross, MD, PhD; David Gandara, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;RNA;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 467 | Poster Presentation | Phase II clinical study of Toripalimab in combination with stereotactic radiotherapy as a neoadjuvant therapy for the treatment of resectable (N1-N2) non-small cell lung cancer | Zhen Wang, MD; Xi-xu Zhu; Yong Song | Clinical Trials In Progress | Clinical study;Immune suppression;Radiotherapy;Solid tumors | |
| 468 | Poster Presentation | A phase Ⅱ study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer | Dongqing Lv, MD; Guixian Wu | Clinical Trials In Progress | Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical study | |
| 469 | Poster Presentation | A Phase 1 First in Human Study of HMBD-002, an IgG4 Monoclonal Antibody Targeting VISTA, as a Monotherapy and Combined with Pembrolizumab in Patients with Advanced Solid Malignancies | Leah DiMascio, PhD; Dipti Thakkar, PhD; Siyu Guan, PhD; Eric Rowinsky, MD; Jordi Rodon; Joshua J. Gruber, MD, PhD; Benjamin L. Musher, MD; Joseph W. Kim, MD; Alain Mita, MD; Monica Mita, MD; Piers J. Ingram, PhD; Jerome D. Boyd-Kirkup, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;MDSC;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 470 | Poster Presentation | A Phase 1/2, Open-Label, Dose Escalation and Expansion Study of GI-101 as a Single Agent and in Combination with a Pembrolizumab, Lenvatinib or Local RT in Advanced Solid Tumors (KEYNOTE-B59) | Byoung Chul Cho, MD, PhD; Sang Joon Shin, MD, PhD; Jae-Lyun Lee, MD, PhD; Byoung Yong Shim, MD, PhD; Hyung Soon Park, MD, PhD; Nari Yun, PhD; Mina Ham, MS; Young Jun Koh, PhD; Myoung Ho Jang, PhD | Clinical Trials In Progress | Bispecifics;Checkpoint blockade;Clinical trial;Cytokine;Radiotherapy;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 471 | Poster Presentation | Pharmacokinetics of first and repeated dosing of non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 in advanced cancer patients | Hung-Yen Chou, PhD; Tianhong Li, MD, PhD; Karen Kelly, MD; Anthony Martinez; Stacy S. Joo; Mei Tang, MD, PhD; Martin Devenport; Yang Liu, PhD; Pan Zheng, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical study;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 472 | Poster Presentation | BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors | Manish R. Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony Tolcher, MD; David Sommerhalder, MD; Omid Hamid, MD; Alexander Chung, PhD; Lixin Li, PhD; Robert H. Andtbacka, MD, CM | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;TLR | |
| 473 | Poster Presentation | Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in Phase I clinical trial | Paula L. Codó, Dr. sc. nat.; Thomas Eigentler, Prof. Dr.; Lucie Heinzerling, Prof. Dr. Med.; Juergen Krauss, Prof. Dr. med.; Carsten Weishaupt, P.D. Dr. med; Sebastian Ochsenreither, P.D. Dr.; Celeste Lebbe, MD, PhD; Peter Mohr, Dr.; Marc Oliva; Honey K. Oberoi, M.D.; Patrick Terheyden, P.D. Dr. med.; José M. Trigo Pérez; Franz-Georg Bauernfeind, Dr. med.; Michael Fluck, Dr. med.; Erika Richtig, Prof. Dr.; Ainara Soria, MD; Marina Gonzalez; Fatma Funkner, Dr.; Peter Wengenmayer; Dominik Vahrenhorst; Tobias Seibel, II, Dr.; Gianluca Quintini, Dr.; Beate Schmitt-Bormann, Dr. med.; Birgit Scheel, Dr.; Martin H. Falk, Dr.; Ulrike Gnad-Vogt, Dr. med. | Clinical Trials In Progress | Clinical study;Clinical trial;Cytokine;Gene expression;Immune monitoring;RNA;Solid tumors;TLR;Tumor microenvironment | |
| 474 | Poster Presentation | Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress) | Diwakar Davar; Vincent Ribrag, MD; Clementine Sarkozy, MD, PhD; Elena Garralda; Honey Kumar Oberoi, MD, MSc; Amitkumar Mehta, MD; Giuseppe Curigliano, MD, PhD; Carmen Belli, MD, PhD; Jasmine Zain, MD; Alex F. Herrera, MD; Rachel E. Sanborn, MD; Ecaterina E. Dumbrava, MD; Andres Forero-Torres, MD; Stephen M. Ansell, MD, PhD | Clinical Trials In Progress | Antibody;Clinical trial;Leukemia/Lymphoma;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy | |
| 475 | Poster Presentation | GEN-011-101 (the TiTAN-1 trial): Phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors | Thomas A. Davis, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Craig Carey; Kevin J. Mancini, MS | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 476 | Poster Presentation | First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results | Arkadiusz Z. Dudek, MD, PhD; Dejan Juric; Afshin Dowlati; Ulka Vaishampayan, MD; Hadeel Assad; Jordi Rodón; Bo Chao; Bingxia Wang; John Gibbs; Vaishali M. Shinde; Sharon Friedlander; Allison J. Berger, PhD; Christine K. Ward; Alonzo Martinez; Robert Gharavi; Alejandro Gomez-Pinillos; Igor Proscurshim; Anthony J. Olszanski, MD, RPh | Clinical Trials In Progress | Clinical trial;Immune adjuvant;Leukemia/Lymphoma;Post-translational modifications;Solid tumors | |
| 477 | Poster Presentation | COM902 (Anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246). | Ecaterina E. Dumbrava, MD; Drew Rasco, MD; Amita Patnaik, MD; Daniel Vaena; Kyriakos P. Papadopoulos, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med, PhD; Ilan Vaknin, PhD; Srinivas Devarakonda, MD; Manish R. Sharma, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;NK/NKT cell;T cell | |
| 478 | Poster Presentation | COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839) | Ecaterina E. Dumbrava, MD; Manish R. Sharma, MD; Gini Fleming, MD; Kyriakos P. Papadopoulos, MD; Ryan J. Sullivan, MD; Daniel Vaena; Amita Patnaik, MD; Adam ElNaggar; Adeboye H. Adewoye, MD; Robina Smith; Pierre Ferré, Dr Vet Med; Inbal Barbiro; Emerson Lim, MD.; Drew Rasco, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical study;Clinical trial;T cell | |
| 479 | Poster Presentation | AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results | Anthony El-Khoueiry, MD; Andrea J. Bullock, MD; Apostolia M. Tsimberidou, MD, PhD; Daruka Mahadevan; Breelyn A. Wilky, MD; Przemyslaw W. Twardowski; Bruno Bockorny; Justin Moser, MD; Waldo Ortuzar Feliu, MD; Joseph E. Grossman; Katherine Rosenthal; Steven J. O'Day; Michael S. Gordon | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy | |
| 480 | Poster Presentation | A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 | Gerald S. Falchook, MD, MS; David R. Spigel, MD; Manish R. Patel, MD; Babar Bashir, MD, MS; Susanna Ulahannan, MD, MMED; Christine Duffy; Daniela Maier; Hisaya Azuma | Clinical Trials In Progress | Clinical trial;Coinhibition;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 481 | Poster Presentation | Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors | Gerald S. Falchook, MD, MS; Hui K. Gan, MBBS PhD; Siqing Fu, MD, PhD; Meredith McKean, MD; Arun Azad, MD; David Sommerhalder; Judy S. Wang, MD; Tira Tan; Chen E. Chee; Minal Barve, MD; charlotte Lemeque; Nicole Acuff; Helene Pham; Jill Mooney; Rui Wang; Neyssa Marina, MD, MS; Giovanni Abbadessa, MD; Tarek Meniawy, MBBS FRACP | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors | |
| 482 | Poster Presentation | Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in Patients With Metastatic Solid Tumors | Aleksandra Filipovic, MD, PhD; Zev A. Wainber, MD; Judy S. Wang, MD; Johanna C. Bendell, MD; Filip Janku, MD, PhD; Manish R. Sharma, MD; Amit Mahipal; Joseph Bolen, PhD; Eric Elenko; Christopher Korth; George Dranitsaris | Clinical Trials In Progress | Antibody;Biomarkers;Clinical trial;Immune monitoring;Immune suppression;Solid tumors;Tumor microenvironment | |
| 483 | Poster Presentation | Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers | Charalampos Floudas, MD, DMSc, MS; Julius Strauss, MD; Clint T. Allen, MD; Renee N. Donahue, PhD; Caroline Jochems, MD, PhD; Seth Steinberg, PhD; Lisa Cordes, PharmD, BCACP, BCOP; Douglas E. Brough, PhD; Amy Lankford, PhD; Sheri McMahon, RN; Jenn Marte, MD, MPH; Jason M. Redman, MD; Fatima Karzai, MD; Ravi A. Madan, MD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;T cell;Vaccine | |
| 484 | Poster Presentation | Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors | Elena Garralda, MD, MSc; Vladimir Galvao, MD; Stephane Champiat; Patricia LoRusso; Peter Grell; Aung Naing, MD; Filip Janku; Richard Sachse; David Bechard; Joachim Kiemle-Kallee; Aurelien Marabelle; Elena Garralda | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Costimulation;Cytokine;Solid tumors | |
| 485 | Poster Presentation | Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors | Maura L. Gillison, MD, PhD; Mark Awad, MD, PhD; Przemyslaw Twardowski, MD; Ammar Sukari, MD; Melissa L. Johnson, MD; Rudy Lackner, MD; Mark N. Stein, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Kevin J. Mancini, MS; Mara G. Shainheit, Ph.D.; Gabriella Santone, MS; Syukri Shukor; Ece Bicak, MS; Vijetha Vemulapalli; Emily Tjon, M.S.; Jessica B. Flechtner, PhD; Thomas A. Davis, MD; Roger B. Cohen, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens;Vaccine | |
| 487 | Poster Presentation | NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors | Han Myint, MD, FRCPath, FRCP; Linjie Tian, PhD; Jahangheer S. Shaik, Ph.D.; Emilia A. Barbu, Ph.D.; Qinjie Zhou, Ph.D.; Aaron Morawski; Hasan Abukharma; Linda N. Liu, PhD; John Shin, MD; Dallas B. Flies, PhD; Ron Copeland, Ph.D.; Megan Nelson; Stephanie Zeidan; Marijo Bilusic, MD; Danielle Pastor, DO, Ph.D.,; Ravi A. Madan, MD; Siqing Fu, MD, PhD; Martin Gutierrez, MD; Solomon Langermann, PhD | Clinical Trials In Progress | Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma | |
| 488 | Poster Presentation | Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors | Omid Hamid, MD; Dawn Baxter; Rachael Easton; Lilian L. Siu, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 489 | Poster Presentation | TWT-101: A Phase 1 Study of the Novel HPK1 Inhibitor CFI-402411 in Patients with Advanced Cancer | Omid Hamid, MD; Johanna Bendell; Siqing Fu, MD, PhD; Kyriakos P. Papadopoulos, MD; Judy S. Wang, MD; Brigette Ma, MD; Anna Spreafico, MD PhD; Alexander I. Spira, MD, PhD, FACP; Mark R. Bray; Graham Fletcher; Glenn Michelson; Emily Roberts-Thomson, MMSc | Clinical Trials In Progress | Clinical study;Clinical trial;Cytokine;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy | |
| 490 | Oral Presentation | Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors | Elaine Shum, MD; Han Myint, MD, FRCPath, FRCP; Jahangheer S. Shaik, Ph.D.; Qinjie Zhou, Ph.D.; Emilia A. Barbu, Ph.D.; Aaron Morawski; Hasan Abukharma; Linda N. Liu, PhD; Megan Nelson; Stephanie Zeidan; Zachary Cusumano, Ph.D.; Anthony Tolcher, MD; Solomon Langermann, PhD; Martin Gutierrez, MD; Omid Hamid, MD | Clinical Trials In Progress | Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 491 | Poster Presentation | BASECAMP-1: An observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy | Julian R. Molina, MD, PhD; William Y. Go, MD, PhD; Scott Kopetz, PhD; Diane M. Simeone, MD; Sandip Patel; Yi Lin, MD PhD; Kirstin B. Liechty; Michelle Fan-Port, PhD; Jason Perera, PhD; Armen Mardiros, PhD; Karl Beutner; Ariane Lozac’hmeur; Eric Ng, MD; David G. Maloney, MD, PhD; J. Randolph Hecht, MD | Clinical Trials In Progress | Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Epidemiology;Solid tumors;T cell;Tumor antigens | |
| 492 | Oral Presentation | Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers | David O'Malley; Sylvia Lee, MD; Amanda Psyrri; Ammar Sukari, MD; Sajeve S. Thomas; Robert Wenham, MD, MS, FACS, FACOG; Helen Gogas, MD, PhD; Amir Jazaeri, MD; Bradley J. Monk, MD FACOG FACS; Peter Rose; Antonio Reuda; Friedrich Graf Finckenstein, MD; Madan Jagasia; Rana Fiaz; Brigid Garelik, MD, MPH; Wen Shi, MD, PhD; Anjali Desai; Giri Sulur; Guang Chen; Xiao Wu; Antonio Jimeno, MD, PhD | Clinical Trials In Progress | Adoptive immunotherapy;Checkpoint blockade;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 493 | Oral Presentation | First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4-1BB (GEN1042) in patients with advanced solid tumors | Melissa Johnson; Juanita Lopez; Patricia LoRusso; Jessica Bauman; Daniel Haggstrom; Eleni Lagkadinou; Gaurav Bajaj; Özlem Türeci; Homer C. Adams III; Ugur Sahin; Yali Fu; Tahamtan Ahmadi; Kristoffer S. Rohrberg | Clinical Trials In Progress | Antibody;Bispecifics;Clinical trial;Costimulation;Dendritic cell;Solid tumors;T cell | |
| 494 | Poster Presentation | Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas | Melissa L. Johnson, MD; Lilian L. Siu, MD; David S. Hong, Professor; Patrick Schoffski; Vladimir Galvao, MD; Fatima Rangwala, MD, PhD; Robert Hernandez, PhD; Louis E. Gonzalez, PhD; Bo Ma, PhD; Lini Pandite, MD; Irene Brana, MD | Clinical Trials In Progress | Biomarkers;Bispecifics;Checkpoint blockade;Clinical trial;Costimulation;Solid tumors | |
| 495 | Poster Presentation | Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas. | Judy S. Wang, MD; Gerald S. Falchook, MD, MS; Salah Nabhan, MS; Meghana M. Kulkarni, PhD; Peter M. Sandy; Ololade Dosunmu, MD; Humphrey A. Gardner, MD, FCAP; Johanna C. Bendell, MD; Melissa L. Johnson, MD | Clinical Trials In Progress | Checkpoint blockade;Dendritic cell;Immune adjuvant | |
| 496 | Poster Presentation | Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients | David Knorr, MD, PhD; Jeffrey V. Ravetch, MD, PhD; Gabriela D'Andrea, MD; Linda T. Vahdat, MD; Christopher A. Klebanoff, MD; Mark Robson | Clinical Trials In Progress | Antibody;Antigen presenting cells;Clinical trial;Dendritic cell | |
| 497 | Poster Presentation | A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies | Nehal J. Lakhani, MD; Meredith McKean, MD; Amita Patnaik, MD FRCP(C); Kristi Manjarrez; Hany Zayed, PhD; Michael Chisamore, PhD; Stanford Peng, MD, PhD; Zelanna Goldberg, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Costimulation;Solid tumors;T cell | |
| 498 | Poster Presentation | Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 | Keun-Wook Lee, MD; Hyun C. Chung, MD, PhD; Tae Min Kim, MD, PhD; Nehal J. Lakhani, MD; Wells A. Messersmith, MD; Rafael Santana-Davila, MD; Won Seog Kim, MD; Patricia LoRusso; Yung-Jue Bang, MD PhD; Laura QM. Chow, MD; Philip S. Fanning, PhD; Pierre Squifflet, MS; Feng Jin, PhD; Alison J. Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin Gainor, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical trial;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy | |
| 499 | Poster Presentation | A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The „IMAG1NE“-trial) | Fiona Thistlethwaite, MD, PhD; Antonia Busse, MD, PhD; Emiliano Calvo, MD, PhD; Marie-Luise Goebeler, MD; Martin Wermke; Sylvie Rottey, MD; Nuria Kotecki, MD; Matthias Obenaus, MD; Vivian Scheuplein, PhD; Ralf Wolter, PhD; Carolina Perdomo-Ortiz, PhD; Ioannis IG. Gavvovidis, PhD; Elisa Kieback, PhD; Thomas Blankenstein, PhD; Eugen Leo, MD PhD MBA | Clinical Trials In Progress | Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 500 | Poster Presentation | SYNB1891, a bacterium engineered to produce a STING agonist, demonstrates target engagement in humans following intratumoral injection | Richard Riese, MD, PhD; Jason J. Luke; Karl Lewis, MD; Filip Janku, MD, PhD; Sarina A. Piha-Paul, MD; Claire F. Verschraegen, MD; Aoife M. Brennan, MD; Michael MB. Armstrong, MD; Mary Varterasian, MD; Anna Sokolovska, PhD; James F. Strauss, MD | Clinical Trials In Progress | Clinical trial;Immune adjuvant;Microbiome | |
| 501 | Poster Presentation | Survival and Immune Response Data from Intratumoral INT230-6 Alone (IT-01) and with Pembrolizumab [KEYNOTE-A10] in Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors | Jacob Thomas, MD; Anthony El-Khoueiry, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Syed Mahmood, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lilian L. Siu, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 502 | Poster Presentation | Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors | Aurelien Marabelle; Stéphane Champiat; Vladimir Galvao, MD; Aung Naing, MD; Filip Janku; Patricia LoRusso; Peter Grell; Richard Sachse; David Bechard; Joachim Kiemle-Kallee; Ellena Garralda | Clinical Trials In Progress | Clinical trial;Costimulation;Cytokine;Solid tumors | |
| 503 | Oral Presentation | Clinical Activity of ICT01, an anti-BTN3A-Targeted, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial | Martin Wermke; Aurelien Marabelle; Christiane Jungels, MD; Johann S. De Bono, PhD; Norbert Vey, MD; Cécile Vicier; Elena Garralda; Steven Le Gouill; Patricia LoRusso; Stephane Champiat; Catrin List; Vladimir Galvaö de Aguiar; Katrin Wetzko; Leo Rhunke; Aude de Gassart, PhD; Patrick Brune; Emmanuel Valentin, PhD; Marina Iche; Daniel OLIVE, M.D., Ph.D.,; Paul A. Frohna, MD, PhD, PharmD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical study;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 504 | Poster Presentation | A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER) | Ignacio J. Melero, Dr., MD, PhD; Emiliano Calvo; Maria-Elisabeth Goebeler, MD; Elena Garralda; Reinhard Dummer, MD; María Rodríguez-Ruiz, MD; Maria J. de Miguel, MD, PhD; Cyrus Michael Sayehli, MD; Guzman Alonso Casal, MD; Egle Ramelyte, MD; Martin Schuler, MD; Tanja Gromke, MD; Miguel Sanmamed, MD, PhD; Irene Moreno, MD, PhD; Ralf Bargou, MD, PhD; Maria Lostes, MD; Julia-Tatjana Maul, MD; Corinne Eggenschwiler, MD; Heike Richly, MD; Petra Fettes, PhD; Kathrin Klar, PhD; Christine Schuberth-Wagner, PhD; Markus Haake, PhD; Jörg Wischhusen, PhD; Eugen Leo, MD PhD MBA | Clinical Trials In Progress | Antibody;Antigen presenting cells;Checkpoint blockade;Clinical trial;Immunoscore;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 505 | Poster Presentation | Relationship of infusion duration and dose to safety, efficacy and pharmacodynamics: second part of a phase 1-2 study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors | Manish R. Patel, MD; Steven F. Powell; James F. Strauss, MD; Melissa Johnson; Timothy P. Cripe; Kah-Whye Peng; Stephen J. Russell; Luke Russell; Monica Reckner; Erol Wiegert; Alice S. Bexon; Jaime R. Merchan, MD | Clinical Trials In Progress | Clinical trial;Targeted therapy;Vaccine | |
| 506 | Poster Presentation | IGNYTE: An open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors | Mark R. Middleton, MD, PhD; Mohammed M. Milhem, MBBS; Francesca Aroldi, MSc; Joseph J. Sacco, MD PhD; Ari M. VanderWalde, MD, MPH, MBioeth; Scott Baum; Adel Samson, PhD; Jason A. Chesney, MD; Jiaxin Niu; Terence Rhodes, MD, PhD; Tawnya L. Bowles, MD; Hamid Emamekhoo, MD; Katy K. Tsai, MD; Gino K. In, MD, MPH; Georgia M. Beasley, MD, MHs; Bartosz Chmielowski; Sophie Dalac-Rat, MD; Katharina Kahler; Eva Muñoz, MD, PhD; Anna C. Olsson-Brown, MD; Praveen K. Bommareddy, MS, PhD; Lavita Menezes, MSc; Andrea Pirzkall, MD; Robert S. Coffin, PhD; Kevin Harrington, PhD, FRCP, FRCR | Clinical Trials In Progress | B cell;Clinical trial;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 507 | Poster Presentation | A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors | Mark R. Middleton, MD, PhD; Joseph J. Sacco, MD PhD; Kevin Harrington, PhD, FRCP, FRCR; Anna C. Olsson-Brown, MD; Tze Y. Chan, MBChB; Pablo Nenclares; Isla Leslie; Francesca Aroldi, MSc; Praveen K. Bommareddy, MS, PhD; Imran Saleem; Henry Castro; Andrea Pirzkall, MD; Robert S. Coffin, PhD | Clinical Trials In Progress | B cell;Checkpoint blockade;Clinical study;Neoantigens;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 509 | Poster Presentation | A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer | Aung Naing, MD; Margaret K. Callahan, MD, PhD; Brian Costello, MD; Carlo D. Bifulco, MD; Evan T. Hall, MD, MPhil; Aaron Hansen, MD; Georgina V. Long, MBBS, PhD, BSc, FRAC; Anthony M. Joshua, MBBS, PhD; Brooke Shankles, MA; Umut Ulge, MD, PhD; Andrew Weickhardt, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 510 | Poster Presentation | SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations. | Lenka Palová, PhD | Clinical Trials In Progress | Clinical study;Immune monitoring;NK/NKT cell;Solid tumors;T cell | |
| 511 | Poster Presentation | Initial results of a Phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced injectable tumors | Jong Chul Park, MD; Hatem Soliman, MD; Gerald S. Falchook, MD, MS; Taofeek K. Owonikoko, MD, PhD; Anna Spreafico, MD PhD; Erminia Massarelli, MD, PhD, MS; Meredith McKean, MD; Laura QM. Chow, MD; Patrick A. Ott, MD, PhD; Robert Wesolowski, MD; Christos Fountzilas, MD, FACP; Corey Whalen; Adrienne G. Yanez, PhD; Christopher D. Dupont, PhD; Julia Auer, MA; Tooba Cheema, PhD; John M. Goldberg, MD; Ted T. Ashburn, MD, PhD; Igor Puzanov, MD, MSCI | Clinical Trials In Progress | Checkpoint blockade;Chemokine;Clinical trial;Cytokine;Dendritic cell;Immune toxicity;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment | |
| 512 | Poster Presentation | Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in metastatic and advanced solid tumors | Jason J. Luke; Anthony J. Olszanski, MD, RPh; Igor Puzanov, MD, MSCI; Christos Fountzilas, MD, FACP; Lee Rosen; Dan Lu, MS; Adrian Hackett; Stella Martomo, PhD; Olivier Schueller; David Eiznhamer; Alessandro Mora; Miranda Ross; Jeegar Patel | Clinical Trials In Progress | Antibody;Biomarkers;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Solid tumors | |
| 513 | Poster Presentation | Trial in progress: Phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors in patients with inoperable locally advanced or metastatic solid tumors | Amita Patnaik, MD; Vivek Subbiah, MD; Geoffrey I. Shapiro, MD, PhD; Sumanta K. Pal, MD; Neeraj Agarwal, MD; Kristopher Wentzel, M.D.; Jing Li; Elizabeth McIlvaine; Jana Waldes; Edward Cha, MD, PhD; Keyvan Tadjalli-Mehr; Manish R. Sharma, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 515 | Poster Presentation | A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours | Ruth Plummer; Mikael H. Sodergren, MD, PhD; David J. Pinato, MD, MRes, PhD; Debashis Sarker; Vikash Reebye; Duncan Spalding; Nina Raulf; Laura Sinigaglia; Thomas Talbot; Alessio AC. Cortellini, MD; Antonio D'Alessio; Ilian Tchakov; Robert Habib; John Rossi; Nagy Habib | Clinical Trials In Progress | Monocyte/Macrophage;RNA;Solid tumors | |
| 516 | Poster Presentation | Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4-1BB (GEN1046) trial | Santiago Ponce Aix; Emiliano Calvo; Victor Moreno; Elena Garralda; Andrés Cervantes; Suresh S. Ramalingam; José M. Trigo Pérez; Patricia LoRusso; Muhammad Furqan; Daniel Cho; Alexander Muik; Eleni Lagkadinou; Özlem Türeci; Suzana Couto; Nora Pencheva; Ulf Forssmann; Ugur Sahin; Tahamtan Ahmadi; Brandon Higgs; Maria Jure-Kunkel; Ignacio J. Melero, Dr., MD, PhD | Clinical Trials In Progress | Antibody;Bispecifics;Clinical trial;Costimulation;Solid tumors;T cell | |
| 517 | Poster Presentation | LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors | Brant A. Inman, MD, MS; Matthew I. Milowsky, MD; Raj S. Pruthi; Marshall R. Posner, MD; Melissa J. Polasek; Shannon Morris, MD, PhD; Lori Mixson; Kristin Orr; Elizabeth Woodson; Andrea T. Kelly; Garrett Nichols; Arjun V. Balar, MD | Clinical Trials In Progress | Antigen presenting cells;Checkpoint blockade;Clinical trial;Cytokine;Dendritic cell;Inflammation;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 518 | Poster Presentation | First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors | John D. Powderly, II, MD; Jeremy Jones; Tanios S. Bekaii-Saab, MD; Yan Xing, MD, PhD; S. John Weroha, MD, PhD; Susanna Ulahannan, MD, MMED; Deborah Doroshow; Frances Valdes-Albini; Carl Millward, MD; Kimberly Walter; Andrew Wrong; Paul Del Castillo; Lixia Wang; Ngan Nguyen; Mark Whidden, PhD; Jonathan Benjamin, MD, PhD; Steven J. Isakoff, MD, PhD | Clinical Trials In Progress | Antibody;Biomarkers;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 519 | Poster Presentation | A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors | John D. Powderly, II, MD; Teleen Norman; Meghan Duncan; Martin Huber, MD; Jennifer O'Neil, PhD; Ekta Patel, PhD; Andrae Vandross, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;Tumor microenvironment | |
| 520 | Poster Presentation | Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors | Debbie Robbrecht; Grob Jean-Jacques; Oliver Bechter; Armando Santoro; Bernard Doger; Ivan Borbath; Butler Marcus; Cheng Tina; Patricia Martin; Bennouna Jaafar; Massimo Di Nicola; Giuseppe Curigliano, MD, PhD; Min-Hee Ryu; Alejo Rodriguez -Vida; Dirk Schadendof; Elena Garralda; Giovanni Abbadessa; Brigitte Demers, MD; Amele Amrate; Tun Tun Lin; Manisha Brahmachary; Joon Sange Lee; Joachim Theilhaber; Debbie Robbrecht, MD; Rui Wang | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 521 | Poster Presentation | GEN-009, a personalized neoantigen vaccine candidate, elicits diverse and durable immune responses associated with clinical efficacy outcomes | Mara G. Shainheit, Ph.D.; Ece Bicak, MS; Masoud Golshadi, Ph.D.; Gabriella Santone, MS; Syukri Shukor; Emily Tjon, M.S.; Li Xue, Ph.D.; Thomas A. Davis, MD; Jessica B. Flechtner, PhD | Clinical Trials In Progress | Biomarkers;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Vaccine | |
| 522 | Poster Presentation | Transcriptomic changes in cancer patients treated with immune-checkpoint inhibitors. | Dmitrii Dr. Shek, MD, MRes; Bo Gao; Joey Lai, BSc, MSc, PHD; Won-Hee Yoon, MD; Tania Moujaber, MBBS, PhD, FRACP; Adnan Nagrial, MBBS, PhD, FRACP; Matteo S. Carlino, M.D., Ph.D.; Scott A. Read, BSc, MSc, PhD; Golo Ahlenstiel, MD, PhD, FRACP | Clinical Trials In Progress | Bioinformatics;Biomarkers;Immune toxicity;RNA;T cell | |
| 523 | Poster Presentation | Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors | Elaine Shum, MD; Matthew J. Reilley, MD; Yana G. Najjar, MD; Adil I. Daud, MD; John A. Thompson, MD; Joaquina Baranda; R. Donald Harvey, PharmD; Anthony F. Shields, MD PhD; Ezra EW. Cohen, MD; Shubham Pant, MD; Rom S. Leidner, MD; Alain Mita, MD; Roger B. Cohen, MD; Bartosz Chmielowski; Mark N. Stein, MD; Siwen Hu-Lieskovan, MD, PhD; Catherine A. Fleener, MS; Ying Ding, PhD; Lei Bao, PhD; Sowmya Chollate, MS; Jolene S. Shorr; Raphael Clynes, MD, PhD; Barbara Hickingbottom, MD | Clinical Trials In Progress | Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Immune toxicity;Solid tumors;T cell | |
| 524 | Poster Presentation | A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors | Vivek Subbiah, MD; Ulka Vaishampayan, MD; Sonam Puri, MD; Lanjia Lin, PhD; Mark Chao, MD, PhD; Giri Ramsingh, MD; Shivaani Kummar, MD; James F. Strauss, MD; Sandip Patel | Clinical Trials In Progress | Antibody;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 525 | Poster Presentation | Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors | Stefan N. Symeonides, MD PhD; Devalingam Mahalingam, MBBChBAO; Young Kwang Chae, MD, MPH, MBA; Emiliano Calvo; Maria Miguel; Hendrik-Tobias Arkenau; Elena Garralda; Vladimir Galvao; Alain Mita, MD; Hariz Hassan, MD; Annette Baumhauer, MD; Timo Völker, PhD; Marie-Cristine Kühnle; Roman Rösemann; Stefan Strobl; Oezlem Tuereci, MD; Ugur Sahin, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Dendritic cell;Solid tumors;T cell;TLR | |
| 526 | Poster Presentation | Removal of Soluble Tumor Necrosis Factors Receptors 1/2 in Patients with Metastatic Solid Tumors Using Immune Apheresis | Ayala Tamir, PhD; Hagit Harati; Nethanel Asher; Ronen Stoff; Shirly Grynberg; Robert Segal; Adam Ostrowski; Lawrence B. Florin; Ronnie Shapira-Frommer; Gal Markel | Clinical Trials In Progress | Biomarkers;Clinical trial;Cytokine;Immune monitoring;Solid tumors | |
| 527 | Poster Presentation | Digital Spatial Profiling of paired tumor biopsies reveals indoleamine 2,3-dioxygenase (IDO)1 as a potential resistance mechanism for a tumor-targeted 4-1BB agonist in patients with solid tumors | Tamara Tanos; Christian Heichinger; Sabine Wilson; Marta Canamero; Mariana Bustamante; Chiahuey Ooi; Irina Klaman; Bruno Gomes, DVM PhD; Maurizio Ceppi | Clinical Trials In Progress | Biomarkers;Bispecifics;Clinical study;Costimulation;Immune contexture;Immune suppression;Myeloid cells;Solid tumors;T cell;Targeted therapy | |
| 528 | Poster Presentation | Correlation of baseline circulating Vg9Vd2 T cell counts and pharmacodynamic activity of ICT01 in cancer patients: preliminary results from EVICTION and a novel patient enrichment strategy | Emmanuel Valentin, PhD; Aude de Gassart, PhD; Patrick Brune; Clément Ghigo; Sophie Agaugué; Daniel Olive; Paul A. Frohna, MD, PhD, PharmD | Clinical Trials In Progress | Antibody;Biomarkers;Immune monitoring;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 529 | Oral Presentation | Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors | Eric Van Cutsem, MD, PhD; Hans Prenen, MD; Brant Delafontaine; Kristen R. Spencer, DO, MPH; Tara C. Mitchell; Howard A. Burris, III, MD; Nuria Kotecki, MD; Rebecca Kristeleit, MD PhD; David J. Pinato, MD, MRes, PhD; Solmaz Sahebjam, MD; Donna M. Graham; Thomas Karasic; Jeannie Daniel; Kevin M. O'Hayer, MD, PhD; Ryan Geschwindt, BS; Sarina A. Piha-Paul, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 530 | Poster Presentation | A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors | Geoffrey A. Watson; Meredith McKean, MD; Anthony W. Tolcher, MD; Anja Victor; Sen Zhang; Vadryn Pierre; Emilia Richter; Aung Naing, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 531 | Poster Presentation | A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts | Ira Winer, mD; Akhila Wimalasingham; Joaquina Baranda; Armando Santoro, MD, PhD; Kristen R. Spencer, DO, MPH; Capucine Baldini, MD; Linda R. Duska, MD; Vivek Subbiah, MD; Sandip Patel; Polina Khrizman; Griet Van Lancker; Lana Andrianova; Sumandeep Atwal; Keerti Sharma; Luis Manso | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 532 | Poster Presentation | First-in-Human Phase 1 trial of SRK-181: a latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors (DRAGON trial) | Timothy A. Yap, MD; Minal Barve, MD; Justin Gainor, MD; Bruno Bockorny; Yawen Ju; Shaun Cote, PhD; Sanela Bilic, PharmD, MBA; Lan Liu, MS; Yung Chyung; Michelle Legler; Lu Gan, PhD; Meredith McKean, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial;Solid tumors | |
| 533 | Poster Presentation | An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors | Pan Zheng, MD, PhD; Kun He, Ph.D.; Yang Liu, PhD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial | |
| 535 | Poster Presentation | A Phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors | Nehal J. Lakhani, MD; Melissa L. Johnson, MD; Roman Groisberg; Hyunsil Han; Kerry A. Casey; Siyu Li, PhD; Dimitris Skokos, PhD; Frank Seebach, MD; Israel Lowy, MD, PhD; Matthew G. Fury, MD, PhD; Melissa Mathias, MD | Clinical Trials In Progress | Antibody;Bispecifics;Clinical study;Costimulation;Solid tumors | |
| 536 | Poster Presentation | Intratumoral INT230-6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with Ipilimumab [Intensity IT-01; BMS#CA184-592] | Matthew Ingham, MD; James Hu, MD; Giles F. Whalen, MD; Jacob Thomas, MD; Anthony El-Khoueiry, MD; Diana Hanna, MD; Anthony J. Olszanski, MD, RPh; Christian F. Meyer; Nilofer Azad, MD; Syed Mahmood, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lilian L. Siu, MD; Albiruni R. Razak | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors | |
| 537 | Poster Presentation | OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma | Yago Pico de Coaña, PhD; Yago Pico de Coaña; Karin Enell Smith, PhD, MS; Anette Fält; Maria Flärdh; Peter Ellmark, PhD; Philippe Cassier, MD; Jean-Luc van Laethem, MD; Malin Carlsson | Clinical Trials In Progress | Antibody;Antigen presenting cells;Chemotherapy;Clinical trial;Coinhibition;Costimulation;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Tumor stroma | |
| 538 | Poster Presentation | Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp | Joseph J. Sacco, MD PhD; Richard D. Carvajal; Marcus O. Butler; Alexander N. Shoushtari, MD; Jessica C. Hassel, MD; Alexandra Ikeguchi; Leonel Hernandez-Aya; Paul Nathan, MD, PhD; Omid Hamid, MD; Josep M. Piulats; Matthew Rioth; Douglas B. Johnson, M.D.; Jason J. Luke; Enrique Espinosa; Serge Leyvraz; Chris Holland; Michelle L. McCully; Shaad E. Abedin, MD, FACP; Takami Sato, MD | Clinical Trials In Progress | Bispecifics;Clinical study;Clinical trial;Solid tumors;T cell | |
| 539 | Poster Presentation | Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ, for intratumoral (ITu) injection +/- durvalumab in advanced solid tumors and lymphoma | Manish R. Patel, MD; Antonio Jimeno, MD, PhD; Ding Wang, MD; Salomon M. Stemmer; Todd Bauer; Randy F. Sweis, MD; Ravit Geva, MD; Shivaani Kummar, MD; Patrick Reagan, MD; Ruth Perets; Patricia LoRusso; Shilpa Gupta; Sima Zacharek, PhD; Andressa S. Laino; Oleg Milberg; Josh Frederick; Sheryl Chen; Stephanie Pascarella; William Randolph; Praveen Aanur; Lisa Johansen; Khanh T. Do, MD; Robert S. Meehan, MD; Ryan J. Sullivan, MD | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Inflammation;NK/NKT cell;Regulatory T cell (Treg cell);RNA;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 540 | Poster Presentation | Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors | Chen Zhao, MD; Matthew Mule; Andrew Martins; Iago Pinal Fernandez; Renee N. Donahue, PhD; Jinguo Chen; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; Andrew L. Mammen; John Tsang; Arun Rajan, MD | Clinical Trials In Progress | Autoimmunity;Checkpoint blockade;Immune toxicity;T cell | |
| 542 | Poster Presentation | Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-Month Analysis | Elizabth L. Carpenter, MD; Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, MD; Franklin A. Valdera, MD; Patrick M. McCarthy, MD; Anne E. O'Shea, MD; Diane F. Hale, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; John W. Myers, III, MD; Jessica L. Cindass, MD; John Hyngstrom, MD; Adam C. Berger, MD; Jeffrey J. Sussman, MD; James W. Jakub, MD; Montaser Shaheen, MD; Xianzhong Yu, MD; Thomas Wagner, PhD; Mark B. Faries, MD; George E. Peoples, MD | Clinical Trials In Progress | Clinical trial;Dendritic cell;Vaccine | |
| 543 | Poster Presentation | Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation | Samra Turajlic, MD PhD; Mariam Jamal-Hanjani, MD PhD; Andrew Furness, MD PhD; Ruth Plummer; Judith Cave, MD MD(Res); Fiona Thistlethwaite, MD, PhD; Emma Leire, PhD; Jen Middleton, BSc PGCert; Eloise Williams, BSc MSc; Amy Baker; Chloe Maine, BA MA; Michael Epstein; Monica Sassi, PhD; Katy Newton, BSc PhD; Michael Grant, MD BSc PGCert; Matilde Saggese, MD MD(Res); Sergio Quezada, BSc PhD; Martin Forster | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 544 | Poster Presentation | DELTA-1: A global, multicenter phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma | Brian Gastman, MD; Omid Hamid, MD; Pippa Corrie; Geoffrey Gibney; Gregory A. Daniels; Bartosz Chmielowski; Sajeve S. Thomas; Evidio Domingo-Musibay; Donald P. Lawrence; Yizhou Jiang; Audrey Kennedy; Jeff Aycock; Ruben Alvarez-Rodriguez; Paul B. Robbins; John Le Gall; Zachary J. Roberts; Robert E. Hawkins, MD, PhD; Amod A. Sarnaik; Brian Gastman | Clinical Trials In Progress | Adoptive immunotherapy;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 545 | Poster Presentation | A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma (MCC) (POD1UM-201) | Giovanni Grignani, MD; Piotr Rutkowski, MD, PhD; Celeste Lebbe, MD, PhD; Natalie Prinzi, MD; Jean-jaques Grob, MD; Enrica Teresa Tanda, MD; Michele Guida, MD; Melissa Burgess, MD; Jennifer Pulini, PharmD; Sadhna Shankar, MD, MPH; Chuan Tian, PhD; Shailender Bhatia, MD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Clinical trial | |
| 546 | Poster Presentation | Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) | Omid Hamid, MD; Jessica C. Hassel; Alexander N. Shoushtari, MD; Friedegund Meier; Todd Bauer; April Salama, MD; John M. Kirkwood, MD, MD; Paolo A. Ascierto, MD; Paul Lorigan, MD; Cornelia Mauch; Marlana Orloff, MD; Jeff Evans, MD, PhD; Ramakrishna Edukulla; Chris Holland; Shaad E. Abedin, MD, FACP; Renee Mundy; Mark R. Middleton, MD, PhD | Clinical Trials In Progress | Bispecifics;Clinical study;Clinical trial;Solid tumors;T cell | |
| 547 | Poster Presentation | CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma | Andrew M. Haydon, PhD; Muhammad Alamgeer; Daniel Brungs, MBBS; Frances A. Collichio, MD; Nikhil I. Khushalani, MD; Dimitrios Colevas, MD; Danny Rischin, MBBS, MD; Ragini R. Kudchadkar, MD; Wanxing Chai-Ho, MD; Gregory Daniels; Jose Lutzky, MD, FACP; Jenny H. Lee, PhD; Samantha E. Bowyer, MBBCh; Michael R. Migden, MD; Ann W. Silk, MD, MS; Celeste Lebbe, MD, PhD; Jean-jaques Grob, MD; Ignacio J. Melero, Dr., MD, PhD; Piyush Sheladia, MS; Praveen K. Bommareddy, MS, PhD; Shui He, PhD; Claudia Andreu-Vieyra, PhD; Matthew G. Fury, MD, PhD; Andrew Hill, BHB, MBChB, FRACP | Clinical Trials In Progress | B cell;Biomarkers;Checkpoint blockade;Clinical trial;Inflammation;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 548 | Poster Presentation | Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma | Rakesh K. Goyal, MD, MRCP; Nicole Nasrah; Dan Johnson; William Y. Ho, MD, PhD | Clinical Trials In Progress | Antibody;Checkpoint blockade;Chemokine;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Solid tumors;Tumor microenvironment | |
| 549 | Poster Presentation | An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion | Carmen Loquai; Jessica C. Hassel; Patrick Brück; Evelyna Derhovanessian; Katarina Cuk; Verena Lörks; Julian Sikorski; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Marion Kästner; Thomas Weisenburger; Ann-Kathrin Eller; Sebastian Attig; Silvana Hempel; Petra Oehm; Tana Omokoko; Lena M. Kranz; Juliane Quinkhardt; Isabel Vogler; Inga Liebig; Stephanie Renken; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Stephan Grabbe; Jochen Utikal; Roland Kaufmann; Ugur Sahin; Özlem Türeci | Clinical Trials In Progress | Clinical study;Clinical trial;RNA;T cell;Tumor antigens;Vaccine | |
| 550 | Poster Presentation | ARTACUS: An open-label, multicenter, phase 1b/2 study of RP1 in solid organ transplant recipients with advanced cutaneous malignancies | Jason J. Luke; Michael R. Migden, MD; Wanxing Chai-Ho, MD; Diana Bolotin, MD, PhD; Trisha M. Wise-Draper, MD, PhD; Andrew Poklepovic, MD; Douglas E. Laux, MD; Meenal K. Kheterpal, MD; Claire F. Verschraegen, MD; Frances A. Collichio, MD; Jose Lutzky, MD, FACP; Gregory Daniels; Katy K. Tsai, MD; Susan Navia, BS, MBA; Henry Castro; Praveen K. Bommareddy, MS, PhD; Andrea Pirzkall, MD; Robert S. Coffin, PhD | Clinical Trials In Progress | Checkpoint blockade;Neoantigens;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 551 | Poster Presentation | Pegasus Skin, a study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers | John PARK, MD; Adyb BAAKILI, MD; Brigitte Demers, MD; Rao Saleem, MD; Alice GOSSELIN; Giovanni Abbadessa, MD; Paolo A. ASCIERTO, MD | Clinical Trials In Progress | Checkpoint blockade;Clinical study;Clinical trial;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 552 | Poster Presentation | Amphiphile-peptide boosting with FMC63-binding surrogate peptide mimotopes induces activation and potent effector function in CAR-T cells targeting CD19 | Ana Castano, MD; Peter C. DeMuth, PhD; Amy Tavares | Combination Immunotherapies | CAR T cells;Dendritic cell;T cell | |
| 553 | Poster Presentation | First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition | Peter I. Joyce, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong, PhD; Kristopher Clark, PhD; Nicola Ternette, PhD; Kate Anderton, BSc; Jessica Sette, BSc; Wayne Paes, PhD; Andrew J. Leishman, PhD | Combination Immunotherapies | Checkpoint blockade;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 554 | Poster Presentation | The panorama of tumor intrinsic immune regulators exhibited by genome-wide CRPISR immune screen integrated with comprehensive clinical dataset analysis | Jiakai Hou, Ph.D; Yunfei Wang; Leilei Shi, PhD; Yuan Chen; Chunyu Xu; Arash Saeedi; Ke Pan; Ritu Bohat; Nicholas A. Egan; Jodi A. McKenzie; Rina M. Mbofung; Leila Williams; Zhenhuang Yang; Ming Sun; Xiaofang Liang; Jordi Rodon Ahnert; Navin Varadarajan, PhD; Cassian Yee; Yiwen Chen; Patrick Hwu; Weiyi Peng, PhD | Combination Immunotherapies | Bioinformatics;Epigenetics;Systems biology;Tumor microenvironment | |
| 555 | Poster Presentation | A high-throughput in situ screen to identify synergistic combinations of immune-oncology drugs with targeted and cytotoxic agents in a patient-derived humanized mouse model of renal cancer | Oliver Jonas, PhD; Eva Oswald, PhD; Kanstantsin Lashuk; Sebastian Ahn, PhD; Julia Schuler, DVM PhD | Combination Immunotherapies | Antibody;Checkpoint blockade;Proteomics;Solid tumors;T cell;Tumor microenvironment | |
| 556 | Poster Presentation | Chemo-immunotherapy to treat bone-metastatic prostate cancer | Shreya Kumar, MS; Marxa L. Figueiredo, Ph.D. | Combination Immunotherapies | Chemotherapy;Cytokine;Solid tumors;Tumor microenvironment | |
| 557 | Poster Presentation | Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC) | Huilai Lv; Yang Tian; Zhenhua Li; Chao Huang; Yanzhao Xu; Ziqiang Tian | Combination Immunotherapies | Antibody;Checkpoint blockade;Chemotherapy;Clinical study;Immune tolerance;Immune toxicity;Surgery;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 559 | Poster Presentation | Preclinical evaluation of pegylated liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6 syngeneic mouse model | Erin Wechsler, PhD; Nikhil Vad, PhD; Danhui Zhang, MD PhD | Combination Immunotherapies | Antibody;Chemotherapy;Costimulation;Solid tumors;Targeted therapy;Tumor antigens | |
| 560 | Poster Presentation | Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer | Takahiro Yamazaki, PhD; Erik Wennerberg, PhD; Michal Hensler; Aitziber Buqué Martinez, PhD; Jeffrey Kraynak; Jitka Fucikova; Xi Zhou; Baldur Sveinbjornsson, PhD; Oystein Rekdal, PhD; Sandra Demaria, MD; Lorenzo Galluzzi, PhD | Combination Immunotherapies | Antigen presenting cells;Chemotherapy;Dendritic cell;NK/NKT cell;Radiotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 561 | Oral Presentation | Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer | Kristin G. Anderson, PhD; Yapeng Su; Madison G. Burnett; Breanna Bates, BS; Magdalia Rodgers Suarez; Susan L. Ruskin; Aesha Vakil; Valentin Voillet, PhD; Raphael Gottardo, PhD; Philip D. Greenberg, MD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;Solid tumors;T cell;Tumor microenvironment | |
| 562 | Poster Presentation | Real-world assessment of current treatment patterns and clinical outcomes among patients with EGFR and ALK wild type non-small cell lung cancer (NSCLC) in the US | Lyudmila Bazhenova, MD; Jonathan K. Kish, PhD MPH; Beilei Cai; Nydia Caro; Bruce Feinberg | Combination Immunotherapies | Checkpoint blockade;Solid tumors | |
| 563 | Poster Presentation | ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation | Aude De Gassart, PhD; Patrick Brune; Maelle Mairesse; Sophie Agaugué; Ryan Swanson, BS; Loui Madakamutil; Carl Walkey; Paul A. Frohna, MD, PhD, PharmD; Aude de Gassart, PhD | Combination Immunotherapies | Antibody;Cytokine;T cell | |
| 564 | Poster Presentation | Single-cell transcriptomic analysis of immune compartments following combination immunotherapy treatment in poorly immunogenic tumors | Ang Cui, PhD; Kelly D. Moynihan, PhD; Shuqiang Li, PhD; Chensu Wang, PhD; Jackson Southard; Nir Hacohen, PhD; Darrell J. Irvine, Ph.D. | Combination Immunotherapies | Bioinformatics;Solid tumors;Systems biology;Tumor microenvironment | |
| 565 | Poster Presentation | Combinatorial HSCs and anti-PD-1 therapy in microsatellite stable colorectal cancer | Bayli DiVita Dean, PhD; John Figg; Laura Falceto Font, BS; Connor Francis; Duane Mitchell; Catherine Flores | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Solid tumors | |
| 566 | Poster Presentation | ATOR-1017, a second generation 4-1BB antibody with potential to enhance efficacy of PD-1 therapies | Karin Enell Smith, PhD, MS; Anneli Nilsson; Peter Ellmark, PhD | Combination Immunotherapies | Antibody;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 567 | Poster Presentation | Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of stroma poor cancers | Sadna Budhu, PhD; Aditi Gupta, MD; Kelly J. Fitzgerald, MD/PhD; Rachel A. Giese, MD; Adam O. Michel, DVM, MVSc, Dr.med.vet., DACVP; Aliya Holland; Luis Felipe F. Campesato, PhD, MS; Jacques Van Snick, PhD; Catherine Uyttenhove, PhD; Gerd Ritter, PhD; Jedd D. Wolchok, MD/PhD; Taha Merghoub, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;Immune suppression;Tumor microenvironment | |
| 568 | Poster Presentation | Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment | Markus Haake, PhD; Tina Schäfer, PhD; Beatrice Haack; Neha Vashist, PhD; Sabrina Genßler, PhD; Patrick Harter, MD; Alexander Martens, PhD; Kilian Wistuba-Hamprecht, PhD; Florian Wedekink; Birgitt Fischer; Michel Mittelbronn, MD; Mitchell Levesque, PhD; Phil Cheng, PhD; Reinhard Dummer, MD; Benjamin Weide, MD; Kathrin Klar, PhD; Eugen Leo, MD, PhD, MBA; Falk Nimmerjahn, PhD; Christine Schuberth-Wagner, PhD; Jörg Wischhusen, PhD | Combination Immunotherapies | Antibody;Checkpoint blockade;Cytokine;Immune suppression;Immune tolerance;Solid tumors;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 569 | Poster Presentation | A novel microbiome-derived peptide reverses resistance to anti-PD-1 therapy | Dhwani D. Haria, MS; Jayamary Divya Ravichandar; Jill Desnoyer; Sabina Lau; Jina Lee; Erica Rutherford; Preeti Lal; Karim Dabbagh; Helena Kiefel, PhD | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Chemokine;Cytokine;Dendritic cell;Microbiome;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 570 | Poster Presentation | Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization | Lucas A. Horn, PhD; Haiyan Qin; Kristen N. Fousek, PhD; Masafumi Iida, MD, PhD; Dallas B. Flies, PhD; Ronald Copeland; Zachary Cusumano, Ph.D.; Han Myint; Solomon Langermann; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Combination Immunotherapies | Monocyte/Macrophage;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 571 | Poster Presentation | IL-2 combination with ImmTAC overcomes CD163+ TAM-like M2 macrophage inhibition of ImmTAC-mediated T cell killing of tumor cells | Rahul Khanolkar; Revashnee Naidoo; Esra Güç; Emma Leach; Sarah Stanhope; Duncan Gascoyne; Laura Collins; Koustubh Ranade; Adel Benlahrech | Combination Immunotherapies | Cytokine;Immune suppression;Monocyte/Macrophage;T cell;Tumor microenvironment | |
| 572 | Poster Presentation | Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity | Katherine Kirwin; Su Chul Jang, PhD; Christine Sia; Kevin Dooley; Tong Zi; Kelvin Zhang, PhD; Yanyan Liu, PhD; Kyriakos Economides, PhD; Shil Patel, PhD; Sriram Sathyanaryanan, PhD | Combination Immunotherapies | Checkpoint blockade;Extracellular vesicles/exosomes;T cell | |
| 573 | Poster Presentation | FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies | Matthew A. Lakins, PhD; Wenjia Liao; Emma McConnell; Quincy Kaka; Jennifer Ofoedu; Cristian Gradinaru; Raffaella Giambalvo; Miguel Gaspar; Edmund Poon; Michelle Morrow, PhD; Neil Brewis | Combination Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 574 | Poster Presentation | Multiplex microscopy reveals unique spatiotemporal effects of cancer immunotherapies | Vivien I. Maltez, PhD; Katelyn Byrne, PhD; Ronald N. Germain, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Regulatory T cell (Treg cell);Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment | |
| 575 | Poster Presentation | Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice | Yun Hu, PhD; James Welsh; Sebastien Paris; Genevieve Bertolet; Hampartsoum Barsoumian; Lily Schuda; Kewen He; Duygu Sezen; Mark Wasley; Joylise Mitchell; Tiffany Voss; Fatemeh Masrorpour; Jordan SILVA; Claudia Kettlun Leyton; Liangpeng Yang; Nahum Puebla-Osorio; Saumil Gandhi; Quynh-Nhu Nguyen; Angelica Cortez | Combination Immunotherapies | Antibody;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 576 | Poster Presentation | Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors | yael Sagi, PhD; Michal Shahar, PhD; Marina Pinsker, MSc | Combination Immunotherapies | Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor microenvironment | |
| 577 | Poster Presentation | Non-clinical efficacy, pharmacokinetics, and pharmacodynamics of a novel bi-functional anti-CD73-TGFβRII-trap molecule in combination with immune checkpoint therapy | Susanna Y. Stinson, MS; Jianhua He; Kyung-Hoon Kim; Becky Yang; Marianna Zavodovskaya, M.S.; Ping Yi; Federico Campigotto; Monika Sobczyk; Rutwij Dave; Brian Carr; In Kyoung Mah; Shiva Zaboli; Jens Brodbeck; Scott Turner; Vivian Barry; Kelli Boyd; Valeria Fantin | Combination Immunotherapies | Immune suppression;Tumor microenvironment | |
| 578 | Oral Presentation | CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines | Hussein Sultan, Ph.D.; Kelly D. Moynihan, Ph.D.; Yuang Song, B.A.; Samuel Ameh, B.A.; Ton N. Schumacher, PhD; Yik Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D.; Robert D. Schreiber, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;Immune adjuvant;Neoantigens;T cell;Tumor antigens;Vaccine | |
| 579 | Poster Presentation | Exploiting tumor neoantigen-targeted immunotherapy in immunologically hot versus cold murine lung cancer models | Changbo Sun, MD; Koji Nagaoka, PhD; Yukari Kobayashi, BS; Jun Nakajima, MD, PhD; Kazuhiro Kakimi, MD, PhD | Combination Immunotherapies | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;Neoantigens;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment;Vaccine | |
| 580 | Poster Presentation | Glutamine blockade in combination with immune checkpoint blockade remodels the myeloid landscape in mouse models of soft tissue sarcomas | Aditya A. Suru, BTech; Marwa Islam; Ada Tam; Dr. John Gross, MD; Nicolas J. Llosa, MD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 581 | Poster Presentation | Multi-dimensional Synergy of Combinations (MuSYC) Algorithm Optimizes Combinatorial STING and TLR Adjuvant Cancer Vaccines | David R. Taylor, B.S. in Chemistry; Michael J. Korrer, PhD | Combination Immunotherapies | Antigen presenting cells;Costimulation;Dendritic cell;Immune adjuvant;Myeloid cells;T cell;TLR;Tumor antigens;Tumor microenvironment;Vaccine | |
| 582 | Poster Presentation | Immune correlates from QuEST1 in men with castration-resistant prostate cancer | Nicole J. Toney, Ph.D; Yo-Ting Tsai, PhD; Jason M. Redman, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD | Combination Immunotherapies | Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;NK/NKT cell;Proteomics;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 583 | Poster Presentation | Exploring the Potential of T Cell Acute Lymphoblastic Leukemia (T-ALL) for Generating Leukemia-Specific T cell Responses that can be Therapeutically Harnessed with Immunotherapy | Todd A. Triplett, PhD; Joshua F. Rios; Alexander Somma; Sarah E. Church, PhD; Khrystyna North; Andrew M. White, BSc; Nisha Holay, B.S.; Andrew D. Weinberg, PhD | Combination Immunotherapies | Checkpoint blockade;Immune contexture;Leukemia/Lymphoma;T cell;T cell lineages;Tumor microenvironment;Tumor stroma | |
| 584 | Poster Presentation | Powerful synergistic effects of a STING agonist and the IL-2 superkine, H9, in eliciting NK and T cell responses against MHC I- and MHC I+ tumors | Natalie K. Wolf, BS; Cristina Blaj, PhD; Lora Picton; Gail Snyder; Li Zhang; Christopher J. Nicolai; Chudi Ndubaku; Kelsey E. Sivick Gauthier; Sarah McWhirter, PhD; K. Christopher Garcia; David Raulet, PhD | Combination Immunotherapies | Checkpoint blockade;Cytokine;NK/NKT cell;T cell | |
| 585 | Poster Presentation | LIGHT (TNFSF14) co-stimulation enhances myeloid cell activation and anti-tumor immunity in the setting of PD-1 and TIGIT checkpoint blockade | George J. Fromm, Jr., Ph.D.; Kyung Jin Yoo; Kellsey Johannes; Casey Shuptrine; Zach Opheim; Arpita Patel; Haley Andreasen; Jaya Miriyala; Suresh De Silva, Ph.D.; Taylor H. Schreiber, MD, PhD | Combination Immunotherapies | Bispecifics;Checkpoint blockade;Costimulation;NK/NKT cell;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
| 586 | Poster Presentation | Monitoring the impact of MDSC targeting drugs in combination with nivolumab on activation and proliferation of tumor resident effector immune cells in patient-derived 3D-EXplore platform | Jared C. Ehrhart, PhD; Brittany Bunch; Kelly Sussman; Kelly Guzman; Soner Altiok, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Costimulation;Immune suppression;MDSC;Solid tumors;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 587 | Poster Presentation | Inducing mismatch repair deficiency in combination with anti-CTLA4 therapy is highly effective against non-immunogenic neuroblastoma tumors | Mikal El-Hajjar, MSc; Lara Gerhardt, BSc; Mithunah Krishnamoorthy, PhD; Rene Figueredo, MSc; Xiufen Zheng, PhD; James Koropatnick, PhD; Saman Maleki, PhD | Combination Immunotherapies | Bioinformatics;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 588 | Poster Presentation | Caloric restriction sensitizes melanoma to anti-PD-1 immune checkpoint inhibition | Alexa D. Melucci, MD; Shuyang S. Qin, M.S; Alexander C. Chacon, MD; Rachel Jewell; Peter A. Prieto, MD, MPH | Combination Immunotherapies | Checkpoint blockade;Immune suppression;Inflammation;T cell | |
| 589 | Poster Presentation | Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy | Denis Beckford, PhD; Sagarika Pachhal; Emily Greer; Jesse Hwang; Qing Liang; Mary Chen; Eileen Geoghegan; Helen Kotanides; Dale Ludwig | Combination Immunotherapies | Antibody;Checkpoint blockade;Radiotherapy;Solid tumors;Targeted therapy | |
| 590 | Poster Presentation | Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia | Denis Beckford, PhD; Sagarika Pachhal; Emily Greer; Jesse Hwang; Qing Liang; Mary Chen; Eileen Geoghegan; Helen Kotanides; Dale Ludwig | Combination Immunotherapies | Antibody;Radiotherapy;Targeted therapy | |
| 591 | Poster Presentation | Survival rates in Stage IV melanoma patients treated with radiation and immunotherapy differ depending on age and radiation treatment site | Catherine Colonna, MS; Nasreen A. Vohra, MD; Aiden Burke, MD; Matthew S. Peach, MD; Andrew W. Ju, MD | Combination Immunotherapies | Checkpoint blockade;Radiotherapy | |
| 592 | Oral Presentation | ATR-mediated CD47 and PD-L1 upregulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer | Rodney Cheng-En Hsieh, MD; Sunil Krishnan; Ren-Chin Wu; Akash R. Boda, MS; Arthur J. Liu, BS; Michelle Winkler, BS; Wen-Hao Hsu; Steven H. Lin; Mien-Chie Hung; Li-Chuan Chan; Krithikaa R. Bhanu; Anupallavi Srinivasamani, MS; Ricardo A. De Azevedo; Yung-Chih Chou; Ronald Depinho; Matthew M. Gubin, PhD; Eduardo Vilar-Sanchez, MD, PhD; Chao-Hsien Chen; Ravaen Slay; Priyamvada Jayaprakash, PhD; Shweta M. Hegde; Genevieve P. Hartley, PhD; Spencer T. Lea, BA; Rishika Prasad, MS; Brittany Morrow; Coline A. Couillault, PhD; Madeline Steiner; Chun-Chieh Wang; Bhanu P. Venkatesulu; Cullen Taniguchi; Betty Y. Kim; Junjie Chen; Nils-Petter Rudqvist, PhD; Michael A. Curran, PhD | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Radiotherapy;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 593 | Poster Presentation | PI3Kγδ inhibitor combined with radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer model and humanized patient-derived xenograft model | MIn Guk Han, PHD student; Bum Sup Jang, PHD; Mi Hyun Kang, MS; Deukchae Na, PhD; In Ah Kim, MD, PhD | Combination Immunotherapies | Checkpoint blockade;Immune tolerance;MDSC;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);Tumor microenvironment | |
| 594 | Poster Presentation | Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model | Hemanth K. Potluri, BA; Carolina A. Ferreira, PhD; Joseph Grudzinski, PhD; Christopher Massey; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD | Combination Immunotherapies | Dendritic cell;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 595 | Poster Presentation | Inhibition of integrin αvβ8 in combination with low dose radiation induces antitumor effect in advanced immune checkpoint blockade refractory tumor model | Natalia J. Reszka-Blanco, PhD; Megan Krumpoch; Michaela Mentzer; Vinod Yadav Yadav; Brianna Bannister; Dan Cui; Elizabeth Konopka; Dooyoung Lee; Fu-Yang Lin; Terence I. Moy; Eugene Nebelitsky; Qi Qiao; Inese Smutske; Charlotte A. Root; Patrick Allison; Sarah A. Krueger; Dawn Troast; Blaise Lippa; Bruce N. Rogers; Adrian S. Ray | Combination Immunotherapies | Antigen presenting cells;Costimulation;Dendritic cell;Immune suppression;Immune tolerance;Radiotherapy;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 596 | Poster Presentation | Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Grace Helen C. McGee; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D. | Combination Immunotherapies | Cytokine;Immune adjuvant;Radiotherapy;T cell;TLR;Tumor infiltrating lymphocytes (TILs) | |
| 597 | Poster Presentation | The role of CCL20 in mediating regulatory T cell infiltration and resistance to radiotherapy in head and neck squamous cell carcinoma | Cleopatra Rutihinda, BSc; Leanié Moreau, BSc; Safia Chelighem, BSc; Ayman J. Oweida, PhD | Combination Immunotherapies | Antibody;Chemokine;Cytokine;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 598 | Poster Presentation | Local radiation in combination with CpG and anti-OX40 induces enhanced T cell activation and proliferation | Dan Spiegelman, BS; Alexander Pieper, B.S.; Luke M. Zangl, BS; Arika S. Feils, BS; Anna Hoefges, MS; Mildred A. Felder, BS; Sritha Moram, BS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Ravi Patel, MD, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD | Combination Immunotherapies | Costimulation;Radiotherapy;T cell;Vaccine | |
| 599 | Poster Presentation | Cyclophosphamide augments the efficacy of an in situ vaccine in a mouse melanoma model | Noah Tsarovsky, BS; Mildred A. Felder, BS; Mackenzie Heck; Jacob Slowinski; Kayla Rasmussen; Sabrina VandenHeuvel; Zachary S. Morris, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Alexander L. Rakhmilevich, MD, PhD | Combination Immunotherapies | Chemotherapy;Cytokine;Immune adjuvant;Radiotherapy;T cell;Vaccine | |
| 600 | Poster Presentation | BR101801 stimulates anti-tumor immunity and enhances the efficacy of radiation in a syngeneic model | Seungho Wang, MS; Yi Na Yoon; Mi kwon Son; Soo Jung Kim; Bo Ram Lee; Eun hee Yang; Byeongwook Jeon; Seung Hyun Lee; Tae-Jin Kim; Jae-Sung Kim; Joo Han Lee | Combination Immunotherapies | Immune adjuvant;MDSC;Myeloid cells;Radiotherapy;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 601 | Oral Presentation | Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC | Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell, BS; Farhoud Faraji, MD PhD; Michael Allevato, BA; Zhiyong Wang, PhD; Victoria H. Wu, BA; Bryan S. Yung, MA; Nana-Ama A. Anang, BS; Ida Franiak-Pietryga, PhD; Aaron B. Simon, MD PhD; Shawn Jensen, PhD; Bernard A. Fox, PhD; Andrew Sharabi, MD, PhD, FACS; Ezra EW. Cohen, MD; Joseph Califano, MD; J. Silvio Gutkind | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Solid tumors;Surgery;Systems biology;Tumor evasion | |
| 602 | Poster Presentation | AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells | Huiyu Li, BS; Zhida Liu, PhD; Longchao Liu, PhD; Hongyi Zhang; Chuanhui Han, PhD; Luc Girard, Ph.D.; Hyunsil Park; Anli Zhang, PhD; Chunbo Dong; Jianfeng Ye; Austin Rayford, MS; Michael Peyton, Ph.D.; Xiaoguang Li; Kim Avila; Xuezhi Cao; Shuiqing Hu; Esra Akbay, PhD; Luisa M. Solis, MD; Carmen Behrens, MD; Sharia Hernandez-Ruiz; Lu Wei; Ignacio Wistuba, MD; John V. Heymach, MD, PhD; Michael Chisamore, PhD; David Micklem, PhD; Hani Gabra, MD, PhD, FRCP; Gro Gausdal, PhD; James B. Lorens, PhD; Bo Li; Yang-Xin Fu, MD, PhD; John D. Minna, M.D.; Rolf A. Brekken, PhD | Combination Immunotherapies | Checkpoint blockade;Dendritic cell;Immune contexture;Immune suppression;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 603 | Poster Presentation | Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy | Joyoti Dey, PhD, MPH; Phillip CC. Liu, PhD; Michele Mayo; Rahul Karnik, PhD; Bin Yang, PhD; Vaishali Dixit, PhD; Jieun Jeong, PhD; Jared Gollob, MD; Chris De Savi, PhD | Combination Immunotherapies | Checkpoint blockade;Gene expression;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 604 | Poster Presentation | Combining a novel dual RAF/MEK inhibitor with immunomodulation to promote an anti-tumor response. | Lauren Dong, BS; Hyejin Choi, PhD; Sadna Budhu, PhD; Isabell Schulze; Nezar Mehanna; Neal Rosen; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD | Combination Immunotherapies | Checkpoint blockade;Costimulation;Targeted therapy | |
| 605 | Poster Presentation | NHS-IL12 plus Entinostat combination effectively targets anti-PD-1/PD-L1 checkpoint resistant murine tumors harboring MHC Class I and antigen processing machinery deficiency | Christine M. Minnar, PhD; Paul L. Chariou, PhD; Kristin C. Hicks, PhD; Jeffrey Schlom, PhD; Sofia R. Gameiro, PharmD, PhD | Combination Immunotherapies | Antigen presenting cells;Cytokine;Epigenetics;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 606 | Poster Presentation | SAR444245 (THOR-707), an engineered non-alpha IL-2, enhances NK mediated antibody-dependent cellular cytotoxicity | Julie-Ann Gavigan; Nicole V. Acuff; Christen Buetz; Michael Lampa; Chaomei Shi; Yu-an Zhang; Liqing Chen; Kelly Balko; Virna Cortez-Retamozo; Jill Mooney; Carolina Caffaro; Marcos Milla; Joachim Theilhaber; Donald Jackson; Timothy Wagenaar; Giovanni Abbadessa; Donald Shaffer; Xiangming Li | Combination Immunotherapies | Antibody;Cytokine;NK/NKT cell;Solid tumors | |
| 607 | Poster Presentation | Regional delivery of a TLR9 agonist to boost checkpoint inhibitor responsiveness in liver metastases | Chandra C. Ghosh, PhD; Kyle O’Connell, BS; Kara Heatherton, BS; Jason Laporte, MS; Prajna Guha, PhD; Bryan Cox; Steven C. Katz, MD | Combination Immunotherapies | Checkpoint blockade;MDSC;Solid tumors;TLR;Tumor microenvironment | |
| 608 | Poster Presentation | Synergistic effect of the combination of ATG-017, an ERK1/2 inhibitor, and immune checkpoint inhibitor in preclinical cancer models | Bing Hou, Ph.D; Peng Chen; Yun Liu; Min Deng; Jian Wang; Dirk Hoenemann; Kevin Lynch; Jay Mei; Bo Shan | Combination Immunotherapies | Checkpoint blockade;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 609 | Poster Presentation | Combining bintrafusp alfa with abituzumab enhances suppression of the TGF-β signaling pathway | Feng Jiang, PHD; Hong Wang; Tsz-Lun Yeung; Guozhong Qin; Bo Marelli; Hui Huang, Ph.D.; Kin-Ming Lo; Yan Lan, MD | Combination Immunotherapies | Bispecifics;Checkpoint blockade;Cytokine;Tumor microenvironment | |
| 610 | Poster Presentation | Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX | Hong Jiang, PhD; Dong Ho Shin; Sagar s. Sohoni, PhD; Teresa T. Nguyen, PhD; Yanhua Yi; Xuejun Fan, BS; Joy Gumin; Sanjay k. Singh, PHD; Frederick Lang, MD; Candelaria Gomez-Manzano; Juan Fueyo | Combination Immunotherapies | Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy | |
| 611 | Poster Presentation | Exploiting T cells as vehicles of liposomal SHP2i to enhance adoptive cell therapy | Xin Li, MSc; Hólmfridur R. Halldórsdóttir; Sven Weller; Anna Colliander; Ditte Jæhger, PhD; Martin Bak; Gael Clergeaud, PhD; Thomas L. Andresen, PhD | Combination Immunotherapies | Adoptive immunotherapy;Checkpoint blockade;T cell;Targeted therapy | |
| 612 | Poster Presentation | Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma | Zhengyu Zha; Chenhao Zhou; Dihua Yu; Mien-Chie Hung; Chunxiao Liu, PhD; Ning Ren | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Targeted therapy;Tumor microenvironment | |
| 613 | Poster Presentation | 9-ING-41, a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta (GSK-3beta), may enhance neuroblastoma immunogenicity | Angela Markovska, MSc; Marianne Boes, PhD; Francis Giles, MD | Combination Immunotherapies | Checkpoint blockade;Metabolism;Pediatric tumors;Solid tumors;T cell;Targeted therapy | |
| 614 | Poster Presentation | Investigating immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC) | Anita K. Mehta, PhD; Madeline G. Townsend; Madisson Oliwa; Patrice A. Lee, PhD; Nicholas A. Saccomano, PhD; Filipa Lynce, MD; Geoffrey I. Shapiro, MD, PhD; Elizabeth A. Mittendorf, MD, PhD; Jennifer L. Guerriero, PhD | Combination Immunotherapies | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 615 | Poster Presentation | Reactivating antitumor immunity in gliomas with osteopontin/integrin blocking peptide | Paulina Pilanc-Kudlek, MSc; Katarzyna Poleszak, PhD; Aleksandra Ellert-Miklaszewska, PhD; Adria-Jaume Roura Canalda, MSc; Salwador Cyranowski, MSc; Julian Swatler, MSc; Bartlomiej Gielniewski, PhD; Bozena Kaminska, Prof. | Combination Immunotherapies | Angiogenesis;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment | |
| 616 | Poster Presentation | CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy | Elizabeth R. Stirling, MS; Adam Wilson, .; Katherine L. Cook, PhD; Alexandra Thomas, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Immune suppression;Metabolism;Solid tumors;Tumor microenvironment | |
| 617 | Poster Presentation | Trastuzumab and Pertuzumab combination therapy activates complement-dependent cytotoxicity and phagocytosis against HER2+ breast cancer | Li-Chung Tsao, PhD; Zachary C. Hartman, PhD | Combination Immunotherapies | Antibody;Coinhibition;Monocyte/Macrophage;Solid tumors;Targeted therapy | |
| 618 | Poster Presentation | Expanding Cancer Immunotherapy by Exploiting Recall Immunity – A New Co-Therapy Option for Checkpoint Inhibitors | Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Anuja Pande | Combination Immunotherapies | Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy | |
| 619 | Poster Presentation | Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy | Svena Verma, BS; Rachana Maniyar, PhD; Myat K. Ko; Sadna Budhu, PhD; Inna Serganova; Roberta Zappasodi, PhD; Ronald Blasberg; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD; Levi M. Mangarin, BS | Combination Immunotherapies | Metabolism | |
| 620 | Poster Presentation | Onco-immunological mechanisms of focal ablation and localized IL-12 immunotherapy | Maura R. Vrabel, B.S.; David A. Zaharoff, PhD; Siena M. Mantooth, BS | Combination Immunotherapies | Immune adjuvant;Solid tumors;Surgery;Targeted therapy | |
| 621 | Poster Presentation | NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients | Amir Horowitz, PhD; Jorge Daza, MD; Y. Alice Wang, PhD; Daniel Ranti; Berengere Salome, PharmD, PhD; Elliot Merritt, PhD; Julie-Ann Cavallo-Fleming, PhD; Everado Hegewisch-Solloa; Emily M. Mace, PhD; Adam M. Farkas, PhD; Sanjana Shroff, PhD; Michelle Tran, MD PhD Candidate; Jingjing Qi, PhD; Manishkumar Patel, PhD; Daniel Geanon; Geoffrey Kelly; Ronaldo de Real; Brian Lee; Seunghee Kim-Schulze, PhD; Tin Htwe Thin, PhD; Monica Garcia-Barros; Kristin G. Beaumont; Ying-Chih Wang; Li Wang, PhD; Dominic LaRoche, PhD; Yong Lee; Robert Sebra; Rachel Brody, MD, PhD; Reza Mehrazin, MD; Jun Zhu, PhD; Anna Tocheva, PhD; Benjamin Hopkins, PhD; Peter Wiklund, MD; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD; John P. Sfakianos, MD | Combination Immunotherapies | Checkpoint blockade;Inflammation;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 622 | Poster Presentation | Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege | Priyamvada Jayaprakash, PhD; Meghan Rice; Krithikaa Rajkumar Bhanu; Brittany Morrow; Joseph R. Marszalek, PhD; Jason P. Gay, PhD; Christopher P. Vellano, PhD; Benjamin R. Cowen, PhD, MBA; Dean J. Welsch, PhD; Michael A. Curran, PhD | Combination Immunotherapies | Checkpoint blockade;Immune suppression;MDSC;Metabolism;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 623 | Poster Presentation | Notch Orchestrates A Multifaceted Immune Evasion Program in Hepatocellular Carcinoma | Katherine E. Lindblad, BS; Marina Ruiz de Galarreta, PhD; Romain Donne, PhD; Marina Bárcena-Varela, PhD; Ian Liebling; David Repáraz; Melissa Yao, B.S.; Maxime Dhainaut, PhD; Brian Brown, PhD; Alice O. Kamphorst, PhD; Amaia Lujambio, PhD | Combination Immunotherapies | Checkpoint blockade;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 624 | Poster Presentation | Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses | Leilei Shi, PhD; Andrew Fedoriw; Shane O'Brien; Kimberly Smitheman; Yunfei Wang; Jiakai Hou, Ph.D; Christian Sherk; Satyajit Rajapurkar; Jenny Laraio; Leila Williams; Chunyu Xu; Guangchun Han; Qin Feng; Mark T. Bedford; Linghua Wang, PhD; Olena Barbash; Ryan G. Kruger; Patrick Hwu; Helai P. Mohammad; Weiyi Peng, PhD | Combination Immunotherapies | Checkpoint blockade;Gene expression;Immune suppression;Post-translational modifications;T cell;Tumor evasion;Tumor microenvironment | |
| 625 | Oral Presentation | COVID-19 vaccination in patients with renal cancer or melanoma receiving immune checkpoint inhibitors | Joyce K. Hwang, MD PhD; Hannah E. Dzimitrowicz, MD; Riddhishkumar Shah, MD PhD; Kathleen Ashcraft, PhD; Daniel J. George, MD; April Salama, MD; Tian Zhang, MD | COVID and Immunotherapy | Checkpoint blockade;COVID and Immunotherapy;Vaccine | |
| 626 | Oral Presentation | Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history | Benedict Tan, PhD; Yi Yang, PhD; Chun Chau Lawrence Cheung, MMedSc; Denise Goh, BBiomedSc (Hons); Mai Chan Lau, PhD; Xinru Lim; Jeffrey C. Lim; Li Wen Justina Nadia Lee; Tracy Z. Tien; Shirin Kalimuddin; Wai Meng David Tai; Jenny G. Low; Cedric Chuan Young Ng; Wei Qiang Leow; Thuan Tong Tan; Tony KH. Lim; Jin Liu; Joe P. Yeong, MD, PhD | COVID and Immunotherapy | B cell;Bioinformatics;COVID and Immunotherapy;Gene expression;Immune contexture;NK/NKT cell;RNA;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 627 | Poster Presentation | ImmunoAtlas: an online public portal for sharing, visualizing, and referencing multiplex immunohistochemistry/immunofluorescence (mIHC/IF) images and results for immuno-oncology | Jia Ying Joey Lee, MSc; Joe P. Yeong, MD, PhD; Li Wen Justina Nadia Lee; Lit-Hsin Loo, PhD; Jiahui Dong | Data Sharing, Handling, and Access | Antibody;Bioinformatics;Biomarkers;Tumor microenvironment | |
| 628 | Poster Presentation | Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States | Shailender Bhatia, MD; Paul T. Nghiem, MD, PhD; S Phani Veeranki; Alejandro Vanegas; Kristina Lachance; Lisa Tachiki; Kevin Chiu; Emily Boller; Murtuza Bharmal, PhD, MS, BPharm | Education and Treatment Management | Checkpoint blockade;Clinical study;Epidemiology;Solid tumors | |
| 629 | Poster Presentation | Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors | Priyanka V. Chablani, MD; Theodore Karrison, PhD; Walter Stadler, MD | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors | |
| 630 | Poster Presentation | Oncologists’ perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US | Petros Grivas; Phani Veeranki; Kevin Chiu; Vivek Pawar; Jane Chang; Murtuza Bharmal, PhD, MS, BPharm | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors | |
| 631 | Poster Presentation | Deep, durable response to PD-1 inhibitor monotherapy in microsatellite-stable, tumor mutational burden-high colorectal cancer | Samuel J. Schellenberg, BS; Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA | Education and Treatment Management | Biomarkers;Checkpoint blockade;Neoantigens;Solid tumors;Tumor antigens | |
| 632 | Poster Presentation | Toripalimab combined with platinum-based chemotherapy as a second-line treatment for small cell lung cancer (SCLC) with brain metastases: A case report | Jieqiong Fan; Yao Zhang; Xiaofei Mo; Jing Guo | Education and Treatment Management | Antibody;Checkpoint blockade;Solid tumors | |
| 633 | Poster Presentation | Incorporating Checkpoint Inhibitors into Cancer Care: A study of the impact of digital education on clinical competence and practice patterns | Tariqa Ackbarali, MS, PhD(c); Elizabeth L. del Nido, BA; Brian I. Rini, MD; Michael J. Overman, MD; Ignacio I. Witsuba, MD | Education and Treatment Management | Biomarkers;Checkpoint blockade;Immune toxicity;Solid tumors;Tumor microenvironment | |
| 635 | Poster Presentation | Online CME improves the interprofessional team’s ability to manage patients with malignant pleural mesothelioma | Michelle A. Worst, PharmD, BCOP, MBA; Emily Van Laar; Megan Whitney, DMD; Anne Tsao, MD; Hossein Borghaei, MS, DO | Education and Treatment Management | Checkpoint blockade;Chemotherapy;Epidemiology;Immune toxicity;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 636 | Poster Presentation | Patient-Reported Distress with Immunotherapy-Based First-Line Treatment for mNSCLC: a Real-World Evidence Study | Monica H. Bodd, BA; Susan C. Locke, PhD; Scott Antonia, MD, PhD; Jeffrey Crawford, MD; John Hartman, PhD; Kris Herring, PhD; Neal Ready, MD, PhD; Thomas E. Stinchcombe, MD; Jesse D. Troy, PhD; Chakita Williams, PhD; Steven Wolf, MS; Jeffrey M. Clarke, MD; Thomas W. LeBlanc, MD MA MHS FAAHPM FASCO | Education and Treatment Management | Chemotherapy;Clinical study;Solid tumors | |
| 637 | Poster Presentation | Exploring the Impact of Immunotherapy on Cancer Patients’ Real World Experience | Helen M. Nichols, PhD; Helen M. Nichols, PhD, MSW; Elise Wu | Education and Treatment Management | Targeted therapy | |
| 638 | Poster Presentation | Hypoxia reprograms natural killer cells and impairs their therapeutic potential | Philippa R. Kennedy; Upasana Sunil Arvindam; Brianna Ettestad; Shee Kwan Phung; Quinlan Kile; Peter Hinderlie; Yunmin Li; James Lim; Jeffrey S. Miller, MD; Martin Felices, PhD | Immune Cell Biology | Epigenetics;Gene expression;Immune suppression;Metabolism;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 639 | Poster Presentation | PIK3IP1/TrIP Immune Regulation on CD8+ T Cells Restricts Anti-Tumor Immunity | Benjamin M. Murter, BS; Hridesh d. Banerjee, PhD; Andrea L. Szymczak-workman, PhD; Lawrence P. Kane, PHD | Immune Cell Biology | Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 640 | Poster Presentation | Stem-like CD4 T cells in cancer | Maria Cardenas; Nataliya Prokhnevska, BS; Caroline S. Jansen, BS; Viraj Master, Dr.; Haydn T. Kissick, PhD | Immune Cell Biology | Regulatory T cell (Treg cell);T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs) | |
| 641 | Poster Presentation | Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. | Jonathan H. Chen, MD/PhD; Karin Pelka, PhD; Matan Hofree, PhD; Marios Giannakis, MD, PhD; Genevieve Boland, PhD; Andrew Aguirre, MD, PhD; Ana C. Anderson, PhD; Orit Rozenblatt-Rosen, PhD; Aviv Regev, PhD; Nir Hacohen, PhD | Immune Cell Biology | Immune contexture;Monocyte/Macrophage;Myeloid cells;Solid tumors;Systems biology;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 642 | Poster Presentation | Decreased host PKC-delta is associated with the T cell-inflamed tumor microenvironment and improves anti-tumor immunity | Kyle R. Cron, B.S, B.A; Ayelet S. Sivan; Keston Aquino-Michaels, PhD; Emily Higgs; Jessica L. Fessler, BS; Seoho Lee; Randy F. Sweis, MD; Thomas F. Gajewski, MD, PhD | Immune Cell Biology | Autoimmunity;Checkpoint blockade;Gene expression;Genetic polymorphism;Immunoscore;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 643 | Poster Presentation | Vasoactive intestinal peptide as a novel immune checkpoint molecule in activated T cells | Sruthi Ravindranathan, PhD, MS; Tenzin Passang Fnu, Bachelor of Arts; Edmund K. Waller, MD/PHD | Immune Cell Biology | Checkpoint blockade;Chemokine;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment | |
| 644 | Poster Presentation | Tumor-mediated suppressive signaling and hypoxia supports altered chromatin landscapes that limit the transcriptional and functional potential of terminal T cell exhaustion | Rhodes Ford, BSc; Natalie Rittenhouse; Nicole E. Scharping, PhD; Paolo DA. Vignali, BA; Greg M. Delgoffe, PhD; Amanda Poholek | Immune Cell Biology | Bioinformatics;Epigenetics;Gene expression;Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 645 | Poster Presentation | Single-cell transcriptional and clonal characterization of CD4+ T cells across tissues in long-term melanoma survivors | Jichang Han, BS; Yanding Zhao; Keisuke Shirai, MD, MS; Tyler G. Searles; Nikhil Khatwani; Jennifer L. Vella; Fatima S. Haidar; Fred W. Kolling; Jiang Gui; Chao Cheng; Mary J. Turk; Christina V. Angeles, MD | Immune Cell Biology | Autoimmunity;Bioinformatics;Checkpoint blockade;Clinical study;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 646 | Poster Presentation | Transcriptome analysis of tumor and matched infiltrating lymphocytes identifies potential new targets for augmenting intra-tumoral NK function in soft tissue sarcomas | Sean J. Judge, MD, MS; Joshua Bloomstein, BS; Sylvia M. Cruz, BS; Aryana M. Razmara, MS; Cyrus J. Sholevar, MD; Robert J. Canter, MD, MAS, FACS | Immune Cell Biology | NK/NKT cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 647 | Poster Presentation | Possibility of immunotherapy for the glioblastoma patients with O6-methyl-guanine DNA methyltransferase (MGMT) expression or promoter unmethylated. | Yoshihiro Kushihara; Yukari Kobayashi, BS; Koji Nagaoka, PhD; Kazuhiro Kakimi, MD, PhD | Immune Cell Biology | Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 648 | Poster Presentation | T cell intrinsic caspase 1 signaling negatively regulates T cell anti-tumor response | Cara Lang, B.S.; Young J. Kim, MD, PhD; Michael J. Korrer, PhD | Immune Cell Biology | Checkpoint blockade;Inflammation;T cell;Tumor microenvironment | |
| 649 | Poster Presentation | Efferocytosis drives myeloid inflammasome signaling and Gasdermin D independent secretion of IL-1β to promote tumor growth | Sohini Roy, PhD; Cara Lang, B.S.; Yu Wang; Diana K. Graves, B.S.; Xu Yaomin; Young J. Kim, MD, PhD | Immune Cell Biology | Immune tolerance;MDSC;Monocyte/Macrophage;Solid tumors | |
| 650 | Poster Presentation | Target the activin receptor 1c on CD4+ T cells to achieve anti-tumor therapeutic effects | Ying Zheng, Ph.D.; Andriana Lebid; Andrew M. Pardoll, MD, PhD; Juan Fu; Chirag H. Patel, PhD; Xiaoxu Wang | Immune Cell Biology | Antibody;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 651 | Oral Presentation | Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction | Frank J. Lowery, III, Ph.D.; Sri Krishna, PhD; Rami Yoseph, PhD; Neilesh B. Parikh, M.D.; Praveen D. Chatani, MD; Yong-Chen William W. Lu, PhD; Nikolaos Zacharakis, PhD, MS; Paul F. Robbins, PhD; Maria Parkhurst, PhD; Steven A. Rosenberg, MD, PhD | Immune Cell Biology | Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 652 | Poster Presentation | Anti-PD-L1/IL-15 KD033 activated macrophages and induced anti-tumor immunity in the tumor-microenvironment | Stella Martomo, PhD; George Wang; Zhanna Polonskaya; Xenia Luna; Dan Lu, MS; Jeegar Patel | Immune Cell Biology | Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment | |
| 653 | Poster Presentation | The immune landscape of primary and recurrent adolescent and young adult bone sarcomas | Anthony R. Cillo, PhD; Elina Mukherjee; Jessica D. Daley; Sayali Onkar; Xiang Li; Dongyan Liu; Dario A. Vignali, PhD; Tullia C. Bruno, PhD; Kelly M. Bailey, MD, PhD | Immune Cell Biology | Bioinformatics;Gene expression;Monocyte/Macrophage;Pediatric tumors;Solid tumors;Systems biology;Tumor microenvironment | |
| 654 | Poster Presentation | Analysis of IDO-1 expression on dendritic cells and factors influencing its up- and downregulation in pancreatic cancer. | Michael A. Hollingsworth, PhD; Kamiya Mehla, PhD; Kirsten C. Eberle, PhD; Ying C. Huang, PhD; Aleata C. Triplett, MS; Paul C. Grandgenett, PhD; Thomas C. Caffrey, MS; Clara S. Mundry, Pharmacist | Immune Cell Biology | Antigen presenting cells;Dendritic cell;Extracellular vesicles/exosomes;Immune suppression;Immune tolerance;Solid tumors;Tumor antigens;Tumor microenvironment | |
| 655 | Oral Presentation | Landscape of helper and regulatory CD4+ T cells in melanoma | Giacomo Oliveira, PhD; Kari Stromhaug; Susan Klaeger; Nicoletta Cieri; Bryan Iorgulescu, MD; Shuqiang Li, PhD; David A. Braun; Donna Neuberg; Steven A. Carr; Kenneth J. Livak; Dennie F. Tompers; Edward F. Fritsch; Megan Wind-Rotolo, PhD; Nir Hacohen, PhD; Moshe Sade-Feldman; Derin B. Keskin, MD PhD; Patrick A. Ott, MD, PhD; Scott J. Rodig, MD, PhD; Genevive M. Boland, MD, PhD; Catherine J. Wu, MD | Immune Cell Biology | Immune suppression;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 657 | Poster Presentation | Characterization and Therapeutic Targeting of a Tumor-associated Tolerogenic DC Subpopulation Driven by SREBP2 and the Mevalonate Metabolic Pathway | Michael P. Plebanek, PhD; Nicholas C. DeVito, MD; Fang Liu, M.D.; Balamayooran BT. Theivanthiran, PhD; Georgia M. Beasley, MD, MHs; Brent A. Hanks, MD, PhD | Immune Cell Biology | Antigen presenting cells;Dendritic cell;Immune suppression;Immune tolerance;Metabolism;Myeloid cells;Tumor evasion;Tumor microenvironment | |
| 658 | Oral Presentation | CD8 T cell activation in cancer is comprised of two distinct phases | Nataliya Prokhnevska, BS; Maria Cardenas; Rajesh M. Valanparambil, PhD; Ewelina Sobierajska, BS; Caroline S. Jansen, BS; Viraj Master, Dr.; Martin Sanda, Dr.; Haydn T. Kissick, PhD | Immune Cell Biology | Antigen presenting cells;Costimulation;Dendritic cell;T cell;T cell lineages | |
| 659 | Poster Presentation | T cell receptor exchange by zygote engineering results in physiological T cell responses for therapeutic use in pancreatic ductal adenocarcinoma | Meagan R. Rollins, BA; Jackson F. Raynor; Ebony A. Miller; Ellen J. Spartz, M.D.; Walker S. Lahr; Adam L. Burrack, Ph.D.; Yun You, Ph.D.; Branden S. Morarity, Ph.D.; Beau R. Webber, PhD; Ingunn M. Stromnes, Ph.D. | Immune Cell Biology | Adoptive immunotherapy | |
| 660 | Oral Presentation | Targeting T cell fates: converting exhaustion to memory to improve immunotherapeutic responses to cancer | Nicole E. Scharping, PhD; Allison Cafferata; Maximilian Heeg; Quynhanh Nguyen; Ananda W. Goldrath | Immune Cell Biology | Adoptive immunotherapy;Checkpoint blockade;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 661 | Poster Presentation | Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function | Joshua R. Veatch, MD, PhD; Naina Singhi; Carolyn Shasha; Sylvia Lee, MD; Julia Szeto; Ata S. Moshiri, MD, MPH; Teresa Kim, MD; John A. Thompson, MD; Scott S. Tykodi, MD, PhD; Venu G. Pillarisetty, MD; David R. Byrd; Kimberly S. Smythe, BS; Shailender Bhatia, MD; Evan T. Hall, MD, MPhil; Evan W. Newell, PhD; Raphael Gottardo, PhD; Stanley R. Riddell, MD | Immune Cell Biology | Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 662 | Poster Presentation | Dissecting the CD226 immune axis in the tumor microenvironment using CyTOF-based high-dimensional immunophenotyping | Katie Vowell, PhD; Michael Conner; Florence Perrin; Paul Bojczuk; Kenneth Hance, PhD, MPH; Iris Roth, PhD; Christine Donahue, PhD; James Smothers, PhD; Jeremy Waight, PhD | Immune Cell Biology | Checkpoint blockade;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 663 | Oral Presentation | Media based on the metabolic composition of tumor interstitial fluid reveals persistent T cell dysfunction induced through arginine deprivation and exposure to the oncometabolite phosphoethanolamine | Yupeng Wang, BD; Chufan Cai; Dayana Rivadeneira, PhD; Alexander Muir; Greg M. Delgoffe, PhD | Immune Cell Biology | Metabolism;Solid tumors;T cell;Tumor microenvironment | |
| 664 | Oral Presentation | Pulmonary priming of tumor-reactive CD8+ T cells by DC1 is impaired by regulatory T cells | Maria Zagorulya, B.S.; Duncan Morgan; Leon Yim; Brendan L. Horton, PhD; Elen Torres-Mejia, PhD; Stefani Spranger, PhD | Immune Cell Biology | Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages | |
| 665 | Poster Presentation | Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma | Jiajia Zhang, MD, MPH; Justina Caushi; Boyang Zhang; Zhicheng Ji; Taibo Li; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie Smith | Immune Cell Biology | Checkpoint blockade;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 666 | Poster Presentation | Deletion of Drp1 in T cells increases OXPHOS and CD8+ memory T cell population | Timothy N. Bullock, PhD; Marissa Gonzales, BS | Immune Cell Biology | Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 667 | Poster Presentation | Tumor-derived alpha-fetoprotein requires polyunsaturated fatty acids for immuno-metabolic dysregulation | Paul V. Munson, PhD; Juraj Adamik, PhD; Lisa H. Butterfield, PhD | Immune Cell Biology | Antigen presenting cells;Dendritic cell;Gene expression;Immune suppression;Metabolism;Monocyte/Macrophage;Tumor evasion | |
| 668 | Oral Presentation | Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8+ T cells. | Teresa Manzo, PhD; Carina Nava Lauveson; Teresa Maria Frasconi; Silvia Tiberti; Ignazio Caruana; Luigi Nezi; Philip D. Greenberg, MD | Immune Cell Biology | Adoptive immunotherapy;Metabolism;T cell;Tumor microenvironment | |
| 669 | Poster Presentation | Lactate uptake through MCT11, a novel monocarboxylate transporter, enforces dysfunction in terminally exhausted T cells | Ronal M. Peralta, B.S; Greg M. Delgoffe, PhD | Immune Cell Biology | Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 670 | Poster Presentation | Oxidative stress originating in the mitochondria damages telomeres sufficient to drive certain features of T cell dysfunction | Dayana Rivadeneira, PhD; Jess Yana; Sanjana Thosar; Marcel Bruchez; Patricia L. Lynn; Greg M. Delgoffe, PhD | Immune Cell Biology | Metabolism;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 671 | Poster Presentation | Biological Impacts of Standard of Care Chemotherapies on Immune Effector Cells from AML Patients | Dmitry Zhigarev, MD; Alexander W. MacFarlane, PhD; Christina Drenberg, PhD; Reza Nejati, MD; Asya Varshavsky, MD PhD; Kerry S. Campbell, PhD | Immune Cell Biology | Biomarkers;Chemotherapy;Clinical study;Immune monitoring;Immune suppression;Leukemia/Lymphoma;NK/NKT cell;Regulatory T cell (Treg cell);T cell | |
| 672 | Poster Presentation | The effect of ChemoRadioTherapy and Tumor Histology on the Immune Contexture of Tumor-Draining Lymph Nodes in NSCLC | Marieke F. Fransen, PhD; Famke L. Schneiders, MD, PhD; Vinitha Kandiah; Teodora Radonic, MD, PhD; Idris Bahce, MD, PhD; Chris Dickhoff, MD, PhD; Tanja D. de Gruijl, PhD | Immune Cell Biology | Checkpoint blockade;Chemotherapy;Dendritic cell;Immune contexture;Monocyte/Macrophage;Radiotherapy;Surgery;T cell | |
| 673 | Poster Presentation | (Re-) Solving the biology of colorectal cancer onset and progression to improve treatment and prevention | Jessica Roelands, MSc; Manon van der Ploeg; Hao Dang; Lukas Hawinkels; Hans Morreau; Noel F. de Miranda, PhD | Immune Cell Biology | Biomarkers;Carcinogenesis;Gene expression;Immune contexture;Immune monitoring;Immune suppression;Monocyte/Macrophage;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 674 | Poster Presentation | IL-27 signaling drives a type 1 interferon-like gene expression program of immunoregulatory pathways associated with cancer progression | Jonathan A. Hill, PhD; Devapregasan Moodley; Jing Hua, MD, MS; Kerry F. White; Christine E. Miller; Secil Koseoglu, PhD; Ricard Masia, MD PhD; Benjamin H. Lee, MD PhD; Vito J. Palombella, PhD | Immune Cell Biology | Bioinformatics;Biomarkers;Cytokine;Immune suppression;Myeloid cells;NK/NKT cell;RNA;Systems biology;T cell lineages;Tumor microenvironment | |
| 675 | Poster Presentation | Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy | Michael D. Jain, M.D., Ph.D.; Bachisio Ziccheddu, Ph.D.; Caroline A. Coughlin, B.S.; Rawan Faramand, M.D.; Anthony J. Griswold, Ph.D.; Kayla M. Reid, M.S.; Ola Landgren, M.D., Ph.D.; Frederick L. Locke, M.D.; Francesco Maura, M.D.; Marco L. Davila, M.D., Ph.D.; Jonathan H. Schatz, M.D. | Immune Cell Biology | B cell;Bioinformatics;Biomarkers;CAR T cells;Immune suppression;Leukemia/Lymphoma;T cell | |
| 676 | Oral Presentation | Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer | Bridget P. Keenan, MD, PhD; Elizabeth E. McCarthy; Arielle Ilano; Hai Yang; Li Zhang, MD PhD; Kathryn Allaire; Zenghua Fan, PhD; Tony Li, BS; David S. Lee; Yang Sun, PhD; Alexander Cheung; Hewitt Chang; Brenna Sheldon; Robin K. Kelley, MD; Chun Jimmie Ye, PhD; Lawrence Fong, MD | Immune Cell Biology | Checkpoint blockade;Clinical study;Immune suppression;Immune tolerance;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell | |
| 677 | Poster Presentation | Reverse Abscopal Effect: Intertumoral Heterogeneity Suppresses Systemic CD8 T Cell-Mediated Antitumor Immunity and Confers PD-1 Inhibitor Resistance in Synchronous Melanoma | Shuyang S. Qin, M.S; Booyeon J. Han, PhD; Alexander C. Chacon, MD; Alexa D. Melucci, MD; Alyssa R. Williams; Rachel Jewell; Minsoo Kim, PhD; David C. Linehan, MD; Scott A. Gerber, PhD; Peter A. Prieto, MD, MPH | Immune Cell Biology | Checkpoint blockade;Immune suppression;Monocyte/Macrophage;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 678 | Poster Presentation | The neonatal Fc receptor is elevated in monocyte-derived immune cells in pancreatic cancer. | Justin Thomas, BS; Molly Torok; Kriti Agrawal; Trang T. Vu; Alyssa MM. Castillo; Min Chen; Bryan Remaily; Kyeongmin Kim; Zhiliang Xie; Samuel K. Kulp; Dwight H. Owen; Mitch A. Phelps; Christopher C. Coss; Thomas A. Mace, PhD | Immune Cell Biology | Dendritic cell;MDSC;Monocyte/Macrophage;Myeloid cells | |
| 679 | Poster Presentation | Tumor hypoxia drives suppressor function in exhausted T cells limiting antitumor immunity | Paolo DA. Vignali, BA; Kristin DePeaux, BS; McLane Watson, BS; Nicole E. Scharping, PhD; Ashley Menk, MS; Greg M. Delgoffe, PhD | Immune Cell Biology | Checkpoint blockade;Immune suppression;Immune tolerance;Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 680 | Poster Presentation | Isoforms of Neuropilin-2 Regulate Distinct Macrophage Functions and are Associated with Unique Tumor-associated Macrophages in Murine and Human Breast Cancer | Rajeev Dhupar, MD; Katherine E. Jones, BS; Amy A. Powers, MS; Seth H. Eisenberg; Kai Ding; Fangyuan Chen; Cecile C. Nasarre, PhD; Amanda C. LaRue, PhD; Elizabeth S. Yeh, PhD; James D. Luketich, MD; Adrian Lee; Steffi Oesterreich, PhD; Michael T. Lotze, MD; Robert M. Gemmill, PhD; Adam C. Soloff, PhD | Immune Cell Biology | Antigen presenting cells;Inflammation;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment | |
| 681 | Poster Presentation | An ex vivo 3D tumoroid model of fresh patient tissue (3D-EXplore) to assess the phagocytic activity of tumor resident innate immune cells | Kelly Guzman; Olivia McIntosh; Brittany Bunch, PhD; Jacob Yarinsky; Jared C. Ehrhart, PhD; Soner Altiok, MD, PhD | Immune Cell Biology | Monocyte/Macrophage;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 682 | Poster Presentation | PKC Agonism Restricts Innate Immune Suppression, Promotes Antigen Cross-Presentation and Synergizes with Agonistic CD40 Therapy in Breast Cancer | Mehdi Chaib, MS; Liza Makowski; John Yarbro; Laura Sipe; Deidre Daria | Immune Cell Types | Antigen presenting cells;Dendritic cell;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor microenvironment | |
| 683 | Oral Presentation | Type-I-interferon activates cross-dressed CD11b+ conventional dendritic cells to enhance anti-tumor immunity | Ellen Duong, Sc.B.; Timothy Fessenden, Ph.D.; Emi Lutz; Teresa Dinter; Leon Yim; Sarah Blatt; Arjun Bhutkar; K. D. Wittrup; Stefani Spranger, PhD | Immune Cell Types | Antigen presenting cells;Costimulation;Cytokine;Dendritic cell;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 684 | Poster Presentation | The in vitro effects of 5-Azacitidine on the immunophenotype of monocyte-derived dendritic cells from patients with higher-risk myelodysplastic syndromes | Randy G. Tsai, BS, BA; Hannah Fields, BS; Xinlian Zhang, PhD; Valentina Ferrari, BA; Soo J. Park, MD; Rafael Bejar, MD, PhD; Tiffany Tanaka, MD | Immune Cell Types | Antigen presenting cells;Dendritic cell | |
| 685 | Poster Presentation | Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma | Pauline Hamon, PhD; Assaf Magen, PhD; Joel Kim; Mark Buckup; Leanna Troncoso; Steven Hamel; Jessica Le Berichel; Oren Barboy; Eyal David; Alexandra Tabachnikova; Christie Chang; Zhen Zhao; Merav Cohen, PhD; Amir Giladi; Nausicaa Malissen; Fiona Desland; Ido Amit; Ephraim Kenigsberg; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD | Immune Cell Types | Antigen presenting cells;Checkpoint blockade;Clinical trial;Dendritic cell;Gene expression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 686 | Poster Presentation | Characterization of a Novel Compound that Inhibits Peroxynitrite Generation by Myeloid Derived Suppressor Cells | Gabriella N. Lapurga, BS; Steven H. Sun; Erick Carlson; Himanshu Savardekar, BS; Kari Kendra, MD; Blake Peterson; William E. Carson, III, MD, FACS | Immune Cell Types | Antibody;Checkpoint blockade;Immune suppression;Inflammation;MDSC;Solid tumors;T cell;Tumor microenvironment | |
| 687 | Poster Presentation | MDSC gene expression analysis in patients with cancer and the response to inhibition of Bruton’s tyrosine kinase | Himanshu Savardekar, BS; Carter Allen, BS; Dionisia Quiroga, DO/PhD; Donjun Chung, PhD; Emily Schwarz, BS; Gabriella N. Lapurga, BS; Jami Shaffer, BS; Bradley Blaser, MD/PhD; Matthew Old, MD; Robert Wesolowski, MD; Kari Kendra, MD; William E. Carson, III, MD, FACS | Immune Cell Types | Bioinformatics;Chemokine;Cytokine;Gene expression;Granulocyte;MDSC;Monocyte/Macrophage;Myeloid cells | |
| 688 | Poster Presentation | Knockout of the inhibitory receptor TIGIT enhances anti-tumor response of ex vivo expanded NK cells | Tayler J. Croom-Perez, PhD; Md Faqrul Hasan, Masters; Thomas A. Dieffenthaller; Liza D. Robles-Carrillo; Jonathan E. Eloriaga; Alicja J. Copik, PhD | Immune Cell Types | Adoptive immunotherapy;NK/NKT cell | |
| 689 | Poster Presentation | Tissue-specific anti-tumor NK cell activation & effector functions | Zerick T. Dunbar, MS; Anil Shanker, PhD | Immune Cell Types | Bioinformatics;Cytokine;NK/NKT cell;Solid tumors;Tumor microenvironment | |
| 690 | Poster Presentation | TIGIT blockade improves anti-tumor activity of ex vivo expanded NK cells | Md Faqrul Hasan, Masters; Alicja J. Copik, PhD | Immune Cell Types | Adoptive immunotherapy;Checkpoint blockade;NK/NKT cell | |
| 691 | Poster Presentation | Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy | Paola Bonaventura, PhD; Vincent Alcazer, MD; Virginie Mutez; Laurie Tonon; Juliette Martin, PhD; Nicolas Chuvin, PhD; Rasha Boulos, PhD; Yann Estornes, PhD; Jenny Valladeau-Guilemond, PhD; Alain Viari, PhD; Christophe Caux, PhD; Stephane Depil, MD, PhD | Immune Cell Types | Antigen presenting cells;Bioinformatics;Dendritic cell;Neoantigens;Solid tumors;T cell;TLR;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine | |
| 692 | Poster Presentation | Tim-3 expression drives phenotypic and functional changes in Treg in secondary lymphoid organs and the tumor microenvironment, effecting tumor burden. | Hridesh d. Banerjee, PhD; Hector Nieves-Rosado, MDPHD(MSTP) candidate; Benjamin M. Murter, BS; Lawrence P. Kane, PHD | Immune Cell Types | Costimulation;Cytokine;Immune suppression;Metabolism;Regulatory T cell (Treg cell);T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 693 | Oral Presentation | Mucosal-Associated Invariant T (MAIT) Cell Regulation Networks in Anti-Tumor Immunity | Benjamin Ruf, M.D.; Vanessa V. Catania, B.A.; Noemi Kedei, MD; Simon Wabitsch, M.D.; Chi Ma, MD, PhD; Laurence P. Diggs, M.D.; Qianfei Zhang, PhD; Bernd Heinrich, MD; Varun Subramanyam, B.A.; Linda Cui, B.A.; Shunsuke Sakai, PhD; Sangmi Oh, Ph.D.; Merrill K. Stovroff, B.A.; Clifton E. Barry III, Ph.D.; Daniel E. Barber, Ph.D.; Alexander Kroemer, M.D.; Firouzeh Korangy, Ph.D.; Tim F. Greten, MD | Immune Cell Types | Solid tumors;T cell;TLR;Tumor microenvironment | |
| 694 | Poster Presentation | Possible immune-modulation of CDK4/6 inhibitors and clinical trial development in betel-nuts related head and neck squamous cell carcinoma in Taiwan | Jo-Pai Chen, MD; Jui-Ying Chang; Hsiang-Fong Kao, MD; Ruey-Long Hong, MD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Clinical study;Solid tumors | |
| 695 | Poster Presentation | Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity | Amir Mahmoodi, MS; Sangeetha Srinivasan, PhD; Michael Zakharian, MS; Nathan A. Yee, PhD; Jesse M. McFarland, PhD; Jose M. Mejia Oneto, MD, PhD | Immune-stimulants and immune modulators | Antigen presenting cells;Dendritic cell;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 696 | Poster Presentation | Single-cell RNA-seq reveals the critical roles of the STING- and MDA5-mediated cytosolic nucleic acid-sensing pathways as well as IFNAR/STAT2 signaling in recombinant MVA-induced antitumor immunity | Shuaitong Liu, MS; Gregory Mazo; Tuo Zhang; Ning Yang; Yi Wang; Adrian Tan; Jiahu Wang; John Choi; Jenny Zhaoying Xiang; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD; Liang Deng, MD, PhD | Immune-stimulants and immune modulators | Chemokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 697 | Poster Presentation | Telomerase-Driven Telomeric DNA Modification in Cancer Cells Leads to Efficient Induction of cGAS-mediated Innate and Adoptive Immune Responses | Mihail Obrocea, MD; Jerry Shay, PhD; Sergei Gryaznov, PhD; Ilgen Mender; Silvia Siteni; Vlad Vitoc | Immune-stimulants and immune modulators | Checkpoint blockade;Costimulation;T cell;Targeted therapy | |
| 698 | Poster Presentation | PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors | Veronica G. Zeng, Ph. D.; Gregory L. Moore, PhD; Juan E. Diaz, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Ruschelle Love; Matthew Dragovich, PhD; Rumana Rashid, PhD; Irene Leung, PhD; Michael J. Hackett, PhD, DABT; Jing Qi, PhD; Charles G. Bakhit, BS; Umesh Muchhal, PhD; Norman J. Barlow, PhD, DVM, MBA; John R. Desjarlais, PhD; Michael Hedvat, PhD | Immune-stimulants and immune modulators | Bispecifics;Checkpoint blockade;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 699 | Poster Presentation | ATYR2810 an anti-NRP2 monoclonal antibody targets tumor-associated macrophages | Samantha K. Tyler, BSc; Michaela Ferrer; Erik Escobedo, BS; Kaitlyn Rauch, BS; Sofia Klopp-Savino; Justin Rahman, BS; Zhiwen Xu, PhD; Esther Chong, PhD; Suzanne Paz, PhD; Leslie Nangle, PhD | Immune-stimulants and immune modulators | Antibody;Gene expression;Immune suppression;Monocyte/Macrophage;Myeloid cells;T cell;Tumor microenvironment | |
| 700 | Oral Presentation | Increasing MHC-I expression to potentiate immune checkpoint blockade therapy | Shengqing Gu, PhD; Wubing Zhang; Xiaoqing Wang; Peng Jiang; Nicole Traugh; Ziyi Li; Clifford Meyer; Blair Stewig; Yingtian Xie; Xia Bu; Michael P. Manos; Alba Font-Tello; Evisa Gjini, PhD; Ana Lako; Klothilda Lim; Jake Conway; Alok K. Tewari; Zexian Zeng; Avinash Das Sahu; Collin Tokheim; Jason L. Weirather, PhD; Jingxin Fu; Yi Zhang; Benjamin Kroger; Jin Hua Liang; Paloma Cejas; Gordon J. Freeman, PhD; Scott J. Rodig, MD, PhD; Henry W. Long; Benjamin E. Gewurz; F. Stephen Hodi, Jr., MD; Myles Brown; X Shirley Liu, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression | |
| 701 | Poster Presentation | Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC) | Jason J. Luke; Jaime R. Merchan, MD; Brett GM. Hughes, MD; Jeffrey A. Sosman, MD; Abhishek Tripathi, MD; Igor Puzanov, MD, MSCI; Thomas U. Marron, MD, PhD; Kristen A. Marrone, MD; Craig M. Hill, PhD; James Janc, PhD; Jenny Rudnick, BS, PhD; Shenshen Hu, PhD; Mehrdad Mobasher, MD, MPH; Suresh Mahabhashyam, MD, MPH; Richard A. Miller, MD | Immune-stimulants and immune modulators | Antibody;B cell;Clinical study;Clinical trial;COVID and Immunotherapy;Tumor antigens | |
| 702 | Poster Presentation | TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies | Wenqing Jiang, PhD; Zhengyi Wang, PhD; Zhen Sheng, PhD; Jaeho Jung, PhD; Taylor B. Guo, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Costimulation;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 703 | Poster Presentation | Favorable pre-clinical safety profile of the novel not-alpha IL-2 agonist ANV419 supports first in human clinical development | Christoph Huber, PhD; Guzman Alonso; Elena Gerralda; Christoph Bucher; Philippe Jacqmin; Andreas Katopodis, PhD; Jennifer Sims | Immune-stimulants and immune modulators | Antibody;Costimulation;Cytokine;Immune adjuvant;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs) | |
| 704 | Poster Presentation | The computationally designed human antibody, AU-007, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 auto-inhibitory loop and preventing Treg expansion | Inbar Amit, Ph.D.; Itay Levin, Ph.D.; Timothy Wyant, Ph.D.; Natali Levitan, M.Sc.; Reut Barak, Ph.D; May Ben-Mayor, M.Sc.; Olga Bluvshtein, M.Sc.; Noam Grossman, M.Sc.; Yehezkel Sasson, Ph.D.; Guy Nimrod, Ph.D.; Michael Zehnin,, Ph.D.; Sharon Fischman, Ph.D.; Marek Štrajbl, Ph.D.; Liron Danielpur, M.Sc.; Aron Knickerbocker, B.Sc., M.B.A.; James Vasselli, M.D.; Yanay Ofran, Ph.D. | Immune-stimulants and immune modulators | Antibody;NK/NKT cell;Regulatory T cell (Treg cell);T cell | |
| 706 | Poster Presentation | Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2b | Alexey Berezhnoy, PhD, DVM; Hsin Wang; Na Cai; Hikmat Assi, PhD; Nicole Lapuyade; Madan Paidhungat; Kenneth R. Wong, MA; Michael Krimm; Robert Dunn, PhD; Dylan L. Daniel, PhD; Marcia Belvin, PhD; Erwan Le Scolan, PhD | Immune-stimulants and immune modulators | Antibody;Checkpoint blockade;Cytokine;Immune contexture;Immune suppression;Immune toxicity;Inflammation;Tumor infiltrating lymphocytes (TILs);Tumor stroma | |
| 707 | Poster Presentation | IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents | Matthew J. Bernett, PhD; Ke Liu, PhD; Christine Bonzon, PhD; Michael J. Hackett, PhD, DABT; Katrina Bykova, PhD; Rumana Rashid, PhD; Nicole Rodriguez, PhD; Nargess Hassanzadeh-Kiabi, PhD; Connie Ardila; Norman J. Barlow, PhD, DVM, MBA; Irene Leung, PhD; Hanh Nguyen; Araz Eivazi; Kendra N. Avery, PhD; Rajat Varma, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment | |
| 708 | Poster Presentation | Novel ways to exploit IL-21 to augment adoptive T cell transfer therapy against tumors | Anna C. Cole, BA; Guillermo O. Rangel RIvera, B.S.; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Brandon Ware, PhD; Hannah M. Knochelmann, BS; Chrystal M. Paulos, PhD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 709 | Poster Presentation | Peptidyl IL-2/15Rβγc-restricted agonists, highly-attenuated and linked to anti-PD-1 antibodies to achieve selectivity and amplified potency in stimulating PD-1high lymphocytes | William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Blake M. Williams, MS; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Michael C. Needels, PhD; Ronald W. Barrett, PhD | Immune-stimulants and immune modulators | Bispecifics;Checkpoint blockade;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 710 | Poster Presentation | Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist) | Kristen N. Fousek, PhD; Lucas A. Horn, PhD; Haiyan Qin; Bobby Reddy, MD; Lennie Sender, MD; Patrick Soon Shiong, MD; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Immune-stimulants and immune modulators | Cytokine;Immune adjuvant;NK/NKT cell;Tumor microenvironment | |
| 711 | Poster Presentation | IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion | Thierry D. Giffon; Melanie Desbois; Dean Ng, Ph.D.; Poonam Yakkundi; Marigold Manlusoc; Miho Oyasu; Rodnie Rosete; Daniel Machado; Susan Calhoun; Tasnim Kothambawala; Avneesh Saini; Beatrice T. Wang, PhD; Maya Kotturi; Bruce A. Keyt, PhD; Angus M. Sinclair, PhD | Immune-stimulants and immune modulators | Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;T cell | |
| 712 | Poster Presentation | Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties | Anika Jaekel; Patrik Kehler; Timo Lischke; Christoph Goletz; Anke Flechner; Antje Danielczyk; Johanna Gellert | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 713 | Poster Presentation | Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model | Emma Langley; Chen Li; Jessica Zaid; Tani-Ann Lee; Deepak Yadav; Brian Grot; Jay Singh; Johnovan Kim | Immune-stimulants and immune modulators | Cytokine;Tumor microenvironment;Tumor stroma | |
| 714 | Poster Presentation | Selective expansion of antigen-specific CD8 T cells with engineered Antigen Presenting Exosome | Tomoyoshi Yamano, phD; Xiabing Lyu; Rikinari Hanayama, M.D., phD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Costimulation;Dendritic cell;T cell;Tumor antigens | |
| 715 | Poster Presentation | WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models | Kristin Morris, PhD; Heather Brodkin; Daniel J. Hicklin, PhD; Nesreen Ismail; Christopher Nirschl, PhD; Andres Salmeron, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna Sullivan; William Winston | Immune-stimulants and immune modulators | Cytokine;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 716 | Poster Presentation | NL-201 induces inflammation in a 'cold' tumor microenvironment through upregulation of MHC-I, expansion of the TCR repertoire, and potent antitumor activity when combined with PD-1 inhibition | Christie Mortales, PhD; Benjamin Dutzar, BS; Jerry Chen, BS; Alex Chen, PhD; Justin Huard, BS; Luis Blancas-Mejia, PhD; Carl Walkey, PhD; Ryan Swanson, BS | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 717 | Poster Presentation | Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety | Kelly D. Moynihan, Ph.D.; Danielle Pappas; Terrence Park; Wei Chen, Ph.D.; Irene Ni; Paul Bessette, Ph.D.; Mike Chin; Ton N. Schumacher, PhD; Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D. | Immune-stimulants and immune modulators | Cytokine;Solid tumors;T cell | |
| 718 | Poster Presentation | WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models | Christopher Nirschl, PhD; Heather Brodkin, PhD; Daniel J. Hicklin, PhD; Nesreen Ismail; Kristin Morris, PhD; Andres Salmeron, PhD; Cindy Seidel-Dugan, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna Sullivan; William Winston, PhD | Immune-stimulants and immune modulators | Cytokine;Inflammation;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 719 | Poster Presentation | XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates | Ekta Patel, PhD; Natalia Malkova; Sallyann Vu; Rebekah O'Donnell; Manoussa Fanny; Wilson Guzman; Parker Johnson; Megan McLaughlin; Oleg Yerov; Kurt Jenkins; Hanumantha Rao Madala; Caitlin O'Toole; Magali Pederzoli-Ribeil; Jia Chen; Benjamin Nicholson; Bill Avery; Huawei Qiu; Ronan O'Hagan; Jennifer O'Neil, PhD | Immune-stimulants and immune modulators | Cytokine;Solid tumors;T cell | |
| 720 | Poster Presentation | CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies | Christie Zhang, PhD; Natasha Girgis, Ph.D.; Zohra Merazga, MSc; Steven Hatfield; Alex Histed, MSc; Fan Zhao, PhD; Raymond J. Moniz, PhD; Kristin Yeung; Fulvio Diaz; Jason Brown; Mark Haydock, B.S.; Luke Witt, B.S.; Wynona Bautista; John F. Ross, Ph.D.; Saso Cemerski, PhD; Anish Suri, PhD; Kenneth J. Pienta, MD; Matteo Levisetti; Steve N. Quayle, PhD | Immune-stimulants and immune modulators | Bispecifics;Cytokine;T cell;Tumor antigens | |
| 721 | Poster Presentation | Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity | Michael M. Schmidt, PhD; Gregory Papastoitsis; Howard L. Kaufman, MD; Darrell J. Irvine, Ph.D.; K. D. Wittrup | Immune-stimulants and immune modulators | Costimulation;Cytokine;Immune adjuvant;Immune toxicity;Solid tumors;Tumor microenvironment | |
| 722 | Poster Presentation | INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities | Florian J. Sulzmaier, PhD; Heather Kinkead, PhD; Anya Polovina; Nadja Kern; Angelica Sanabria; Chelsie Macedo; Abrahim Hussain; Sae Jeong Ahn; Rajay Pandit; William Crago; John C. Timmer, PhD; Analeah B. Heidt, PhD; Brendan P. Eckelman, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Cytokine;NK/NKT cell;Targeted therapy | |
| 723 | Poster Presentation | WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models | Ethika Tyagi, PhD; Heather Brodkin, PhD; Josue Canales; Dan Hicklin; Nesreen Ismail; Kristin Morris, PhD; Christopher Nirschl, PhD; Andres Salmeron, PhD; Cindy Seidel-Dugan, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna Sullivan; William Winston, PhD | Immune-stimulants and immune modulators | Cytokine;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 724 | Poster Presentation | Evaluation of an Anti-human IL-1β Antibody in Monosodium Urate Crystals-Induced Peritonitis Model in hIL-1β HuGEMM™ Mice | Xiaoyu An, MS; Kaixia Lian; Jia Zheng; Fei Jian; Henry Q. Li; Tao Yang, PhD | Immune-stimulants and immune modulators | Autoimmunity;Cytokine;Inflammation | |
| 725 | Poster Presentation | Immunomodulation by targeting PDL-1 in colon cancer using nuclear receptor 4A1 (NR4A1) antagonists | Maen Abdelrahim, MD, PhD; Kumaravel Mohankumar, Ph.D.; Keshav Karki, PhD; Stephen Safe | Immune-stimulants and immune modulators | Gene expression;Immune adjuvant;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment | |
| 726 | Poster Presentation | Tumor Treating Fields (TTFields) induce an altered polarization program in M1/M2 macrophages | Yiftah Barsheshet, PhD; Boris Brant; Tali Voloshin; Alexandra Volodin; Lilach Koren; Anat Klein-Goldberg; Efrat Zemer-Tov; Rom Paz; Moshe Giladi, PhD; Uri Weinberg, MD PhD; Yoram Palti | Immune-stimulants and immune modulators | Antigen presenting cells;Immune adjuvant;Inflammation;Monocyte/Macrophage | |
| 727 | Poster Presentation | Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity | Madeline Dahut, BS; Kristen N. Fousek, PhD; Lucas A. Horn, PhD; Haiyan Qin; Jeffrey Schlom, PhD; Claudia M. Palena, PhD | Immune-stimulants and immune modulators | NK/NKT cell;Tumor evasion;Tumor microenvironment | |
| 729 | Poster Presentation | Immunologic tumor cell intrinsic effects of standard of care therapies for ovarian cancer | Nicole E. James, PhD; Melih A. Ozsoy; Payton De La Cruz; Morgan Woodman; Jennifer Ribeiro | Immune-stimulants and immune modulators | Chemotherapy;Cytokine;Solid tumors | |
| 730 | Poster Presentation | Hypoxia reduction in tandem with anti-angiogenic therapy remodels the PDAC microenvironment and potentiates CD40 agonist therapy | Arthur J. Liu, BS; Michael A. Curran, PhD | Immune-stimulants and immune modulators | Angiogenesis;Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma | |
| 731 | Poster Presentation | Concurrent immunotherapy and dipeptidyl peptidase-4 inhibition among patients with solid tumors | Kayla W. Miranda, MD; Matthew D. Tucker, MD; Yu-Wei Chen, MD; Kathryn E. Beckermann, MD, PhD; Brian I. Rini, MD | Immune-stimulants and immune modulators | Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors;Tumor microenvironment | |
| 732 | Poster Presentation | A novel nuclear receptor 4A1 (NR4A1) antagonists attenuates T-cell exhaustion in colorectal cancer | Kumaravel Mohankumar, Ph.D.; Gus Wright, Ph.D.; Subhashree Kumaravel; Rupesh Shrestha; Maen Abdelrahim, MD, PhD; Robert S. Chapkin, Ph.D; Stephen Safe | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 733 | Poster Presentation | Immunological mechanisms of resistance to CDK4/CDK6 inhibitors in breast cancer | Giulia Petroni, PhD; Kenneth Gouin; Aitziber Buqué Martinez, PhD; Simon Knott; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD | Immune-stimulants and immune modulators | Immune contexture;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);T cell;Tumor microenvironment | |
| 734 | Poster Presentation | BET inhibitors synergize with anti-PD1 by rescuing TCF1+ progenitor exhausted T cells in Acute Myeloid Leukemia | Kyle A. Romine; Hyun-Jun Cho; Yoko Kosaka, PhD; Kaelan Byrd; Jesse Coy; Patrick Flynn; Matthew Newman; Christopher Loo; Evan F. Lind, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Epigenetics;Leukemia/Lymphoma | |
| 735 | Poster Presentation | Identification of a small molecule that prevents T cell Exhaustion using machine learning algorithms paired with high-resolution single cell RNAseq | Isabelle Le Mercier, PhD; Sunny Sun; Dongmei Xiao; Laura Isacco; Daniel Treacy; Emilie Artru; Scott Steelman; John Bradley; Alex Wolf; Morag Stewart; Effie Tozzo | Immune-stimulants and immune modulators | Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 736 | Poster Presentation | Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer | Nassiba Taib, Mater's degree; Maysaloun Merhi; Varghese Inchakalody; Sarra Mestiri; Afsheen Raza, PhD; Shahab Uddin; Cristina Maccalli; Mohammed Ussama AlHomsi; Said Dermime | Immune-stimulants and immune modulators | Chemotherapy;Epigenetics;Neoantigens | |
| 737 | Poster Presentation | Inhibition of P21-activated kinase 4 (PAK4) reverts immune exclusion and restores anti-tumor immunity in the tumor microenvironment | Yu 'Jerry' Zhou; Gina Chu; Eleanore Hendrickson; Johnni Gullo-Brown; Brandy Chavez; Indrawan McAlpine; Eugene Rui; Shawn Doran; Sergei Timofeevski; Jonathan Heyen; Jennifer Kinong; Szu-Yu Tang; Jon Oyer; Vinayak Rayannavar; Andrew Nager; Keith Ching; Stephanie Shi; Rajarshi Bhadra; Christopher Dillon; Murali Gururajan | Immune-stimulants and immune modulators | Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 738 | Poster Presentation | Intratumoral administration of alum-tethered engineered inflammatory cytokines safely elicits potent local and systemic immunity | Yash Agarwal, B.Sc.; K. D. Wittrup; Darrell J. Irvine, Ph.D. | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;Immune adjuvant;Solid tumors | |
| 739 | Poster Presentation | Intratumor childhood vaccine-specific CD4+ T cell recall helps antitumor CD8 T cells | Michael C. Brown, PhD; Zachary P. McKay; Yuanfan Yang, MD; Darell D. Bigner, MD, PhD; Smita Nair, PhD; Matthias Gromeier, MD | Immune-stimulants and immune modulators | Antigen presenting cells;Costimulation;Dendritic cell;Immune adjuvant;Immune contexture;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 740 | Poster Presentation | Radiotherapy-activated NBTXR3 nanoparticles Increase CD8+ T cell infiltration and diversity in tumors, and modulate the immunopeptidome of cancer cells | Audrey Darmon, BS; Ping Zhang, PhD; Jordan Da silva; Sebastien Paris | Immune-stimulants and immune modulators | Biomarkers;Radiotherapy;Surfaceome;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 741 | Poster Presentation | Expression of galectin-3 inhibitors from a self-replicating RNA vector as treatment for pediatric osteasarcoma | Guillermo Herrador Cañete, Jr., MSc; Marta Zalacain, PhD; Sara Labiano, PhD; Javier Martinez, MSc; Cristian Smerdou, PhD; Marta M. Alonso | Immune-stimulants and immune modulators | Gene expression;Immune suppression;Pediatric tumors;Solid tumors;Tumor microenvironment | |
| 742 | Poster Presentation | Multi-armed myxoma virus induces potent anti-tumor responses in vitro and in vivo | Wazir Abdullahi, PhD; Lina S. Franco, PhD; Christopher Fraser, PhD; Heather Hrach, PhD; Nicole Grigaitis; Mario Abrantes; Zachary Tacner; Ana L. de Matos, PhD; Leslie L. Sharp, PhD; LESLIE L. SHARP, PhD | Immune-stimulants and immune modulators | Costimulation;Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor stroma | |
| 743 | Poster Presentation | Resistance to oncolytic vaccinia can be reversed by targeting regulatory T cells with vaccinia-directed delivery of a TGFβ inhibitor | Kristin DePeaux, BS; Dayana Rivadeneira, PhD; McLane Watson, BS; Andrew P. Hinck; Stephen Thorne; Greg M. Delgoffe, PhD | Immune-stimulants and immune modulators | Immune adjuvant;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 744 | Poster Presentation | Multi-armed myxoma virus has therapeutic potential for treatment of multiple myeloma | Lina S. Franco, PhD; Christopher Fraser, PhD; Lino E. Torres-Dominguez, PhD; Nicole Grigaitis; Jack St. Peter; Mario Abrantes; Zachary Tacner; Heather Hrach, PhD; Ana L. de Matos, PhD; Leslie L. Sharp, PhD | Immune-stimulants and immune modulators | Costimulation;Cytokine;Leukemia/Lymphoma;NK/NKT cell;T cell | |
| 745 | Poster Presentation | Oncolytic adenovirus expressing 4-1BBL demonstrates a significant increase of survival in Diffuse Midline Glioma models | Virginia Laspidea; Sara Labiano, MSc; Iker Ausejo-Mauleon, MSc; Daniel de la Nava; Marc García-Moure; Javier Marco-Sanz; Juan Fueyo; Candelaria Gomez-Manzano; Ana Patiño-García; Marta M. Alonso | Immune-stimulants and immune modulators | Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 746 | Poster Presentation | Vectorized Treg-depleting anti-CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors | Monika Semmrich, PhD; Jean-Baptiste j. Marchand, PhD; Matilda Rehn, PhD; Laetitia Fend, PhD; Christelle Remy-Ziller, Engineer; Petra Holmkvist, PhD; Nathalie Silvestre, PhD; Carolin Svensson; Patricia Kleinpeter, MSc; Jules Deforges; Fred Junghus; Linda Martensson; Johann Foloppe, PhD; Ingrid Teige, M.Sc, PhD; Eric Quemeneur, PharmD, PhD; Bjorn Frendeus, PhD | Immune-stimulants and immune modulators | Antibody;Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors | |
| 747 | Poster Presentation | CodaLytic™, a novel codon-pair deoptimized influenza virus creates an immune-stimulatory tumor microenvironment leading to monotherapy efficacy in a preclinical model of breast cancer | Marcin Stawowczyk, PhD; Katie Pfeffer; Juliana Tafrova, PhD; Charles B. Stauft, PhD; Anna Kushnir, PhD; Sybil A. Tasker, MD, MPH, FIDSA; Steffen Mueller, PhD; J Robert Coleman, PhD, MBA; Johanna K. Kaufmann, PhD | Immune-stimulants and immune modulators | B cell;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 748 | Oral Presentation | Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade | Sruthi Ravindranathan, PhD, MS; Tenzin Passang Fnu; Jian Ming Li; Rohan Dhamsania; Michael B. Ware, PhD; Mohammad Y. Zaidi; Shuhua Wang; Jingru Zhu; Maria Cardenas; Yuan Liu, PhD; Sanjeev Gumber; Brian Robinson; Anish Majumdar,; Shanmuganathan Chandrakasan; Haydn T. Kissick, PhD; Alan B. Frey; Susan N. Thomas; Bassel El-Rayes, MD; Gregory B. Lesinski, PhD; Edmund K. Waller, MD/PHD | Immune-stimulants and immune modulators | Solid tumors;Targeted therapy | |
| 749 | Poster Presentation | A novel translational mouse model for assessment of human STING-targeting therapies | Fabiane Sônego; Fabiane Sônego, PhD; Gaëlle Martin; Audrey Beringer; Chloé Beuraud; Angela Pappalardo; Yacine Cherifi; Patricia Isnard-Petit; Kader Thiam | Immune-stimulants and immune modulators | Inflammation;Targeted therapy | |
| 750 | Poster Presentation | AK119, A CD73 Targeting Antibody with Dual Mechanism of Action | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; Chunshan Jin; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Immune-stimulants and immune modulators | Antibody;B cell;COVID and Immunotherapy;Immune suppression;T cell | |
| 751 | Poster Presentation | Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb | Karin Hagerbrand, PhD; Mattias Levin; Laura Von Schantz, -; Laura Varas, PhD; Anna Säll; Adnan Deronic, PhD; Anette Sundstedt; Lill Ljung; Karin Barchan; Doreen Werchau, BS; Anna Rosén; Barnabas Nyesiga; Eva Lindqvist; Mia Thagesson; Peter Ellmark, PhD | Immune-stimulants and immune modulators | Antibody;Bispecifics;Costimulation;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor antigens;Tumor microenvironment | |
| 752 | Poster Presentation | Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response | Stefan Chmielewski, PhD; Maciej Kujawa; Eliza Zimolag; Michal Galezowski; Andrzej Gondela; Pawel Guzik; Agata Dudek; Joanna Szeremeta-Spisak; Marta Bugaj; Iana Levenets; Marcin Nowogrodzki; Marianna Girardi; Anna Zagorska; Przemyslaw Wyrebek; Magdalena Zastawna; Agnieszka Gibas; Sylwia Sudol; Oleksandr Levenets; Mateusz Swirski; Sujit Sasmal; Adam Radzimierski; Marta Sowinska; Paulina Niedziejko; Karol Zuchowicz; Martin Swarbrick; Karolina Gluza; Patryk Kret; Mateusz Ogorek; Dominika Stanko; Kinga Michalik; Agnieszka Piatek; Katarzyna Banaszak; Adrian Podkowa; Aniela Golas; Peter Littlewood; Krzysztof Brzozka; Stefan Chielewski | Immune-stimulants and immune modulators | Cytokine;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 753 | Poster Presentation | InhibigenTM administration promotes aberrant T cell responses in cancer but may be beneficial for amelioration of autoimmune disease | Victoria L. DeVault, PhD; Hanna Starobinets, PhD; Julie N. Arnold; Stephanie Rinaldi; Charley Hubbard, PhD; Osaruese Odeh; Cindy Nguyen; Laura Apolloni; Dimitry Lineker; Jessica B. Flechtner, PhD; Hubert Lam, PhD | Immune-stimulants and immune modulators | Adoptive immunotherapy;Checkpoint blockade;Immune suppression;Neoantigens;T cell;Targeted therapy;Tumor antigens;Vaccine | |
| 754 | Poster Presentation | TIGIT-PVR is a key immune checkpoint and therapeutic target in HPV-positive head and neck squamous cell carcinomas | Xiuning Le, MD, PhD; Minghao Dang; Venkatesh L. Hegde, PhD; Bo Jiang; Ravaen Slay; Weihong Xiao, MD; Keiko Akagi, PhD; Joseph Fresquez; Kathrina L. Marcelo, PhD; Qianyun Luo; Pragya Sinha; Ananta V. Yanamandra; Diana Bell, MD; Michelle Williams, MD; Edwin Parra Cuentas, PhD; Ryan Goepfert, MD; Stephen H. Lai, MD, PhD; Neil Gross, MD; Amit Agrawal, MD; Alexandre Reuben, PhD; Jeffrey Myers, MD, PhD; Michael A. Curran, PhD; Jagannadha Sastry, PhD; Linghua Wang, PhD; Maura L. Gillison, MD, PhD | Immune-stimulants and immune modulators | Biomarkers;Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;Tumor microenvironment | |
| 755 | Poster Presentation | Pharmacologic tumor PD-L1 depletion reduces Chk2 content and sensitizes tumors to small molecule Chk1 DNA damage repair inhibitors | Clare E. Murray; Anand V. Kornepati; Alvaro S. Padron; Myrna G. Garcia, BS; Haiyan HB. Bai, PhD; Yilun Deng, PhD; Tyler J. Curiel, MD | Immune-stimulants and immune modulators | Biomarkers;Checkpoint blockade;Chemotherapy;Coinhibition;Immune monitoring;Solid tumors;Targeted therapy;Tumor antigens;Tumor evasion;Tumor microenvironment | |
| 756 | Poster Presentation | Identifying the role of B7-H4 as a suppressor of tumor infiltrating lymphocytes and a target for immunotherapy in breast cancer | Elizabeth Wescott, BS; Paula I. Gonzalez-Ericcson, MD; Violeta I. Sanchez, BS; Melinda Sanders, MD; Justin M. Balko, PharmD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Immune suppression;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 757 | Poster Presentation | M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity | Chunxiao Xu, PhD; Brain Rabinovich; Amit Deshpande; Xueyuan Zhou; Frederic Christian Pipp; Rene Schweickhardt; Lindsay Webb; Sireesha Yalavarthi; Clotilde Bourin; Payel Ghatak; Barroq Safi; Francisca Wollerton; Neil Brewis; Jose Munoz-Olaya; Natalya Belousova; Marat Alimzhanov; Martina Hubensack; Joern-Peter Halle; Andree Blaukat; Jacques Moisan | Immune-stimulants and immune modulators | Costimulation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 758 | Poster Presentation | High-potency synthetic STING agonists rewire the myeloid stroma in the tumour microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma. | Akash R. Boda, MS; Casey R. Ager, PhD; Kimal Rajapakshe, PhD; Spencer T. Lea, BA; Maria Emilia Di Francesco, PhD; Philip Jones, PhD; Michael A. Curran, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 759 | Poster Presentation | Single-Cell Proteogenomics (Cite-seq) analysis of cGAS-STING pathway activation alone and in combination with nivolumab using a patient-derived 3D ex vivo tumoroid platform | Brittany Bunch, PhD; Autumn Joerger, PA; Nino Mtchedlidze; Olivia Hoff; Kelly Guzman; Jared C. Ehrhart, PhD; Soner Altiok, MD, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 760 | Poster Presentation | In vivo demethylation-mediated reversal of tumor cell-intrinsic cGAS silencing improves the efficacy of STING agonist therapy | Rana Falahat, PhD; Patricio Perez-Villarroel; Anders Berglund, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; James J. Mule, PhD | Immune-stimulants and immune modulators | Chemokine;Epigenetics;Immune adjuvant;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 761 | Poster Presentation | exoSTING demonstrates potent anti-tumor activity in a mouse model of leptomeningeal disease | Xudong Feng, PhD; John Lin, PhD; Su Chul Jang, PhD; Sevda Lule, PhD; Paloma Sanchez-Jauregui; Katherine Kirwin; Tong Zi; Samuel Kasera; Silvia Siso, PhD; Kelvin Zhang, PhD; Shil Patel, PhD; Sriram Sathyanarayanan, PhD; Kyriakos Economides, PhD; Wendy Broom, PhD | Immune-stimulants and immune modulators | Extracellular vesicles/exosomes;Solid tumors | |
| 762 | Poster Presentation | STING agonism combined with arginase, NOS2, and PTGES/COX2 inhibitors for improved anti-tumor immunotherapeutic benefit | Jessica Filderman, BS; Manoj Chelvanambi, BS; Walter J. Storkus, PhD | Immune-stimulants and immune modulators | Angiogenesis;Inflammation;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 763 | Poster Presentation | Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory Glioblastoma models | Spencer T. Lea, BA; Chao-Hsien Chen, MD, PhD; Genevieve P. Hartley, PhD; Rodney Cheng-En Hsieh, MD; Michael A. Curran, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Immune adjuvant;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 764 | Poster Presentation | Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration | Maciej K. Rogacki, MSc; Stefan Chmielewski, PhD; Magdalena Zawadzka; Aniela Golas; Aleksandra Poczkaj; Katarzyna Dziedzic; Kamil Kus; Magnus Widegren; Jolanta Mazurek; Miroslawa Gladysz; Justyna Jablonska; Izabela Strojny; Grzegorz Cwiertnia; Lukasz Dudek; Marcin Les; Urszula Glowniak-Kwitek; Nilesh Gaud; Arkadiusz Bialas; Kinga Michalik; Raghuram Tangirala; Peter Littlewood; Krzysztof Brzózka | Immune-stimulants and immune modulators | Antigen presenting cells;Cytokine;Inflammation | |
| 765 | Poster Presentation | The first-in-class small molecule TREX1 inhibitor CPI-381 demonstrates type I IFN induction and sensitization of tumors to immune checkpoint blockade | Costa Salojin, MD, PhD; Costa Salojin; Anna S. Gardberg; Valerie Vivat; Lei Cui; Jeffrey Lauer; Nico R. Cantone; Jacob I. Stuckey; Florence Poy; Ingrid Almeciga; Richard T. Cummings; Jonathan Wilson; Julian R. Levell; Jennifer L. Rocnik; Patrick Trojer | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;Dendritic cell;Immune adjuvant;Solid tumors;Tumor microenvironment | |
| 766 | Poster Presentation | Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs) | Sachin H. Bhagchandani, M.S.; Lauren Milling, Ph.D.; Bin Liu, Ph.D.; Timothy Fessenden, Ph.D.; Stefani Spranger, PhD; Darrell J. Irvine, Ph.D.; Jeremiah A. Johnson, Ph.D. | Immune-stimulants and immune modulators | Antigen presenting cells;Checkpoint blockade;Immune adjuvant;Immune toxicity;TLR;Tumor microenvironment | |
| 767 | Poster Presentation | Activation of CD8+ T cells in the presence of multiple TLR agonists affects the expression of T-cell checkpoint receptors via IL-12 and type-1 interferon | Donghwan Jeon, MS; Douglas G. McNeel, MD, PhD | Immune-stimulants and immune modulators | Immune adjuvant;T cell;TLR;Vaccine | |
| 768 | Poster Presentation | Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice | Caitlyn Miller, PhD Candidate; Idit Sagiv-Barfi, PhD; Patrick Neuhoefer, PhD; Debra K. Czerwinski, BS; Steven Artandi, MD; Carolyn Bertozzi, PhD; Ronald Levy, MD; Jennifer Cochran, PhD | Immune-stimulants and immune modulators | Immune adjuvant;Immune suppression;Inflammation;MDSC;Solid tumors;T cell;Targeted therapy;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 769 | Poster Presentation | A Single Dose of Intratumoral TransCon™ TLR7/8 Agonist Monotherapy Promoted Sustained Activation of Antigen Presenting Cells Resulting in CD4+ and CD8+ T cell Activation and Tumor Growth Inhibition | Luis Zuniga, PhD; Karan Uppal, PhD; Kathy Bang; Enping Hong, PhD; Simran Sabharwal, PhD; Yuchi Lee, PhD; Solomon Martinez; David Rosen, PhD; Amer M. Mirza, PhD; Juha Punnonen, MD, PhD; Luis A. Zuniga, PhD | Immune-stimulants and immune modulators | Antigen presenting cells;Inflammation;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 770 | Poster Presentation | Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity | Jeroen J. Van Bergen, PhD; Tsolere Arakelian, PhD; Kedar Moharana, PhD; Bram Teunisse; Iris Zoutendijk; Marcel Camps; Ramon Arens; Ferry Ossendorp, PhD; Gerben Zondag, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Cytokine;Immune adjuvant;Inflammation;Neoantigens;T cell;Vaccine | |
| 771 | Poster Presentation | Novel lipid nanoparticle vaccine platform for efficient delivery of high- and low-affinity epitopes | Unnur Jóna Björgvinsdóttir; Laura Stentoft Carstensen; Anna Colliander; Ditte Elisabeth Jæhger; Gael Clergeaud Veiga; Hólmfríður Rósa Halldórsdóttir; Matilde Smærup Jørgensen; Esben Christensen; Sara Vangsgaard; Aristeidis Koukos; Martin Bak; Paul Kempen; Thomas Lars Andresen; Unnur Jóna Ms. Björgvinsdóttir, MSc | Immune-stimulants and immune modulators | Adoptive immunotherapy;Antigen presenting cells;Immune adjuvant;T cell;TLR;Vaccine | |
| 772 | Poster Presentation | MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination | Mathieu Gigoux, PhD; Roberta Zappasodi, PhD; Joseph J. Park; Cansu Cimen Bozkus; Levi M. Mangarin, BS; David Redmond; Svena Verma, BS; Sara Schad, BS; Mariam M. George; Divya Venkatesh; Arnab Ghosh, MD, PhD; Zaki Molvi, BS; Baransel Kamaz; Anna Marneth; William Duke; Matthew J. Leventhal; Max Jan; Vincent Ho; Gabriela S. Hobbs; Trine A. Knudsen; Vibe Skov; Lasse Kjær; Thomas S. Larsen; Dennis L. Hansen; R. C. Lindsley; Hans Hasselbalch; Jacob H. Grauslund; Mads H. Andersen, Professor, PhD, dr.techn; Morten O. Holmstrom; Timothy A. Chan, MD, PhD; Raajit Rampal; Omar Abdel-Wahab, M.D.; Nina Bhardwaj, MD, PhD; Jedd D. Wolchok, MD/PhD; Ann Mullally, M.D.; Taha Merghoub, PhD | Immune-stimulants and immune modulators | Neoantigens;Tumor antigens;Tumor evasion;Vaccine | |
| 773 | Poster Presentation | A novel cancer immunotherapy; vaccination against tumor vascular extracellular vimentin | Elisabeth J. Huijbers, PhD; Karlijn van Loon; Judy R. van Beijnum; Arjan W. Griffioen | Immune-stimulants and immune modulators | Angiogenesis;Solid tumors;Vaccine | |
| 774 | Poster Presentation | An induced pluripotent stem cell (iPSC) vaccine is highly immunogenic and reduces lung metastases in a mouse model of melanoma | Matthias Hundt, MD; Peter F. Bove, PhD; Ivan Hernandez, MS; Michelle Li, MS; Lucia Beviglia, PhD; Pratima Kundu, PhD; Babacar C. Ndoye, BS; Nigel G. Kooreman, MD; Stephen D. Wolpe, PhD; Lynne A. Bui, MD | Immune-stimulants and immune modulators | Antibody;B cell;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell;TLR;Vaccine | |
| 775 | Poster Presentation | An induced pluripotent stem cell (iPSC) vaccine decreases tumor growth and improves survival in a therapeutic mouse model of colon cancer | Matthias Hundt, MD; Michelle Li, MS; Hui Huang, MD; Carlos A. Obejero-Paz, MD; Peter F. Bove, PhD; Ivan Hernandez, MS; Pratima Kundu, PhD; Nigel G. Kooreman, MD; Stephen D. Wolpe, PhD; Lynne A. Bui, MD | Immune-stimulants and immune modulators | Antibody;B cell;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell;TLR;Vaccine | |
| 776 | Poster Presentation | The anti-tumor activity of HER-2/neu ICD therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in Her2-expressed gastric cancer xenograft model | Gyeong Seok Jo; Eunkyo Joung, MD; Jung Hyu Shin; Hye Lim Lee; Jinback Lim; Yoonyi Kim; Hyo-Hyun Park; Hunwoo Shin; Hun JH. Jung, MD./PhD. | Immune-stimulants and immune modulators | Carcinogenesis;Cytokine;Immune monitoring;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine | |
| 777 | Poster Presentation | Personalized DNA vaccine in combination with plasmid encoded IL-12 for the treatment of a patient with anaplastic astrocytoma | Tanner M. Johanns, MD, PhD; ALFREDO PERALES-PUCHALT, MD, PhD; Sarah Rochestie; Neil Cooch; Joann Peters; Gavin P. Dunn, MD, PhD; Niranjan Y. Sardesai | Immune-stimulants and immune modulators | Immune monitoring;T cell;Tumor antigens;Vaccine | |
| 778 | Poster Presentation | Modulating tumor microenvironment with arginase-1 specific T cells | Evelina Martinenaite, PhD; Mia Aaboe Jørgensen; Rasmus Erik Johansson Mortensen; Shamaila Munir Ahmad; Stine Emilie Weis-Banke; Morten Orebo Holmström; Ayako Wakatsuki Pedersen; Özcan Met; Inge M. Svane, Professor, MD, PhD; Mads Hald Andersen | Immune-stimulants and immune modulators | Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;T cell;Targeted therapy;Tumor microenvironment;Vaccine | |
| 779 | Poster Presentation | Inhibiting Type-I Interferon signaling promotes memory T-cell formation following immunization with Listeria anti-cancer vaccines | Zachary T. Morrow, BS; John-Demian Sauer, PhD, BS | Immune-stimulants and immune modulators | Antigen presenting cells;Dendritic cell;Granulocyte;Immune monitoring;Inflammation;Microbiome;Monocyte/Macrophage;T cell lineages;TLR;Vaccine | |
| 780 | Poster Presentation | ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity | Ons Harrabi, BA; Amy Chen; Emma R. Sangalang; Danielle Fontaine; Min Li, PhD; Jaume Pons, PhD; Hong I. Wan, PhD; Janet Sim, PhD; Tracy C. Kuo, PhD | Immuno-conjugates and chimeric molecules | Antibody;Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR | |
| 781 | Poster Presentation | GT-001 - anti-Lewis Y antibody with superior fine-specificity and reduced off-target binding | Anika Jaekel; Patrik Kehler; Timo Lischke; Lisa Weiß; Christoph Goletz; Evelyn Hartung; Anke Flechner; Sven Bahrke; Johanna Gellert; Antje Danielczyk | Immuno-conjugates and chimeric molecules | Antibody;Solid tumors;Targeted therapy;Tumor antigens | |
| 782 | Poster Presentation | PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models | Justin A. Kenkel, PhD; Rishali Gadkari; Karla A. Henning, PhD; Romas Kudirka; William G. Mallet; Po Y. Ho; Ganapathy Sarma; Steven J. Chapin, PhD; Liz Bogaert; Jennifer E. Melrose; Matthew N. Zhou; Suprit Deol; Cindy L. Kreder; Yuyi Shen; Puneet Anand; Arthur Lee; Hai Li; Shelley E. Ackerman; Brian S. Safina; David Dornan, PhD; Michael N. Alonso, PhD; Marcin Kowanetz, Ph.D. | Immuno-conjugates and chimeric molecules | Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Myeloid cells;Targeted therapy;TLR;Tumor antigens | |
| 783 | Poster Presentation | SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors | Byron Kwan, PhD; Megan Ramirez; Steven Jin; Changpu Yu; Serena W. Wo; Priyanka Gupta; Sean Allred; Jessica K. Simmons; Kelly M. Hensley; Christina Zuch de Zafra; Haley Neff-LaFord; Shawna Hengel; Andres Forero-Torres, MD; Heather Van Epps | Immuno-conjugates and chimeric molecules | Antibody;Chemotherapy;Solid tumors;Targeted therapy | |
| 784 | Poster Presentation | BDC-2034: Discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors | William G. Mallet; Rishali Gadkari; Cecelia I. Pearson; Laughing Bear Torrez Dulgeroff; Angela Luo; Andrew Luo; Jennifer E. Melrose; Jess L. Nolin; Arthur Lee; Matthew N. Zhou; Puneet Anand; Ganapathy Sarma; Karla A. Henning, PhD; Lisa K. Blum; Steven J. Chapin, PhD; Liz Bogaert; Shelley E. Ackerman; Romas Kudirka; Yuyi Shen; Amreen Husain; Edith A. Perez; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Brian S. Safina; David Dornan, PhD | Immuno-conjugates and chimeric molecules | Antibody;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;TLR;Tumor antigens | |
| 785 | Poster Presentation | STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells | Phonphimon Wongthida, PhD; Kalli C. Catcott, PhD; Kelly Lancaster; Keith Bentley, PhD; Anouk Dirksen, PhD; Bingfan Du; Timothy Eitas, PhD; Eugene W. Kelleher; Naniye Malli, PhD; Rebecca Mosher, MD; Marina Protopopova, PhD; Pamela Shaw; Cheri Stevenson; Joshua D. Thomas, PhD; Alex Uttard; Jeremy Duvall, PhD; Dorin Toader, PhD; Marc Damelin, PhD; Raghida A. Bukhalid, PhD; Timothy B. Lowinger, PhD | Immuno-conjugates and chimeric molecules | Antibody;Chemokine;Cytokine;Monocyte/Macrophage;T cell;Targeted therapy;Tumor microenvironment | |
| 786 | Poster Presentation | Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data | Gaurav Bajaj; Fereshteh Nazari; Marc Presler; Craig Thalhauser; Ulf Forssmann; Maria Jure-Kunkel; Alexander Muik; Eleni Lagkadinou; Özlem Tureci; Ugur Sahin; Tahamtan Ahmadi; Manish Gupta | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Costimulation;NK/NKT cell;Solid tumors;T cell | |
| 787 | Poster Presentation | Natural Killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines | Katrina Bykova, PhD; Matthew S. Faber, PhD; Ke Liu, PhD; Noor Siddiqi; Matthew J. Bernett, PhD; Christine Bonzon, PhD; Juan E. Diaz, PhD; Dong Hyun Nam, PhD; Kendra N. Avery, PhD; Jing Qi, PhD; Rumana Rashid, PhD; Rena Bahjat, PhD; John R. Desjarlais, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Cytokine;NK/NKT cell;Solid tumors;T cell | |
| 788 | Poster Presentation | A Novel T- Lymphocyte Binding Aptamer Assembled into a Bispecifc Compound for the Treatment of Solid Tumors | Irit Carmi Levy, PhD; Erez Lavi; Neta Zilony Hanin; Zohar Pode; Karin Mizrahi; Ronit Farhi; Anastasia Paz; Neria Reiss; Chen Shimoni; Vitaliy Buravenkov; Liron Levy-Efrati; Rotem Haimovich; Ohad Glaich; Itay Liron; Hadas Aharoni Zazrin; Ido Bachelet; Raanan Berger, MD; Guy Neev | Immuno-conjugates and chimeric molecules | Antigen presenting cells;Bispecifics;Solid tumors;T cell;TLR | |
| 789 | Poster Presentation | Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule to enhance targeted tumor cytotoxicity | Fay Dufort, PhD; Christopher Leitheiser, PhD; Gemma Mudd, PhD; Julia Kristensson, .; Alexandra Rezvaya, MS; Elizabeth M. Repash, MSc; Eric Haines, PhD; Katie Gaynor, PhD; Sandra Uhlenbroich, PhD; Liudvikas Urbonas; Heather Allen; Helen Harrison; Liuhong Chen; Philip E. Brandish; Kevin McDonnell; Nicholas Keen | Immuno-conjugates and chimeric molecules | NK/NKT cell;Solid tumors | |
| 790 | Poster Presentation | DSP502 — A Novel Approach For Targeting TIGIT And PD1 Pathways For Cancer Immunotherapy | Ayelet Chajut; Shirley Greenwald; Matthew C. Weber, PhD; Ami Tamir, PhD; Iris Pecker, PhD; Rinat Tabakman, PhD; Lucy Ganthous; Liat Tamir, PhD; Roy Kahn, PhD; Jasmine Avichzer; Alexandra Aronin; Elina Zorde-Khvalevsky; Amnon Peled, PhD; Michal Michal Elhalel Dranitzki, Dr.; Adam Foley-Comer, Dr.; Mark L. Tykocinski, Dr. | Immuno-conjugates and chimeric molecules | Bispecifics;Checkpoint blockade;Coinhibition;NK/NKT cell;Targeted therapy;Tumor microenvironment | |
| 791 | Poster Presentation | Multi-specific Guidance and Navigation Control (GNC) T cell engagers convert PDL1 adaptive resistance to drug sensitivity | Jahan S. Khalili, Ph.D.; Mark Gilchrist; Sarah Rickli; Daphne Toglia; Yi Zhu | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;T cell;Tumor antigens;Tumor microenvironment | |
| 792 | Poster Presentation | Creating an Immune-favorable Tumor Microenvironment by A Novel Anti-CD39/TGFβ-Trap Bispecific Antibody | Hongtao Lu, PhD; Dawei Sun, Ph.D.; Jun Sun; Yanan Geng; Jinhui Zhang, Ph.D.; Rui Gao, Ph.D.; Lei Li; Zhihao Wu, Ph.D; Lily Tang; Yangsheng Qiu, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 793 | Poster Presentation | Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platforms | Raymond J. Moniz, PhD; Ahmet Vakkasoglu; Zohra Merazga, MSc; Tina Daigneault; Steve N. Quayle, PhD; Natasha Girgis, Ph.D.; Ronald D. Seidel, PhD; John F. Ross, Ph.D.; Simon Low, MSc; Anish Suri, PhD | Immuno-conjugates and chimeric molecules | Bispecifics;Cytokine;Neoantigens;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Vaccine | |
| 794 | Poster Presentation | Long-term anti-tumor preclinical efficacy of an optimized anti PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity | Aurore morello; Margaux Seite; justine durand; Geraldine Teppaz; Virginie Thepenier; caroline Mary; Isabelle Girault; Emmanuelle Wilhem; Nicolas Poirier | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 795 | Poster Presentation | APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTM technology designed to deliver a conditional T cell/NK response against solid tumors | Michelle H. Nelson, PhD; Ashly Lucas; Rebecca Gottschalk; Catherine McMahan; Jane Gross; Hilario Ramos | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Costimulation;NK/NKT cell;T cell | |
| 796 | Poster Presentation | ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors | Michelle H. Nelson, PhD; Anette Sundstedt; Yago Pico de Coaña, PhD; Ashly Lucas; Anneli Nilsson; Lill Ljung; Allison Chunyk; Lena Schultz; Catherine McMahan; Jane Gross; Sara Frizell, PhD; Hilario Ramos; Peter Ellmark, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy | |
| 797 | Poster Presentation | A novel anti-PD-1/IL15 bi-functional antibody with robust anti-tumor activity in multiple solid tumors | DAN LU, MS; Tzu-Pei Chang, PhD; Zhanna Polonskaya; Stella Martomo, PhD; Xenia Luna; zhikai zhang; Stanley Ng; Jeegar Patel | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Checkpoint blockade;Cytokine;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 798 | Poster Presentation | CDX-585, A bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways | Laura Vitale; Michael Murphy, Ph.D.; Collin Xia; Zeyu Peng; Thomas O'Neill; Ed Natoli; Jay Lillquist; Linda Crew; Anna Wasiuk, Ph.D.; Jeff Weidlick; Jenifer Widger; Laura Mills-Chen; Andrea Crocker; Colleen Patterson; James Boyer; April R. Baronas; Russell Hammond, Ph.D.; Hugh Davis; Mark Ma; Joel J. Goldstein, PhD; Lawrence J. Thomas, PhD; Diego Alvarado, Ph.D.; Henry Marsh, BS PhD; Tibor Keler, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;T cell;TLR | |
| 799 | Poster Presentation | Neoantigen-cytokine-chemokine Multifunctional Natural Killer Cell Engager for Immunotherapy of Solid Tumors | Xue Yao, Master; Sandro Matosevic, PHD | Immuno-conjugates and chimeric molecules | Bispecifics;Chemokine;Cytokine;Immune suppression;Neoantigens;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment | |
| 800 | Poster Presentation | Dual targeting of CTLA-4 and CD47 on Treg cells rejuvenates immunity against solid tumors | Anli Zhang, PhD; Zhenhua Ren, PhD; Kuo-fu Tseng; Xiajuan Liu; Huiyu Li, BS; Changzheng Lu; Yueqi Cai; John D. Minna, M.D.; Yang-Xin Fu, MD, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Immune suppression;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy | |
| 802 | Poster Presentation | An electronic health record-based approach to identify and characterize patients with immune checkpoint inhibitor-associated arthritis | Steven Tran, BS; Luke Rasmussen, MS; Jennifer Pacheco, MS; Carlos Galvez, MD; Kyle Tegtmeyer, MD; Yuan Luo, PhD; Jeffrey A. Sosman, MD; Abel Kho, MD; Theresa Walunas, PhD, MS | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity | |
| 803 | Poster Presentation | Immune-related adverse events correlate with improved outcomes in patients with advanced non-small cell lung cancer treated with combinations of immune-checkpoint inhibitors and chemotherapy | Lindsey Shantzer, MD; Sean C. Dougherty, MD; Wendy Novicoff, PhD; John W. Melson, MD; Daniel R. Reed, MD; Alia C. Lynch, PharmD; Ryan D. Gentzler, MD, MS; Richard D. Hall, MD, MS | Immunotherapy Toxicities | Chemotherapy;Immune toxicity;Solid tumors | |
| 804 | Poster Presentation | Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors | Bruce C. Tiu, BS; Leyre Zubiri; James Iheke; Vartan Pahalyants, MD, MBA; Nicholas Theodosakis, MD; Pearl O. Ugwu-Dike; Jayhyun Seo; Kimberly Tang; Ryan J. Sullivan, MD; Meghan J. Mooradian, MD; Yevgeniy R. Semenov, MD; Kerry L. Reynolds, MD | Immunotherapy Toxicities | Checkpoint blockade;Clinical study;Epidemiology;Immune toxicity;Solid tumors;T cell;Targeted therapy | |
| 805 | Oral Presentation | Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice | Margaret L. Axelrod, BS; Wouter C. Meijers, MD,PhD; Elie Tannous, MD; Xiaopeng Sun, BS; Juan Qin, PhD; Ayaka Sugiura, BS; Elizabeth Wescott, BS; Elles M. Screever, BS; Spencer C. Wei, PhD; Susan Opalenik, BS, PhD; Yueli Zhang; Douglas B. Johnson, M.D.; James P. Allison, PhD; Javid Moslehi; Justin M. Balko, PhD, PharmD | Immunotherapy Toxicities | Autoimmunity;Checkpoint blockade;Immune tolerance;Immune toxicity;Inflammation;Neoantigens;T cell;Tumor antigens | |
| 806 | Oral Presentation | PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events | Steven M. Bronson, DVM; Elizabeth R. Stirling, MS; Brian Westwood, MS; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity;Inflammation;Metabolism | |
| 807 | Poster Presentation | Immunotherapy Related Adverse Events: A Single Center Experience | Wei Yang, MD; Sophia Lee, MD; Julie Rowe, MD; Jing Zhang; Mohammad Rahbar | Immunotherapy Toxicities | Chemotherapy;Immune toxicity | |
| 808 | Poster Presentation | Tertiary lymphoid structure gene signature detected in immune checkpoint inhibitor-associated renal immune related adverse event | Jamie S. Lin, MD; Amanda Tchakarov; Noha Abdel-Wahab; Houssein Safa, MD; Salah-Eddine Bentebibel; Maen Abdelrahim, MD, PhD; Cassian Yee, MD; Adi Diab, MD; Ala Abudayyeh, MD | Immunotherapy Toxicities | Checkpoint blockade;Gene expression;Immune toxicity | |
| 810 | Poster Presentation | Impact of immune-related adverse event development on overall survival in hospitalized lung cancer patients | Eric Olson, MD; Greg Russell; Jeffrey Lantz, DO; Andy Dothard, MD; Vanya Aggarwal, MD; Thomas W. Lycan, Jr., DO | Immunotherapy Toxicities | Checkpoint blockade;Immune monitoring;Immune toxicity;Solid tumors | |
| 811 | Poster Presentation | Allelic variation in Human Leukocyte Antigen class II genes is associated with pneumonitis risk in cancer patients treated with immune checkpoint inhibitors | Ashis Saha, PhD; Christine N. Spencer, PhD; Zia Khan, PhD; Jonathan Carroll, PhD; Claudia Yanez Arellano; Julie Hunkapiller, PhD; Nicholas L. Bayless; Leonardo Nissola, MD; Roslyn Wallace, MBBS; Ira Mellman; Rajat Mohindra, MD; Samantha Bucktrout, PhD; Shahneen Sandhu, MBBS FRACP; G. Scott Chandler, MD; Christian Hammer, PhD | Immunotherapy Toxicities | Antigen presenting cells;Checkpoint blockade;Genetic polymorphism;Immune toxicity;Solid tumors;Systems biology;T cell | |
| 812 | Poster Presentation | Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells | Xiaopeng Sun, BS; Margaret L. Axelrod, BS; Yu Wang, PhD; Sanchez Violeta; Paula I. Gonzalez-Ericsson, MD; Douglas B. Johnson, M.D.; Justin M. Balko, PhD, PharmD | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity;T cell | |
| 813 | Poster Presentation | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect | Mingyue Liu, PhD; Xu Wang; Peng Zhang; Juanjuan Su; Xuexiang Du; Yan Zhang; Yang Liu, PhD; Pan Zheng, MD, PhD | Immunotherapy Toxicities | Immune toxicity | |
| 814 | Oral Presentation | Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study | Yevgeniy R. Semenov, MD; Kimberly Tang; Jayhyun Seo; Kerry L. Reynolds, MD; Bruce Tiu; Thomas Le; Vartan Pahalyants; Neel Raval; Pearl O. Ugwu-Dike; Leyre Zubiri; Vivek Naranbhai; Alexander Gusev; Nicole LeBoeuf; Maryam Asgari; Shawn Kwatra | Immunotherapy Toxicities | Biomarkers;Checkpoint blockade;Immune toxicity | |
| 815 | Poster Presentation | Single-center retrospective cohort of all patients suspected to have immunotherapy-mediated diarrhea and colitis | Vanya Aggarwal, MD; Ella M. LePage, M.D.; Andrew Faucheux, M.D.; Hiral S. Patel, M.D.; Gregory B. Russell, M.S.; Eric Olson, MD; Jared J. Rejeski, M.D.; Thomas W. Lycan, Jr., DO | Immunotherapy Toxicities | Autoimmunity;Checkpoint blockade;Clinical study;Immune monitoring;Immune tolerance;Immune toxicity;Inflammation | |
| 816 | Poster Presentation | Selective Immune Suppression using Interleukin-6 blockade in Immune Related Adverse Events | Faisal Fa'ak, MD; Faisal Fa'ak; Chrystia M. Zobniw; Maryam Buni; Linda Lu; Adewunmi Falohun; VanAnh Trinh; Muhammad Osama Awiwi; Khaled M Elsayes; Kaysia Ludford; Maya Dimitrova; Sabina Sandigursky; Amy Cunningham-Bussel; Jeffrey A. Sparks; Osama Abu-Shawer; Uma Thanarajasingam; Ashley M. Zeman; Rafee Talukder; Namrata Singh; Sarah H. Chung; Petros Grivas; May Daher; Ala Abudayyeh; Daniel Johnson; Maria Suarez-Almazor; Osama E. Rahma; Jeffrey S. Weber; Jean Tayar; Adi Diab; Noha Abdel-Wahab | Immunotherapy Toxicities | Checkpoint blockade;Cytokine;Immune suppression;Immune toxicity | |
| 817 | Poster Presentation | Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study | Pankti Reid, MD, MPH; David F. Liew; Rajshi Akruwala; Anne Bass, MD; Karmela K. Chan, MD | Immunotherapy Toxicities | Checkpoint blockade;Immune monitoring;Immune toxicity | |
| 818 | Poster Presentation | Using deep learning approaches with mIF images to enhance T cell identification for tumor -Automation of infiltrating lymphocytes (TILs) scoring on H&E images | Abu Bakr Azam, M.Engg; Yu Qing Chang, MB BCh BAO; Matthew Leong Tze Ker, MBBS; Denise Goh, BBiomedSc (Hons); Jeffrey Chun Tatt Lim, BSc.; Mai Chan Lau, PhD; Benedict Tan, PhD; Lihui Huang, PhD; Joe P. Yeong, MD, PhD; Yiyu Cai, Assoc Prof. | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers;Immunoscore;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 819 | Poster Presentation | Radiomic Markers Associated with Clinical Benefit in Advanced Uveal Melanoma Patients with Radiographic Progression on Tebentafusp | Volkan Beylergil, MD; Laura Collins; Lawrence H. Schwartz, MD; Thomas Eche; Binsheng Zhao; Richard D. Carvajal; Shaad E. Abedin, MD, FACP; Laurent Dercle, MD | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics;Bispecifics;T cell;Targeted therapy;Tumor antigens | |
| 820 | Poster Presentation | Machine learning significantly improves neoantigen-HLA predictions utilizing > 26,000 data points from the PACTImmuneTM Database | Vinnu Bhardwaj, PhD; Amin Momin; Jonathan Johnston; Elizabeth Speltz; Tyler Borrman; Stefanie Mandl; Olivier Dalmas, Ph.D.; Zheng Pan, PhD; Ashish Kheterpal; Eric Stawiski | Machine Learning, Artificial Intelligence, and Computational Modeling | Adoptive immunotherapy;Bioinformatics;Neoantigens;Solid tumors;T cell;Tumor antigens | |
| 821 | Poster Presentation | Machine Learning Models Can Quantify CD8 Positivity in Lymphocytes in Melanoma Clinical Trial Samples | Benjamin Glass, MS; S Adam Stanford-Moore; Diksha Meghwal; Nishant Agrawal; Mary Lin; Cyrus Hedvat; George Lee, PhD; Scott Ely; Michael Montalto; Ilan Wapinski; Vipul Baxi, MS; Andrew Beck | Machine Learning, Artificial Intelligence, and Computational Modeling | Solid tumors;T cell;Tumor microenvironment | |
| 822 | Poster Presentation | GraphITE: Unsupervised Graph Embeddings Approach to Multiplex Immunofluorescence Image Exploration Reveals New Insights into NSCLC and HNSCC Tumor Microenvironment | Michael J. Surace, PhD; Helen K. Angell, PhD, BSc; Christopher Innocenti; Zhenning Zhang; Isabelle Gaffney; Andreas Spitzmüller; Balaji Selvaraj; Khan Baykaner | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 823 | Poster Presentation | Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab | Tae Won Kim, MD; Keun-Wook Lee, MD; Joong Bae Ahn, MD; Young Suk Park, MD; Gahee Park, PhD; Kyunghyun Paeng; Chan-Young Ock, MD, PhD; Hyejoo Park, PhD; Jiyeon Ryu, PhD; Bitna Oh, MD; Bo-Kyoung Kim, MD; Sunjin Hwang, MD; Ki Baik Hahm, MD; Seong-Jin Kim, PhD | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 824 | Poster Presentation | High quality neoantigens are immunoedited in long-term pancreatic cancer survivors | Zachary Sethna, PhD; Marta Luksza, PhD; Luis A. Rojas; Kevin Soares, MD; Joanne Leung, PhD; Jayon Lihm; David Hoyos; Anton Dobrin; Rajya Kappagantula; Alvin Makohon-Moore; Amber Johns; Antony Gill; Masataka Amisaki, MD, PhD; Pablo Guasp, PhD; Abderezak Zebboudj, PhD; Rebecca Yu; Adrienne Kaya Chandra; Zagaa Odgerel; Michel Sadelain; Erin Patterson; Christine Iacobuzio-Donahue, PhD, MD; Benjamin D. Greenbaum, PhD; Vinod Balachandran, MD | Machine Learning, Artificial Intelligence, and Computational Modeling | Antigen presenting cells;Autoimmunity;Bioinformatics;Immune tolerance;Neoantigens;Systems biology;T cell;Tumor antigens | |
| 825 | Poster Presentation | High-dimensional Image Cytometry Reveals Spatially Organized Tumor-immune Microenvironment in Hepatocellular Carcinoma | Haoyang Mi, MS; Aleksander S. Popel, Ph.D.; Mark Yarchoan, MD | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Monocyte/Macrophage;Systems biology;T cell;Targeted therapy;Tumor microenvironment | |
| 826 | Poster Presentation | Establishing the preclinical/translational PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) | Hitesh Mistry; Fernando Ortega; Johanna Lahdenranta; Punit Upadhyaya, PhD; Kristen Hurov; Phil Jeffrey; CHRISTOPHE D. CHASSAGNOLE, PhD | Machine Learning, Artificial Intelligence, and Computational Modeling | Bispecifics;Solid tumors;Systems biology;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 827 | Poster Presentation | Streamlining design of safe and effective TCR therapies with AI | Mikolaj Mizera, PhD; Anna Sanecka-Duin, PhD, MS; Maciej Jasinski, PhD; Paulina Król; Giovanni Mazzocco, M.Sc.; Victor Murcia Pienkowski, PhD; Alexander Myronov; Iga Niemiec; Piotr Skoczylas, M.Sc.; Slawomir Stachura, PhD; Piotr Stepniak; Daniel Wojciechowski; Lukasz Grochowalski; Oskar Gniewek; Jan Kaczmarczyk, PhD; Agnieszka Blum, PhD, MD | Machine Learning, Artificial Intelligence, and Computational Modeling | Adoptive immunotherapy;Bioinformatics;Clinical study;Immune monitoring;Immune toxicity;Neoantigens;T cell;T cell lineages;Targeted therapy;Tumor antigens | |
| 828 | Poster Presentation | Quantifying perivascular immune cells in the stroma of human triple negative breast tumors using deep learning spatial analytics | Anna Juncker-Jensen, PhD; Nicholas Stavrou, MS; Mohammed R. Moamin; Mate L. Nagy; Richard J. Allen; Angela Cox; Claire Lewis | Machine Learning, Artificial Intelligence, and Computational Modeling | Immune contexture;Immune suppression;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 829 | Poster Presentation | Spatial arrangement and density of tumor-infiltrating lymphocytes (TILs) predicts response to immunotherapy in head and neck squamous cell carcinoma patients | Reetoja Nag, PhD; Germán Corredor; Vidya S. Viswanathan; Pingfu Fu, PhD; James Lewis Jr.; Jay Wasman; Theodoros N. Teknos; Monaliben Patel, MD; Quintin Pan; Anant Madabhushi, PhD | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers;Tumor infiltrating lymphocytes (TILs) | |
| 830 | Poster Presentation | Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals Immune-excluded phenotype related to APOBEC signature and clonal evolution of cancer | Chan-Young Ock, MD, PhD; Sanghoon Song, MS; Gahee Park, PhD; Changhee Park, MD; Soo Ick Cho, MD, PhD; Seunghwan Shin, MD; Yoojoo Lim, MD; Wonkyung Jung, MD; Heon Song; Jeongun Ryu; Minuk Ma; Seonwook Park, PhD; Sergio Pereira, PhD; Donggeun Yoo, PhD; Kyunghyun Paeng | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers;Immune suppression;Immune tolerance;Systems biology;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 831 | Poster Presentation | Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research | Heinrich Roder, DPhil; Lelia Net, PhD; Joanna Roder, PhD; Thomas Campbell, PhD; Mark McCleland, PhD; Wei Zou, PhD; Minu Srivastava, PhD; David Shames, PhD; Laura Maguire, PhD; Robert Georgantas III, PhD | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics;Biomarkers;Checkpoint blockade;Proteomics;Solid tumors | |
| 832 | Oral Presentation | Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy | John-William Sidhom, M.D., PhD.; Petra B. Ross-Macdonald, PhD; Megan Wind-Rotolo, PhD; Andrew M. Pardoll, MD, PhD; Alexander Baras, M.D., Ph.D. | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics;Biomarkers;Checkpoint blockade;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 833 | Poster Presentation | A scalable deep learning framework for rapid automated annotation of histologic and morphologic features from large unlabeled pan-cancer H&E datasets | David Soong, PhD.; Anantharaman Muthuswamy, PhD; Clifton Drew, PhD; Nora Pencheva; Maria Jure-Kunkel; Kate Sasser, PhD; Hisham Hamadeh, PhD; Suzana Couto; Brandon Higgs | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics;Immune contexture;Solid tumors;Tumor microenvironment | |
| 834 | Poster Presentation | A Robust Deep Learning Approach for Precisely Segmenting Cells in Multiplex Tissue Images | Daniel Winkowski, PHD; Jeni Caldara; Brit Boehmer; Regan Baird, PhD | Machine Learning, Artificial Intelligence, and Computational Modeling | Immune suppression;Inflammation;Monocyte/Macrophage;NK/NKT cell;Regulatory T cell (Treg cell);T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 835 | Poster Presentation | Harnessing the microbiota to increase response rates to immunotherapy. | Valentina Ferrari, BA; Alessia Melacarne; Francesca Algieri; Maria Rescigno, PhD | Microbiome and other environmental factors | Checkpoint blockade;Microbiome;Solid tumors | |
| 836 | Poster Presentation | Murine fecal microbiota transfer models colonize human microbes selectively and reveal transcriptional pathways associated with response to neoadjuvant checkpoint inhibitors | Fyza Y. Shaikh, MD, PhD; Joell Gills; Fuad Mohammad; James R. White; Courtney Stevens; Hua Ding; Juan Fu; Ada Tam; Richard Blosser; Tatianna Larman; Jarushka Naidoo, MD, MHS; Patrick Forde; Sudipto Ganguly; Franck Housseau; Drew M. Pardoll; Cynthia L. Sears | Microbiome and other environmental factors | Biomarkers;Checkpoint blockade;Microbiome;Solid tumors;T cell;Tumor microenvironment | |
| 837 | Poster Presentation | Preliminary insights into the impact of tumor microbiome in head and neck squamous cell carcinoma | Vidhya Karivedu, MD; Rebecca Hoyd; Caroline Wheeler; Sachin Jhawar; Priyanka Bhateja; Marcelo Bonomi, MD; Daniel Spakowicz, PhD, MS | Microbiome and other environmental factors | Biomarkers;Microbiome | |
| 838 | Poster Presentation | The role of microbiota in metastatic brain tumors | Sarah B. Johnson; Golnaz Morad, DDS, PhD; Nadim J. Ajami, PhD; Jennifer A. Wargo, MD, MMSc; Matthew C. Wong; Matthew Lastrapes | Microbiome and other environmental factors | Immune suppression;Microbiome;Solid tumors;T cell;Tumor microenvironment | |
| 839 | Oral Presentation | Microbiota-specific T follicular helper cells drive tertiary lymphoid structure formation and anti-tumor immunity in colorectal cancer. | Abigail E. Overacre-Delgoffe, PhD; Hannah J. Bumgarner, BS; Anthony R. Cillo, PhD; Ansen H. Burr; Justin Tometich; Amrita Bhattacharjee; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Timothy W. Hand, PhD | Microbiome and other environmental factors | B cell;Microbiome;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 840 | Poster Presentation | A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression | Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Christopher B. Cole, MD; Christina M. Annunziata, MD, PHD; Philip Arlen | Novel Single-Agent Immunotherapies | Antibody;Immune monitoring;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor antigens | |
| 841 | Poster Presentation | Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-Thioredoxin antibody | Gabriella Willman; Max Davidson; Carolina Trkulja; Owe Orwar; Sreesha P. Srinivasa, PhD | Novel Single-Agent Immunotherapies | Chemokine;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 842 | Poster Presentation | Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of Hepatocellular Carcinoma (HCC) | Sushrut Kamerkar, PhD; Charan Leng; Kelvin Zhang, PhD; Olga Burenkova; Su Chul Jang, PhD; Samuel Kasera; Tong Zi; Kyriakos Economides, PhD; Timothy J. Soos; Dalia Burzyn, PhD; Sriram Sathyanaryanan, PhD | Novel Single-Agent Immunotherapies | Extracellular vesicles/exosomes;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 843 | Poster Presentation | Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer | Li Peng, PhD; Lizhi Cao; Sujata Nerle; Robert LeBlanc; Abhishek Das, Ph.D.; Sandip Shelke; Autumn Turner; Jenny Che; Zakir Siddiquee; Hui Xu; Lihui Xu, BS; Wayne Gatlin; James Broderick, M.D. | Novel Single-Agent Immunotherapies | Checkpoint blockade;Dendritic cell;Immune suppression;Immune tolerance;T cell;Tumor evasion | |
| 844 | Poster Presentation | A trispecific ROR1 x CD3 T cell engager mediates in vitro tumor cell killing and in vivo tumor eradication | Bithi Chatterjee, PhD; Daniel Snell, PhD; Christian Hess, PhD; Matthias Brock, PhD; Fabio Spiga, PhD; Alexandre Simonin, PhD; Tea Gunde, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Nicole Bassler; Niels Kirk; Nina Schumacher; Dana Mahler; Yasemin Yaman; Bettina Bommer; Giorgio Gambino; Noreen Giezendanner; Benjamin Kuettner; Naomi Flueckiger; Robin Heiz; Sandro Wagen; Dania Diem; Julia Zeberer; David Urech, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;T cell;Targeted therapy;Tumor antigens | |
| 845 | Poster Presentation | A colony stimulating factor 1 receptor-blocking bifunctional protein simultaneously targets tumor-associated macrophages and exhausted T cells for the treatment of triple-negative breast cancer | Pandelakis Koni; Hung-Kai Chen; Yao-Wen Chang; Huey-Wen Hsiao; Chih-Lun Hsiao; Jing-Yi Huang; Ju-Pei Chen; Muh-Hwa Yang | Novel Single-Agent Immunotherapies | Antibody;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 846 | Poster Presentation | Pre-clinical validation of a FLT3L-fusion protein for dendritic cell expansion and anti-tumor efficacy | Michelle R. Kuhne, PhD; Hamlet Chu; Sarah Ng; Christopher Clarke, PhD; Brian Carr; Manuel Baca, PhD; Magdeleine Hung; Mark R. Nagel; Alexandre Ambrogelly, PhD; Nicholas Wilson, PhD | Novel Single-Agent Immunotherapies | Antigen presenting cells;Dendritic cell;Tumor infiltrating lymphocytes (TILs) | |
| 847 | Poster Presentation | Pharmacokinetics and pharmacodynamics of GS-3583 in cynomolgus monkeys | Michelle R. Kuhne, PhD; Hamlet Chu; Christopher Clarke, PhD; Brian Carr; Manuel Baca, PhD; Magdeleine Hung; Mark R. Nagel; Alexandre Ambrogelly, PhD; Nishanathan Rajakumaraswamy | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Dendritic cell | |
| 848 | Poster Presentation | Novel small molecule HPK1 inhibitor PCC-1 induces strong anti-tumor activity | Sanjib Das, PhD; Sravan Mandadi, PhD; Jagmohan Saini, PhD; Sachin S. Chaudhari, PhD; Ameya Deshpande; Murugan Chinnapattu, PhD; Malini Bajpai, PhD; Priyanka Pangre; Varada Potdar; Megha Marathe; Pooja Sawant; Atul Akarte, PhD; Chandrasekhar Misra, PhD; Subhadip Das, PhD; Anuj Singh; Avratanu Das; Pandurang Lambade; Chaitanya Tirumalasetty; Raju Patole; Nilanjana Biswas, PhD; Vikas Karande; Heta Shah; Dayanidhi Behera; Nagaraj Gowda, PhD; Pravin S. Iyer, PhD | Novel Single-Agent Immunotherapies | Checkpoint blockade;Cytokine;Immune suppression;Solid tumors;T cell;Tumor microenvironment | |
| 849 | Poster Presentation | ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity | Sterling C. Eckard, PhD; Bianca Rojo, PharmD; Li Mei; Alberto Ponce; Patrick Chun, MD; Victoria Smith, PhD | Novel Single-Agent Immunotherapies | Immune suppression;MDSC;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor microenvironment | |
| 850 | Poster Presentation | Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway | Brian Francica, PhD; Justine Lopez; Anja Holtz; Dave Freund; Dingzhi Wang, PhD; Amanda Enstrom; Sam H. Whiting, MD, PhD; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD | Novel Single-Agent Immunotherapies | Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 851 | Poster Presentation | Harnessing innate immunity in cancer therapies: the example of Natural Killer Cell Engagers | Olivier Demaria, PhD; Eric Vivier, PhD; Marie Vetizou, PhD; Audrey Blanchard Alvarez; Guillaume Habif, PhD; Cécile Bonnafous, PhD; Sivan Bokobza, PhD; Agnès Represa; Benjamin Rossi, PhD; Luciana Batista, PhD; Constance Vagne, PhD; Sabrina Carpentier; Stéphanie Cornen, PhD; Ariane Morel, PhD; Ivan Perrot, PhD; Yannis Morel, PhD; Laurent Gauthier, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Cytokine;NK/NKT cell;Targeted therapy;Tumor antigens;Tumor microenvironment | |
| 852 | Poster Presentation | Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC | Laurent Gauthier, PhD; Angela Virone-Oddos; Jochen Beninga, PhD; Benjamin Rossi; Céline Nicolazzi; Céline Amara; Audrey Blanchard-Alvarez; Nicolas Gourdin; Jacqueline Courta; Alexandra Basset; Franceline Guillot; Gwendoline Grondin; Hélène Bonnevaux; Anne-Laure Bauchet; Ariane Morel, PhD; Yannis Morel, PhD; Marielle Chiron, PhD; Eric Vivier, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy;Tumor antigens | |
| 853 | Poster Presentation | ACTM-838: A microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs After IV dosing in T-cell excluded solid tumors | Haixing Kehoe, M.S.; Alexandre Iannello, PhD; Keith Cheung, PhD; Bret Peterson, PhD; Marie Marotel, PhD; Sara Tribble, B.S.; Hailey He, B.S.; Jonathan J. Hodgins, B.S.; Michele Ardolino, PhD; Christopher Rae, PhD; Christopher D. Thanos, PhD; Laura H. Glickman, PhD | Novel Single-Agent Immunotherapies | Antigen presenting cells;Cytokine;Immune adjuvant;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 854 | Poster Presentation | SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models | Elizabeth Gray, PhD; Angela D. Epp; Michelle Ulrich, BS; Disha Sahetya; Kelly M. Hensley; Julie Hahn; Sean Allred; Jane Haass; Katie Snead; Sasha Lucas; John Gosink; Rogely Boyce; Esther Trueblood; Piper Treuting; Chris Frantz; Alyson J. Smith, PhD; Jason Schrum; Natalya Nazarenko; Shyra J. Gardai, PhD | Novel Single-Agent Immunotherapies | Antibody;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor antigens | |
| 855 | Poster Presentation | Development of a Novel Anti-Multiple Myeloma Chimeric Antigen Receptor T Cell Therapy | Chuck Hay, PhD; Mary Faber, PhD; Kemi Adeyanju, PhD; Jeffrey A. Medin, PhD | Novel Single-Agent Immunotherapies | Adoptive immunotherapy;Antibody;CAR T cells;Granulocyte;T cell;T cell lineages;Targeted therapy;Tumor antigens | |
| 856 | Poster Presentation | INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors | Emily Rowell, Ph.D.; Heather Kinkead, PhD; Elisabeth Torretti; Bryan R. Becklund, PhD; Florian J. Sulzmaier, PhD; William Crago; Kyle Jones; John C. Timmer, PhD; Quinn Deveraux, PhD; Brendan P. Eckelman, PhD; Analeah B. Heidt, PhD | Novel Single-Agent Immunotherapies | Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 857 | Poster Presentation | SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY. | Jemila Houacine; Anne Marie-Cardine; Aude Le Roy; Jérôme Giustiniani; Riad Abes; Anne-Sophie Chrétien; Stéphane Fattori; Laurent Gorvel; Armand Bensussan; Daniel Olive; Arnaud Foussat | Novel Single-Agent Immunotherapies | Antibody;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell | |
| 858 | Poster Presentation | TILKine-2: A novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer. | Sreerupa Challa, PhD; Yao-Te Hsieh, PhD; Jonathan M. Carnino; Andrea Umana; Yuesheng Li; Jing Xu; Lingyun Rui | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 859 | Poster Presentation | Tuning the tumor microenvironment by reprogramming TREM1+ myeloid cells to unleash anti-tumor immunity in solid tumors | Nadine Jahchan, PhD; Hanna Ramoth; Vladi Juric, PhD; Erin Mayes; Shilpa Mankikar; Ranna Mehta; Mikhail Binnewies, PhD; Subhadra Dash; Rachael Palmer; Joshua L. Pollack; Joshua Rudolph; Pamela Canaday; Linnea Haeggblom; Carlos Santamaria; xiaoyan Du, PhD; Leonard Reyno, MD; Kevin P. Baker, PhD; Linda Liang, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Checkpoint blockade;Cytokine;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 860 | Poster Presentation | The anti-tumor activity of HSP-90 therapeutic cancer vaccine (AST-021p) combine with TLR2/3 agonist in a MMTV-neu transgenic model | Jinho Kang; Eunkyo Joung, MD; Hunwoo Shin; Byung cheol Ahn; Eunjung Jung; Hun JH. Jung, MD./PhD.; Kyong Hwa Park | Novel Single-Agent Immunotherapies | Clinical study;Immune adjuvant;Immune monitoring;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor stroma;Vaccine | |
| 861 | Poster Presentation | Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy | Peter Keller; Irina Mazo; Yun Gao; Vijayapal Reddy; Francisco Caballero; Sam Kazer; Amina Fu; Yi Sun; Dannah Miller; Roberto Gianani, MD, FCAP; James E. Marvin; Bret Stephens; Gregory L. Beatty, MD, PhD; Russell W. Jenkins; Ulrich Von Andrian, MD, PhD; Daniel Krappmann; Thorsten Mempel, MD, PhD | Novel Single-Agent Immunotherapies | Clinical study;Clinical trial;Cytokine;Immune tolerance;Regulatory T cell (Treg cell);Solid tumors;Tumor microenvironment | |
| 862 | Poster Presentation | Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy | Justin A. Kenkel, PhD; Po Y. Ho; Sameera Kongara, PhD; Karla A. Henning, PhD; Cindy L. Kreder; Jess L. Nolin; Steven J. Chapin, PhD; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Shelley E. Ackerman; Edgar G. Engleman, MD; David Dornan, PhD | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 863 | Poster Presentation | In vitro and in vivo studies establish DuoBody®-CD3xB7H4 as a novel drug candidate for the treatment of solid cancers | Louise A. Koopman, PhD; Laura Smits-de Vries; Frederikke Lihme Egerod; Sebastiaan Wubben; Mischa Houtkamp, PhD; Stefanie A. De Poot; Madelon Paauwe; Edward van den Brink; Andrea Gorlani; Dennis Verzijl; Kate Sasser, PhD; Esther Breij, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 864 | Poster Presentation | Identification of A Novel Allosteric Oral Cbl-b Inhibitor that Augmented T Cell Response and Enhanced NK Cell Killing in vitro and in vivo | Jun Kuai, Ph D; Yingzhi Bi; Yilin Qi; Deborah G. Conrady; Rajiv G. Govindaraj; Graham Hone; R. Aldrin Denny; Ken Carson; Geraldine Harriman; Fang Wang | Novel Single-Agent Immunotherapies | Checkpoint blockade;Costimulation;Immune suppression;Immune tolerance;NK/NKT cell;T cell;Targeted therapy | |
| 865 | Poster Presentation | iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling | Osiris Marroquin Belaunzaran, PhD; Anahita Rafiei; Anil Kumar; Marco Gualandi; Magdalena Westphal; Lorenz Vogt; Sean R. Smith; Michael A. Curran, PhD; Christoph Renner | Novel Single-Agent Immunotherapies | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors | |
| 866 | Poster Presentation | RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic Type I interferon responses and adaptive immunity in preclinical models and patient tumors | Kristy G. Kuplast-Barr, Bachelor of Science; Melissa L. Johnson, MD; Manish R. Patel, MD; Timothy A. Yap, MD; Gerald S. Falchook, MD, MS; Patricia LoRusso; Ryan Abo, PhD; Chang Liu, PhD; Erika Manyak; Lisa Cleary; Viviana Bozon; Sudha Parasuraman, MD; Heike Keilhack; Kristen McEachern, PhD | Novel Single-Agent Immunotherapies | Biomarkers;Clinical study;Gene expression;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor microenvironment;Tumor stroma | |
| 867 | Poster Presentation | TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation | Kathryn S. Kwant, Ph.D.; Sony S. Rocha; Katrina Stephenson; Maria R. Dayao; Subramanian Thothathri; Rose Banzon; Wade H. Aaron, BS; Golzar Hemmati; Evan Callihan; Timothy Yu; Jessica O'Rear; Eric Bragg; Willis Kwong; Hubert Situ; Avneel Hundal; Stephen Yu; Taggra Jackson; Kevin J. Wright, Ph.D.; Yinghua Xiao, Master Degree; Linh To; Richard Austin, Ph.D.; Bryan Lemon, Ph.D.; Holger Wesche, Ph.D.; S. Jack Lin, Ph.D. | Novel Single-Agent Immunotherapies | Antibody;Immune toxicity;Solid tumors;T cell;Targeted therapy | |
| 868 | Poster Presentation | Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels | Emma Leach; Sarah Stanhope; Revashnee Naidoo; Shaad E. Abedin, MD, FACP; Laura Collins; Koustubh Ranade | Novel Single-Agent Immunotherapies | Bispecifics;Clinical trial;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 869 | Poster Presentation | Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model | Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan, PhD; Brianna Rivest, BS; James Cardia, PhD; Simon P. Fricker, PhD | Novel Single-Agent Immunotherapies | Checkpoint blockade;RNA;Solid tumors;Tumor microenvironment | |
| 870 | Poster Presentation | Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer | Hariprasad Vankayalapati, Ph.D.; Kyle Medley, MS; Zhaoliang Li, PhD; Dongqing Yan, PhD; David Bearss, PhD; Alana Welm, PhD | Novel Single-Agent Immunotherapies | Biomarkers;MDSC;Myeloid cells;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor microenvironment | |
| 871 | Poster Presentation | Construction and Evaluation of Interleukin 3 (IL3)-Zetakine Redirected Cytolytic T Cells for the Treatment of CD123 Expressing Acute Myeloid Leukemia | Rebecca Moeller, MSc; Julian Scherer, PhD; Sadik H. Kassim, PhD | Novel Single-Agent Immunotherapies | CAR T cells;Cytokine;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor antigens | |
| 872 | Poster Presentation | PD1 x TGFbR2 and CD5 x TGFbR2 bispecifics selectively block TGFbR2 on target-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors | Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, BS; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 873 | Poster Presentation | S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs | Ryohei Nagai, Ph.D.; Ryohei Nagai; Morio Nagira; Wataru Nogami; Michinari Hirata; Azumi Ueyama; Mai Yoshikawa, Ph.D.; Naganari Ohkura; Hisashi Wada; Yoji Nagira | Novel Single-Agent Immunotherapies | Antibody;Chemokine;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 874 | Poster Presentation | Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy | Srinivas R. Boreddy, Ph. D; Reshmi Nair; Arindam Banerjee; Anshu Kuriakose; Prashant Kumar Pandey; Chaitali Dey; Meena Shri; Shruthi Rao; Bhadravathi Marigowda Shivakumar; Moni Abhram Kuriakose; Ram Bhupal Reddy; Amritha Suresh; Praveen Reddy Moole; Usha Bughani; Seng-Lai Tan, PhD; Pradip Nair | Novel Single-Agent Immunotherapies | Angiogenesis;Antibody;Bispecifics;Coinhibition;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment | |
| 875 | Poster Presentation | AL009, a fusion protein and multi-Siglec inhibitor, repolarizes suppressive myeloid cells and potentiates anti-cancer effects | Sam Nalle, PhD; Helen Lam; Ling Leung; Spencer Liang; Daniel Maslyar, MD | Novel Single-Agent Immunotherapies | Checkpoint blockade;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 876 | Poster Presentation | Intratumoral administration and local retention of IL-2/IL-12 fusion proteins drive a potent systemic anti-tumor immune response | Mehta K. Naveen, PhD; Bochong Li; Dane Wittrup; Patrick A. Baeuerle; Jennifer S. Michaelson | Novel Single-Agent Immunotherapies | Cytokine;Solid tumors;Tumor microenvironment | |
| 877 | Poster Presentation | PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth | Phuong A. Nguyen, PhD; Jessica Ritter, PhD; Mohammad Zafari; Denise Manfra, PhD; Veronica Komoroski; Brian O'Nuallain, PhD; Ryan Phennicie; Kevin Kauffman, PhD; Dominika Nowakowska, PhD; Joe Wahle, PhD; Steve Sazinsky, PhD; Michael A. Brehm, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 878 | Poster Presentation | Novel microbial immunotherapy approach for the treatment of bladder cancer | Nicholas Glanville, PhD; Tobi Oke, BSc; Sonia Domingos-Pereira; Lenka Polak; Denise Nardelli-Haefliger, PhD; Livija Deban, PhD | Novel Single-Agent Immunotherapies | Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Targeted therapy | |
| 879 | Poster Presentation | A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27 | Thierry Guillaudeux, PhD; Yulia Ovechkina; Shaarwari Sridhar; David Jurchen; David Peckham; Emily Frazier; Eric Tarcha, PhD; Shawn Iadonato, PhD | Novel Single-Agent Immunotherapies | Antibody;Costimulation;Cytokine;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 880 | Poster Presentation | Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis | Sheena Pinto, PhD; Susanne Wingert, PhD; Jens Pahl, PhD; Armin Beez; Sabrina Purr; Uwe Reusch, PhD; Arndt Schottelius, MD, PhD; Joachim Koch, Prof. | Novel Single-Agent Immunotherapies | Bispecifics;Monocyte/Macrophage;Solid tumors | |
| 881 | Poster Presentation | Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate cell engagers (ICE®) in 3D spheroids | Sheena Pinto, PhD; Savannah Jackson; Julia Knoch; Christian Breunig, PhD; Arndt Schottelius, MD, PhD; Joachim Koch, Prof. | Novel Single-Agent Immunotherapies | Bispecifics;Monocyte/Macrophage;Solid tumors | |
| 882 | Poster Presentation | Selective affinity-enhanced T cell receptor bispecific targeting of KRAS G12D neoantigen driven cancers | Andrew D. Whale, PhD; Andrew Poole; Vijaykumar Karuppiah; Annabelle Hartt; Jaafar N. Haidar; Sylvie Moureau; Aimee Bence Lin; Marc Van der Kamp; Gregory D. Plowman; Annelise Vuidepot; David K. Cole; Chandramouli Chillakuri | Novel Single-Agent Immunotherapies | Bispecifics;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 883 | Poster Presentation | An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human acute myeloid leukemia (AML) cell lines in vitro. | Alessandra Romano, M.D., PhD; Nunziatina Parrinello; Sara Marino; Enrico La Spina1; Massimo Fantini, PhD; Philip Arlen; Kwong Tsang; Francesco Di Raimondo | Novel Single-Agent Immunotherapies | Antibody;Leukemia/Lymphoma;Myeloid cells;Regulatory T cell (Treg cell);Targeted therapy;Tumor antigens | |
| 884 | Poster Presentation | Engineered Toxin Body mediated depletion of TIGIT expressing immune cells for cancer immunotherapy | Elizabeth Saputra; Garrett Cornelison; Jennifer Mitchell; Karia Williams; Andrea Mendiola; Rachael Orlandella; John Majercak; Joseph D. Dekker, Ph.D.; Chris B. Moore; Swati Khanna, Ph.D. | Novel Single-Agent Immunotherapies | Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 885 | Oral Presentation | Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients – Studies of sexual immune dimorphism in the tumor microenvironment | Dhifaf Sarhan, PhD; Fei D. He; Ahmed D. Calandigary; Enana Malki; Carlos Fernández Moro; Marina Kaisso; Peter Olofsson-Sahl; Marit Melssen; Matthias Löhr; Mikael Karlsson; Rainer Heuchel | Novel Single-Agent Immunotherapies | Immune suppression;Monocyte/Macrophage;T cell;Tumor microenvironment | |
| 886 | Poster Presentation | Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures | Steve Sazinsky, PhD; Phuong A. Nguyen, PhD; Mohammad Zafari; Ryan Phennicie; Joe Wahle, PhD; Veronica Komoroski; Kathryn Rooney; Craig Mizzoni; Boris Klebanov; Denise Manfra, PhD; Jessica Ritter, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 887 | Poster Presentation | Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade | Victoria Smith, PhD; Sterling C. Eckard, PhD; Bianca Rojo, MSc; Patrick Chun, MD | Novel Single-Agent Immunotherapies | Bispecifics;Clinical trial;Immune contexture;Immune monitoring;Immune suppression;MDSC;Myeloid cells;Regulatory T cell (Treg cell);T cell | |
| 888 | Poster Presentation | An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity | Punit Upadhyaya, PhD; Gemma Mudd, .; Kristen Hurov; Johanna Lahdenranta; Elizabeth M. Repash, MSc; Julia Kristensson, .; Kevin McDonnell; Philip E. Brandish; Phil Jeffrey; Nicholas Keen | Novel Single-Agent Immunotherapies | Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy | |
| 889 | Poster Presentation | DuoBody®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo | Rieneke van de Ven; Sonja H. Ganzevles, B.Sc; Myrthe Veth, B.sc; Patrick Franken; Esther Breij, PhD; Ruud H. Brakenhoff, Prof. dr.; Kristel Kemper, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens | |
| 890 | Poster Presentation | Manipulation of epithelial-to-mesenchymal transition reveals metastatic breast cancers support immune suppression via heme metabolism | Michelle M. Williams, Ph.D.; Jessica L. Christenson, Ph.D.; Sabrina A. Hafeez, B.S.; Nicole S. Spoelstra, B.S.; Jill E. Slansky, PhD; Jennifer K. Richer, Ph.D. | Novel Single-Agent Immunotherapies | Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor evasion;Tumor microenvironment | |
| 891 | Poster Presentation | S-531011, a novel anti-human CCR8 antibody: Antibody screening and evaluation of biological profiles | Mai Yoshikawa, Ph.D.; Yoji Nagira; Morio Nagira; Tetsuya Yoshida; Shinpei Yoshida; Tetsuyoshi Soh; Hisashi Wada; Naganari Ohkura; Tatsuya Takahashi | Novel Single-Agent Immunotherapies | Antibody;Chemokine;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 892 | Poster Presentation | ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T cells in tumor microenvironment | Gihoon You, Ph.D.; Uijung Jung; Jaehyoung Jeon; Shinai Lee; Hyung-Seung Jin; Youngkwang Kim; Eunsil Sung, Ph.D.; Hyunjoo Kim, Ph.D.; Yangmi Lim, Ph.D.; Jonghwa Won, Ph.D.; Zhengyi Wang, PhD; Wenqing Jiang, PhD; Jaeho Jung, PhD | Novel Single-Agent Immunotherapies | Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Costimulation;T cell | |
| 893 | Poster Presentation | ATG-101, a novel PD-L1/4-1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4-1BB activation | Hui Yuwen; Tengteng Li; Yijing Ren; Dirk Hoenemann; Jay Mei; Bo Shan; Bing Hou, Ph.D | Novel Single-Agent Immunotherapies | Bispecifics;Checkpoint blockade;Costimulation;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 894 | Poster Presentation | The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing | Chiara Zambarda, PhD; Karolin Guldevall, PhD; Christian Breunig, PhD; Damien Toullec, PhD; Jacopo Fontana, PhD; Sheena Pinto, PhD; Jens Pahl, PhD; Susanne Wingert, PhD; Joachim Koch, Prof.; Björn Önfelt, Prof. | Novel Single-Agent Immunotherapies | Antibody;Antigen presenting cells;Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;Tumor antigens | |
| 895 | Poster Presentation | Discovery of a safer 4-1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging | Andy Tsun, PhD; Tianhang Zhai; Xiaoniu Miao; Weifeng Huang; Chao Wang; Yifeng Xu; Zhijun Yuan; Tao Wang; Shuang Dai; Shaogang Peng; Tuling Pang; Wenchao Jiang; Yuhua Huang; Yuefeng Zou; Yingda Xu; Joanne Sun; Xinjiang Gong; Bin Li | Novel Single-Agent Immunotherapies | Antibody;Bispecifics;Checkpoint blockade;Immune toxicity;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 896 | Poster Presentation | Fighting the war against COVID-19: administration of Bamlanivimab (BAM) or Bamlanivimab + Etesivimab (BAM + E); a cooperative effort between a community cancer center and an urgent care (UC) facility | Patrick J. Skeffington, PharmD; Robert Aisenberg, MD; janice Dallacosta, RN, BSN; Ian Donaghy, RN; Dani Hackner, MD; Kelly Houde, RN, BSN; Kathy Moraes, MHA, RN, OCN; Annemarie Santos, RPh | Nursing/Pharmacy | COVID and Immunotherapy;Immune suppression | |
| 897 | Poster Presentation | Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US). | Raquel A. Aguiar-Ibanez, MSc; Emilie Scherrer, MSc; Dmitri D. Grebennik; Anvi A. Khandelwal; John J. Cook; Shalini S. Bagga; Baanie B. Sawhney; Scott S. Soefje, Pharm.D., R.Ph | Other | Checkpoint blockade;COVID and Immunotherapy;Immune adjuvant | |
| 898 | Poster Presentation | Intratumoral administration of NL-201, an alpha-independent IL-2/15 receptor agonist, inhibits the growth of both injected and uninjected tumors in preclinical models | Laurie Tatalick, DVM, PhD, DAC; Kevin Yu, BS, MS; Justin Huard, BS; Marianne Riley, BS; Ryan Swanson, BS; Carl Walkey, PhD | Other | Cytokine;Immune toxicity;Solid tumors | |
| 899 | Poster Presentation | Population coverage of HLA-A*02:01, *02:05, *02:06 across selected cancer types in the United States | Nashita Patel, MBBS PhD MSc BSc (Hons); Charlotte Carroll; Ken Culver; Shibani Pokras | Regulatory, Financial, and Access Considerations | Adoptive immunotherapy;Biomarkers;Epidemiology;Solid tumors;T cell | |
| 900 | Oral Presentation | Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner | Anand V. Kornepati; Clare E. Murray; Barbara Avalos, PhD; Cody Rogers; Kavya Ramkumar; Harshita Gupta; Yilun Deng, PhD; Zexuan Liu; Alvaro Padron; Ratna Vadlamudi; Eloise Dray; Weixing Zhao; Patrick Sung; Lauren A. Byers; Tyler J. Curiel, MD | Tumor and Stromal Cell Biology | Checkpoint blockade;Chemotherapy;Immune suppression;Post-translational modifications;Solid tumors;Targeted therapy;Tumor evasion;Tumor microenvironment | |
| 901 | Poster Presentation | Bacillus Calmette-Guerin can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells | Mathieu Rouanne, MD; Julien Adam; Camelia Radulescu; Diane Letourneur; Severine Mouraud; Delphine Bredel; Anne-Gaelle Goubet; Tuan Zea Tan; Amelie Bigorgne; Michael Dussiot; Lambros Tselikas, MD; Sandrine Susini; François-Xavier Danlos; Roman Chabanon; Nicolas Signolle; Anna Schneider; Sophie Vacher; Ivan Bieche; Thierry Lebret; Yves Allory; Jean-Charles Soria, MD, PhD; Jean Paul Thiery; Laurence Zitvogel, MD, PhD; Aurelien Marabelle | Tumor and Stromal Cell Biology | Biomarkers;Chemokine;Immune adjuvant;Immune suppression;Myeloid cells;T cell;TLR;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 902 | Poster Presentation | Comprehensive multi-omics meta-analysis of pancreatic cancer mouse models and human PDAC data sets identifies unique cancer-associated fibroblast subsets | Candace Wai Sze Lei, MS; John Holt, MS; Brianna Flynn, MS; Richard Barrett, PhD; Pratha Budhani, MS; Mohanapriya Kamalakannan; Ruby Wasti; Lucinda Thiede; Joshua Tagore; Jessica Potts; Jacqueline Larouche; Marie Marcher; Xiaoyun Liao, PhD; Sarah O'Brien, PhD; Abhishek Kashyap, PhD; Jeanine Pignatelli, PhD; Kang Liu, PhD; Joseph Tumang, PhD; Emily Corse, PhD; Ben Stanger, MD, PhD; Ellen Pure, PhD; Varenka Rodriguez DiBlasi, PhD | Tumor and Stromal Cell Biology | Angiogenesis;Bioinformatics;Epigenetics;Gene expression;Immune suppression;Inflammation;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 903 | Poster Presentation | Human cancer-associated fibroblast subsets can predict immune checkpoint response in head and neck cancer patients | Diana K. Graves, B.S.; Aleksandar Obradovic; Michael J. Korrer, PhD; Yu Wang; Sohini Roy, PhD; Yaomin Xu; Adam Luginbuhl, MD; Joseph Curry, MD; Michael K. Gibson, MD PhD; Paula Hurley, PhD; Ravindra Uppaluri, MD/PhD; Charles G. Drake, MD, PhD; Andrea Califano, PhD; Young J. Kim, MD, PhD | Tumor and Stromal Cell Biology | Bioinformatics;Biomarkers;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 904 | Poster Presentation | Repurposing CD26 (DPP4) inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma | Maggie J. Phillips, BS; Michael B. Ware, PhD; Cameron Herting, PhD; Thomas A. Mace, PhD; Shishir K. Maithel, MD; Juan M. Sarmiento, MD; Bassel El-Rayes, MD; Chrystal M. Paulos, PhD; Megan M. Wyatt, MS; Gregory B. Lesinski, PhD | Tumor and Stromal Cell Biology | Checkpoint blockade;Gene expression;Immune suppression;Tumor evasion;Tumor microenvironment;Tumor stroma | |
| 905 | Poster Presentation | FASN prevents immunogenicity of irradiated glioblastoma by inhibiting ER stress | Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD | Tumor and Stromal Cell Biology | Dendritic cell;Immune contexture;Immune suppression;Metabolism;Radiotherapy;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs) | |
| 906 | Poster Presentation | Immunogenomic evaluation of Clear Cell Renal Carcinoma uncovers HK3 as a myeloid specific metabolic enzyme | Bradley I. Reinfeld, BA; Matthew z. Madden, BS; Melissa M. Wolf; Agi de Cubas, PhD; Scott Haake, MD; Rachel Hongo; Margaret L. Axelrod, BS; Jackie E. Bader, PhD; Aleksandar Obradovic; Dalton Greenwood; Xiang Ye, PhD; Justin M. Balko, PhD, PharmD; Katy Beckermann, MD/PhD; Benjamin G. Vincent, MD; Brian I. Rini, MD; Charles G. Drake, MD, PhD; Jeffrey C. Rathmell, PhD; W. K. Rathmell, MD, PhD | Tumor and Stromal Cell Biology | Inflammation;Metabolism;Monocyte/Macrophage;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 907 | Poster Presentation | Modulation of tumor immunogenicity by DNA methylation of immune synapse genes in cancers | Imene Hamaidi, PhD; Anders Berglund, PhD; Matthew Mills; Ryan M. Putney; James J. Mule, PhD; Sungjune Kim, MD PhD | Tumor and Stromal Cell Biology | Carcinogenesis;Epigenetics;Immune suppression;Immune tolerance;T cell;Tumor evasion | |
| 908 | Poster Presentation | Humanized model for assessment of therapies targeting either lymphoid or myeloid compartment: enhanced evaluation of clinical relevancy & translatability | Florence Renart-Depontieu; Gaëlle Martin; Chloé Beuraud; Poonam Yakkundi; Angus M. Sinclair, PhD; Morgane Denis; Léa Magadoux; Elsa Kress; Charles Dumontet; Ludovic Bourre; Dean O. Campbell; Astrid Doerner; Patricia Isnard-Petit; Alexandre Fraichard; Yacine Cherifi; Kader Thiam | Tumor and Stromal Cell Biology | Cytokine;Immune monitoring;Immune toxicity;Inflammation;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 909 | Poster Presentation | Differentiation subgroups within LKB1-deficient lung cancer influence both the immune exclusion phenotype and cellular composition of the immune microenvironment | Jacob Kaufman, MD, PhD; Doug Cress; Theresa Boyle, PhD, MD; David P. Carbone, MD, PhD; Neal Ready, MD, PhD; Kris Wood | Tumor and Stromal Cell Biology | B cell;Bioinformatics;Biomarkers;Gene expression;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 910 | Poster Presentation | Overexpression of miR-155-5p can upregulate antigen processing and presentation pathway via targeting tapasin | Yuan Wang, M.Sc.; Maria-Filothei Lazaridou; Chiara Massa, PhD; Barbara Seliger, MD, PhD | Tumor and Stromal Cell Biology | Antigen presenting cells;RNA;Tumor evasion | |
| 911 | Poster Presentation | Immune profiling reveals enrichment of distinct immune signatures in high-risk oral potentially malignant disorders | Chai Gan, MSc; Bernard Kok Bang Lee; Shin Hin Lau; Thomas George Kallarakkal; Zuraiza Mohamad Zaini; Rosnah Binti Zain; Hans Prakash Sathasivam; Joe Poh Sheng Yeong; Natalia Savelyeva; Gareth Thomas; Christian Ottensmeier; Hany Ariffin; Sok Ching Cheong; Kue Peng Lim | Tumor and Stromal Cell Biology | Bioinformatics;Gene expression;Immune contexture;Inflammation | |
| 912 | Poster Presentation | Preferential recognition of neoantigens over non-canonical peptides in cancer patients | Maria Lozano-Rabella, MsC; Andrea Garcia-Garijo, MsC; Jara Palomero, PhD; Florian Erhard; Juan Martín-Liberal, MD; Ignacio Matos, MD; Jared Gartner; Steven A. Rosenberg, MD, PhD; Michael Ghosh; Francesc Canals, PhD; August Vidal, MD; Josep Maria Piulats, MD; Xavier Matias-Guiu; Irene Braña, MD; Eva Muñoz, MD; Elena Garralda; Andreas Schlosser, PhD; Alena Gros, PhD | Tumor and Stromal Cell Biology | Adoptive immunotherapy;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 913 | Poster Presentation | A murine gastric cancer YTN16 model for the rational design of combination immunotherapy | Koji Nagaoka, PhD; Changbo Sun, MD; Yukari Kobayashi, BS; Kazuhiro Kakimi, MD, PhD | Tumor and Stromal Cell Biology | Neoantigens;T cell;Tumor antigens;Vaccine | |
| 914 | Poster Presentation | Loss of LKB1 is associated with resistance to IFN-gamma and T cell killing in non-small cell lung cancer | Alexandre Reuben, PhD; Peixin Jiang; Hui Nie; Ana Galan Cobo; Minghao Dang; Yu Qian, PhD; Meredith Frank, MSc; Emily Blitz; Haifa Hamdi; Warren L. Denning; Monique Nilsson; Alissa Poteete; Li Shen; Qi Wang; Irene Guijarro; Keri Nichols; Roohussaba Khairullah; Jiexin RP. Zhang, PhD; Ferdinandos Skoulidis; Jing Wang; Linghua Wang, PhD; John V. Heymach, MD, PhD | Tumor and Stromal Cell Biology | Antigen presenting cells;Checkpoint blockade;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs) | |
| 915 | Poster Presentation | Molecular characterization of AXL in solid tumor malignancies using real-world data | Han Si, PhD; Maria Jure-Kunkel; Nora Pencheva; Steven Xu; Brandon Higgs; Kate Sasser, PhD; Hisham Hamadeh, PhD; Phaedra Agius; Kristina Grigaityte | Tumor and Stromal Cell Biology | Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Gene expression;Solid tumors;Tumor antigens | |
| 916 | Poster Presentation | Understanding the effect of M1 macrophage subset on regulation of cancer stem cells | Udit Basak, Bachelor of Technology | Tumor and Stromal Cell Biology | Epigenetics;Monocyte/Macrophage;Solid tumors;Tumor microenvironment | |
| 917 | Poster Presentation | Immune landscape at the invasion front of surgically resected oral squamous cell carcinomas shows significant associations with disease specific survival | Jebrane BOUAOUD, MD PhD Student; Frank Rojas Alvarez, MD; Lucas Michon; Nicolas Gadot; Sylvie Lantuejoul; Auriole Tamegnon; Mei Jiang; Shanyu Zhang; Pandurengan Renganayaki; Philippe Zrounba; Jean-Philippe Foy; Karène Mahtouk, PhD; Chloé Bertolus, MD PhD; Edwin Roger Parra Cuentas, MD PhD; Pierre Saintigny | Tumor and Stromal Cell Biology | Immune contexture;Immune suppression;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 918 | Poster Presentation | Doxycycline regulatable ß-catenin demonstrates inducible immune evasion in a melanoma GEM model. | Alexandra Cabanov, BS; Stefani Spranger, PhD; Thomas F. Gajewski, MD, PhD; Elen Torres-Mejia, PhD | Tumor and Stromal Cell Biology | Checkpoint blockade;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 919 | Poster Presentation | Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment | Raghav Chandra, M.D.; Josiah Flaming, B.S.; Aiden Nguyen, B.S.; Michael Peyton, Ph.D.; Amit Das, Ph.D.; Boning Gao, Ph.D.; Steven K. Horrigan, Ph.D.; Rolf A. Brekken, PhD; John D. Minna, M.D. | Tumor and Stromal Cell Biology | Monocyte/Macrophage;Tumor microenvironment | |
| 920 | Poster Presentation | A Single-Cell Spatially Resolved MERFISH Map of the Colorectal Tumor Immune Microenvironment | Colles Price, MS, PhD; Jonathan H. Chen, MD/PhD; Karin Pelka, PhD; Sherry Chao; Jiang He, PhD; Genevieve Boland, PhD; George Emanuel, PhD; Nir Hacohen, PhD | Tumor and Stromal Cell Biology | Bioinformatics;Gene expression;Immune monitoring;Monocyte/Macrophage;RNA;Solid tumors;T cell;Tumor microenvironment | |
| 921 | Poster Presentation | Comparison of PI3K/AKT/mTOR pathway profiles amongst three immune phenotypes classified by artificial intelligence-powered H&E analyzer in non-small cell lung cancer | Hyung-Gyo Cho, MD; Grace Lee; Hye Sung Kim, MD; Sanghoon Song, MS; Kyunghyun Paeng; Chan-Young Ock, MD, PhD; Young Kwang Chae, MD, MPH, MBA | Tumor and Stromal Cell Biology | Gene expression;Immune contexture;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 922 | Poster Presentation | A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell function and has monotherapy activity in fibrotic cancer models | Marcel Deken; Karolina Niewola, PhD; Elisa Matas-Rico, PhD; Ragini Medhi, PhD; Alan Carruthers, PhD; Anne Cheasty, PhD; Olivier Peyruchaud, PhD; Amy Fraser, PhD; Pritom Shah, PhD; Wouter Moolenaar, PhD; Lars van der Veen, PhD; Michael Lahn, PhD, MD; ZOE JOHNSON, PhD | Tumor and Stromal Cell Biology | Bioinformatics;Biomarkers;Cytokine;Monocyte/Macrophage;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 923 | Poster Presentation | Hedgehog Signaling Drives Epithelial-to-Mesenchymal Transition, Immune Evasion, and Anti-PD-1 Resistance through Coordinated Upregulation of Wnt Ligands and PGE2 Synthesis | Nicholas C. DeVito, MD; Michael Sturdivant; Balamayooran BT. Theivanthiran, PhD; Y-Van Nguyen; Michael P. Plebanek, PhD; Brent A. Hanks, MD, PhD | Tumor and Stromal Cell Biology | Antigen presenting cells;Checkpoint blockade;Dendritic cell;Gene expression;Immune suppression;MDSC;NK/NKT cell;Solid tumors;Tumor evasion;Tumor microenvironment | |
| 924 | Poster Presentation | The Spatial Hierarchy of Primary and Recurrent Medulloblastoma Tumor Ecosystems | Laura K. Donovan, PhD; Bei Hopkins; Ben Draper; Rivani Shah; Kristin Roman; Bethany Remeniuk, PhD | Tumor and Stromal Cell Biology | Immune suppression;Monocyte/Macrophage;Pediatric tumors;T cell;Tumor microenvironment | |
| 925 | Poster Presentation | Utilizing multiplex immunofluorescence to explore the epithelial-mesenchymal transition in breast, ovarian cancers | Danielle M. Fails, MS; Michael L. Spencer, PhD | Tumor and Stromal Cell Biology | Antibody;Biomarkers;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 926 | Poster Presentation | Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy | Ana Galan-Cobo, PhD; Yu Qian, PhD; Fuduan Peng, PhD; Daniel J. McGrail, PhD; Fahao Zhang; Xiang Zhang; Edwin R. Parra, MD, PhD; Minghao Dang; Saxon Rodriguez; Alexandre Reuben, PhD; Ignacio Wistuba, MD; Ferdinandos Skoulidis; Linghua Wang, PhD; John V. Heymach, MD, PhD | Tumor and Stromal Cell Biology | Biomarkers;Checkpoint blockade;Tumor microenvironment | |
| 927 | Poster Presentation | Wilms tumor reveals DNA repair gene hyper-expression is linked to lack of immune infiltration | Emily Higgs; Riyue Bao, PhD; Ken Hatogai, MD PhD; Thomas F. Gajewski, MD, PhD | Tumor and Stromal Cell Biology | Bioinformatics;Gene expression;Immunoscore;Inflammation;Pediatric tumors;RNA;Tumor evasion;Tumor microenvironment | |
| 928 | Poster Presentation | A translational approach to catalog pancreatic cancer heterogeneity using spatial genomics in large patient cohorts for target validation and rational combination selection | Omar J. Jabado, PhD; Li Fan; Patricia Coutinho de Souza, DVM, PhD; Angelo Harris; Arturo Chaparro; Mohammed Qutaish, PhD; Han Si, PhD; Jan-Hermen Dannenberg, PhD; Kate Sasser, PhD; Suzana Couto; Mark Fereshteh, PhD | Tumor and Stromal Cell Biology | Bioinformatics;Bispecifics;Gene expression;Immune contexture;Monocyte/Macrophage;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 929 | Poster Presentation | Dissecting intratumoral immune organization: defining the comparative cellular composition of tertiary lymphoid structures T-cell supportive antigen presenting niches in renal tumors | Caroline S. Jansen, BS; Ewelina Sobierajska; Rachel Greenwald; Jennifer Carlisle, MD; Patrick Mullane, MD; Nataliya Prokhnevska, BS; Maria Cardenas; Mehmet A. Bilen, MD; Adeboye O. Osunkoya, MD; Viraj Master, Dr.; Haydn T. Kissick, PhD | Tumor and Stromal Cell Biology | Antigen presenting cells;Dendritic cell;Immune contexture;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 930 | Poster Presentation | Fibroblast activation protein alpha expression in tumor stroma and its association with immuno-regulatory circuits across epithelial tumors | Anton Kraxner; Franziska Braun; Wei-Yi Cheng; Marta Canamero; Emilia Andersson; Suzana Vega Harring; Sebastian Dziadek; Ann-Marie Broeske; Maurizio Ceppi; Volker Teichgraeber; Jehad Charo | Tumor and Stromal Cell Biology | Biomarkers;Immune contexture;Inflammation;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 931 | Poster Presentation | LncRNA Malat1 Regulated Serpinb6b Signaling Suppresses Pyroptosis and Governs Breast Cancer Dormancy Reactivation and Through Immune Evasion | Dhiraj Kumar, PhD; Filippo Giancotti, MD, PhD | Tumor and Stromal Cell Biology | Checkpoint blockade;MDSC;RNA;T cell;Tumor microenvironment;Tumor stroma | |
| 933 | Poster Presentation | Immune infiltrates differences between central and periphery regions of colorectal and pancreas adenocarcinomas | Andreia Maia, PhD candidate; Joana R. Lérias, DVM, PhD; Luis Miguel Borrego, MD, PhD; Markus J. Maeurer, MD, PhD, FRCP(London); Mireia Castillo-Martin, MD, PhD | Tumor and Stromal Cell Biology | Adoptive immunotherapy;B cell;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 934 | Poster Presentation | Biological mechanisms in the different etiologies of Merkel cell carcinoma patients: polyomavirus or UV exposure | Domenico Mallardo, MD; Giosuè Scognamiglio; Khrystyna North; Mariaelena Capone, MD; Michael Bailey; Luigi Scarpato; Sarah E. Church, PhD; Gabriele Madonna, MS; Jason W. Reeves, PhD; Marcello Curvietto; Marilena Tuffanelli; grazia d'angelo; Ester Simeone, MD; Lucia Festino; Vito Vanella; Claudia Trojaniello; Maria Grazia Vitale, MD; Salvatore Tafuto; Corrado Caracò; Anna Maria Anniciello; Nicola Normanno; Maurizio Di Bonito; Sarah E. Warren, PhD; Paolo A. Ascierto, MD | Tumor and Stromal Cell Biology | Biomarkers;Carcinogenesis;Gene expression;Immune monitoring;Immune suppression;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 935 | Poster Presentation | Attraction of immune cells by head and neck cancer cell lines and primary tumor-conditioned supernatants | Tara Muijlwijk, MSc; Naomi Remkes; Jos B. Poell, Dr.; René C. Leemans, Prof. dr.; Ruud H. Brakenhoff, Prof. dr.; Rieneke van de Ven, Dr. | Tumor and Stromal Cell Biology | Chemokine;Dendritic cell;Immune contexture;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 936 | Oral Presentation | Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment | Athanasios Papadas, MD; Gauri Deb; Adam Officer; Chelsea Hope; Philip Emmerich; Alexander Cicala; Joshua Wiesner; Garrett Arauz; Adam Pagenkopf; Kristina Matkowskyj; Dustin Deming; Katerina Politi, PhD; Scott I. Abrams, PhD; Olivier Harismendy; Fotis Asimakopoulos, MD PhD | Tumor and Stromal Cell Biology | Antigen presenting cells;Dendritic cell;Glycoproteomics;Immune contexture;Inflammation;Myeloid cells;Tumor evasion;Tumor microenvironment;Tumor stroma;Vaccine | |
| 937 | Poster Presentation | Advanced Understanding of the Tumor Microenvironment with Multiplex Analysis: An automated 7-color multiplex assay using Akoya’s Opal Technology | Bhavika Patel, PhD; Stephanie Allen; Tania Eliseeva, MS; Najiba Mammadova, PhD; Agnes Haggerty, PhD; Navi Mehra, PhD | Tumor and Stromal Cell Biology | Biomarkers;Immune contexture;Immune monitoring;Immune suppression;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 938 | Poster Presentation | Study of the tumor microenvironment of oral squamous cell carcinoma using multiplex immunofluorescence and image analysis approaches | Frank Rojas, MD; Jebrane BOUAOUD, MD PhD Student; Edwin R. Parra, MD, PhD; Pierre Saintigny; Auriole Tamegnon; Mei Jiang; Shanyu Zhang; Pandurengan Renganayaki; Lucas Michon; Nicolas Gadot; Sylvie Lantuejoul; Philippe Zrounba; Jean-Philippe Foy; Karene Mahtouk; Chloe Bertolus | Tumor and Stromal Cell Biology | Biomarkers;Immune suppression;Tumor microenvironment | |
| 939 | Poster Presentation | Autocrine/paracrine factors in cancer associated fibroblasts drive immunosuppression through impaired myeloid cell functions | Nikita S. Sharma, PhD; Priya Govindaraju, PhD; Shermineh Bradford, BS; Yarong Wang, BS; Brianna Flynn, MS; Candace Wai Sze Lei; Varenka Rodriguez Di Blasi, PhD; Jeanine Pignatelli, PhD; Kang Liu, PhD; Emily Corse, PhD; Abhishek Kashyap, PhD | Tumor and Stromal Cell Biology | Antigen presenting cells;Dendritic cell;Immune suppression;Immune tolerance;Inflammation;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs) | |
| 940 | Poster Presentation | Targeting DKK1 to reverse immunosuppressive macrophages and enhance PD-1 blockade therapy in gastric cancer | Tao Shi, PhD; Yipeng Zhang; Yue Wang; Yunfeng Pan; Hanbing Wang; Yuting Luo; Kaijie Liang; Fangcen Liu; Qin Liu; Keying Che; Xuan Wang; Lixia Yu; Baorui Liu, PhD MD; Jia Wei, MD PhD | Tumor and Stromal Cell Biology | Monocyte/Macrophage;NK/NKT cell;T cell;Tumor microenvironment | |
| 941 | Poster Presentation | Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: A new tumour stromal cell immune checkpoint? | Oliver Treacy, PhD; Hannah Egan, BSc; Kevin Lynch, PhD; Niamh A. Leonard, MSc; Kim De Veirman, PhD; Karin Vanderkerken, Prof.; Laurence Egan, Prof; Thomas Ritter, Prof; Aisling M. Hogan, MD; Keara Redmond, PhD; Janusz Krawczyk, MD; Sean Hynes, PhD; Emma Kerr, PhD; Philip D. Dunne, PhD; Michael E. O'Dwyer, Prof.; Aideen E. Ryan, PhD | Tumor and Stromal Cell Biology | Solid tumors;Tumor microenvironment;Tumor stroma | |
| 942 | Poster Presentation | The tumor microbiome correlates with response to immune checkpoint inhibitors in renal cell carcinoma | Caroline Wheeler; Yuanquan Yang, MD, PhD; Daniel Spakowicz, PhD, MS; Rebecca Hoyd; Mingjia Li, MD | Tumor and Stromal Cell Biology | Microbiome;RNA;Tumor microenvironment | |
| 943 | Poster Presentation | 3D in vitro tumor model platform rapidly assays immunotherapy efficacy with high content imaging and downstream phenotypic changes with flow cytometry and cytokine analysis | Bin Xue, PhD; Julia Schuler, DVM PhD; Christopher M. Harrod; Kolin C. Hribar, PhD | Tumor and Stromal Cell Biology | Immune suppression;T cell;Tumor microenvironment;Tumor stroma | |
| 944 | Poster Presentation | Fibroblasts as paracrine targets of the oncometabolite D-2-HG in the IDH1-mutant cholangiocarcinoma tumor microenvironment | Daniel Zabransky, MD, PhD; Prerna Jain; Kabir Mody, MD; Sherif El-Refai, PhamD, PhD; Elizabeth M. Jaffee, MD; Mark Yarchoan, MD | Tumor and Stromal Cell Biology | Gene expression;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma | |
Late-Breaking | ||||||
| 945 | Poster Presentation | Characterization of the immune landscape of malignant pleural effusion composition from patients with metastatic breast carcinoma: A Pilot study | Caddie Dy Laberiano, MD; Edwin R. Parra, MD, PhD; Qiong Gan; Heladio Ibarguen; Shanyu RP. Zang; Esther Yoon; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 946 | Poster Presentation | Standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration | Sarah E. Church, PhD; Christina M. Bailey, MS; Sarah E. Warren, PhD; Lisa H. Butterfield, PhD; | Cellular Therapies | RNA;Adoptive immunotherapy;Bioinformatics;Biomarkers;CAR T cells;Gene expression;Immune monitoring;Immune toxicity;Leukemia/Lymphoma;Solid tumors | |
| 947 | Poster Presentation | Recombinant Myxoma Virus MC509-N1 Demonstrates Antitumor Efficacy as Monotherapy and in Combination with Immune Checkpoint Inhibitors | Enkhtaivan Gansukh, PhD; Tommy Alain, PhD; Tae-Geuk Kim; Ye-Na Namgung; Ka-Yeon Son; Yeo-Jin Jeong; Yeon-Sook Lee; | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 948 | Poster Presentation | Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC | Hans Wildiers, MD; Luc Dirix; Anne Armstrong; Eveline De Cuypere; Florence Dalenc; Steven Chan; Frederik Marme; Carolina Pia Schröder; Jens Huober; Peter Vuylsteke; Jean-Philippe Jacquin; Etienne Brain; Sherko Kümmel; Zsuzsanna Pápai; Christian Mueller, MSc; Chrystelle Brignone; Frederic Triebel, MD, PhD; | Clinical Trials Complete | Antigen presenting cells;Chemotherapy;Clinical study;Clinical trial;Dendritic cell;T cell | |
| 949 | Poster Presentation | First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody that preserves the immune tolerance checkpoint to avoid immunotherapy-related adverse events in cancer patients | Tianhong Li, MD, PhD; Mei Tang, MD, PhD; Karen Kelly, MD; Hui Amy Chen, MD; Stacy S. Joo; Imaan Khan; Nicole Do; Raymond Touomou; Dan Chen, MD, PhD; Yang Liu, PhD; Pan Zheng, MD, PhD; | Clinical Trials Complete | Antibody;Checkpoint blockade;Clinical trial;Solid tumors | |
| 950 | Poster Presentation | Final analysis: phase 1b study investigating intratumoral injection of Toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma | John M. Kirkwood, MD, MD; Yousef Zakharia; Diwakar Davar; Elizabeth Buchbinder; Theresa Medina; Adil Daud; Antoni Ribas, MD, PhD; Bartosz Chmielowski; Jiaxin Niu; Geoffrey Gibney; Kim Margolin; Anthony J. Olszanski, MD, RPh; Inderjit Mehmi; Takami Sato, MD; Montaser Shaheen, MD; Luping Zhao; Hong Liu; Heather Kelley, MA; George J. Weiner, MD; Jason J. Luke; Dmitri Bobilev; Arthur M. Krieg; James E. Wooldridge, MD; Mohammed M. Milhem, MBBS; | Clinical Trials Complete | Checkpoint blockade;Clinical study;Dendritic cell;Solid tumors;T cell;TLR;Tumor microenvironment | |
| 951 | Oral Presentation | A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data | Kim A. Reiss, MD; Yuan Yuan, MD, PhD; Debora Barton, MD; Amy Ronczka, BS; Daniel Cushing, PhD; Michael Klichinsky, PharmD, PhD; Sascha Abramson, PhD; Rehman Qureshi; Thomas Condamine, PhD; Elizabeth C. Dees, MD, MSC; | Clinical Trials In Progress | Adoptive immunotherapy;Antigen presenting cells;Clinical study;Clinical trial;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment | |
| 952 | Poster Presentation | Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma | Daniela A. Bota, MD., PhD; David E. Piccioni, MD,PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Mehrdad Abedi, MD; Jose A. Carrillo, MD; Robert D. Aiken, MD; Frank Hsu, MD PhD; Xiaotang Kong, MD, PhD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD; | Clinical Trials In Progress | Clinical trial;Dendritic cell;Stem cell/cancer-initiating cell;Vaccine | |
| 953 | Poster Presentation | Transcriptional Analysis of Leukocytes from COVID Convalescent Donors Reveals Persistent Activation of the Innate and Adaptive Immune System | Mallikarjuna R. Gedda, PhD; Patrick Danaher, PhD; Lipei Saho, PhD; Martin Ongkeko, PhD; Leonard Chen, MD; Mame Thioye Sall, MS; Opal L. Reddy, MD; Christina M. Bailey, MS; Amy Wahba, PhD; Inna Dzekunova, MS; Valeria De Giorgi, PhD; Robert Somerville, PhD; Jin Ping, PhD; Kamille West, MD; Sandhya Panch, MD, MPH; David F. Stroncek, MD; | Clinical Trials In Progress | RNA;COVID and Immunotherapy;Antibody;Clinical study;Gene expression;Granulocyte;Immune monitoring;Inflammation;Regulatory T cell (Treg cell);T cell | |
| 954 | Poster Presentation | Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus | Tereza Brachtlova; Allan Abramovitch, MD; Jonathan Giddens, MD; Peter Incze, MD; Kenneth Jansz, MD; Richard Casey, MD; Victor W. van Beusechem; Wenliang Dong, PhD, MBA; | Clinical Trials In Progress | Clinical study;Clinical trial;Solid tumors;Targeted therapy | |
| 955 | Oral Presentation | CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) | Roger Li, MD; Gary D. Steinberg, MD; Donald Lamm, MD, FACS; Ed M. Uchio, MD; Vignesh Packiam, MD; Ashish M. Kamat, MD; Michael Chisamore, PhD; John McAdory, MHA; Paola Grandi, PhD, MBA; Jee-Hyun Kim, PhD; James Burke, MD; | Clinical Trials In Progress | Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Immune monitoring;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs) | |
| 956 | Poster Presentation | Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: Results from the POD1UM-101 study | Dominique Berton, MD; Patricia Pautier, MD; Domenica Lorusso, MD; Christine Gennigens, MD; Laurence Gladieff, MD; Anna Kryzhanivska, MD; Sulabha Ranganathan, PhD; Chuan Tian, PhD; Nawel Bourayou, MD; Ignace Vergote, MD; | Clinical Trials In Progress | Checkpoint blockade;Clinical trial;Solid tumors | |
| 957 | Poster Presentation | NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the Phase 1b dose-escalation study | Mehmet Altan, MD; Amita Patnaik, MD; Minal A. Barve, MD; Lara A. Dunn, MD; Patrick W. Cobb, MD; Ari Rosenberg, MD; Sunil Sharma, MD; Ammar Sukari, MD; Manish R. Patel, MD; Xiaoli Wang, PhD, MBA; Haijun Ma, PhD; Neha Dixit, PhD; Wildaliz Nieves, PhD; Christie Fanton, PhD; Sue L. Currie, PhD; Zachary Lee, PharmD; Mario Q. Marcondes, MD, PhD; Johnathan Zalevsky, PhD; Mary A. Tagliaferri, MD; Assuntina G. Sacco, MD; | Clinical Trials In Progress | Clinical study;Clinical trial;Cytokine;NK/NK T cell;Solid tumors;T cell;Tumor microenvironment | |
| 958 | Oral Presentation | BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors | Andreas Mackensen, MD; Christian Koenecke, MD; John B. Haanen, MD; Winfried Alsdorf; Alexander Desuki, MD; Eva Wagner-Drouet, MD; Daniel Heudobler, MD; Peter Borchmann, MD; Erol Wiegert; Catrine Schulz; Benjamin Rengstl, MD, PhD; Liane Preussner, MD; Oezlem Tuereci, MD; Ugur Sahin, MD; | Clinical Trials In Progress | RNA;Adoptive immunotherapy;CAR T cells;Clinical trial;Costimulation;Solid tumors;T cell;Tumor antigens;Vaccine | |
| 959 | Oral Presentation | Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial | Martin Wermke; Apostolia-Maria Tsimberidou; Ali Mohamed; Andrea Mayer-Mokler; Arun Satelli; Carsten Reinhardt; Dejka Araujo; Dominik Maurer; George Jr Blumenschein; Harpreet Singh; Jason J. Luke; Kerstin Guenther; Mamta Kalra; Manik Chatterjee; Norbert Hilf; Regina Mendrzyk; Steffen Walter; Stephen Eck; Tobias A.W. Holderried; Toni Weinschenk; Van Morris; Winfried Alsdorf; Cedrik M. Britten; | Clinical Trials In Progress | Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy | |
| 960 | Poster Presentation | Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer | Osama E. Rahma, MD; Mathew HG. Katz, MD; Todd W. Bauer, MD; Brian Wolpin, MD; Chee-Chee H. Stucky, MD; Tanios S. Bekaii-Saab, MD; Rawad Elias, MD; Andressa Dias-Costa, MD; Jonathan Nowak, MD; Lenehan Patrick, MD; Gina R. Petroni; Stephanie Dougan, PhD; Craig L. Slingluff, Jr., MD; | Clinical Trials In Progress | Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Radiotherapy;Surgery;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 961 | Poster Presentation | Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy | Iván Márquez Rodas; Philippe Saiag; Luis de la Cruz Merino; Caroline Dutriaux; Juan F. Rodríguez-Moreno; Caroline Robert, MD, PhD; Ana Arance; Eduardo Castañón Álvarez; Pablo Cerezuela-Fuentes; Henry Montaudie, MD, PhD; Miguel Sanmamed, MD, PhD; María González Cao, MD; Julie Charles, MD; María Pilar López Criado; Alfonso Berrocal; Enrique de Miguel; Elisa Funk-Brentano; Sorilla Prey; Roberto M. Huertas; Delvys Rodríguez Abreu; Eva Muñoz Couselo; Juan Martin-Liberal; Javier Sánchez López; Helena Escuin-Ordinas; Marisol Quintero; Sonia Maciá, MD, PhD; Iván Márquez-Rodas, MD, PhD; Marya F. Chaney, PhD; Stephane Dalle; | Clinical Trials In Progress | RNA;Biomarkers;Clinical study;Clinical trial;Dendritic cell;Regulatory T cell (Treg cell);T cell;TLR;Tumor antigens;Tumor microenvironment | |
| 962 | Poster Presentation | Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer | Stephanie T. Schmidt, PhD; Younghee Lee, PhD; Cheuk H. Leung, MS; Lorenzo Federico, PhD; Heather Lin, PhD; Annikka Weissferdt, MD; Apar Pataer, MD, PhD; Hitoshi Dejima, PhD; Alejandro Francisco-Cruz, PhD; Frank Rojas, MD; Luisa M. Solis, MD; Edwin R. Parra, MD, PhD; Monika Pradhan, PhD; Haiping Guo; William N. William, MD; Alexandre Reuben, PhD; Humam Kadara, PhD; Ignacio Wistuba, MD; Jianjun Zhang, MD, PhD; Stephen G. Swisher, MD; Ara A. Vaporciyan, MD; Marcelo V. Negrao, MD; Christopher A. Bristow, PhD; Timothy P. Heffernan, PhD; Chantale Bernatchez, PhD; Jack J. Lee, PhD/DDS; John V. Heymach, MD, PhD; Boris Sepesi, MD; Don L. Gibbons, MD, PhD; Cara Haymaker, PhD; Tina Cascone, MD, PhD; | Combination Immunotherapies | Bioinformatics;Checkpoint blockade;Chemotherapy;Tumor microenvironment | |
Presented By:
